form10ksb_2007.htm
U.S.
Securities and Exchange Commission
Washington,
D.C. 20549
FORM
10-KSB
[X]
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
|
For
the fiscal year
endedDecember
31,
2007
|
[ ]
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
[No Fee Required]
|
|
For
the transition period
from
to .
|
Commission
File No.
0-30379
CHEMBIO
DIAGNOSTICS, INC.
(Name
of
small business issuer in its charter)
|
|
|
(State
or jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
3661
Horseblock Road, Medford, NY
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (631) 924-1135
Securities
registered pursuant to
Section 12(b) of the Act:
Title
of each class
|
|
Name
of each exchange on which registered
|
|
|
|
Securities
registered pursuant to Section 12(g) of the Act:
|
Common
Stock, $0.01 par value
|
(Title
of Class)
|
Check
whether the issuer is not required to file reports pursuant to Section 13
or
15(d) of the Exchange Act.
Yes
__ No
_X_
Check
whether the issuer (1) filed all reports required to be filed by Section
13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter
period
that the registrant was required to file such report), and (2) has been subject
to such filing requirements for the past 90 days. Yes
X No__
Check
if
there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained,
to
the best of registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [ X ]
Indicate
by check mark whether the Registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act.
Yes
__ No
_X_
State
issuer’s revenues for its most recent fiscal
year: $9,230,948.
As
of
March 5, 2008, the registrant had 60,537,534 common shares outstanding, and
the
aggregate market value of the common shares held by non-affiliates (*) was
approximately $5,247,000. This calculation is based upon the closing
sale price of $0.21 per share on March 5, 2008.
*
Without
asserting that any of the issuer’s directors or executive officers, or the
entities that own 35,552,013 shares of common stock are affiliates, the shares
of which they are beneficial owners have been deemed to be owned by affiliates
solely for this calculation.
TABLE
OF CONTENTS
|
|
|
Page
|
PART
I
|
|
3
|
ITEM
1.
|
DESCRIPTION
OF BUSINESS
|
3
|
ITEM
2.
|
DESCRIPTION
OF PROPERTY
|
16
|
ITEM
3.
|
LEGAL
PROCEEDINGS
|
16
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
16
|
PART
II
|
|
17
|
ITEM
5.
|
MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
|
17
|
ITEM
6.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
18
|
ITEM
7.
|
FINANCIAL
STATEMENTS
|
30
|
ITEM
8.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
|
30
|
ITEM
8A.
|
CONTROLS
AND PROCEDURES
|
30
|
ITEM
8B.
|
OTHER
INFORMATION
|
30
|
PART
III
|
|
31
|
ITEM
9.
|
DIRECTORS,
EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH
SECTION
16(A) OF THE EXCHANGE ACT
|
31
|
ITEM
10.
|
EXECUTIVE
COMPENSATION
|
33
|
ITEM
11.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
36
|
ITEM
12.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
|
38
|
ITEM
13.
|
EXHIBITS
|
42
|
ITEM
14.
|
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
|
44
|
SIGNATURES
|
|
45
|
PART
I
ITEM
1.
|
DESCRIPTION
OF BUSINESS
|
FORWARD-LOOKING
STATEMENTS
This
report contains forward-looking statements within the meaning of Section
21E of
the Securities Exchange Act of 1934, and Section 27A of the Securities Act
of
1933. Any statements contained in this report that are not statements of
historical fact may be forward-looking statements. When we use the words
“intends,” “estimates,” “predicts,” “potential,” “continues,”
“anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,”
“will” or the negative of these terms or other comparable terminology,
we are identifying forward-looking statements. Forward-looking statements
involve risks and uncertainties, which may cause our actual results, performance
or achievements to be materially different from those expressed or implied
by
forward-looking statements. These factors include our; research and
development activities, distributor channel; compliance with regulatory
impositions; and our capital needs. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
Except
as may be required by applicable law, we do not undertake or intend to update
or
revise our forward-looking statements, and we assume no obligation to update
any
forward-looking statements contained in this report as a result of new
information or future events or developments. Thus, you should not assume
that
our silence over time means that actual events are bearing out as expressed
or
implied in such forward-looking statements. You should carefully review and
consider the various disclosures we make in this report and our other reports
filed with the Securities and Exchange Commission that attempt to advise
interested parties of the risks, uncertainties and other factors that may
affect
our business.
For
further information about these and other risks, uncertainties and factors,
please review the disclosure included in this report under “Part I, Item 1,
Description of Business - Risk Factors.”
General
Chembio
Diagnostics, Inc. (the “Company”) and its subsidiaries develop, manufacture and
market rapid diagnostic tests that detect infectious diseases. The Company’s
main products presently commercially available are three rapid tests for
the
detection of HIV antibodies in whole blood, serum and plasma samples, two
of
which were approved by the FDA in 2006. These products employ single
path lateral flow technology which we have licensed from Inverness Medical
Innovations, Inc. (“Inverness”), which is also our exclusive marketing partner
for those two products in the United States under its Clearview®
brand. Inverness launched its marketing of these products in the
United States in February 2007. Chembio’s two HIV STAT-PAK® rapid HIV
tests are marketed outside the United States through different partners and
channels under license from Inverness. We also have a rapid test for Chagas
disease (a parasitic disease endemic in Latin America) and two rapid tests
for
detecting tuberculosis antibodies in animals for which we have received USDA
approval.
On
March
13, 2007, we were issued United States patent #7,189,522 for our Dual Path
Platform (DPP™) rapid test system. Additional patent protection for
DPP™ is pending worldwide. DPP™ enables Chembio to participate in the
growing point of care diagnostics market with a patent-protected point-of-care
platform technology. The independent sample strip on our DPP™ devices
enables the development of products whose performance we believe exceeds
that of
comparable tests developed on a single path lateral flow platform. We
therefore believe that as a result of the patent protection we now have with
DPP™, we have a significant opportunity to develop and/or license many new rapid
tests in a number of fields including but not limited to infectious
diseases. During both 2007 and 2008 year to date we have made
significant progress in establishing commercial opportunities for this new
platform that are now in development (see Research and Development”). We
have completed initial development of an oral fluid HIV test on this
new platform and are currently conducting pre-clinical studies on this
product We believe the DPP™ provides significant advantages over
standard single path lateral flow assays particularly where challenging sample
matrices, such as oral fluid, are involved, or where multiplexing is
desired. We are developing all of our new products using this
platform. Our strategy for the development of this platform
technology is also dual; we are entering into exclusive collaborations with
large marketing partners for whom we will develop and manufacture products
on
the DPP™ and we are developing our own products that we may choose to
market through selected distribution partners either under a Chembio or
other brand.
Our
products are sold to medical laboratories and hospitals, governmental and
public
health entities, non-governmental organizations, and medical professionals.
Our
products are sold either under our STAT-PAK® or SURE CHECK® registered
trademarks and/or the private labels of our marketing partners, such as is
the
case with the Inverness Clearview® label for our rapid HIV tests in the United
States.
Rapid
HIV Tests
The
major
component of our revenue growth in 2007 was increased sales of our rapid
HIV tests, and most of that increase was a result of our entry into the US
rapid
HIV test market as a result of the launch of our tests by
Inverness. A large percentage of individuals that are HIV positive
worldwide are unaware of their status. Part of the reason for this is that
even
those that do get tested in public health settings will often not return
or call
back for their test results when samples have to be sent out to a laboratory
that can take at least several days to process. The increased
availability, greater efficacy and reduced costs for anti-retroviral treatments
(ARVs) for HIV is also having a tremendous impact on the demand for testing,
as
the stigma associated with the disease is lessened and the ability to resume
normal activities is substantially improved. All three of our rapid HIV
tests are qualitative “yes/no” tests for the detection of antibodies to HIV 1
& 2 with results available within approximately 15 minutes. The
tests differ principally only in the method of sample collection and test
procedure, flexibility with different sample types, and cost of manufacture.
Our
rapid HIV tests have been marketed under our SURE CHECK® and STAT-PAK®
trademarks. Pursuant to our agreement with Inverness Medical
Innovations, Inc., the SURE CHECK® product is now being marketed globally (with
limited exceptions) by Inverness as Clearview® Complete HIV 1/2 and the cassette
format of our STAT-PAK (we also have a third product known as HIV 1/2 STAT-PAK
dipstick) is now being marketed by Inverness in the United States as Clearview®
HIV 1/2 STAT-PAK®. We continue to market our STAT-PAK® cassette and
dipstick outside the United States through other marketing
channels.
Regulatory
Status:
Rapid
HIV Tests
The
FDA
approved our Pre-Market Applications for our SURE CHECK HIV 1/2 (now Inverness’
Clearview® Complete HIV 1-2 worldwide) and HIV 1/2 STAT-PAK (now Inverness’
Clearview® HIV 1/2 STAT-PAK in the United States only) products on May 25,
2006. A Clinical Laboratory Improvement Act (“CLIA”) waiver was
granted by the FDA for the HIV 1/2 STAT-PAK on November 20,
2006. Labeling changes to the Inverness Clearview® brands for both
products were approved during the first quarter of 2007. CLIA
waiver for the Clearview® Complete HIV 1-2 was granted on October 22,
2007. CLIA waiver is required in order to market the products in
public health clinics and physicians’ offices where the level of training is
traditionally less than the training at clinical laboratories and
hospitals. Public health clinics and physicians’ offices now
constitute the largest portion of the available market for our products.
Our
third rapid HIV test, HIV 1/2 STAT-PAK Dipstick,
though not FDA approved, qualifies under FDA export regulations to sell,
subject
to any required approval by the importing country, to customers outside the
United States. The dipstick product is our most competitively priced
version of our three rapid HIV tests, and was designed primarily for
resource-constrained, donor-funded markets that have large test volume
needs. In 2006 we made certain improvements to this product so
that it could be run flat on an adhesive backing card as an alternative to
being
dipped in a vial containing the sample and buffer solution. This
change made the product procedure similar to a cassette format with less
cost
than those associated with producing the cassette format.
Although
we have received approval from a number of potential importing countries
for all
three of our HIV tests, Brazil, Mexico, Nigeria, Ethiopia and Uganda are
the
only countries in which we have realized significant sales. As a
result of favorable evaluations of our HIV 1/2 STAT-PAK and HIV 1/2
STAT-PAK Dipstick products by the World Health Organization (the “WHO”), these
products are qualified for procurements from programs funded by the United
Nations and their partners’ programs. All three of our HIV tests have
qualified for procurements under the President’s Emergency Plan for AIDS Relief
(“PEPFAR”).
Partners
Involved in the Products:
On
September 29, 2006 we executed marketing and license agreements with
Inverness. These agreements provide for the marketing of our
rapid HIV tests in the United States; the agreements also grant us a license
to
Inverness’ single path lateral flow patents that may be applicable to our other
products, including those that we had under development at the time of the
grant. As part of these agreements we settled litigation that had
been ongoing with another company, StatSure Diagnostics, Inc., relating to
the
barrel device that is incorporated into our Sure Check® (now Inverness Clearview
Complete) HIV 1/2 product.
In
September 2005 we were designated as the confirmatory test in Uganda’s national
rapid testing protocol. In February 2006 our HIV 1/2 STAT-PAK® was
designated by the Nigerian Ministry of Health in four out of the eight screening
protocols in the Nigerian Interim Rapid Testing Algorithm. In
February 2008, Nigeria changed from a parallel algorithm to a serial algorithm,
and this designation was changed to that of a confirmatory test. In
October, 2007 our HIV 1/2 STAT-PAK® was designated by the Ethiopian Ministry of
Health as the confirmatory test in that country’s national rapid testing
algorithm. We have identified and/or appointed distributors in
these and other countries in Africa so that we are positioned to service
those
new markets if we are selected in their national testing protocols. Our focus
is
on those African countries that are receiving funding from PEPFAR and other
large relief programs.
In
November 2006, we received an order for 990,000 units of our Sure Check product
from our distributor in Mexico, a division of Bio-Rad Laboratories, Inc.
This
distribution agreement is the one exception to our otherwise global exclusive
agreement with Inverness as it relates to this product. Approximately one-half
of this order was shipped during the fourth quarter of 2006 and the balance
was
shipped during the first quarter of 2007. Additional orders
were received and shipped during the first and second quarters of 2007 in
the
amount of approximately $600,000. Absent other arrangements, which
are under discussion this exception to Inverness’ global exclusivity will be
eliminated on September 29, 2008.
We
have
established or are establishing distributors in a number of other markets
where
we believe there is or will be a significant market opportunity for our
products.
CHAGAS
RAPID TEST
We
have a
rapid test for the detection of antibodies to Chagas disease. This
product, Chagas STAT-PAK, was developed in collaboration with a consortium
of
leading researchers in Latin America that have granted us an exclusive license
to their recombinant antigens. In January 2006, the Company
received a $1.2 million order from the Pan American Health
Organization to supply its Chagas disease rapid tests for a screening
program in Bolivia. These tests were delivered in the first three
quarters of 2006. The Pan American Health Organization (the “PAHO”),
headquartered in Washington D.C., is affiliated with the WHO, and this
procurement was used to implement a nationwide Chagas screening program for
all
children under the age of 10 in endemic regions of Bolivia. Although
the Company is actively looking at developing additional business opportunities
for this product in those regions of Latin America that are impacted by this
disease, these opportunities must be funded by donors such as the
PAHO. The private commercial market for this disease is very
limited. We do anticipate completing the requirements for
obtaining a CE mark (Community European) for this product, and registration
in Mexico, which may provide additional sales opportunities. This
certification is necessary to obtain CE Markings for our products which are
required in order to sell in most European countries, as well as many other
countries in the world.
Other
Products
In
2007
our facility was licensed by the USDA to manufacture and market two products
for
veterinary tuberculosis. Revenues from these products have not been material
and
the market opportunity for the products approved thus far is limited due
to
certain restrictions placed on sales by the USDA pending further
discussions. The USDA manufacturing facility approval is however very
material to our being able to pursue collaborations to develop and manufacture
other veterinary products on our DPP™ platform that would be
marketed by companies that are engaged in these markets, and we are
actively pursuing such collaborations. We also are involved in the development
of several new products, for our own account and for others pursuant to
existing and pending agreements as described below under “Research and
Development”.
Lateral
Flow Technology
All
of
our commercially available current products employ single path lateral flow
technology. Lateral flow, whether single or dual path, generally refers to
the
process of a sample flowing from the point of application on a test strip
to
provide a test result on a portion of a strip downstream from either the
point
of application of the sample or of another reagent. Single path
lateral flow technology is well established and widely applied in the
development of rapid diagnostic tests. The functionality of our
lateral flow tests is based on the ability of an antibody to bind with a
specific antigen (or vice versa) and for the binding to become visible through
the use of the colloidal gold and/or colored latex that we use in our
products. The colloidal gold or the colored latex produces a colored
line if the binding has occurred (the test line), in which case it means
there
has been a reactive or positive result. In any case, a separate line
(the control line) will appear to confirm that the test has been validly
run in
accordance with the instructions for use.
Our
lateral flow technology, whether single or dual path, allows the development
of
accurate, easy-to-perform, single-use diagnostic tests for rapid, visual
detection of specific antigen-antibody complexes on a test
strip. This format provides a test that is simple (requires neither
electricity nor expensive equipment for test execution or reading, nor skilled
personnel for test interpretation), rapid (turnaround time approximately
15
minutes), safe (minimizes handling of specimens potentially infected),
non-invasive (requires 5-20 micro liters of whole blood easily obtained with
a
finger prick, or alternatively, serum or plasma), stable (24 months at room
temperature storage in the case of our HIV tests), and highly
reproducible. The sensitivity of a test indicates how strong the sample
must be before it can be detected by the test.
The
specificity of a test measures the ability of the test to analyze, isolate,
and
detect only the matters targeted by the test. The sensitivity and
specificity of our rapid HIV tests during our clinical trials undertaken
in
connection with our FDA Pre-Marketing Applications were 99.7% and 99.9%,
respectively.
We
can
develop and produce lateral flow tests that are qualitative
(reactive/non-reactive), as in the case of our HIV tests, and we can develop
semi-quantitative tests, reflecting different concentrations of the target
marker(s) using different colored latex test lines for each
concentration. We can also develop tests for multiple conditions,
using different colored lines. We have developed proprietary
techniques that enable us to achieve high levels of sensitivity and specificity
[see definition above] in our diagnostic tests using our proprietary latex
and
colloidal gold conjugates and buffer systems. These techniques
include the methods we employ in manufacturing and fusing the reagents with
the
colored latex, or colloidal gold, blocking procedures used to reduce false
positives, and methods used in treating the materials used in our tests to
obtain maximum stability and resulting longer shelf life. We also
have extensive experience with a variety of lateral flow devices, including
the
sample collection device used in our SURE CHECK rapid HIV test which eliminates
the need for transferring finger-stick whole blood samples from the fingertip
onto a test device, because the collection of the sample is performed within
a
tubular test chamber that contains the lateral flow test strip. The
whole blood sample is absorbed directly onto the test strip through a small
opening in one end of the test chamber and an absorbent pad positioned just
inside this same end of the test chamber.
On
March
13, 2007, we were issued United States patent number #7,189,522 describing
a
Dual Path Immunoassay system which we believe provides several advantages
over
standard single path lateral flow test systems (See “Intellectual
Property”). We believe that this system, which we refer to as DPP™
(for Dual Path Platform), provides the Company with significant new product
development and licensing opportunities.
During
2007 we entered a collaborative agreement with Alverix, which was formerly
a
business unit of Avago Technologies. Alverix has developed
cost-effective reflectance and fluorescent readers that can objectively measure,
quantify, record and report test results. The readers have been customized
and
private labeled for us to use with our DPP™ cassette. We believe that
combining DPP™ with this reader feature will help to broaden the potential
market applications of DPP™.
Target
Market
Rapid
HIV Tests
We
believe that the September 2006 recommendations by the United States Centers
for
Disease Control (“CDC”) that called for testing for HIV as part of routine
medical care in the United States and that reversed a long standing policy
of
informed consent will drive the demand for testing in the United
States. Similarly, because HIV medicines have become much less
expensive and more widely available, unprecedented multi-billion dollar
financial commitments have been made for prevention, treatment and care.
For example, the largest commitment ever to funding the fight against the
epidemic in Africa and other countries was authorized by President Bush in
2003. This was a five-year, fifteen billion dollar program known as
the President’s Emergency Plan for AIDS Relief, or PEPFAR. PEPFAR is
now expected to be re-authorized for another five years beginning in fiscal
2009. In January 2008, President Bush stated in his State of the
Union Address that PEPFAR “II” should be doubled to $30 billion. On
February 27, 2008, the Foreign Affairs Committee of the United States
House of Representatives approved the reauthorization of PEPFAR in the amount
of
$50 billion. Approval by the U.S. House of Representatives, the
Senate, and President is pending. The other large funding source for HIV
testing, care and treatment is the Global Fund for AIDS, Tuberculosis and
Malaria. This fund is primarily supported by the United States (21.9%
of which is appropriated from PEPFAR), the European community, Japan and
certain
other countries.
According
to UNAIDS, as of the end of 2007, there were an estimated 33.2 million people
living with HIV/AIDS worldwide. There were nearly 2.5 million new infections
in
2007 and 2.1 million AIDS-related deaths in 2007. In order for more infected
individuals to gain access to life-saving treatments, treatments that are
made
increasingly available by PEPFAR and other large bilateral and multilateral
donor funded programs, testing and early detection will need to
increase. Therefore, based upon the treatment goals of PEPFAR and
other large programs, we believe that there will be a funded increasing global
demand for several hundred million rapid HIV tests for the foreseeable future.
The
marketing of our FDA-approved rapid HIV tests in the United States was launched
by Inverness during the first quarter of 2007. In the United States the need
for
rapid HIV tests has been developing first in the public health and hospital
emergency room segments, and also in the physicians’ office
laboratories. There are approximately 20-25 million HIV tests
performed in clinical settings in the United States. Rapid HIV
tests account for approximately 20-25% of this market, or approximately 5-6
million tests. We believe that the total number of HIV tests will
continue to grow, and that the share available to rapid HIV tests will also
grow.
Chagas
Rapid Test
Chagas
disease is endemic only in regions of Latin
America where there are an estimated 16-18 million
existing Chagas disease cases, resulting in approximately 20,000 deaths
annually, and an estimated 300,000 new cases each year. Chagas
disease is transmitted by a parasitic bug which lives in cracks and crevices
of
poor-quality houses usually in rural areas, through blood transfusions or
congenitally from infected mother to fetus. There is an effective
therapy available to treat the early chronic phase, but this therapy only
eliminates the infection if it is administered to children that are diagnosed
with the disease.
Other
Products
Veterinary
Tuberculosis Tests
Tuberculosis
in animal species can become a significant problem either because of potential
transmission to humans, costs in lost agricultural productivity or because
of
the cost of the animal species themselves. For example, nonhuman
primates used in research or in zoos are quite costly, and whole colonies
can be
lost if transmission is not effectively controlled through routine and accurate
diagnosis. In 2007 we received approval from the USDA to manufacture and
market
our single path lateral-flow test for the detection of TB in Non-Human Primates
(PrimaTB STAT-PAK™). The test can use serum, plasma, or whole blood,
is simple and easy to use, has up to a 12-month shelf life at room
temperature (RT) storage, and provides results within 20 minutes. This
compares to the only currently available technology, the eye-lid tuberculin
test, which is inconvenient, subjective, and unreliable.
Marketing
Strategy
Our
marketing strategy is to:
·
|
Support,
review and assess the marketing and distribution efforts of our
rapid HIV
tests by Inverness Medical Innovations, Inc. Inverness, which
is a leading marketer of point of care diagnostic products, has
significantly expanded its distribution footprint since we signed
our
agreement with them, and we believe that this will enhance opportunities
for them to market our rapid HIV tests. In particular, Inverness
has been
very active in acquiring point of care product lines serving hospital
emergency rooms and physicians’
offices.
|
·
|
Leverage
our DPP™ intellectual property and regulated product development and
manufacturing experience to create new collaborations where Chembio
can be
the exclusive development and manufacturing partner with world
class
marketing partners. Beginning with our Cooperative Research Development
Agreement entered into in November 2006 with the United States
Centers for
Disease Control, we have entered several new collaborations related
to
DPP™ that are described below (see “Research &
Development”).
|
·
|
Develop
a small number of Chembio brand DPP™ products that capitalize on the
advantages of this newly patented point of care technology and
select
distribution partners for such
products.
|
Competition
The
diagnostics industry is a multi-billion dollar international industry and
is
intensely competitive. Many of our competitors are substantially
larger and have greater financial, research, manufacturing and marketing
resources.
Industry
competition in general is based on the following:
·
|
Scientific
and technological capability;
|
·
|
The
ability to develop and market products and
processes;
|
·
|
The
ability to obtain FDA or other required regulatory
approvals;
|
·
|
The
ability to manufacture products that meet applicable FDA requirements,
(i.e. FDA’s Quality System Regulations) (see Governmental Regulation
section);
|
·
|
The
ability to manufacture products
cost-effectively;
|
·
|
Access
to adequate capital;
|
·
|
The
ability to attract and retain qualified personnel;
and
|
·
|
The
availability of patent protection.
|
We
believe our scientific and technological capabilities and our proprietary
know-how relating to lateral flow rapid tests, particularly tests for detection
of antibodies to infectious diseases such as HIV and Chagas disease, are
very strong.
Our
ability to develop and market other products is in large measure dependent
on
our having additional resources and/or collaborative
relationships. Some of our product development efforts have been
funded on a project or milestone basis. We believe that our
proprietary know-how in lateral flow technology has been instrumental in
our
obtaining the collaborations we have and that we continue to
pursue. The patent protection that we now have with our Dual Path
Platform™ should enhance our ability to develop more profitable collaborative
relationships and to license out the technology.
We
believe our regulatory achievements are a strong asset for developing new
products collaborations. There are only three companies that have approved
PMA’s
for lateral flow rapid tests, all HIV tests: Trinity Biotech (Ireland), Orasure
Technologies, Inc. (PA) and Chembio. We believe that this is a
significant competitive advantage when considering new products and
collaborations. During 2006 and 2007 we obtained
two CLIA waivers for each of our FDA PMA approved HIV
tests. These products therefore represent two of the four CLIA waived
rapid HIV tests. Also, during 2007 we received facility and product
licenses from the USDA, and became certified under ISO 13.485.This combination
of regulatory credentials is unique.
Our
access to capital is much less than that of several of our competitors, and
this
is a competitive disadvantage. We believe however that our access to
capital may increase if we continue our trend of improved sales and operating
results. Establishment of collaborations for our DPP™ with large
companies should provide us with additional credibility in the investment
community and may also facilitate our access to strategic capital. The
simplification of our capital structure that was completed in December 2007
should also improve our access to capital (See Management’s Discussion and
Analysis of Financial Condition and Results of Operations –
Overview).
To
date,
we believe we have been competitive in the industry in attracting and retaining
qualified personnel. Because of the greater financial resources of
many of our competitors, we may not be able to compete effectively for the
same
individuals to the extent that a competitor uses its substantial resources
to
attract any such individuals.
We
have
been able to obtain patent protection by entering into licensing arrangements
for reagents and lateral flow technologies. The March 2007 issuance by the
United States Patent & Trademark Office of our Dual Path Platform™ patent
gives us our first patent protection on a rapid test platform, which we believe
enhances our competitive position. Additional protection of
this intellectual property is pending worldwide.
Competitive
factors specifically related to our HIV tests are product quality, delivery,
sensitivity, specificity, ease-of-use, shelf life and price. Other
factors can be sample size required, the presence of a true IgG control,
and
time to result. During the last few years, the competitive features
of certain products produced by some international competitors have
improved. In addition, these companies typically have
substantially lower costs of labor, regulatory approval and compliance,
and intellectual property (if any) as compared with Chembio. Price
has therefore become an increasingly important factor, especially for
products based upon the conventional single path lateral flow platform which
are
currently marketed HIV and other tests are based upon.
The
leading competitors in the international rapid HIV test market are Trinity
Biotech (Ireland), Inverness (U.S.) and Standard Diagnostics
(Korea). Uni-Gold HIV®, marketed by Trinity Biotech of Ireland and
Determine®, formerly a Japanese division of Abbott Diagnostics that is now owned
by Inverness, are the market leaders in the developing world , particularly
sub-Saharan Africa which is where most of the funding for rapid HIV tests
is being allocated from donor funded programs such as PEPFAR. Neither
of these products is FDA-approved although Trinity does manufacture in Ireland
an FDA-approved rapid HIV test, Uni-Gold Recombigen, for marketing in the
United
States. Inverness’ Orgenics subsidiary in Israel also has a rapid HIV test,
Double Check Gold as does its subsidiary in China, ABON; neither of these
products is FDA-approved. As such, while Inverness is our exclusive marketing
partner in the United States, it is also the principal competitor to our
rapid
HIV tests outside the United States. Furthermore, in 2007 Trinity Biotech
settled litigation with Inverness, and as part of that settlement it has
contracted with ABON, an Inverness subsidiary, to manufacture the Uni-Gold® HIV
products for marketing outside the United States. Standard
Diagnostics of Korea also has a low-cost product that has been increasingly
competitive against each of the other competitors in the developing
world. There are a number of additional competitors, including
several based in China and India, that produce competitive rapid HIV tests,
though they are not FDA approved. Nevertheless, all of these products
are eligible for procurement under the current PEPFAR USAID waiver program
due
to the fact that there were no FDA-approved products when PEPFAR was originally
authorized several years ago. In order to realize sales in the markets where
the
donor funds are allocated, the product must additionally be selected by a
country’s ministry of health or their designees to be part of a national testing
protocol or “algorithm”. The algorithms typically use multiple rapid
tests in sequence or in parallel to screen and confirm patients at the point
of
care and are increasingly allowing for multiple tests to be qualified in
these
algorithms. Chembio’s sales in Africa and certain other markets are
therefore based on the fact that its test has been one of those
selected. The selection process in each of these countries
is very challenging based upon a number of factors, including but not limited
to
product performance and price.
In
the
developed world, particularly the United States and Europe, the competitive
landscape is quite different. There are only two companies that have
products that are FDA PMA approved and are CLIA-waived: Orasure Technologies
(Bethlehem, PA) with OraQuick®, and Trinity Biotech Ltd. with its
UniGold® Recombigen product (manufactured by Trinity at its facility in
Ireland). The requirements for the PMA and CLIA waiver are difficult,
costly, time-consuming, and represent a competitive advantage. We do not
anticipate that Inverness has any plan to submit any of its products
produced outside the U.S. to the FDA. Further, our agreements with
Inverness provide that in the event one of those submissions is made (or if
Inverness markets a competitive product in the United States), we have the
right
to terminate our agreement with Inverness or make Inverness’ marketing rights
non-exclusive. In either case, we would retain a license under the
Inverness lateral flow patents to market the products under a Chembio brand
and/or through third party distribution partners.
The
comparative competitive features of Chembio’s products (marketed under
Inverness’ Clearview® brand in the U.S.) in comparison to the other FDA PMA
approved and CLIA-waived products are shown below.
|
|
Chembio
|
|
Orasure
|
|
Trinity
|
No.
of Rapid Test Formats FDA PMA approved and CLIA
waived
|
|
2
|
|
1
|
|
1
|
Sensitivity
|
|
99.7%
|
|
99.6%*
|
|
100.0%
|
Specificity
|
|
99.9%
|
|
99.9%
|
|
99.7%
|
Analyte(s)
|
|
HIV
1&2
|
|
HIV
1&2
|
|
HIV1
|
Format(s)
|
|
Standard
SPLF Cassette & Proprietary Unitized Barrel
Format
|
|
Oral
fluid Swab connected to Standard SPLF Cassette
|
|
Standard
SPLF Cassette
|
Sample
Types
|
|
Plasma,
Serum, Venous Whole Blood, Fingerstick Whole
Blood
|
|
Plasma,
Oral Fluid, Serum, Venous Whole Blood, Fingerstick Whole
Blood
|
|
Plasma,
Serum, Venous Whole Blood, Fingerstick Whole
Blood
|
Sample
Size
|
|
~5
microliters
|
|
~5
microliters
|
|
~50
microliters
|
U.S.
Pricing
|
|
$7-$13
|
|
$11.50-$20
|
|
$7.50-$20
|
Estimated
US Market Share
|
|
<5%
|
|
75%
|
|
15%
|
US
Marketing Partner
|
|
Inverness
|
|
Abbott
& Direct
|
|
Direct
|
True
IgG Control
|
|
Yes
|
|
Yes
|
|
No
|
Shelf
Life
|
|
24
mos.
|
|
6
mos.
|
|
12
mos.
|
*
Orasure sensitivity on oral fluid are lower
|
|
|
|
|
Orasure
has a dominant market share in the United States market. Orasure’s main
advantage is that its test was first to market and that, for certain market
segments (primarily public health), the fact that it can be performed with
oral
fluid samples is an attractive feature. Orasure’s Oraquick product’s
main disadvantages are its price, limited shelf life, that it is more difficult
to use with whole blood samples, and that it is not approved for use with
serum
samples. Also, Orasure’s claimed sensitivity with oral fluid samples
is lower, and there have been some reports of performance problems on oral
fluid
samples. Orasure markets its products directly through its own sales
organization to the public health market, has made a significant investment
in
that market, and has nearly 100% of this market with its oral fluid
test. Orasure has an exclusive marketing arrangement with Abbott
Diagnostics for its sales effort to the hospital market.
The
Uni-Gold product that is marketed by Trinity accounts for an estimated 15%
of
the market. This product does not detect HIV-2. Though HIV-2 is a
rare strain of HIV, there have been more cases identified of
late. Trinity’s product also requires a much larger sample size, and
does not have a true IgG control. This means that a control line,
which is intended to confirm that the test procedure has been performed
correctly, will appear on their product so long as any liquid material is
applied to its sampling area; Chembio’s (and Orasure’s) control line will appear
only if a biological sample is applied. Trinity also relies on its
own sales force to market is product, and does not have any other rapid tests
to
sell to distributors.
We
believe Chembio, through its marketing agreement with Inverness, is well
positioned to compete for market share against these two US market competitors,
at least in the hospital and physicians’ office market. Inverness has made a
significant investment in its launch of our products and we believe this
is a
very important product for Inverness in the United States market. The
shelf life of our HIV products’ is 24 months, which is double that of Uni-Gold
and four times that of Orasure’s product. Our products have been
approved by the FDA for finger-stick whole blood, venous whole blood, serum
and
plasma. We believe that our products are extremely convenient and easier
to use
than OraQuick on finger-stick whole blood samples.
Chembio’s
HIV Tests
One
of
our two product formats, the “barrel” format now marketed by Inverness as
Clearview® Complete HIV 1-2, is a unique product format and is a unitized
product (meaning that all components necessary to perform a single test are
contained in a single pouch). The “barrel” has a proprietary method of
collecting finger-stick whole blood samples that eliminates the need for
a
transfer loop or other device to transfer the sample from the fingertip to
the
sample well. Also, the buffer solution is in a unitized vial that is
pierced by the barrel tip to initiate the sample migration up the test strip
contained inside the “barrel”, and thereby creates a closed system that helps to
minimize possible exposure to potentially infectious samples. The
“barrel” product did not receive the CLIA waiver until October 22, 2007 so sales
of this product were nominal in 2007. We anticipate that sales of this
format will increase in 2008.
Our
other
FDA PMA approved rapid HIV test, marketed by Inverness as Clearview® HIV 1-2
STAT PAK®, is a standard lateral flow plastic cassette format wherein the sample
is transferred to the sample port in the cassette by means of a transfer
loop. Though this step is not required in the barrel format, the
cassette is less costly to manufacture, is more familiar to customers that
have
performed other lateral flow tests, and is a more flexible format that utilizes
the same procedure for all approved sample matrices (venous whole blood,
finger-stick whole blood, serum and plasma). To date this format has accounted
for almost all of the sales we have had through Inverness.
We
are
currently pursuing certain improvements and amendments to the cassette and
barrel formats which, if successfully completed, could enhance their
marketability. These items include lowering of the lower age limits
(currently the lower age limit is 18) of individuals that the tests are approved
for. We anticipate completing the testing requirements for this
amendment during the first quarter, and approval of the amendment by the
FDA
before the end of the second quarter.
Research
and Development
During
2007 and 2006, $1.9 million and $1.4 million, respectively, was spent on
research and development activities. Substantially all of our new
product development activities involve employment of our Dual Path Platform
(DPP™) technology for which we were awarded a U.S patent in 2007. We
believe that this platform enables us to pursue many new product development
and
licensing opportunities, and we have developed a dual path strategy for doing
this. The DPP™ can provide improved features on certain tests developed
with it that include higher sensitivity, earlier detection, use of multiple
sample types including oral fluid, and improved ability to detect multiple
analytes (multi-plexing) in one test device. We have completed
several studies that confirm this and we are currently conducting a pre-clinical
trial on our DPP™ HIV test for use with oral fluid. We also believe
tests developed on our DPP™ platform, such as our oral fluid HIV test, will be
simple for untrained users to perform, thereby enabling CLIA waiver
for such a product.
We
currently have the following products in development on the
DPP:
Technology
Transfer and Supply Agreements with Bio-Manguinhos
On
January 29, 2008 we signed three new technology transfer, supply and license
agreements with the Bio-Manguinhos unit of the Oswaldo Cruz Foundation of
Brazil
for products being developed by Chembio with its patented DPP™
technology. Previously, in 2004, Bio Manguinhos and Chembio entered
into a similar agreement concerning one of Chembio’s HIV rapid
tests.
Two
of
the products being developed will be used in screening programs funded by
Brazil’s Ministry of Health for the control and eradication of Leishmaniasis and
Leptospirosis, respectively, which are both blood-borne infectious diseases
that
are endemic to Brazil. A third test being developed is for the
confirmation of HIV-1 in patients who have tested positive with a screening
test. Bio-Manguinhos, also known as the Immunobiological Technology Institute,
is the largest producer of vaccines and kits for diagnosis of infectious
and
parasitic diseases in Latin America. Chembio’s DPP™ test platform was selected
for the screening programs because of its high sensitivity and specificity
of
prototypes evaluated by Bio-Manguinhos and because of the unique multiplexing
capabilities of DPP™ for the confirmatory assay. The DPP™
point-of-care screening tests will complement the current Bio-Manguinhos
national program, which currently only uses laboratory-based technologies.
The
HIV confirmatory test will allow for the simultaneous binding and uniform
delivery of samples to multiple HIV antigens printed in the detection zone,
providing results equivalent to Western blot in a simple point-of-care format
that provides results within 20 minutes. Under the new agreements, once the
products meet mutually agreed-upon performance specifications and are approved
for sale in Brazil, Chembio will receive a minimum purchase order for at
least
one million tests within a one-year period. Thereafter, the agreement allows
for
production of the products to be transferred to Brazil, subject to certain
royalty payments.
Based
upon the initial prototypes we have developed for each of these products,
we
anticipate that these products will be successfully developed in accordance
with
the agreed-upon specifications. Also, based upon our experience with
Bio-Manguinhos through the earlier agreement, we anticipate that the other
aspects of our agreement will be successful, though there can be no assurance
that this will in fact occur.
Cooperative
Research & Development Agreement with the CDC for Syphilis
Test
In
November 2006 we signed a Cooperative Research and Development Agreement
(CRADA)
with the United States Centers for Disease Control and Prevention to develop
a
rapid combination test for syphilis, capable of detecting treponemal and
non-treponemal antibodies in the same device, utilizing Chembio’s Dual Path
Platform (DPP™) technology and the CDC’s patented Syphilis
antigens. This test could serve both as a screening and
confirmatory test in a point-of-care setting.
Syphilis
is a sexually transmitted disease (STD) caused by the bacterium Treponema
pallidum. Infection rates have been on the increase lately; worldwide, 12
million individuals are diagnosed with syphilis each year and are at increased
risk of becoming infected with and transmitting HIV. In addition, syphilis
can
be transmitted from an infected woman to her unborn child during pregnancy.
Early and appropriate diagnosis and treatment prevents infection of the child
and development of severe complications.
The
difficulty in following up with patients who have undergone syphilis testing
in
a variety of settings and testing for syphilis in many prenatal settings
are
major obstacles to effective syphilis control. The development of a
rapid, point-of-care test, that combines the sensitivity of a screening test
with the specificity of a confirmatory test is important in aiding clinicians
to
provide appropriate treatment at an initial clinic
visit.
While
development work continues with good progress, there can be no assurance
that a
product will be successfully developed and/or successfully
commercialized.
We
have
several other DPP™ research and development projects in various stages,
including products that we are or may be developing under contract for third
party marketing partners. There can be no assurance that any of these
projects will result in completed products or that such products, if
successfully completed, will be successfully commercialized.
Employees
At
December 31, 2007, we employed 109 people, including 97 full-time
employees. Effective May 2006, we entered into an employment
agreement with Lawrence Siebert, President and Chairman. Effective
March 2007, we entered into an employment agreement with Javan Esfandiari,
Executive Vice-President of Research and Development.
Governmental
Regulation
The
manufacturing and marketing of the Company’s existing and proposed diagnostic
products are regulated by the United States Food and Drug Administration
(“FDA”), United States Department of Agriculture (“USDA”), certain state and
local agencies, and/or comparable regulatory bodies in other
countries. These regulations govern almost all aspects of
development, production and marketing, including product testing, authorizations
to market, labeling, promotion, manufacturing and record keeping. The
Company’s FDA and USDA regulated products require some form of action by each
agency before they can be marketed in the United States, and, after approval
or
clearance, the Company must continue to comply with other FDA requirements
applicable to marketed products, e.g. CLIA regulations (for medical
devices). Failure to comply with the FDA’s requirements can lead to
significant penalties, both before and after approval or clearance.
Most
of
the Company’s diagnostic products are regulated as medical devices, and some are
regulated as biologics. There are two review procedures by which
medical devices can receive FDA clearance or approval. Some products
may qualify for clearance under Section 510(k) of the Federal Food, Drug
and
Cosmetic Act, in which the manufacturer provides a pre-market notification
that
it intends to begin marketing the product, and shows that the product is
substantially equivalent to another legally marketed product (i.e., that
it has
the same intended use and is as safe and effective as a legally marketed
device
and does not raise different questions of safety and
effectiveness). In some cases, the submission must include data from
human clinical studies. Marketing may commence when the FDA issues a
clearance letter finding such substantial equivalence. An applicant
must submit a 510(k) application at least 90 days before marketing of the
affected product commences. Although FDA clearance may be granted
within that 90-day period, in some cases as much as a year or more may be
required before clearance is obtained, if at all.
If
the
medical device does not qualify for the 510(k) procedure (either because
it is
not substantially equivalent to a legally marketed device or because it is
required by statute and the FDA’s implementing regulations to have an approved
application), the FDA must approve a pre-market approval (PMA) application
before marketing can begin. Pre-market approvals must demonstrate,
among other matters, that the medical device provides a reasonable assurance
of
safety and effectiveness. A pre-market approval is typically a
complex submission, including the results of preclinical and clinical
studies. Preparing a pre-market approval is a much more expensive,
detailed and time-consuming process as compared with a 510(K) pre-market
notification. Once a pre-market approval has been submitted, the FDA is
required to review the submission within a statutory period of
time. However, the FDA’s review may be, and often is, much longer,
often requiring one year or more, and may include requests for additional
data. The Company has approved PMAs for the two rapid HIV tests now
marketed by Inverness Medical as Clearview® Complete HIV 1-2 and Clearview® HIV
1-2 STAT PAK®.
Every
company that manufactures medical devices distributed in the United States
must
comply with the FDA’s Quality System Regulations. These regulations
govern the manufacturing process, including design, manufacture, testing,
release, packaging, distribution, documentation and
purchasing. Compliance with the Quality System Regulations is
required before the FDA will approve an application, and these requirements
also
apply to marketed products. Companies are also subject to other
post-market and general requirements, including compliance with restrictions
imposed on marketed products, compliance with promotional standards, record
keeping and reporting of certain adverse reactions or events. The FDA
regularly inspects companies to determine compliance with the Quality System
Regulations and other post-approval requirements. Failure to comply
with statutory requirements and the FDA’s regulations can lead to substantial
penalties, including monetary penalties, injunctions, product recalls, seizure
of products, and criminal prosecution.
The
Clinical Laboratory Improvement Act of 1988 (“CLIA”) prohibits laboratories from
performing in vitro tests for the purpose of providing information for the
diagnosis, prevention or treatment of any disease or impairment of, or the
assessment of, the health of human beings unless there is in effect for such
laboratories a certificate issued by the United States Department of Health
and
Human Services (via the FDA) applicable to the category of examination or
procedure performed. Although a certificate is not required for the
Company, it considers the applicability of the requirements of CLIA in the
design and development of its products. The statutory definition of
“laboratory” is very broad, and many of our customers are considered
labs. A CLIA waiver will remove certain quality control and other
requirements that must be met for certain customers to use the Company’s
products and this is in fact critical to the marketability of a product into
the
point of care diagnostics market. The Company has received a
CLIA waiver for each of the two rapid HIV tests now marketed by Inverness
Medical as Clearview® Complete HIV 1-2 and Clearview® HIV 1-2 STAT
PAK®. The CLIA waiver was granted by the FDA for HIV 1-2 STAT-PAK on
November 20, 2006 and for the Clearview® Complete HIV 1-2 on October 22,
2007.
In
addition, the FDA regulates the export of medical devices that have not been
approved for marketing in the United States. The Federal Food, Drug
and Cosmetic Act contains general requirements for any medical device that
may
not be sold in the United States and is intended for
export. Specifically, a medical device intended for export is not
deemed to be adulterated or misbranded if the product: (1) complies with
the
specifications of the foreign purchaser; (2) is not in conflict with the
laws of
the country to which it is intended for export; (3) is prominently labeled
on
the outside of the shipping package that it is intended for export; and (4)
is
not sold or offered for sale in the United States. Some medical
devices face additional statutory requirements before they can be
exported. If an unapproved device does not comply with an applicable
performance standard or pre-market approval requirement, is exempt from either
such requirement because it is an investigational device, or is a banned
device,
the device may be deemed to be adulterated or misbranded unless the FDA has
determined that exportation of the device is not contrary to the public health
and safety and has the approval of the country to which it is intended for
export. However, the Federal Food, Drug and Cosmetic Act does
permit the export of devices to any country in the world, if the device complies
with the laws of the importing country and has valid marketing authorization
in
one of several “listed” countries under the theory that these listed countries
have sophisticated mechanisms for the review of medical devices for safety
and
effectiveness.
The
Company is also subject to regulations in foreign countries governing products,
human clinical trials and marketing, and may need to obtain approval or
evaluations by international public health agencies, such as the World Health
Organization, in order to sell diagnostic products in certain
countries. Approval processes vary from country to country, and the
length of time required for approval or to obtain other clearances may in
some cases be longer than that required for United States governmental
approvals. On the other hand, the fact that our HIV diagnostic tests are
of
value in the AIDS epidemic may lead to some government process being
expedited. The extent of potentially adverse governmental regulation
affecting Chembio that might arise from future legislative or administrative
action cannot be predicted.
One
or
more of the Company’s rapid HIV tests are also approved for marketing in several
foreign jurisdictions, including but not limited to Brazil, Mexico, India
and a
number of other nations in the developing world.
In
2007
Chembio received certification under ISO 13.485:2003. ISO
(International Organization for Standardization) is the world's largest
developer and publisher of International Standards. It is comprised of a
network
of the national standards institutes of 155 countries, one member per country,
with a Central Secretariat in Geneva, Switzerland, that coordinates the system.
ISO 13485:2003, in particular, specifies requirements for a quality management
system where an organization needs to demonstrate its ability to provide
medical
devices and related services that consistently meet customer requirements
and
regulatory requirements applicable to medical devices and related services.
The
primary objective of ISO 13485:2003 is to facilitate harmonized medical device
regulatory requirements for quality management systems. ISO 13.485:2003 is
the
quality system that is most recognized globally, including throughout the
European Community for products seeking a CE mark. Chembio has
engaged a European Notified Body and Authorized Representative in connection
with its plans to obtain a CE mark for its products.
Environmental
Laws
To
date,
we have not encountered any costs relating to compliance with any environmental
laws.
Intellectual
Property
Intellectual
Property Strategy
Our
intellectual property strategy is to: (1) build our owned
intellectual property portfolio around our Dual Path Platform technology;
(2)
pursue licenses, trade secrets and know-how within the area of lateral flow
technology and DPP™; and (3) develop and acquire proprietary positions to
reagents and new hardware platforms for the development and manufacture of
rapid
diagnostic tests.
Trade
Secrets and Know-How
We
believe that we have developed a substantial body of trade secrets and know-how
relating to the development of lateral flow diagnostic tests, including but
not
limited to the sourcing and optimization of materials for such tests, and
how to
maximize sensitivity, speed-to-result, specificity, stability and
reproducibility. The Company possesses proprietary know-how to develop
tests for multiple conditions using colored latex. Our buffer
formulations enable extremely long shelf lives of our rapid HIV tests and
we
believe that this provides us with an important competitive
advantage.
Lateral
Flow Technology and Reagent Licenses
Prior
to
the issuance of our United States patent covering our Dual Path Platform
(DPP™),
we owned no issued patents covering lateral flow
technology. Therefore we obtained non-exclusive licenses from
Inverness Medical Innovations, Inc. and Abbott Laboratories with respect
to
their portfolios of single path lateral flow patents. Although we
believe our DPP™ is outside of the scope of single path lateral flow patents, we
consult with patent counsel, and seek licenses and/or redesigns of products
that
we believe to be in the best interests of the Company and our
stockholders. Because of the costs and other negative consequences of
time-consuming patent litigation, we often attempt to obtain a license on
reasonable terms. Nevertheless there is no assurance that Abbott’s
and/or Inverness’ lateral flow patents will not be challenged or that other
patents containing claims relevant to the Company’s products will be not be
granted and that licenses to such patents if any will be available on reasonable
terms, if any.
In
the
event that it is determined that a license is required and it is not possible
to
negotiate a license agreement under a necessary patent, we may be able to
modify
the applicable product such that a license would not be necessary. However,
this
alternative could delay or limit our ability to sell these products in the
United States and/or other markets, and/or increase penalties all of which
would adversely affect our results of operations, cash flows and
business.
The
DPP™
technology provides improved sensitivity as compared with conventional platforms
in a number of preliminary studies using well characterized HIV, Tuberculosis
and other samples. The Company anticipates signing new development projects
based upon these new technologies in the near future that will provide new
product applications and marketing opportunities. We have also filed
two patents relating to our veterinary tuberculosis rapid tests and improvements
to the sample collection method in our “barrel” (SURE CHECK) device which is one
of the formats which Inverness is marketing.
The
peptides used in our rapid HIV tests are patented by Adaltis Inc. and are
licensed to us under a 10-year non-exclusive license agreement dated August
30,
2002, which was recently amended to reduce the royalty rate. We also
have licensed the antigens used in our tuberculosis and Chagas disease
tests. In prior years we concluded license agreements related to
intellectual property rights associated with HIV- 1, and during the first
quarter of 2008 we entered into a license agreement for HIV-2.
Corporate
History
On
May 5,
2004, we completed a merger with Chembio Diagnostic Systems Inc. through
which
Chembio Diagnostics Systems Inc. became our wholly-owned subsidiary, and
through
which the management and business of Chembio Diagnostic Systems Inc. became
our
management and business. As part of this transaction, we changed our
name to Chembio Diagnostics, Inc. In 2003, we had sold our prior
business, and as a result, we had no specific business immediately prior
to the
merger.
Since
the
formation of Chembio Diagnostic Systems Inc. in 1985, it has been involved
in
developing, manufacturing, selling and distributing in-vitro diagnostic tests,
including rapid tests beginning in 1995, for a number of conditions in humans
and animals.
On
March
12, 2004, we implemented a 1-for-17 reverse split of our common
stock. All references in this Form 10-KSB to shares of our common
stock have been adjusted to reflect this reverse split.
Glossary
AIDS
|
Acquired
Immunodeficiency Syndrome. AIDS is caused by the Human
Immunodeficiency Virus, HIV.
|
ALGORITHM |
For
rapid HIV testing this refers both to method or protocol for using
rapid
tests from different manufacturers in combination to screen and confirm
patients at the point of care, and may also refer to the specific
tests
that have been selected by an agency or ministry of health to be
used in
this way. |
ANTIBODY
|
A
protein which is a natural part of the human immune system produced
by
specialized cells to neutralize antigens, including viruses and
bacteria
that invade the body. Each antibody producing cell manufactures
a unique antibody that is directed against, binds to and eliminates
one,
and only one, specific type of antigen.
|
ANTIGEN
|
Any
substance which, upon entering the body, stimulates the immune
system
leading to the formation of antibodies. Among the more common antigens
are
bacteria, pollens, toxins, and viruses.
|
ARVs
|
Anti-Retroviral
Treatments for AIDS
|
CD-4
|
The
CD4+ T-lymphocyte is the primary target for HIV infection because
of the
affinity of the virus for the CD4 surface marker. Measures of
CD4+ T-lymphocytes are used to guide clinical and therapeutic management
of HIV-infected persons.
|
CDC
|
United
States Centers for Disease Control and Prevention
|
CHAGAS
DISEASE
|
Chagas
disease is an infection caused by the parasite Trypanosoma cruzi.
Worldwide, it is estimated that 16 to 18 million people are infected
with
Chagas disease; of those infected, 50,000 will die each
year.
|
CHAI
|
Clinton
HIV/AIDS Initiative
|
CLIA
|
Clinical
Laboratory Improvement Act
|
DIAGNOSTIC
|
Pertaining
to the determination of the nature or cause of a disease or
condition. Also refers to reagents or procedures used in
diagnosis to measure proteins in a clinical sample.
|
EITF
|
Emerging
Issues Task Force
|
FASB
|
Financial
Accounting Standards Board
|
FDA
|
United
States Food and Drug Administration
|
FDIC
|
Federal
Deposit Insurance Corporation
|
HIV
|
Human
Immunodeficiency Virus. HIV (also called HIV-1), a retrovirus,
causes AIDS. A similar retrovirus, HIV-2, causes a variant
disease, sometimes referred to as West African AIDS. HIV
infection leads to the destruction of the immune
system.
|
IgG
|
IgG
or Immunoglobulin are proteins found in human blood. This protein
is
called an “antibody” and is an important part of the body’s defense
against disease. When the body is attacked by harmful bacteria
or viruses,
antibodies help fight these invaders.
|
MOH
|
Ministry
of Health
|
MOU
|
Memoranda
of Understanding
|
NGO
|
Non-Governmental
Organization
|
OTC
|
Over-the-Counter
|
PEPFAR
|
The
President’s Emergency Plan for AIDS Relief
|
PMA
|
Pre-Marketing
Approval
|
PROTOCOL
|
A
procedure pursuant to which an immunodiagnostic test is performed
on a
particular specimen in order to obtain the desired
reaction.
|
REAGENT
|
A
chemical added to a sample under investigation in order to cause
a
chemical or biological reaction which will enable measurement or
identification of a target substance.
|
RETROVIRUS
|
A
type of virus which contains the enzyme Reverse Transcriptase and
is
capable of transforming infected cells to produce diseases in the
host
such as AIDS.
|
Ryan
White CARE Act
|
The
Ryan White Comprehensive AIDS Resources Emergency (CARE) Act is
Federal
legislation that addresses the unmet health needs of persons living
with
HIV disease by funding primary health care and support services.
The CARE
Act was named after Ryan White, an Indiana teenager whose courageous
struggle with HIV/AIDS and against AIDS-related discrimination
helped
educate the nation.
|
SAB
|
Staff
Accounting Bulletin
|
SENSITIVITY
|
Refers
to the ability of an assay to detect and measure small quantities
of a
substance of interest. The greater the sensitivity, the smaller
the
quantity of the substance of interest the assay can
detect. Also refers to the likelihood of detecting the antigen
when present.
|
SFAS
|
Statement
of Financial Accounting Standards
|
SPECIFICITY
|
The
ability of an assay to distinguish between similar
materials. The greater the specificity, the better an assay is
at identifying a substance in the presence of substances of similar
makeup.
|
SPUTUM
|
Expectorated
matter; saliva mixed with discharges from the respiratory
passages
|
TB
|
Tuberculosis
(TB) is a disease caused by bacteria called Mycobacterium tuberculosis.
The bacteria usually attack the lungs. But, TB bacteria can attack
any
part of the body such as the kidney, spine, and brain. If not treated
properly, TB disease can be fatal. TB is spread through the air
from one person to another. The bacteria are put into the air when
a
person with active TB disease of the lungs or throat coughs or
sneezes.
People nearby may breathe in these bacteria and become
infected.
|
UNAIDS
|
Joint
United Nations Program on HIV/AIDS
|
USAID
|
United
States Agency for International Development
|
USDA
|
U.S
Department of Agriculture
|
WHO
|
World
Health Organization
|
ITEM
2.
|
DESCRIPTION
OF PROPERTY
|
Our
administrative offices and research facilities are located in Medford, New
York. We lease approximately 16,640 square feet of industrial space
for $10,680 per month. The space is utilized for research and
development activities (approximately 2,600 square feet), offices (approximately
4,040 square feet) and production (approximately 10,000 square
feet). The lease term expires on April 30, 2009, and the Company has
an option to renew for an additional two
years. Additional space may be required as we expand our
research and development activities. We do not foresee any
significant difficulties in obtaining any required additional
facilities.
ITEM
3.
|
LEGAL
PROCEEDINGS
|
From
time
to time, we may be involved in litigation relating to claims arising out
of our
operations in the normal course of business. We know of no material,
existing or pending legal proceedings against us, nor are we involved as
a
plaintiff in any material proceeding or pending litigation. There are
no proceedings in which any of our directors, officers or affiliates, or
any
registered or beneficial shareholder, is an adverse party or has a material
interest that is adverse to our interest.
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
Please
refer to the description of the Company’s equity simplification plan in Note 1
to the Financial Statements for a description of matters submitted to a vote
of
the holders of the Company’s preferred stock and warrants and options not
including options or warrants issued to employees or directors in their capacity
as such.
PART
II
ITEM
5.
|
MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS AND SMALL BUSINESS
ISSUER PURCHASES OF EQUITY
SECURITIES
|
Market
Information
Our
common stock is quoted on the OTC Bulletin Board under the symbol
“CEMI.” The table below sets forth the high and low bid prices per
share of our common stock for each quarter of our two most recently completed
fiscal years. These prices represent inter-dealer quotations without
retail markup, markdown, or commission and may not necessarily represent
actual
transactions.
Fiscal
Year 2007
|
High
Bid
|
Low
Bid
|
First
Quarter
|
$0.93
|
$0.61
|
Second
Quarter
|
$0.65
|
$0.47
|
Third
Quarter
|
$0.65
|
$0.37
|
Fourth
Quarter
|
$0.57
|
$0.26
|
|
|
|
Fiscal
Year 2006
|
High
Bid
|
Low
Bid
|
First
Quarter
|
$0.75
|
$0.33
|
Second
Quarter
|
$1.15
|
$0.65
|
Third
Quarter
|
$0.85
|
$0.68
|
Fourth
Quarter
|
$0.92
|
$0.63
|
Rule
15g-9 of the Securities and Exchange Commission, known as the Penny Stock
Rule,
imposes requirements on broker/dealers who sell securities subject to the
rule
to persons other than established customers and accredited
investors. For transactions covered by the rule, brokers/dealers must
make a special suitability determination for purchasers of the securities
and
receive the purchaser’s written agreement to the transaction prior to
sale. The Securities and Exchange Commission also has rules that
regulate broker/dealer practices in connection with transactions in “penny
stocks.” Penny stocks generally are equity securities with a price of
less than $5.00 (other than securities registered on certain national securities
exchanges or quoted on the NASDAQ system, provided that current price and
volume
information with respect to transactions in that security is provided by
the
exchange or system), except for securities of companies that have tangible
net
assets in excess of $2,000,000 or average revenue of at least $6,000,000
for the
previous three years. The Penny Stock Rule requires a broker/ dealer,
prior to a transaction in a penny stock not otherwise exempt from the rules,
to
deliver a standardized risk disclosure document prepared by the Commission
that
provides information about penny stocks and the nature and level of risks
in the
penny stock market. The broker/dealer also must provide the customer
with current bid and offer quotations for the penny stock, the compensation
of
the broker/dealer and its salesperson in the transaction, and monthly account
statements showing the market value of each penny stock held in the customer’s
account. The bid and offer quotations, and the broker/dealer and
salesperson compensation information, must be given to the customer orally
or in
writing prior to effecting the transaction and must be given to the customer
in
writing before or with the customer’s confirmation. These disclosure
requirements have the effect of reducing the level of trading activity in
the
secondary market for penny stock issues. As a result of these rules,
investors sometimes find it difficult to sell shares of penny stock
issuers. At the present time, transactions in our common stock are
not subject to the Penny Stock Rule because our average revenue for 2005,
2006
and 2007 exceeded $6 million per year. However, there can be no
assurance that transactions in our common stock will not be subject to the
Penny
Stock Rule in the future.
Holders
As
of
January 29, 2008, there were approximately 905 record owners of our common
stock.
Dividends
The
Company has never paid cash dividends on its common stock and has no plans
to do
so in the foreseeable future. Our future dividend policy will be
determined by our board of directors and will depend upon a number of factors,
including our financial condition and performance, our cash needs and expansion
plans, income tax consequences, and the restrictions that applicable laws,
our
current preferred stock instruments, and our future credit arrangements may
then
impose.
Currently
under Nevada law, a dividend may not be made by a corporation if, after giving
it effect:
·
|
the
corporation would not be able to pay its debts as they become due
in the
usual course of business; or
|
·
|
except
as otherwise specifically allowed by the corporation’s articles of
incorporation, the corporation’s total assets would be less than the sum
of its total liabilities plus the amount that would be needed,
if the
corporation were to be dissolved at the time of distribution, to
satisfy
the preferential rights upon dissolution of stockholders whose
preferential rights are superior to those receiving the
distribution.
|
Equity
Compensation Plan Information
Equity
Compensation Plan Information as of December 31,
2007
|
|
Number
of Securities to be Issued Upon Exercise of Outstanding Options,
Warrants
and Rights
|
Weighted-Average
Exercise Price of Outstanding Options, Warrants and
Rights
|
Number
of Securities Remaining Available for Future Issuance under Equity
Compensation Plans (Excluding Securities Reflected in Column
(a))
|
|
(a)
|
(b)
|
(c)
|
Equity
compensation plans approved by security holders
|
2,201,500
|
$0.64
|
433,500
|
Equity
compensation plans not approved by security holders
|
--
|
--
|
--
|
Total
|
2,201,500
|
$0.64
|
433,500
|
ITEM
6.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
Overview
This
discussion and analysis should be read in conjunction with the accompanying
Consolidated Financial Statements and related notes. Our discussion
and analysis of our financial condition and results of operations are based
upon
our consolidated financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States. The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities,
disclosure of any contingent liabilities at the financial statement date
and
reported amounts of revenue and expenses during the reporting period. On
an
on-going basis we review our estimates and assumptions. Our estimates were
based
on our historical experience and other assumptions that we believe to be
reasonable under the circumstances. Actual results are likely to differ from
those estimates under different assumptions or conditions, but we do not
believe
such differences will materially affect our financial position or results
of
operations. Our critical accounting policies, the policies we believe are
most
important to the presentation of our financial statements and require the
most
difficult, subjective and complex judgments, are outlined below in ‘‘Critical
Accounting Policies,’’ and have not changed significantly.
In
addition, certain statements made in this report may constitute “forward-looking
statements”. These forward-looking statements involve known or
unknown risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied
by the
forward-looking statements. Specifically, 1) our ability to obtain necessary
regulatory approvals for our products; and 2) our ability to increase revenues
and operating income, is dependent upon our ability to develop and sell our
products, general economic conditions, and other factors. You can identify
forward-looking statements by terminology such as “may,” “could”, “will,”
“should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential,” “continues” or the negative of these terms or other
comparable terminology. Although we believe that the expectations reflected-in
the forward-looking statements are reasonable, we cannot guarantee future
results, levels of activity, performance or achievements.
Except
as
may be required by applicable law, we do not undertake or intend to update
or
revise our forward-looking statements, and we assume no obligation to update
any
forward-looking statements contained in this report as a result of new
information or future events or developments. Thus, you should not
assume that our silence over time means that actual events are bearing out
as
expressed or implied in such forward-looking statements. You should
carefully review and consider the various disclosures we make in this report
and
our other reports filed with the Securities and Exchange Commission that
attempt
to advise interested parties of the risks, uncertainties and other factors
that
may affect our business.
The
following management discussion and analysis relates to the business of the
Company and its subsidiaries, which develop, manufacture, and market rapid
diagnostic tests that detect infectious diseases. The Company’s main products
presently commercially available are three rapid tests for the detection
of HIV
antibodies in whole blood, serum and plasma samples, two of which were approved
by the FDA in 2006; the third is sold for export only. These products
all employ single path lateral flow technology. The Company
also has a rapid test for Chagas disease (a parasitic disease endemic in
Latin
America) as well as a line of rapid tests for tuberculosis, including tests
for
tuberculosis in animals which is USDA approved. The Company’s
products are sold to medical laboratories and hospitals, governmental and
public
health entities, non-governmental organizations, medical professionals and
retail establishments. Chembio’s products are sold either under the Company’s
STAT-PAK® or SURE CHECK® registered trademarks or under the private labels of
its marketing partners, such as is the case with the Clearview® label owned by
Inverness Medical Innovations, Inc., which is the Company’s exclusive marketing
partner for its rapid HIV test products in the United States.
Recent
Events
On
December 19, 2007 (the “Closing Date”) amendments to the governing documents for
the Company’s Series A, Series B and Series C Convertible Preferred Stock
(collectively, the “Preferred Stock”) and for certain warrants and options
(collectively, the “Non-Employee Warrants”) not including options or warrants
issued to employees or directors in their capacity as such (these actions
collectively, the “Plan”) were approved by the Company and the requisite
percentages of the holders of the Preferred Stock and of the Non-Employee
Warrants. Subsequent to these amendments, among other matters, all the
Preferred Stock and certain of the Non-Employee Warrants were converted to
shares of the Company’s common stock. A description of the terms of
the Plan is included in Note 1 to the consolidated financial statements in
Part
II, Item 7 of this Form 10-KSB.
RESULTS
OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2007 AS COMPARED WITH THE YEAR
ENDED DECEMBER 31, 2006
Revenues
Selected
Product Categories:
|
|
For
the years ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
HIV
|
|
$ |
7,927,676
|
|
|
$ |
4,434,432
|
|
|
$ |
3,493,244
|
|
|
|
78.78 |
% |
Chagas
|
|
|
67,888
|
|
|
|
1,216,794
|
|
|
|
(1,148,906 |
) |
|
|
-94.42 |
% |
Other
|
|
|
769,313
|
|
|
|
642,786
|
|
|
|
126,527
|
|
|
|
19.68 |
% |
Net
Sales
|
|
|
8,764,877
|
|
|
|
6,294,012
|
|
|
|
2,470,865
|
|
|
|
39.26 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
grant income
|
|
|
466,071
|
|
|
|
208,468
|
|
|
|
257,603
|
|
|
|
123.57 |
% |
Total
Revenues
|
|
$ |
9,230,948
|
|
|
$ |
6,502,480
|
|
|
$ |
2,728,468
|
|
|
|
41.96 |
% |
Revenues
for our HIV tests during the year ended December 31, 2007 increased by $3.5
million over the same period in 2006. This was primarily attributable
to increased sales in Africa and sales to our distributor in the United States,
offset by the reduction of sales to Brazil in 2006 that were not repeated
in
2007. Sales of our Chagas product declined because a $1.2 million
order received in 2006 was not repeated. The increase in grant and
development income was due to revenue generated from grant and feasibility
studies for our DPP™ platform of which $509,000 was received and $466,000 was
earned in 2007. The $43,000 balance is reflected in deferred
revenues. Sales to Africa (see Note 3 of the financial statements)
were primarily from Nigeria of approximately $2.7 million. We have
been advised recently that our designation in Nigeria as one of the screening
tests has changed to that of the confirmatory test as this country moves
from a
parallel to a serial testing algorithm, which we expect to significantly
reduce
our sales to Nigeria in 2008.
Gross
Margin:
Gross
Margin related to
|
|
For
the years ended
|
|
|
|
|
|
|
|
Net
Product Sales:
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Gross
Margin per Statement of Operations
|
|
$ |
3,862,303
|
|
|
$ |
2,016,568
|
|
|
$ |
1,845,735
|
|
|
|
91.53 |
% |
Less:
Research grant income
|
|
|
466,071
|
|
|
|
208,468
|
|
|
|
257,603
|
|
|
|
123.57 |
% |
Gross
Margin from Net Product Sales
|
|
$ |
3,396,232
|
|
|
$ |
1,808,100
|
|
|
$ |
1,588,132
|
|
|
|
87.83 |
% |
Gross
Margin %
|
|
|
38.75 |
% |
|
|
28.73 |
% |
|
|
|
|
|
|
|
|
The
increase in our gross margin resulted primarily from increased quantities
of our
product sales and increased average unit prices on product sales to our U.S.
distributor.
Research
and Development:
This
category includes costs incurred for regulatory approvals, product evaluations
and registrations.
Selected
expense lines:
|
|
For
the years ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Clinical
& Regulatory Affairs:
|
|
|
|
|
|
|
|
|
|
|
|
|
Wages
and related costs
|
|
$ |
186,428
|
|
|
$ |
174,489
|
|
|
$ |
11,939
|
|
|
|
6.84 |
% |
Consulting
|
|
|
40,813
|
|
|
|
78,249
|
|
|
|
(37,436 |
) |
|
|
-47.84 |
% |
Clinical
Trials
|
|
|
29,664
|
|
|
|
61,427
|
|
|
|
(31,763 |
) |
|
|
-51.71 |
% |
Other
|
|
|
12,657
|
|
|
|
8,942
|
|
|
|
3,715
|
|
|
|
41.55 |
% |
Total
Regulatory
|
|
$ |
269,562
|
|
|
$ |
323,107
|
|
|
$ |
(53,545 |
) |
|
|
-16.57 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R&D
Other than Regulatory:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Wages
and related costs
|
|
$ |
952,557
|
|
|
$ |
756,902
|
|
|
|
195,655
|
|
|
|
25.85 |
% |
Consulting
|
|
|
70,237
|
|
|
|
12,605
|
|
|
|
57,632
|
|
|
|
457.22 |
% |
Share-based
compensation
|
|
|
189,843
|
|
|
|
60,547
|
|
|
|
129,296
|
|
|
|
213.55 |
% |
Materials
and supplies
|
|
|
300,604
|
|
|
|
135,576
|
|
|
|
165,028
|
|
|
|
121.72 |
% |
Other
|
|
|
123,850
|
|
|
|
112,735
|
|
|
|
11,115
|
|
|
|
9.86 |
% |
Total
other than Regulatory
|
|
$ |
1,637,091
|
|
|
$ |
1,078,365
|
|
|
$ |
558,726
|
|
|
|
51.81 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Research and Development
|
|
$ |
1,906,653
|
|
|
$ |
1,401,472
|
|
|
$ |
505,181
|
|
|
|
36.05 |
% |
Expenses
for Clinical & Regulatory Affairs for the year ended December 31, 2007
decreased by $53,500 as compared to the same period in 2006. This was primarily
due to a reduction in consulting and clinical trail expenses related to CLIA
waiver for our HIV products, which were performed on both FDA approved HIV
products in 2006 and repeated for only one of these products in
2007.
Expenses
other than Clinical & Regulatory Affairs increased by $558,700 in the
year ended December 31, 2007 as compared with the same period in 2006 and
were
primarily related to an increase in the work related to feasibility studies
of
our DPP™ platform and grant income resulting in an increase in our personnel and
material costs. In addition the cost of share-based compensation
related to the value of common stock and employee stock options issued to
an
employee pursuant to a contract also contributed to the
increase.
Subject
to cash availability, the Company currently plans to continue to increase
its
spending on research and development in 2008 because it believes such spending
will result in the deployment of new and innovative products that are based
on
the newly patented DPP™ technology.
The
Company entered into five externally funded research agreements during 2007
that
accounted for total financial commitments of $600,000, of which $439,000
was
received by the Company during 2007 (approximately $396,000 of which was
earned
in 2007 on a percentage of completion basis) with clinical diagnostics, life
science, companion animal, academic, and government-affiliated public health
entities. These agreements all related to potential applications for
point of care tests that would employ our DPP™ technology. The Company has
several Research & Development and Regulatory projects
underway. Some highlights include:
Research
& Development - Dual Path Platform (DPP™)
During
2007 we made significant progress in implementing our strategy for the
deployment of our Dual Path Platform technology. We have further
confirmed that this platform technology has potential application to a broad
range of point-of-care/point-of-use products and markets. We believe
that our DPP™ intellectual property, product development and regulated
manufacturing know-how and experience are core strengths, but that significant
additional resources would be required for the associated product development
and marketing needed to adequately address such a wide range of opportunities.
A
key aspect of our strategy is therefore to leverage our strengths in developing
collaborations with premier organizations that have significant sales, marketing
and distribution capabilities. We have received a substantial amount
of interest in these kinds of collaborations. If successful, in each
case we would be an exclusive development and long-term manufacturing partner
to
these companies, and the companies would also acquire an exclusive license
to
our DPP™ intellectual property with respect to marketing the product
in the field of interest. We have several projects in discussion and in
negotiation, and we anticipate that we will consummate agreements during
2008
relative to these activities. There can be no assurance however that
these discussions will be successfully concluded or, even if they are, that
products will be developed and successfully commercialized as a result of
such
agreements.
On
January 29th
2008 we signed three new technology transfer, supply and license agreements
with
the Bio-Manguinhos (B-M) unit of the Oswaldo Cruz Foundation of Brazil for
products being developed by Chembio with its patented Dual Path Platform
(DPP™)
technology. Previously, in 2004, B-M and Chembio entered into a
similar agreement concerning one of Chembio’s HIV rapid tests.
Two
of
the products being developed will be used in screening programs funded by
Brazil’s Ministry of Health for the control and eradication of Leishmaniasis and
Leptospirosis, respectively, which are both blood-borne infectious diseases
that
are endemic in Brazil. A third test being developed is for the
confirmation of HIV-1 in patients who have tested positive with a screening
test. Bio-Manguinhos, also known as the Immunobiological Technology Institute,
is the largest producer of vaccines and kits for diagnosis of infectious
and
parasitic diseases in Latin America. Chembio’s DPP™ test platform was selected
for the screening programs because of its high sensitivity and specificity
of
prototypes evaluated by Bio-Manguinhos and because of the unique multiplexing
capabilities of DPP™ for the confirmatory assay. The DPP™ point-of-care
screening tests will complement the current Bio-Manguinhos national program,
which currently only uses laboratory-based technologies. The HIV confirmatory
test will allow for the simultaneous binding and uniform delivery of samples
to
multiple HIV antigens printed in the detection zone, providing results
equivalent to Western blot in a simple point-of-care format that provides
results within 20 minutes. Under the new agreements, once the products meet
mutually agreed-upon performance specifications and are approved for sale
in
Brazil, Chembio will receive a minimum purchase order for at least one million
tests within a one-year period. Thereafter, the agreement allows for production
of the products to be transferred to Brazil, subject to certain royalty
payments. This is similar to Chembio’s 2004 agreement with B-M for one of the
Company’s rapid HIV tests.
Based
upon the initial prototypes we have developed for each of these products,
we
anticipate that these products will be successfully developed in accordance
with
the agreed-upon specifications. Also, based upon our experience with
Bio-Manguinhos through the earlier agreement, we anticipate that the other
aspects of our agreement will be successful, though there can be no assurance
that this will in fact occur.
We
have
several other DPP™ research and development projects in various stages,
including products that we are or may be developing under contract for
third-party marketing partners. There can be no assurance that any of
these projects will result in completed products or that such products, if
successfully completed, will be successfully commercialized.
We
are
also pursuing under Chembio brands the development of products on the DPP™
platform that we believe will address market opportunities in point-of-care
testing. We anticipate that we will select such products during the
first quarter of 2008. We are attempting to identify
products that could generate attractive revenues and margins, address
significant market opportunities and that would feature the unique advantages
of
DPP™, such as its improved sensitivity, sample management and/or multiplexing
features. There can be no assurance that these efforts
will be successful in developing a Chembio-branded product or products, and
that
if developed such product or products will be successfully
commercialized.
Regulatory
Activities
In
July
2007, we submitted to the FDA the results of our untrained user studies in
connection with our pending CLIA waiver application for the HIV barrel product
marketed by Inverness under the name Clearview® Complete™ HIV 1/2. In October
2007, we announced that the FDA granted a CLIA waiver for this product. We
believe that CLIA waiver for this product will create additional sales
opportunities for Inverness with this product that were not available previously
without the CLIA waiver.
In
August
2007, we received ISO 13.485 certification. ISO 13.485 is a directive
of the International Standards Organization (ISO) that is specifically related
to manufacturers of in-vitro diagnostic products. This certification is
necessary to obtain CE (Community European) Markings for our products which
are
required in order to sell in most European countries, as well as many other
countries in the world. We have made progress in pursuing CE Markings
for all of our rapid HIV tests, which we anticipate receiving
during 2008. We have also made progress in pursuing CE
Marking for our Chagas rapid test, which we anticipate receiving
during 2008.
During
the fourth quarter we were granted an Investigational Device Exemption (IDE)
by
the FDA in connection with a study for which we have agreed upon a protocol
with
FDA. If this program is successfully completed, it would enable us and therefore
Inverness to expand the age range of our two FDA-approved rapid HIV tests
beyond
the current 18-64 year old range down to individuals 13 years of age and
above. We believe that this study and associated
submission, which will be a supplement to our Pre-Marketing Approval (PMA),
will
be completed during the first quarter of 2008. However there is no
assurance that this study will be completed successfully or that the FDA
will
approve these additional claims based upon our submission.
The
Company received its first USDA approval during the second quarter of 2007
for
manufacturing and marketing its Prima-TB STAT PAK™ test, a rapid test for the
detection of active pulmonary tuberculosis in non-human primate whole blood
samples. There is no assurance that commercialization of these
products will be successful.
Selling,
General and Administrative Expense:
Selected
expense lines:
|
|
For
the years ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Wages
and related costs
|
|
$ |
1,517,728
|
|
|
$ |
1,502,747
|
|
|
$ |
14,981
|
|
|
|
1.00 |
% |
Consulting
|
|
|
229,322
|
|
|
|
318,536
|
|
|
|
(89,214 |
) |
|
|
-28.01 |
% |
Commissons,
License and Royalties
|
|
|
1,098,356
|
|
|
|
900,431
|
|
|
|
197,925
|
|
|
|
21.98 |
% |
Options
(per SFAS 123R)
|
|
|
152,319
|
|
|
|
182,674
|
|
|
|
(30,355 |
) |
|
|
-16.62 |
% |
Marketing
Materials
|
|
|
75,570
|
|
|
|
55,734
|
|
|
|
19,836
|
|
|
|
35.59 |
% |
Investor
Relations
|
|
|
224,843
|
|
|
|
574,557
|
|
|
|
(349,714 |
) |
|
|
-60.87 |
% |
Legal,
Accounting and 404
|
|
|
613,603
|
|
|
|
792,460
|
|
|
|
(178,857 |
) |
|
|
-22.57 |
% |
Travel,
Entertainment and shows
|
|
|
121,433
|
|
|
|
186,551
|
|
|
|
(65,118 |
) |
|
|
-34.91 |
% |
Bad
Debt Allowance
|
|
|
(11,210 |
) |
|
|
22,479
|
|
|
|
(33,689 |
) |
|
|
-149.87 |
% |
Other
|
|
|
809,850
|
|
|
|
659,120
|
|
|
|
150,730
|
|
|
|
22.87 |
% |
Total
S, G &A
|
|
$ |
4,831,814
|
|
|
$ |
5,195,289
|
|
|
$ |
(363,475 |
) |
|
|
-7.00 |
% |
Selling,
general and administrative expense for the year ended December 31, 2007
decreased by 7 percent as compared with the same period in
2006. Reduction in spending on investor relations and decreased
professional fees were partially offset by increases in commission, license
and
royalty expenses. The decreased cost of professional fees (legal,
accounting and section 404 of Sarbanes-Oxley) were related to the reduction
of
legal fees related a patent lawsuit that was settled in late 2006, which
was
partially offset by the added cost of section 404 related
expenses. The increase in commission, license and royalty expenses
were due to added royalty burden due to our agreements with Inverness Medical
Systems, Inc. as well as the settlement with Bio-Rad Laboratories for past
royalties on HIV-2 offset by reduced commissions on sales to Brazil which
occurred in 2006 but were not repeated in 2007. Our periodic review
of our allowance for doubtful accounts resulted in a reduction of the allowance
in the year ended December 31, 2007.
As
the
Company’s sales of its rapid test products increase, it will incur increased
costs for commissions and royalties on intellectual property
licenses.
Other
Income and Expense:
Other
Income and Expense
|
|
For
the years ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Other
income (expense)
|
|
$ |
120,862
|
|
|
$ |
30,000
|
|
|
$ |
90,862
|
|
|
|
302.87 |
% |
Interest
income
|
|
|
145,289
|
|
|
|
29,532
|
|
|
|
115,757
|
|
|
|
391.97 |
% |
Interest
expense
|
|
|
(16,879 |
) |
|
|
(87,464 |
) |
|
|
70,585
|
|
|
|
-80.70 |
% |
Loss
on extinguishment of debt
|
|
|
-
|
|
|
|
(386,895 |
) |
|
|
-
|
|
|
|
0.00 |
% |
Total
Other Income and Expense
|
|
$ |
249,272
|
|
|
$ |
(414,827 |
) |
|
$ |
664,099
|
|
|
|
-160.09 |
% |
Interest
income for the year ended December 31, 2007 increased due to the additional
availability of funds to invest. In addition the Company received
$133,000 in 2007, net of expenses, from New York State related to a program
for
qualified emerging technology companies, which was partially offset by the
retirement of a fixed asset in 2007 of $12,000, resulting in the increase
in
other income. The conversion of a bridge loan in 2006 related to the
loss on extinguishment of debt. The lack of interest expense related
to the bridge loan in 2006 and the effect of several of our operating leases
approaching the end of their terms, resulted in the decrease in interest
expense
in 2007 over 2006.
SELECTED
FOURTH QUARTER INFORMATION FOR THE THREE MONTHS ENDED DECEMBER 31, 2007 AND
2006.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
SELECTED
OPERATION INFORMATION
|
FOR
THE THREE MONTHS ENDED
|
UNAUDITED
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
REVENUES:
|
|
|
|
|
|
|
Net
sales
|
|
$ |
2,160,901
|
|
|
$ |
2,610,413
|
|
Research
grant income
|
|
|
215,416
|
|
|
|
(1,026 |
) |
TOTAL
REVENUES
|
|
|
2,376,317
|
|
|
|
2,609,387
|
|
|
|
|
|
|
|
|
|
|
Cost
of sales
|
|
|
1,150,742
|
|
|
|
1,780,163
|
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT
|
|
|
1,225,575
|
|
|
|
829,224
|
|
|
|
|
|
|
|
|
|
|
OVERHEAD
COSTS:
|
|
|
|
|
|
|
|
|
Research
and development expenses
|
|
|
521,580
|
|
|
|
339,153
|
|
Selling,
general and administrative expenses
|
|
|
1,341,715
|
|
|
|
1,454,524
|
|
|
|
|
1,863,295
|
|
|
|
1,793,677
|
|
LOSS
FROM OPERATIONS
|
|
|
(637,720 |
) |
|
|
(964,453 |
) |
Revenues:
Selected
Product Categories:
|
|
For
the three months ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
HIV
|
|
$ |
2,001,279
|
|
|
$ |
2,464,192
|
|
|
$ |
(462,913 |
) |
|
|
-18.79 |
% |
Chagas
|
|
|
6,808
|
|
|
|
15,887
|
|
|
|
(9,079 |
) |
|
|
-57.15 |
% |
Other
|
|
|
152,814
|
|
|
|
130,334
|
|
|
|
22,480
|
|
|
|
17.25 |
% |
Net
Sales
|
|
|
2,160,901
|
|
|
|
2,610,413
|
|
|
|
(449,512 |
) |
|
|
-17.22 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
grant income
|
|
|
215,416
|
|
|
|
(1,026 |
) |
|
|
216,442
|
|
|
|
21095.71 |
% |
Total
Revenues
|
|
$ |
2,376,317
|
|
|
$ |
2,609,387
|
|
|
$ |
(233,070 |
) |
|
|
-8.93 |
% |
Revenues
for our HIV tests during the three months ended December 31, 2007 decreased
by
$463,000 over the same period in 2006. This was primarily due to $1.1
million of revenues realized during the three months ended December 31, 2006
received from a division of Bio-Rad Laboratories in Mexico that did not recur
in
2007 as well as sales to Brazil of $845,000 in 2006 that did not recur in
2007
offset by increased rapid HIV test sales to Africa of $740,000 and to
our distributor in the United States of $875,000, including an adjustment
of
$94,000 for sales prior to the fourth quarter of 2007.
Gross
Margin:
Gross
Margin related to
|
|
For
the three months ended
|
|
|
|
|
|
|
|
Net
Product Sales:
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Gross
Margin per Statement of Operations
|
|
$ |
1,225,575
|
|
|
$ |
829,224
|
|
|
$ |
396,351
|
|
|
|
47.80 |
% |
Less:
Research grant income
|
|
|
215,416
|
|
|
|
(1,026 |
) |
|
|
216,442
|
|
|
|
21095.71 |
% |
Gross
Margin from Net Product Sales
|
|
$ |
1,010,159
|
|
|
$ |
830,250
|
|
|
$ |
179,909
|
|
|
|
21.67 |
% |
Gross
Margin %
|
|
|
46.75 |
% |
|
|
31.81 |
% |
|
|
|
|
|
|
|
|
Our
gross
margins increased for the three months ended December 31, 2007 as compared
to
the same period in 2006. This increase was due to several factors
some of which included: a) improved average selling prices due to sales in
the
United States, and b) the timing of certain additional payments under our
U.S.
rapid HIV test marketing agreements, and c) a change in the overhead allocated
to inventories based on actual results for the year.
Research
and Development:
This
category includes costs incurred for regulatory approvals, product evaluations
and registrations. Clinical & Regulatory Affairs totaled $14,000
for the three months ended December 31, 2007 as compared to $73,600 for the
same
period in 2006. Research & Development costs other than
Regulatory totaled $507,600 for the three months ended December 31, 2007
as
compared to$ 265,600 for the same period in 2006.
Expenses
for Clinical & Regulatory Affairs for the three months ended December 31,
2007 decreased by $59,600 as compared to the same period in 2006. This was
primarily due to credit for certain regulatory expenses we incurred during
2007
that we billed to our U.S. marketing partner in the fourth quarter of
2007 under our agreements.
Expenses
other than Clinical & Regulatory Affairs increased in the three months ended
December 31, 2007 as compared with the same period in 2006 and were primarily
related to an increase in the work related to feasibility studies of our
DPP™
platform and to research grants that resulted in an increase in personnel,
consulting and material costs. In addition the cost of share-based
compensation related to the value of common stock and employee stock options
issued to an employee pursuant to a contract also contributed to the
increase.
Selling,
General and Administrative Expense:
Selling,
general and administrative expense for the three months ended December 31,
2007
decreased by 7.8 percent as compared with the same period in
2006. Reduction in spending on investor relations and decreased
professional fees were offset partially by increases in commission, license
and
royalty expenses. The decreased cost of professional fees (legal,
accounting and section 404 -Sarbanes-Oxley) were related to the reduction
of
legal fees related to the Plan (see Note 1) of $250,000 which were charged
to
paid in capital (some of this amount was charged to legal expenses in the
third
quarter of 2007) offset by the added cost of section 404 related
expenses. The increase in commission, license and royalty expenses
were due to added royalty burden due to the settlement with Bio-Rad Laboratories
for past royalties on HIV-2.
Operating
Loss
The
operating loss shown was impacted by the number of adjustments described
above
that were made during the fourth quarter of 2007, please see our analysis
of the
full year results for a more complete understanding of our financial results
for
2007.
LIQUIDITY
AND CAPITAL RESOURCES
|
|
For
the years ended
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
|
$
Change
|
|
|
%
Change
|
|
Net
cash used in operating activities
|
|
$ |
(1,345,796 |
) |
|
$ |
(4,202,923 |
) |
|
$ |
2,857,127
|
|
|
|
-67.98 |
% |
Net
cash used in investing activities
|
|
|
(410,425 |
) |
|
|
(374,513 |
) |
|
|
(35,912 |
) |
|
|
9.59 |
% |
Net
cash provided by financing activities
|
|
|
293,204
|
|
|
|
8,635,674
|
|
|
|
(8,342,470 |
) |
|
|
-96.60 |
% |
NET
(DECREASE) INCREASE IN CASH
|
|
$ |
(1,463,017 |
) |
|
$ |
4,058,238
|
|
|
$ |
(5,521,255 |
) |
|
|
-136.05 |
% |
The
Company had a decrease in cash for the year ended December 31, 2007 as compared
to an increase in cash for the same period in 2006. The decrease during the
2007
period is primarily attributable to the cash used in operations. The
increase during the 2006 year was primarily due to cash from the sale of
additional Series B Preferred of $1,000,000, proceeds from a bridge loan
of
$1,300,000 and net proceeds from the sales of Series C Preferred of $7,440,000,
all received in 2006.
The
Company had a working capital surplus of $3,229,000 at December 31, 2007
and a
working capital surplus of $5,113,000 at December 31, 2006. The
Company believes its resources are sufficient to fund its needs through the
end
of 2008 and into early 2009. Its liquidity and cash requirements will
depend on several factors. These factors include (1) the level of revenue
growth; (2) the extent, if any, to which that revenue growth improves operating
cash flows; (3) the Company’s expenditures for research and development,
facilities, marketing, regulatory approvals, and other expenditures it may
determine to make; and (4) the Company’s investment in capital equipment and the
extent to which this investment improves cash flow through operating
efficiencies.
The
following table lists the future payments required on the Company’s debt and
certain other contractual obligations as of December 31, 2007:
OBLIGATIONS
|
|
Total
|
|
|
Less
than
|
|
|
1-3
Years
|
|
|
4-5
Years
|
|
|
Greater
than
|
|
|
|
|
|
|
1
Year
|
|
|
|
|
|
|
|
|
5
Years
|
|
Capital
Leases (1)
|
|
$ |
136,752
|
|
|
$ |
35,832
|
|
|
$ |
85,716
|
|
|
$ |
15,204
|
|
|
$ |
-
|
|
Operating
Leases
|
|
|
170,880
|
|
|
|
128,160
|
|
|
|
42,720
|
|
|
|
-
|
|
|
|
-
|
|
Other
Long Term Obligations(2)
|
|
|
1,775,666
|
|
|
|
897,666
|
|
|
|
810,500
|
|
|
|
27,000
|
|
|
|
40,500
|
|
Total
Obligations
|
|
$ |
2,083,298
|
|
|
$ |
1,061,658
|
|
|
$ |
938,936
|
|
|
$ |
42,204
|
|
|
$ |
40,500
|
|
|
(1)
|
This
represents capital leases used to purchase capital equipment. (Obligations
inclusive of interest).
|
|
(2)
|
This
represents contractual obligations for fixed cost licenses and
employment
contracts.
|
RECENT
DEVELOPMENTS AND CHEMBIO’S PLAN OF OPERATIONS FOR THE NEXT TWELVE
MONTHS
Please
see section entitled Recent Events above.
On
September 29, 2006, the Company executed several agreements by and among
the
Company, Inverness Medical Innovations, Inc. (“Inverness”) and StatSure
Diagnostic Systems, Inc. (“StatSure”). Pursuant to these agreements,
Inverness markets the Company’s FDA-approved rapid HIV tests under Inverness’
Clearview® brand, Chembio received a nonexclusive license to Inverness’ lateral
flow patents, and the Company and StatSure settled their patent litigation
related to the HIV barrel format product, marketed exclusively now by Inverness
(except in Mexico) as Clearview Complete HIV 1/2HIV ½. . Inverness
markets Chembio’s cassette format rapid HIV test under the Clearview and
Chembio’s HIV 1/2 STAT-PAK® brand, i.e., as Clearview HIV 1/2
STAT-PAK. This enables Chembio to have brand identity for its
cassette product which Chembio markets directly, not through Inverness, outside
the United States. The distribution agreements with Inverness contain
gross margin sharing formulae among Inverness, the Company and, in the case
of
the HIV barrel product, StatSure. The specific terms of these
agreements are available for review in the Company’s Current Report on Form 8-K
filed with the Commission on October 5, 2006 (SEC Accession No. 000085),
which
is incorporated by reference herein.
Inverness
launched marketing of our two FDA approved rapid HIV tests in the United
States
during the first quarter of 2007. Though both products are now CLIA
waived, we only received the CLIA waiver for the HIV barrel product in October
of 2007. We believe that Inverness’ distribution network in the point of care
markets for HIV tests, namely hospital emergency departments, public health
clinics, and physicians’ offices, is outstanding and superior to the networks of
the two other CLIA-waived competitive products. However, Inverness,
in the development of the market for our products, is competing against a
well
established product manufactured by the principal competitor in the US market,
Orasure Technologies. Furthermore Orasure’s product has certain
product features and specifications not currently available in our products
being marketed by Inverness. These features and specifications
include the inability to currently use our product with oral fluid samples
and
the current limitation of the regulatory approval of our product that is
only
approved for use in testing individuals that are over 18 years of
age. We are currently completing steps to address these
issues. There can be no assurance that we will successfully complete
these steps or that, assuming we do, that Inverness will take all steps
reasonably necessary to exploit the improved market opportunity in that
case. We do believe however that there are other features and
specifications, such as test performance (sensitivity and specificity), shelf
life, ease of use, and price that we believe should help to offset those
disadvantages in the interim. We therefore believe that Inverness
will be successful in increasing its share of the growing Unites States rapid
HIV test market, although there are risks and uncertainties associated with
this.
During
2007 we signed a contract with the Partnership for Supply Chain Management
(“PSCM”) based in Washington D.C. PSCM is the organization now
charged with centralizing procurement, distribution, logistics and forecasting
under the United States President’s Emergency Plan for AIDS Relief (“PEPFAR”)
and other donor-funded relief programs in the developing
world. Our sales to the PEPFAR program are increasingly
through this organization. However, sales into PEPFAR countries still largely
depend upon being selected in national testing protocols. Currently
our STAT-PAK test is designated as the confirmatory test in all of the national
rapid HIV testing protocols in the Republic of Uganda, and in four of the
eight
parallel testing algorithms (two tests are used on each patient) adopted
by the
Nigerian Ministry of Health. We have been advised recently that our
designation in Nigeria as one of the screening tests has changed to that
of the
confirmatory test as this country moves from a parallel to a serial testing
algorithm. Sales to Nigeria for 2007 approximated $2.7 million and a substantial
amount is not expected to recur in 2008. In October 2007, we were
also selected as the confirmatory test to be used in Ethiopia, and initial
orders have been shipped to this market. Progress in being selected in
additional countries is unpredictable and very price competitive.
Numerous
other distribution opportunities are being pursued directly by Chembio for
its
HIV 1/2 STAT-PAK cassette and dipstick tests outside the United States, and
progress is being made. However there can be no assurance that these
efforts will result in successful distribution arrangements.
During
2007 we sold our HIV barrel product under our SURE CHECK® brand to our
distributor in Mexico, a division of Bio-Rad Laboratories, Inc. We
shipped approximately $1.4 million of this product to this customer during
2007. Our agreement with Inverness provides that this distribution
arrangement, which is currently the only exception to our otherwise global
exclusive agreement with Inverness for this product, was to terminate on
September 29, 2007. However, during 2007 Inverness agreed to extend
this carve-out to at least September 2008. We believe that additional
sales will be realized to Mexico although there can be no assurance that
this
will occur.
With
the
additional revenues at higher margins as a result of the introduction of
our
FDA-approved rapid HIV tests in the United States, and continued growth in
our
export revenues from our rapid HIV tests, we increased our sales and gross
margins significantly as compared with 2006. We believe that we will
experience continued revenue growth from our HIV tests in 2008 as we believe
that the market demand for rapid HIV tests will continue to increase in 2008,
and we believe we will participate in this continued growth. We
believe that growth in the United States market will occur as rapid tests
continue to replace laboratory based technologies, as routine HIV testing
recommendations by the CDC are increasingly implemented, and as our US marketing
partner participates in this growth with our tests with our
support. We also believe that the demand for rapid HIV tests will
increase in the donor funded markets as large amounts of funding for testing
is
appropriated for PEPFAR in 2008 and beyond. However, in order to compete
against
manufacturers in Asia that currently dominate the supply of rapid HIV tests
to
PEPFAR-funded markets, we will need to underscore the quality of our
fully-licensed, FDA-approved products and the justification for providing
US-based manufacturers with a fair opportunity to participate in US
taxpayer-funded programs. If we can continue to grow our revenues, we
will also continue to realize economies of scale as we did in 2007, thereby
improving margins. We have also implemented a series of process and
efficiency projects that if successfully implemented will also improve margins
and lower costs.
In
2007
we exclusively focused our business development efforts on Dual Path Platform
(DPP™), a rapid, point-of-care testing technology platform for which we were
granted a U.S. patent in March, 2007. This will continue in
2008. We have made significant progress in implementing our
strategies for the deployment of our DPP technology. We have
confirmed, through our own studies and those that we are performing for
prospective marketing partners, that this technology has potential application
to a broad range of point-of-care/point-of-use products and
markets. We believe that our DPP intellectual property, product
development and regulated manufacturing know-how and experience are core
strengths. Because significant additional resources would be required for
the
associated product development and marketing needed to adequately address
such a
wide range of opportunities, a major aspect of our DPP business development
strategy is to develop collaborations with premier organizations that have
significant sales, marketing and distribution capabilities. We have
received a substantial amount of interest in these kinds of
collaborations. In each case we would be an exclusive development and
long term manufacturing partner with these companies, and the companies would
also acquire an exclusive license to our DPP intellectual property to market
the
product in the field of interest. Our focus is on opportunities with partners
that can address large markets where the proposed product fills an unmet
need. We believe that during 2008 we will complete additional
commercial opportunities for the license, development and manufacture of
new
products based upon our DPP™ technology based upon this business development
strategy.
On
January 29, 2008 we signed three agreements with the Bio-Manguinhos division
of
the Oswald Cruz Foundation, part of Brazil’s Ministry of Health, for three
products (two neglected diseases, Leishmaniasis and Leptospirosis, and a
confirmatory test for HIV-1) based on our DPP technology. Pursuant to
these agreements, we have contracted to develop, supply and license these
products, and transfer the production of these products to the Bio-Manguinhos
facility. We believe that this agreement will enable us to scale up
the development, validation, and production of DPP products, and this will
facilitate additional development projects for DPP.
Provided
we successfully develop these products and that they are granted regulatory
approval in Brazil, these agreements provide us with the opportunity to realize
a total of approximately $3.4 million of product and license
revenues. We anticipate that approximately $1.7 million of these
revenues will be realized during the 2nd half
of 2008, and
the balance in 2009. However there can be no assurance of the amount
or timing of these revenues.
We
are
also pursuing under Chembio brands the development of products on the DPP
platform that we believe will address market opportunities in point-of-care
testing. We anticipate that we will select such products during the
first quarter of 2008. We are attempting to identify
products that could generate attractive revenues and margins, address
significant market opportunities and that would feature the unique advantages
of
DPP™, such as its improved sensitivity, sample management and/or multiplexing
features. There can be no assurance that these efforts
will be successful in developing a Chembio-branded product or products, and
that
if developed such product or products will be successfully
commercialized.
Critical
Accounting Policies and Estimates
The
preparation of the financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to
make
estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ
materially from those estimates.
We
believe that there are several accounting policies that are critical to
understanding our historical and future performance, as these policies affect
the reported amounts of revenue and the more significant areas involving
management’s judgments and estimates. These significant accounting
policies relate to revenue recognition, research and development costs,
valuation of inventory, valuation of long-lived assets and income
taxes. These policies, and the related procedures, are described in
detail below.
Revenue
Recognition –
We
sell
our products directly through our sales force and through
distributors. Revenue from direct sales of our product are recognized
upon shipment to the customer. Income from research grants are
recognized when earned. Sales are recorded net of discounts, rebates
and returns.
Research
& Development Costs –
Research
and development activities consist primarily of new product development,
continuing engineering for existing products, regulatory and clinical trial
costs. Costs related to research and development efforts on existing
or potential products are expensed as incurred.
Valuation
of Inventories –
Inventories
are stated at the lower of cost or market, using the first-in, first-out
method
(FIFO) to determine cost. Our policy is to periodically evaluate the
market value of the inventory and the stage of product life cycle, and record
a
reserve for any inventory considered slow moving or
obsolete. For example, each additional 1% of obsolete
inventory would reduce such inventory by approximately $14,000.
Allowance
for doubtful accounts –
Our
policy is to review our accounts receivable on a periodic basis, no less
than
monthly. On a quarterly basis an analysis is made of the adequacy of
our allowance for doubtful accounts and adjustments are made
accordingly. The current allowance is approximately 1.05% of
accounts receivable. For example each additional 1% of accounts
receivable that becomes uncollectible would reduce such balance of accounts
receivable by approximately $10,000.
Income
Taxes–
Income
taxes are accounted for under SFAS No. 109, “Accounting for Income
Taxes.” SFAS No. 109 requires the asset and liability method of
accounting for deferred income taxes. Deferred tax assets and
liabilities are determined based on the difference between the financial
statement and tax bases of assets and liabilities. Deferred tax
assets or liabilities at the end of each period are determined using the
tax
rate expected to be in effect when taxes are actually paid or
recovered. For example, if we do not become profitable, we may be
unable to utilize our deferred tax asset, which approximates $7,988,000 at
December 31, 2007.
SFAS
109
also requires that a valuation allowance be established when it is more likely
than not that all or a portion of a deferred tax asset will not be
realized. A review of all available positive and negative evidence
needs to be considered, including a company’s current and past performance, the
market environment in which the company operates, length of carryback and
carryforward periods and existing contracts that will result in future
profits.
Forming
a
conclusion that a valuation allowance is not needed is difficult when there
is
negative objective evidence such as cumulative losses in recent
years. Cumulative losses weigh heavily in the overall
assessment. As a result, we determined that it was appropriate to
establish a valuation allowance for the full amount of our deferred tax
assets.
The
Company adopted the provisions of FASB Interpretation No. 48, Accounting
for Uncertainty in Income Taxes (“FIN 48”) on January 1, 2007. FIN 48 prescribes
a comprehensive model for recognizing, measuring, presenting and disclosing
in
the consolidated financial statements tax positions taken or expected to
be
taken on a tax return, including a decision whether to file or not to file
in a
particular jurisdiction.
The
calculation of our tax liabilities involves the inherent uncertainty associated
with the application of complex tax laws. We are subject to examination by
various taxing authorities. We believe that as a result of our losses sustained
to date, any examination would result in a reduction of our net operating
losses
rather than a tax liability. As such, we have not provided for
additional taxes estimated under FIN 48, Accounting for Uncertainty in Income
Taxes.
The
above
listing is not intended to be a comprehensive list of all of our accounting
policies. In many cases, the accounting treatment of a particular
transaction is specifically dictated by accounting principles, generally
accepted in the United States of America, with no need for management’s judgment
in their application. There are also areas in which management’s
judgment in selecting any viable alternative would not produce a materially
different result. See our audited financial statements and notes
thereto which contain accounting policies and other disclosures required
by
accounting principles generally accepted in the United States of
America.
ITEM
7.
|
FINANCIAL
STATEMENTS
|
The
Consolidated Financial Statements and schedules that constitute Item 7 are
attached at the end of this Annual Report on Form 10-KSB. An index to
these Financial Statements and schedules is also included on page F-1 of
this
Annual Report on Form 10-KSB.
ITEM
8.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
|
Not
applicable.
ITEM
8A.
|
CONTROLS
AND PROCEDURES
|
(a) Management's
Annual Report on Internal Control Over Financial Reporting. The
Company's management is responsible for establishing and maintaining an adequate
system of internal control over financial reporting (as defined in Exchange
Act
Rule 13a-15(f)). Under the supervision and with the participation of
our senior management, consisting of our chief executive officer and our
chief
financial officer, we conducted an evaluation of the effectiveness of the
design
and operation of our disclosure controls and procedures, (as
defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of
1934, as amended, as of the end of the period covered by this report (the
"Evaluation Date"). Based on that evaluation, the Company’s
management, including our chief executive officer and chief financial officer,
concluded that as of the Evaluation Date our disclosure controls and procedures
are effective such that the information relating to us required to be disclosed
in our Securities and Exchange Commission ("SEC") reports (i) is recorded,
processed, summarized and reported within the time periods specified in SEC
rules and forms, and (ii) is accumulated and communicated to our management,
including our chief executive officer and chief financial officer, as
appropriate to allow timely decisions regarding required
disclosure.
Our
internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and
the
preparation of financial statements in accordance with generally accepted
accounting principles in the United States. Because of its inherent
limitations, internal control over financial reporting may not prevent or
detect
misstatements. Therefore, even those systems determined to be
effective can provide only reasonable assurance of achieving their control
objectives. In evaluating the effectiveness of our internal control
over financial reporting, our management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO) in
Internal Control - Integrated Framework. This annual report does not
include an attestation report of our registered public accounting firm regarding
internal control over financial reporting. Management's report was
not subject to attestation by the our registered public accounting firm pursuant
to temporary rules of the Securities and Exchange Commission that permit
the
Company to provide only management's report in this annual report.
(b) Changes
in Internal Control over Financial Reporting. There were no changes
in our internal control over financial reporting that occurred during the
last
fiscal quarter of the period covered by this report that have materially
affected or are reasonably likely to materially affect our internal control
over
financial reporting.
ITEM
8B.
|
OTHER
INFORMATION
|
Not
applicable.
PART
III
ITEM
9.
|
DIRECTORS,
EXECUTIVE OFFICERS, PROMOTERS, CONTROL PERSONS AND CORPORATE GOVERNANCE;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE
ACT
|
Directors
and Executive Officers
Lawrence
A. Siebert (51),
President, Chief Executive Officer and Director. Mr. Siebert was
appointed President of Chembio Diagnostics, Inc. and a member of our board
of
directors upon consummation of the merger. Mr. Siebert has been
Chairman of Chembio Diagnostic Systems Inc. for approximately 12 years and
its
President since May 2002. Mr. Siebert’s background is in private
equity and venture capital investing. From 1982 to 1991, Mr. Siebert
was associated with Stanwich Partners, Inc, which during that period invested
in
middle market manufacturing and distribution companies. From 1992 to
1999, Mr. Siebert was an investment consultant and business broker with Siebert
Capital Corp. and Siebert Associates LLC, and was a principal investor in
a
privately held test and measurement company which was sold in
2002. Mr. Siebert received a JD from Case Western Reserve University
School of Law in 1981 and a BA with Distinction in Economics from
the University of Connecticut in 1978.
Richard
J. Larkin (51),
Chief Financial Officer. Mr. Larkin was appointed as Chief Financial
Officer of Chembio Diagnostics, Inc. upon consummation of the
merger. Mr. Larkin oversees our financial activities and information
systems. Mr. Larkin has been the Chief Financial Officer of Chembio
Diagnostic Systems Inc. since September 2003. Prior to joining
Chembio Diagnostic Systems Inc., Mr. Larkin served as CFO at Visual Technology
Group from May 2000 to September 2003, and also led their consultancy
program that provided hands-on expertise in all aspects of financial service,
including the initial assessment of client financial reporting requirements
within an Enterprise Resource Planning (Manufacturing)
environment through training and implementation. Prior to joining
VTG, he served as CFO at Protex International Corporation from May 1987 to
January 2000. Mr. Larkin holds a BBA in Accounting from
Dowling College and is a member of the American Institute of Certified
Public Accountants.
Javan
Esfandiari (41), Executive
VP of Research and Development. Mr. Esfandiari joined Chembio
Diagnostic Systems, Inc, in 2000. Mr. Esfandiari co-founded, and
became a co-owner of Sinovus Biotech AB where he served as Director of Research
and Development concerning lateral flow technology until Chembio Diagnostic
Systems Inc. acquired Sinovus Biotech AB in 2000. From 1993 to 1997,
Mr. Esfandiari was Director of Research and Development with On-Site
Biotech/National Veterinary Institute, Uppsala, Sweden, which was working
in
collaboration with Sinovus Biotech AB on development of veterinary lateral
flow
technology. Mr. Esfandiari received his B.Sc. in Clinical Chemistry
and his M. Sc. in Molecular Biology from Lund University, Sweden. He has
published articles in various veterinary journals and has co-authored articles
on tuberculosis serology with Dr. Lyashchenko.
Richard
Bruce (53), Vice President,
Operations. Mr. Bruce was hired in April 2000 as Director of Operations.
He is
responsible for manufacturing, maintenance, inventory, shipping, receiving,
and
warehouse operations. Prior to joining Chembio Diagnostic Systems
Inc., he held director level positions at Wyeth Laboratories from 1984 to
1993.
From 1993 to 1998, he held various management positions in the Operations
department at Biomerieux. From 1998 to 2000, he held a management
position at V.I. Technologies. Mr. Bruce has over 25 years of
operations management experience with Fortune 500 companies in the field
of
in-vitro diagnostics and blood fractionation. Mr. Bruce received his
BS in Management from National Louis University in 1997.
Les
Stutzman
(56), VP of Sales
& Marketing – Vet TB. In 2005, Mr. Stutzman joined Chembio
as Vice President of Marketing to lead the development and launch of rapid
tests
for veterinary and human TB and other veterinary products. Mr. Stutzman has
spent over twenty years in marketing leadership positions within various
diagnostics companies. He has held Global Director and Business Development
Director positions in Marketing for diagnostic companies including bioMérieux
Inc., (formerly Organon Teknika Corp.), Durham, North Carolina from 1997
to 2002
and TREK Diagnostic Systems, Cleveland, Ohio from 2002 to 2005. Mr.
Stutzman received his MBA in Marketing from Duke University Fuqua School of
Business in 1988 and his Masters in Microbiology from Wagner College in
1982. Mr. Stutzman is MT (ASCP) SM certified.
Tom
Ippolito
(45), VP of
Regulatory Affairs, QA and QC. Mr. Ippolito joined Chembio in June
2005. He has over twenty years experience with in vitro diagnostics for
infectious diseases, protein therapeutics, vaccine development, Process
Development, Regulatory Affairs and Quality Management. Over the years, Mr.
Ippolito has held Vice President level positions at Biospecific Technologies,
Corp. from 2000 - 2005, Director level positions in Quality Assurance, Quality
Control, Process Development and Regulatory Affairs at United Biomedical,
Inc.
from 1987 - 2000. Mr. Ippolito is the Course Director for “drug development
process” and “FDA Regulatory Process” for the BioScience Certificate Program at
the New York State University of Stony Brook, a program he has been a part
of
since its inception in 2003.
Cathy
Dudnanski (48), VP
of Marketing, Ms. Dudnanski joined Chembio in 2005 as Marketing Director
for
human diagnostic products including HIV 1/ 2 and Chagas disease. She was
promoted to Vice President in 2007. Ms. Dudnanski brings over 20 years of
domestic and international marketing and sales experience in medical devices
and
diagnostics to the company. Between 2003 to 2005, Ms. Dudnanski was the
Global Marketing Manager for Suction and Oxygen Care for GE Healthcare. From
2000-2003, Ms. Dudnanski was the Director of Sales & Marketing for
ZeptoMetrix Corporation (former Division of Hemagen Diagnostics, Inc.) where
her
responsibilities included sales and marketing of research products to
biotechnology firms and academia. From 1992-1999, Ms. Dudnanski was the
Director of Sales & Marketing for Hemagen Diagnostics, Inc. where she was
responsible for the infectious disease and autoimmune disease product lines.
She
received a B.S. in Medical Technology from Roanoke College and an MBA from
Loyola. Ms. Dudnanski is MT (ASCP) certified and a member of the American
Society of Microbiology.
Robert
L. Aromando, Jr. (52),Executive VP of
Commercial Operations. Mr. Aromando joined the Company in May
2007. Prior to this position, between 2001 and 2007, Mr. Aromando was
Vice President of Marketing for Bracco Diagnostics Inc., a Princeton, New
Jersey-based pharmaceutical company and part of the Bracco Group. Most of
his
focus at Bracco was on managing the efforts of a marketing department, launching
new products, business development and life cycle management. Prior to joining
Bracco Mr. Aromando completed a one-year contract as interim President and
Chief
Executive Officer for American Bio Medica Corporation, a publicly-traded
diagnostic healthcare company. Prior to American Bio Medica Corporation,
Mr.
Aromando was Director of Global Marketing for Covance, a leading pharmaceutical
development organization headquartered in Princeton, New Jersey where is
had
responsibility for managing the strategic direction of the clinical development
marketing department. He also spent eight years at Roche Diagnostic Systems
(member of the Roche Group) as Director of Global Marketing responsible for
the
drugs of abuse business unit. His focus at Roche was allocated to government
affairs as well as providing solutions for substance abuse programs in the
workplace, criminal justice, drug treatment and school sectors. Mr. Aromando’s
career in healthcare also included stints at American Home Products and Litton
Bionetics Laboratory Products
Alan
Carus, CPA (69),
Director, Audit Committee chair. Mr. Carus was elected to Chembio’s
Board of Directors on April 15, 2005, and currently serves on the Company’s
Audit, Compensation, and Nominating and Corporate Governance Committees,
including as Chairman of the Audit Committee. He is a co-founder of
LARC Strategic Concepts LLC, a consulting firm dedicated to guiding emerging
companies to next stage development. Prior to co-founding LARC Strategic
Concepts LLC, Mr. Carus was Senior Vice President of Maritime Overseas
Corporation (“MOC”) and a senior executive of Overseas Shipholding Group, Inc.
(“OSG”) from 1981 to 1998 when he retired. MOC was managing agent for OSG, one
of the world’s largest ship-owners. He was a member of OSG’s senior management
committee and had senior responsibility in areas relating to administration,
accounting, tax, finance, budgets, long-range projections, and human resources.
Mr. Carus was involved in numerous acquisitions, debt and equity offerings,
complex transaction structuring, and was active in the management of OSG’s major
investments in the cruise industry and other development stage companies.
From
1964 to 1981, he was with Ernst & Young (including predecessors), the last
seven years as a partner. Mr. Carus has a B.B.A. from the Baruch School of
Business of the City College of New York.
Dr.
Gary Meller
(57), Director. Dr. Meller
was elected to our Board of Directors on March 15, 2005, and currently serves
on
the Company’s Audit, Compensation and Nominating and Corporate Governance
Committees, including as Chairman of the Compensation Committee. Dr.
Meller has been the president of CommSense Inc., a healthcare business
development company, since 2001. CommSense Inc. works with clients in
Europe, Asia, North America, and the Middle East on medical information
technology, medical records, pharmaceutical product development and financing,
health services operations and strategy, and new product and new market
development. From 1999 until 2001 Dr. Meller was the executive vice
president, North America, of NextEd Ltd., a leading internet educational
services company in the Asia Pacific region. Dr. Meller also is a
limited partner and a member of the Advisory Board of Crestview Capital Master
LLC, which is our largest stockholder. Dr. Meller is a graduate of the
University of New Mexico School of Medicine and has an MBA from the
Harvard Business School.
Kathy
Davis (51), Director. Ms.
Davis was elected to the Company’s Board of Directors in May 2007, and currently
serves on the Company’s Audit, Compensation and Nominating and Corporate
Governance Committees, including as Chairman of the Nominating and Corporate
Governance Committee. Ms. Davis is presently the owner of Davis
Design Group LLC, a company that provides analytical and visual tools for
public
policy design. Previously she served as the Chief Executive Officer of
Global Access Point, a start up company with products for data transport,
data
processing, and data storage network and hub facilities. From October 2003
to January 2005 Ms. Davis was Lieutenant Governor of the State of Indiana,
and
from January 2000 to October 2003 was Controller of the City of
Indianapolis. From 1989 to 2003 Ms. Davis held leadership positions with
agencies and programs in the State of Indiana including State Budget Director,
Secretary of Family & Social Services Administration, and Deputy
Commissioner of Transportation. From 1982 to 1989 Ms. Davis held increasingly
senior positions with Cummins Engine, where she managed purchasing, product
cost, manufacturing, engineering, and assembly of certain engine product
lines. Ms. Davis also led the startup of and initial investments by a $50
million Indiana state technology fund, serves on the not-for-profit boards
of
Noble of Indiana, Indiana Museum of African American History, University
of
Evansville Institute of Global Enterprise, and Purdue College of Science
Dean’s
Leadership Council. She has a Masters of Business Administration from
Harvard Business School and a Bachelor of Science in Mechanical
Engineering from the Massachusetts Institute of Technology.
Section
16(a) Beneficial Ownership Reporting Compliances
Section
16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
requires the Company’s directors, executive officers and beneficial owners of
more than 10% of the Company’s common stock to file with the Securities and
Exchange Commission initial reports of ownership and reports of changes in
ownership of common stock and other equity securities of the
Company. The Company believes that during the year ended December 31,
2007, each person who was an officer, director and beneficial owner of more
than
10% of the Company’s common stock complied with all Section 16(a) filing
requirements, except for the following: (i) Form 4 for Lawrence A. Siebert,
due on November 15, 2007, filed on November 19, 2007; (ii) Form 4 for
Richard Larkin, due on November 15, 2007, filed on November 19,
2007.
Code
of Ethics
The
Company has adopted a code of ethics that applies to its principal executive
officer, principal financial officer, principal accounting officer, controller,
and persons performing similar functions. A copy of the Company’s
code of ethics is filed as Exhibit 14.1 to this Form 10-KSB.
Identification
of Audit Committee; Audit Committee Financial Expert
The
Company’s board of directors has established an audit committee. Alan
Carus, Katherine L. Davis and Dr. Gary Meller each serve on the audit committee,
with Mr. Carus serving as chairman. The Company’s board of directors
has determined that Alan Carus is an audit committee financial expert and
is
independent.
ITEM
10. EXECUTIVE
COMPENSATION
The
following table summarizes all compensation recorded by the Company in each
of
the last two completed fiscal years for our principal executive officer,
our two
most highly compensated executive officers other than our principal executive
officer whose annual compensation exceeded $100,000, and two additional
individuals for whom disclosure would have been made in this table but for
the
fact that the individual was not serving as an executive officer of our company
at December 31, 2007.
Name
/
Principal
Position
|
|
Year
|
|
Salary
($)
|
|
Bonus
($)
|
|
Option
Awards
($)
|
|
Stock
Awards
($)
|
|
All
Other Compensation
($)
|
|
Total
($)
|
Lawrence
A. Siebert
|
|
2007
|
|
$ |
249,135
|
|
$ |
26,000
|
|
$ |
-
|
|
$ |
-
|
|
$ |
9,314
|
|
$ |
284,449
|
CEO
|
|
2006
|
|
|
207,115
|
|
|
20,000
|
|
|
21,017
|
|
|
-
|
|
|
7,200
|
|
|
255,332
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Richard
J. Larkin
|
|
2007
|
|
$ |
153,654
|
|
$ |
15,000
|
|
$ |
-
|
|
$ |
-
|
|
$ |
1,304
|
|
$ |
169,958
|
CFO
|
|
2006
|
|
|
140,385
|
|
|
15,000
|
|
|
27,300
|
|
|
-
|
|
|
-
|
|
|
182,685
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Javan
Esfandiari
|
|
2007
|
|
$ |
180,192
|
|
$ |
21,000
|
|
$ |
99,993
|
|
$ |
89,850
|
|
$ |
5,510
|
|
$ |
396,545
|
VP-R&D
|
|
2006
|
|
|
150,385
|
|
|
12,000
|
|
|
41,390
|
|
|
-
|
|
|
4,800
|
|
|
208,575
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tom
Ippolito
|
|
2007
|
|
$ |
155,481
|
|
$ |
12,000
|
|
$ |
-
|
|
$ |
-
|
|
$ |
381
|
|
$ |
167,862
|
VP-Regulatory
|
|
2006
|
|
|
140,385
|
|
|
9,000
|
|
|
7,754
|
|
|
-
|
|
|
-
|
|
|
157,139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Richard
Bruce
|
|
2007
|
|
$ |
143,654
|
|
$ |
12,000
|
|
$ |
-
|
|
$ |
-
|
|
$ |
990
|
|
$ |
156,644
|
VP-Operations
|
|
2006
|
|
|
127,981
|
|
|
9,000
|
|
|
24,516
|
|
|
-
|
|
|
-
|
|
|
161,497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
Salary
is total base salary.
2
Any
bonus earned was paid solely on a discretionary basis, and not pursuant to
any
bonus plan.
3
The
estimated fair value of any option or common stock granted was determined
at the
date of grant by using the Black-Scholes option pricing model.
4
Mr.
Siebert also serves as a director on the Company’s board of
directors. Mr. Siebert does not receive any compensation for this
director role.
5
Other
compensation includes an employer match to 401(K) contributions and a car
allowances where applicable.
Employment
Agreements
Mr.
Siebert. On June 15, 2006, Mr. Siebert and the Company
entered into an employment agreement, effective May 10, 2006, which
terminates on May 10, 2008. Pursuant to the employment agreement, Mr.
Siebert serves as the President and Chief Executive Officer of the Company
and
is entitled to receive a base compensation of $240,000 per year, subject
to
review by the board of directors of the Company at the end of the first twelve
months. Mr. Siebert also shall be eligible for a bonus of up to 50%
of his salary, consisting of (i) a bonus of up to 25% of his salary that
is at
the complete discretion and determination of the board of directors, and
(ii) a
bonus of up to an additional 25% of his salary that will be determined based
upon revenue and earnings performance criteria established each year by the
board of directors. Mr. Siebert is eligible to participate in any
profit sharing, stock option, retirement plan, medical and/or hospitalization
plan, and/or other benefit plans except for disability and life insurance
that
the Company may from time to time place in effect for the Company’s executives
during the term of Mr. Siebert’s employment agreement. If Mr.
Siebert’s employment agreement is terminated by the Company without cause, or if
Mr. Siebert terminates his employment agreement for a reasonable basis,
including within 12 months of a change in control, the Company is required
to
pay as severance Mr. Siebert’s salary for six months. Mr. Siebert has
agreed for a period of two years after the termination of his employment
with
the Company not to induce customers, agents, or other sources of distribution
of
the Company’s business under contract or doing business with the Company to
terminate, reduce, alter, or divert business with or from the
Company.
Mr.
Esfandiari. The Company entered into a new employment
agreement dated April 23, 2007, and to be effective March 5, 2007 (the
"Employment Agreement"), with Mr. Esfandiari to continue as the Company's
Senior
Vice President of Research and Development for an additional term of three
years. Mr. Esfandiari's salary under the Employment Agreement is
$185,000 for the first year, $210,000 for the second year, and $235,000 for
the
final year. Mr. Esfandiari is eligible for a cash bonus of up to 50%
of his base salary for each respective year, consisting of (i) a cash bonus
of
up to 37.5% of his calendar year base salary based on the performance of
the
Company's Dual Path Platform Technology, which is directly related to certain
annual revenue targets budgeted by management of the Company, and (ii) a
cash
bonus of up to 12.5% of his calendar year base salary that is at the complete
discretion and determination of the board of directors. The Company
also granted Mr. Esfandiari a stock grant of 200,000 shares of the Company's
common stock. 100,000 shares will vest immediately, 50,000 shares will vest
on
the first anniversary date of the Employment Agreement, and 50,000 shares
will
vest on the second anniversary of the Employment Agreement. In addition,
the
Company will grant Mr. Esfandiari up to 50,000 shares of the Company's common
stock for 2007 and 2008 based upon the performance of the Company's Dual
Path
Platform Technology, which is directly related to certain annual revenue
targets
budgeted by management of the Company. Pursuant to the Company's 1999
Equity Incentive Plan and Stock Option Agreement, the Company also granted
Mr.
Esfandiari incentive stock options to purchase 300,000 shares of the Company's
common stock. The price per share of these options is equal to the fair market
value of the Company's common stock on April 23, 2007, which is the date
on
which the Agreement was entered into. 100,000 shares of the stock options
vest
immediately, 100,000 shares of the stock options will vest on the first
anniversary of the Employment Agreement, and 100,000 shares of the stock
options
will vest on the second anniversary of the Employment Agreement. Mr.
Esfandiari is eligible to participate in any profit sharing, stock option,
retirement plan, medical and/or hospitalization plan, and/or other benefit
plans
except for disability and life insurance that the Company may from time to
time
place in effect for the Company’s executives during the term of Mr. Esfandiari’s
employment agreement. If Mr. Esfandiari’s employment agreement
is terminated by the Company without cause, or if Mr. Esfandiari terminates
his
employment agreement for a reasonable basis, including within 12 months of
a
change in control, the Company is required to pay as severance Mr. Esfandiari’s
salary for twelve months.
Neither
Mr. Larkin, Mr. Ippolito nor Mr. Bruce has an employment contract with the
Company.
OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END 2007
Name
|
Number
of Securities Underlying Unexcercised Options Excerciseable
(#)
|
Number
of Securities Underlying Unexcercised Options
Unexcersable
(#)
|
Option
Exercise Price (5)
($)
|
Option
Expiration Date
|
Option
Vesting Date
|
Foot-
note
|
Lawrence
A. Siebert
|
10,000
|
|
0.75
|
12/31/2008
|
4/17/2006
|
2
|
|
10,000
|
|
0.75
|
5/4/2011
|
4/17/2006
|
2
|
|
50,000
|
|
0.75
|
5/28/2011
|
4/17/2006
|
2,
3
|
|
50,000
|
|
0.75
|
5/28/2011
|
1/1/2007
|
2,
3
|
|
50,000
|
|
0.75
|
5/4/2011
|
5/5/2004
|
4
|
Richard
J. Larkin
|
25,000
|
|
0.75
|
5/17/2010
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/17/2010
|
1/1/2007
|
2
|
|
18,750
|
|
0.62
|
3/24/2011
|
3/24/2006
|
1
|
|
18,750
|
|
0.62
|
3/24/2011
|
1/1/2007
|
1
|
|
50,000
|
|
0.45
|
9/15/2010
|
5/5/2004
|
4
|
Javan
Esfandiari
|
30,000
|
|
0.75
|
3/31/2008
|
4/17/2006
|
2
|
|
5,000
|
|
0.75
|
12/31/2008
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/17/2010
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/17/2010
|
1/1/2007
|
2
|
|
18,750
|
|
0.62
|
3/24/2011
|
3/24/2006
|
1
|
|
18,750
|
|
0.62
|
3/24/2011
|
1/1/2007
|
1
|
|
5,000
|
|
0.75
|
5/4/2011
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/28/2011
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/28/2011
|
4/17/2006
|
2
|
|
25,000
|
|
0.75
|
5/28/2011
|
5/28/2007
|
2
|
|
30,000
|
|
0.75
|
5/4/2011
|
5/5/2004
|
4
|
|
100,000
|
|
0.599
|
4/23/2012
|
4/23/2007
|
2,
3
|
|
100,000
|
|
0.599
|
4/23/2012
|
3/5/2008
|
2,
3
|
|
|
100,000
|
0.599
|
4/23/2012
|
3/5/2009
|
2,
3
|
Tom
Ippolito
|
15,000
|
|
0.62
|
3/24/2011
|
3/24/2006
|
1
|
Richard
Bruce
|
5,000
|
|
0.75
|
12/31/2008
|
4/17/2006
|
2
|
|
12,500
|
|
0.75
|
5/17/2010
|
4/17/2006
|
2
|
|
12,500
|
|
0.75
|
5/17/2010
|
1/1/2007
|
2
|
|
12,500
|
|
0.62
|
3/24/2011
|
3/24/2006
|
1
|
|
12,500
|
|
0.62
|
3/24/2011
|
1/1/2007
|
1
|
|
5,000
|
|
0.75
|
5/4/2011
|
4/17/2006
|
2
|
|
10,000
|
|
0.75
|
5/4/2011
|
5/5/2004
|
4
|
1
All options issued with a $.62 exercise price were issued during 2006 as
part of
the Company’s 1999 Option Plan. Pursuant to this plan, the Company
granted 244,000 options to all employees.
2
All options issued with a $.75 exercise price and an April 17, 2006 vesting
date
were issued on April 17, 2006 as part of the Company’s 1999 Option
Plan. Pursuant to this plan, the Company granted 244,000 options to
all employees. On April 17, 2006, the Company’s Compensation
Committee approved the cancellation of each employee stock option award issued
under the 1999 Equity Incentive Plan where the exercise price was greater
than
$0.75 per share of the Company’s common stock, and the issuance of a new stock
option award under the 1999 Equity Incentive Plan, for the same number of
shares
of the Company’s common stock, with an exercise price of $0.75 per share of the
Company’s common stock for each cancelled stock option award. The market price
of the common stock of the Company on April 17, 2006 was $0.72 per share.
In
total, stock option awards to acquire 795,000 shares of Company common stock
were cancelled, and stock option awards to acquire 795,000 shares of Company
common stock were issued. Other than the change in the exercise price, all
of
the terms and conditions in each newly issued stock option award are identical
to the cancelled stock option award it replaces, with the following exceptions:
(i) Lawrence A. Siebert’s stock option award for 50,000 shares of the Company’s
common stock, exercisable on May 28, 2006 and terminating on May 28, 2011
was
replaced with a stock option award for 50,000 shares of the Company’s common
stock, exercisable on January 1, 2007 and terminating on May 28, 2011;(ii)
Avi
Pelossof’s stock option awards for 72,500 shares of the Company’s common stock,
exercisable on May 28, 2005 and on May 28, 2006 and both terminating on May
28,
2011 was replaced with a stock option award for 72,500 shares of the Company’s
common stock, exercisable on January 1, 2007 and terminating on May 28,
2011.
3
Options Issued in connection with an employment contract.
4
All other options shown were issued prior to 2006 as part of the Company's
1999
Option Plan.
5
On February 15, 2008, the Company’s Compensation Committee approved the
reduction of the exercise price to $0.48 per share of each employee stock
option
award issued under the 1999 Equity Incentive Plan for which the exercise
price
was greater than $0.48 per share.
DIRECTOR
COMPENSATION
Name
|
Fees
Earned or Paid in Cash
($)
1
|
Option
Awards
($)
2
|
Total
($)
|
Alan
Carus
|
$ 30,500
|
$
38,148
|
$
68,648
|
Gary
Meller
|
26,750
|
42,090
|
68,840
|
Katherine
L. Davis
|
23,000
|
33,008
|
56,008
|
Gerald
Eppner3
|
21,500
|
4,782
|
26,282
|
1 Fees
earned or paid in cash represents a yearly fee and fees for meeting
expenses: (a) Mr. Carus received an $18,000 annual fee as a member of the
board
of directors, a $2,500 annual fee as audit committee chairman and $10,000
in
meeting fees paid during 2007; (b) Mr. Eppner received a $20,000 fee
as a member of the board of directors, and $1,500 in meeting fees paid during
2007; (c) Dr. Meller received an $18,000 annual fee as a member of the board
of
directors, and $8,750 in meeting fees; (d) Ms. Davis received an $18,000
annual
fee as a member of the board of directors, and $5,000 in meeting
fees.
2Each
outside member of the board of
directors is granted the right to purchase 180,000 shares of the company’s
common stock with an exercise price equal to the market price on the date
of the
grant as part of their annual compensation. One-fifth of these options are
exercisable on the date of grant, one-fifth become exercisable on the first
anniversary of the date of grant, and additional one-fifths become exercisable
on the second through fourth anniversary of the date of grant. The
fair value of options at the date of grant was estimated using the Black-Scholes
option pricing model.
3Mr.
Eppner resigned from our Board of
Directors on January 30, 2007.
Director
Compensation
All
non-employee directors are paid an $18,000 annual retainer, semi-annually,
and
once every five years stock options to acquire 180,000 shares of the Company's
common stock, with an exercise price equal to the market price on the date
of
the grant. Stock options to acquire 36,000 shares become exercisable
on the date of grant, and options to acquire an additional 36,000 shares
become
exercisable on the date of each of the four succeeding annual meetings of
stockholders if and to the extent that the non-employee director is reelected
as
a director at each such annual meeting. The audit committee chairman
is paid an annual retainer of $2,500, paid semi-annually. In
addition, the non-employee directors are paid $1,000 in cash for each board
of
directors' meeting attended, and paid $500 in cash for each telephonic board
of
directors meeting. The non-employee directors who are members of a
committee of the board of directors are paid $500 in cash for each committee
meeting attended, or $750 in cash for each committee meeting attended if
that
non-employee director is the committee chairman.
ITEM
11.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
The
following table sets forth certain information regarding the beneficial
ownership of our common stock by each person or entity known by us to be
the
beneficial owner of more than 5% of the outstanding shares of common stock,
each
of our directors and each of our “named executive officers” and all of our
directors and executive officers as a group as of March 5, 2008.
Name
and Address of Beneficial Owner
|
Amount
and Nature of Beneficial Owner
|
Percent
of Class
|
Siebert,
Lawrence (1)
3661
Horseblock Road
Medford,
NY 11763
|
7,314,605
|
11.61%
|
Esfandiari,
Javan (2)
3661
Horseblock Road
Medford,
NY 11763
|
714,580
|
1.17%
|
Larkin,
Richard (3)
3661
Horseblock Road
Medford,
NY 11763
|
290,967
|
0.48%
|
Ippolito,
Tom (4)
3661
Horseblock Road
Medford,
NY 11763
|
65,000
|
0.11%
|
Bruce,
Richard (5)
3661
Horseblock Road
Medford,
NY 11763
|
140,000
|
0.23%
|
Carus,
Al (6)
3661
Horseblock Road
Medford,
NY 11763
|
126,000
|
0.21%
|
Meller,
Gary (7)
3661
Horseblock Road
Medford,
NY 11763
|
111,000
|
0.18%
|
Davis,
Katherine L. (8)
3661
Horseblock Road
Medford,
NY 11763
|
36,000
|
0.06%
|
GROUP
(9)
|
8,798,152
|
13.71%
|
|
|
|
Vicis
Capital Master Fund
126
East 56th Street, Tower 56, Suite 700
New
York, NY 10022
|
4,608,707
|
7.61%
|
Millenium
3 Opportunity Fund, LLC (10)
4
Becker Farm Road
Roseland,
NJ 07068
|
4,006,610
|
6.45%
|
Inverness
Medical Innovations, Inc.
51
Sawyer Road, Suite 200
Waltham,
MA 02453
|
5,367,840
|
8.87%
|
Crestview
Capital Master, LLC (11)
95
Revere Drive, Suite A
Northbrook,
IL 60062
|
24,145,310
|
36.20%
|
Beneficial
ownership is determined in accordance with the Rule 13d-3(a) of the Securities
Exchange Act of 1934, as amended, and generally includes voting or investment
power with respect to securities. Except as subject to community
property laws, where applicable, the person named above has sole voting and
investment power with respect to all shares of our common stock shown as
beneficially owned by him.
The
beneficial ownership percent in the table is calculated with respect to the
number of outstanding shares (60,537,534) of the Company's common stock
outstanding as of March 5, 2008. Each stockholder's ownership is
calculated as the number of shares of common stock owned plus the number
of
shares of common stock into which any preferred stock, warrants, options
or
other convertible securities owned by that stockholder can be converted within
60 days.
The
term
“named executive officer” refers to our principal executive officer, our two
most highly compensated executive officers other than the principal executive
officer who were serving as executive officers at the end of 2007, and two
additional individuals for whom disclosure would have been provided but for
the
fact that the individuals were not serving as executive officers of the Company
at the end of 2007.
|
(1)
|
Includes
245,000 shares issuable upon exercise of options exercisable within
60
days and 2,205,731 warrants.
|
|
(2)
|
Includes
492,000 shares issuable upon exercise of options exercisable within
60
days and 2,007 shares issuable upon exercise of warrants. Does
not include 100,000 shares issuable upon exercise of options that
are not
exercisable within the next 60 days
|
|
(3)
|
Includes
212,500 shares issuable upon exercise of options exercisable within
60
days and 27,436 shares issuable upon exercise of
warrants.
|
|
(4)
|
Includes
65,000 shares issuable upon exercise of options exercisable within
60
days.
|
|
(5)
|
Includes
140,000 shares issuable upon exercise of options exercisable within
60
days.
|
|
(6)
|
Includes
111,000 shares issuable upon exercise of options exercisable within
60
days. Does not include 156,000 shares issuable upon exercise of
options that are not exercisable within the next 60
days.
|
|
(7)
|
Includes
111,000 shares issuable upon exercise of options exercisable within
60
days. Does not include 156,000 shares issuable upon exercise of
options that are not exercisable within the next 60
days.
|
|
(8)
|
Includes
36,000 shares issuable upon exercise of options exercisable within
60
days. Does not include 144,000 shares issuable upon exercise of
options
that are not exercisable within the next 60
days.
|
|
(9)
|
Includes
footnotes (1)-(8)
|
|
(10)
|
Includes
1,557,376 shares issuable upon exercise of
warrants.
|
|
(11)
|
Includes
6,169,056 shares issuable upon exercise of
warrants.
|
Equity
Compensation Plan Information
Equity
Compensation Plan Information as of December 31,
2007
|
|
Number
of Securities to be Issued Upon Exercise of Outstanding Options,
Warrants
and Rights
|
Weighted-Average
Exercise Price of Outstanding Options, Warrants and
Rights
|
Number
of Securities Remaining Available for Future Issuance under Equity
Compensation Plans (Excluding Securities Reflected in Column
(a))
|
|
(a)
|
(b)
|
(c)
|
Equity
compensation plans approved by security holders
|
2,201,500
|
$0.64
|
433,500
|
Equity
compensation plans not approved by security holders
|
--
|
--
|
--
|
Total
|
2,201,500
|
$0.64
|
433,500
|
ITEM
12.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.
|
Lawrence
A. Siebert, the president and chairman of the board of directors of Chembio
Diagnostics, Inc. (the “Company”) beginning at the time of and after the merger,
and the president and chairman of Chembio Diagnostic Systems Inc. since May
2002, held two promissory notes issued by Chembio Diagnostic Systems
Inc. One note was issued on August 1, 1999 in the original principal
amount of $338,125, bearing interest at a rate of 11% per annum. The
other was issued on April 25, 2001 in the original principal amount of $795,937,
bearing interest at a rate of 12% per annum. On May 5, 2004, Mr.
Siebert converted the entire outstanding principal amount of the 11% note
and
$561,875 principal amount of the 12% note into 30 shares of the Company’s Series
A Preferred Stock, together with warrants to acquire 1,800,000 shares of
common
stock at $0.90 per share, pursuant to the Company’s private placement of its
Series A Preferred Stock on May 5, 2004. Pursuant to the terms
of the original Series A Preferred Stock, the shares of Series A Preferred
Stock
held by Mr. Siebert were convertible into 1,547,100 shares of the Company’s
common stock at $0.60 per share. The remaining debt of $234,062 held
by Mr. Siebert was exchanged on May 5, 2004 into 7.80208 shares of the
Company’s Series A Preferred Stock, together with warrants to acquire 468,125
shares of common stock at $0.90 per share, pursuant to the terms of the
Company’s private placement of its Series A Preferred Stock on May 5,
2004. As of December 31, 2006, $65,287.39 of accrued interest on the
debt was also due to Mr. Siebert, but was not accruing interest. As
of December 31, 2007, the accrued interest had been repaid. Mr.
Siebert also invested $50,000 in the Company’s Series B Preferred Stock private
placement pursuant to which he received 1 share of Series B Preferred Stock,
which was originally convertible into 81,967 shares of common stock at $0.80
per
share, together with a warrant to purchase 77,868 shares of common stock
at an
exercise price of $0.61 per share.
Mr.
Siebert invested $18,700 in Chembio Diagnostic Systems Inc. pursuant to a
private placement of convertible notes on March 22, 2004. Mr.
Siebert converted the entire principal amount of the note that he received,
together with accrued interest thereon, into .942 shares of the Company’s Series
A Preferred Stock, together with warrants to acquire 56,520 shares of common
stock at $0.90 per share, pursuant to the Company’s private placement of its
Series A Preferred Stock on May 5, 2004.
Mr.
Siebert prior to March 22, 2004 had either advanced funds to Chembio
Diagnostic Systems, Inc. or paid vendors directly on Chembio Diagnostic Systems,
Inc.’s behalf. The total amount so paid or advanced totaled $182,181
and was repaid in the fourth quarter of 2006. In addition as of
December 31, 2007, all of the accrued interest on the debt due to Mr. Siebert
had been paid.
On
February 15, 2008, the Compensation Committee approved the reduction of the
exercise price to $0.48 per share of each employee stock option award issued
under the 1999 Equity Incentive Plan for which the exercise price was greater
than $0.48 per share. As a result of this price reduction, the
following number of employee stock options awarded to the Company’s officers and
directors under the 1999 Equity Incentive Plan qualified for this price
reduction: (i) Mr. Siebert: 170,000 options; (ii) Mr. Larkin: 87,500 options;
(iii) Mr. Esfandiari: 532,500 options; (iv) Mr. Aromando: 100,000 options;
(v)
Mr. Ippolito: 15,000 options; (vi) Mr. Bruce: 90,000 options; (vii) Mr. Carus:
252,000 options; (viii) Dr. Meller: 252,000 options; and (ix) Ms. Davis:
180,000
options.
In
addition, on February 15, 2008 the Compensation Committee granted, to certain
of
the Company’s officers, options to purchase the Company’s common stock under the
1999 Equity Incentive Plan as follows: (i) Mr. Siebert received 75,000 options;
(ii) Mr. Larkin received 75,000 options; (iii) Mr. Esfandiari received 60,000
options; (iv) Mr. Bruce received 50,000 options; (v) Mr. Ippolito received
50,000 options; and (vi) Mr. Aromando received 25,000 options. The
exercise price for each of these options is $0.22 per share, which was the
closing market price for the Company’s common stock on February 15,
2008. The options vest on the date of the grant, and each option
granted will expire and terminate, if not exercised sooner, upon the earlier
to
occur of (a) 30 days after termination of the employee’s employment with the
Company or (b) the fifth anniversary of the date of grant.
Avi
Pelossof, the Company’s Vice President of Sales and Marketing from May 5, 2004
to January 31, 2007, exercised 100,000 options in December 2006 at $0.60
per
share, and another 50,000 options in January 2007 at $0.75 per
share.
Robert
Aromando, the Company’s Executive Vice President of Commercial Operations was
hired in May of 2007. In June 2007 in connection with his joining the
Company, he was granted options to purchase 100,000 shares of common stock
at an
exercise price of $0.62 per share. These options will become
exercisable one year from the date of grant. As discussed above, on
February 15, 2008, the exercise price for these options was reduced to
$0.48.
Dr.
Gary
Meller, a non-employee director of the Company, currently serves as a limited
partner and a member of the Advisory Board of Crestview Capital Master LLC,
referred to herein as Crestview, which was the lead investor, investing $3
million, in our Series B Preferred Stock private placement in January 2005,
and
which subsequently invested an additional $1 million in our Series B Preferred
Stock private placement in March 2006. Crestview also invested $2
million in our Series C Preferred Stock private placement in September
2006. Details of these transactions are set forth below. Crestview
currently is the largest stockholder of the Company.
As
referred to above, in January 2005, for a purchase price of $3 million,
Crestview acquired 60 shares of our Series B Preferred Stock, and warrants
to
purchase 4,672,130 shares of our common stock at a warrant exercise price
of
$0.61 per share.
In
March
2006, for a purchase price of $1 million, Crestview acquired 20 shares of
Series
B Preferred Stock with warrants to purchase 1,557,377 shares of common stock
at
a warrant exercise price of $0.61 per share. These shares were issued
in connection with the Company’s January 2005 private placement as described
herein. In September 2006, for a purchase price of $2 million, we
issued 40 shares of Series C Preferred Stock to Crestview together with warrants
to purchase 625,000 shares of common stock at an exercise price of $1.00
per
share.
In
January 2007, because of comments from the staff of the SEC concerning the
Company’s registration statement No. 333-138266 (the “Prospectus”), Crestview
agreed to reduce the number of its shares of common stock covered by the
Prospectus to 2,000,000. Crestview also agreed to waive any penalties
that the Company would otherwise owe Crestview because of the failure to
register all of Crestview’s shares in the Prospectus. In
consideration for this waiver, the Company agreed that, upon request by
Crestview, the Company will file one or more registration statements with
the
SEC in order to register the resale of other shares beneficially owned by
Crestview. The cost of any such registration statements shall be
borne by the Company.
In
addition to Crestview’s $2,000,000 investment in the Company’s September 2006
private placement of Series C Preferred Stock, the Company also received
an
investment of $2,000,000 on that date from Inverness Medical Innovations,
Inc.
(“Inverness”). At that time, a Certificate of Designation for the
Series C Preferred Stock was filed with the Secretary of State of Nevada
reflecting the agreed upon conversion price of $0.85 per share of common
stock. This private placement of Series C Preferred Stock was
completed on October 5, 2006, and it raised an aggregate of $8,150,000
(including the $2,000,000 invested by each of Crestview and
Inverness). During the period between September 29, 2006 and October
5, 2006, we requested the assistance of Crestview and others in identifying
prospective investors for us. On October 3, 2006, a Crestview
representative informed Mr. Siebert of a conversation he had earlier that
day
with a fund manager who indicated that his fund would be interested in investing
a substantial amount in the offering, but only at a conversion price of no
more
than $0.80.
At
a
board of directors meeting on October 4, 2006, Mr. Siebert expressed his
recommendation that the board approve lowering the conversion price to $0.80
in
order to be able to obtain the additional funds. The board discussed
the $1,300,000 promissory note bridge financing which had been completed
in June
2006, the noteholders who expected to convert their notes into Series C
Preferred Stock, and the restrictions on future equity sales by the Company
in
the bridge financing purchase agreement that necessitated finalizing promptly
the Series C Preferred Stock offering. After discussion to approve
the funding, the motion was approved unanimously, with the exception of Gerald
Eppner who abstained. Mr. Eppner stated that he understood the
benefits of the economics of the transaction and the Company’s need to proceed
so quickly, but that he did not wish to vote in favor.
At
a
board meeting held on October 11, 2006, the board members discussed the Series
C
Preferred Stock private placement. Mr. Eppner indicated that in his
view it would be desirable to review the sequence of events in this transaction
to assure proper guidelines for corporate governance and to determine if
disclosure or other issues needed to be considered. At a board
meeting held on October 26, 2006, it was discussed that a subcommittee of
the
audit committee, whose members would be Mr. Eppner and Alan Carus, would
review
certain issues related to the Series C Preferred Stock private
placement.
The
first
meeting of the audit committee to review the Series C Preferred Stock offering
was held on October 27, 2006. The audit committee decided it would
review the role of Crestview in the Series C Preferred Stock offering,
Crestview’s status as a possible control person, the role of Dr. Gary Meller in
the offering and his relationship with Crestview, and whether the audit
committee should recommend new corporate governance procedures to be implemented
or any action to be taken by the Board. The audit committee utilized
legal counsel to assist in its review. The audit committee held seven
meetings during the period from October 27, 2006 to January 10,
2007. Messrs. Carus and Eppner attended all of the
meetings. Mr. Carus concluded that: (i) he was satisfied
with the review, and (ii) although with fewer time constraints, there could
have
been more deliberation regarding the change in the conversion price, he believed
there was no inappropriate conduct, that the Company had not suffered any
damage
and that the matter should be closed. Mr. Eppner stated his concerns
that: (i) Crestview is an affiliate of the Company, (ii)
there was no participation by the Company in the reduction in the conversion
price from $0.85 to $0.80, (iii) although he agreed with Mr. Carus that the
$0.80 price may have been acceptable to the Company, it was not as good as
a
higher price, (iv) Mr. Siebert should not have allowed this to happen, and
that
because he did, it was evidence of control by Crestview, and (v) disclosure
of
the review of the audit committee should be made in a registration statement
that was to be filed shortly thereafter.
On
January 30, 2007, Gerald Eppner resigned from his position as a director
of the
Company, effective immediately. At the time of his resignation, as
additional consideration of his time and efforts as a member of the board
of
directors, the Company granted Mr. Eppner $20,000, and caused his outstanding
unvested stock options to become vested immediately. In his
resignation letter, Mr. Eppner stated that he did not resign due to any
disagreement with the Company, or because of any matter relating to the
Company's operations, policies or practices.
On
December 19, 2007 (the “Closing Date”), amendments to the governing documents
for the Company’s Series A, Series B and Series C Convertible Preferred Stock
(collectively, the “Preferred Stock”) and for certain warrants and options
(collectively, the “Non-Employee Warrants”), not including options or warrants
issued to employees or directors in their capacity as such (these actions
collectively, the “Plan”), were approved by the Company and the requisite
percentages of the holders of the Preferred Stock and of the Non-Employee
Warrants (See - Note 1 to the condensed consolidated financial
statements). Subsequent to these amendments, all shares of Preferred
Stock were converted to common stock and certain of the Non-Employee Warrants
were exercised, including the following: Mr. Siebert’s 38.74442 shares of Series
A Preferred Stock were converted into 2,421,526 shares of common stock at
$0.48
per share, his 1.08545 shares of Series B Preferred Stock were converted
into
113,067 shares of common stock at $0.48 per share, and Mr. Siebert purchased
337,500 shares of common stock through the exercise of warrants at an exercise
price of $0.40 per share, for a total of $135,000 in cash; and Crestview’s
82.32274 shares of Series B Preferred Stock were converted into 10,290,342
shares of the Company’s common stock, Crestview’s 40 shares of Series C
Preferred Stock were converted into 4,166,666 shares of common stock, Crestview
exercised a portion of its Series B Warrants to purchase a total of 60,451
shares of common stock for an aggregate purchase price of $24,180.40, and
Crestview exercised all of its Series C Warrants to purchase a total of 625,000
shares of common stock for an aggregate purchase price of $250,000.
Our
common stock trades on the OTC Bulletin Board. As such, we are not
currently subject to corporate governance standards of listed companies,
which
require, among other things, that the majority of the board of directors
be
independent.
We
are not currently subject to
corporate governance standards defining the independence of our directors,
and
we have chosen to define an “independent” director in accordance with the NASDAQ
Global Market's requirements for independent directors (NASDAQ Marketplace
Rule
4200). Under this definition, we have determined that Katherine L.
Davis and Al Carus currently qualify as independent directors. We do
not list the “independent” definition we use on our Internet
website.
3.1
|
Articles
of Incorporation, as amended. (3)
|
3.2
|
Amended
and Restated Bylaws. (1)
|
4.1
|
Second
Amended and Restated Certificate of Designation of the Relative
Rights and
Preferences of the Series A Convertible Preferred Stock of the
Registrant.
|
4.2
|
Registration
Rights Agreement, dated as of May 5, 2004, by and among the Registrant
and
the Purchasers listed therein. (2)
|
4.3
|
Lock-Up
Agreement, dated as of May 5, 2004, by and among the Registrant
and the
shareholders of the Registrant listed therein.
(2)
|
4.4
|
Amended
Form of Common Stock Warrant issued pursuant to the May 4, 2004
Stock and
Warrant Purchase Agreement.
|
4.5
|
Form
of $0.90 Warrant issued to Mark L. Baum pursuant to the Consulting
Agreement dated as of May 5, 2004 between the Registrant and Mark
L. Baum.
(2)
|
4.6
|
Form
of $0.60 Warrant issued to Mark L. Baum pursuant to the Consulting
Agreement dated as of May 5, 2004 between the Registrant and Mark
L. Baum.
(2)
|
4.7
|
Second
Amended and Restated Certificate of Designation of Preferences,
Rights,
and Limitations of Series B 9% Convertible Preferred Stock of the
Registrant.
|
4.8
|
Form
of Common Stock Warrant issued pursuant to the January 26, 2005
Securities
Purchase Agreement. (9)
|
4.9
|
Amended
Form of Common Stock Warrant issued pursuant to the January 26,
2005
Securities Purchase Agreement.
|
4.10
|
Registration
Rights Agreement, dated as of January 26, 2005, by and among the
Registrant and the purchasers listed therein.
(9)
|
4.11
|
Form
of Warrant, dated June 29, 2006, issued pursuant to Company and
purchasers
of the Company’s Secured Debentures.
(4)
|
4.12
|
Registration
Rights Agreement, dated June 29, 2006.
(4)
|
4.13
|
Second
Amended and Restated Certificate of Designation of Preferences,
Rights and
Limitations of Series C 7% Convertible Preferred Stock of the
Registrant.
|
4.14
|
Registration
Rights Agreement, dated as of September 29, 2006, by and among
the
Registrant and the Purchasers listed therein.
(6)
|
4.15
|
Form
of Common Stock Warrant issued pursuant to the Securities Purchase
Agreements dated September 29, 2006
(6).
|
4.16
|
Amended
Form of Common Stock Warrant issued pursuant to the Securities
Purchase
Agreements dated October 5, 2006
|
4.17
|
Amended
Form of Common Stock Warrant issued to Placement Agents pursuant
to the
October 5, 2005 Securities Purchase
Agreement.
|
4.18*
|
Form
of Employee Option Agreement.
|
4.19
|
Amended
Form of Warrant used for Consultant Services, and in connection
with the
Company’s 2004 merger.
|
4.20 |
1999
Equity Incentive Plan (14) |
10.1*
|
Employment
Agreement dated June 15, 2006 with Lawrence A. Siebert.
(5)
|
10.2*
|
Employment
Agreement dated April 23, 2007 with Javan Esfandiari.
(13)
|
10.3
|
Series
A Convertible Preferred Stock and Warrant Purchase Agreement (the
“Stock
and Warrant Purchase Agreement”), dated as of May 5, 2004, by and among
the Registrant and the purchasers listed therein.
(2)
|
10.4
|
Securities
Purchase Agreement (the “Securities Purchase Agreement”), dated as of
January 26, 2005, by and among the Registrant and the purchasers
listed
therein. (9)
|
10.5
|
Amendment
No. 1 to Securities Purchase Agreement, dated as of January 28,
2005 by
and among the Registrant and the purchasers listed therein.
(10)
|
10.6
|
Equity
Exchange Agreement, dated as of January 28, 2005, by and between
the
Registrant and Kurzman Partners, LP.
(10)
|
10.7
|
Security
Purchase Agreement, dated June 29, 2006, among the Company and
purchasers
of the Company’s Secured Debentures.
(4)
|
10.8
|
Form
of Secured Debenture, dated June 29, 2006.
(4)
|
10.9
|
Security
Agreement, dated June 29, 2006, among the Company, Chembio Diagnostic
Systems, Inc., and purchasers of the Company’s Secured Debentures.
(4)
|
10.10
|
Subsidiary
Guarantee, dated June 29, 2006, made by Chembio Diagnostic Systems,
Inc.,
in favor of Purchasers of the Company’s Secured Debentures.
(4)
|
10.11
|
Securities
Purchase Agreement (the “Securities Purchase Agreement”), dated as of
September 29, 2006, by and among the Registrant and the Purchasers
listed
therein. (6)
|
10.12
|
Letter
of Amendment to Securities Purchase Agreements dated as of September
29,
2006 by and among the Registrant and the Purchasers listed therein.
(6)
|
10.13
|
HIV
Barrel License, Marketing and Distribution Agreement, dated as
of
September 29, 2006, by and among the Registrant, Inverness and
StatSure.
(6)
|
10.14
|
HIV
Cassette License, Marketing and Distribution Agreement, dated as
of
September 29, 2006, between the Registrant and Inverness.
(6)
|
10.15
|
Non-Exclusive
License, Marketing and Distribution Agreement, dated as of September
29,
2006, between the Registrant and Inverness.
(6)
|
10.16
|
Joint
HIV Barrel Product Commercialization Agreement, dated as of September
29,
2006, between the Registrant and StatSure.
(6)
|
10.17
|
Settlement
Agreement, dated September 29, 2006, between the Registrant and
StatSure.
(6)
|
10.18
|
Contract
for Transfer of Technology and Materials with Bio-Manguinhos.
(7)
|
10.19
|
License
and Supply Agreement dated as of August 30, 2002 by and between
Chembio
Diagnostic Systems Inc. and Adaltis Inc.
(8)
|
17.1
|
Letter
of Resignation from Gerald A. Eppner.
(12)
|
23.1
|
Consent
of Lazar, Levine & Felix LLP, Independent
Accountants.
|
31.1
|
Certification
of the Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
31.2
|
Certification
of the Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
32
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant
to 18
U.S.C. Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
|
(1)
Incorporated by reference to the Registrant’s registration statement on
Form SB-2 filed with the Commission on August 23, 1999 and the Registrant's
Form 8-K filed on December 20, 2007.
(2)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed
with the Commission on May 14, 2004.
(3)
Incorporated by reference to the Registrant’s annual report on Form 10-KSB filed
with the Commission on March 31, 2005.
(4)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed
with the Commission on July 3, 2006.
(5)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed
with the Commission on June 21, 2006.
(6)
Incorporated by reference to the Registrant’s Current Report on Form 8-K filed
with the Commission on October 5, 2006.
(7)
Incorporated by reference to the Registrant’s registration statement on
Form SB-2/A filed with the Commission on August 4, 2004.
(8)
Incorporated by reference to the Registrant’s registration statement on
Form SB-2 filed with the Commission on June 7, 2004.
(9)
Incorporated by reference to the Registrant’s Current Report on Form 8-K
filed with the Commission on January 31, 2005.
(10)
Incorporated by reference to the Registrant’s registration statement on Form
SB-2 filed with the Commission on March 28, 2005.
(11)
Incorporated by reference to the Registrant’s annual report on Form 10-KSB filed
with the Commission on March 30, 2006.
(12) Incorporated
by reference to the Registrant’s Current Report on Form 8-K filed with the
Commission on January 30, 2007.
(13) Incorporated
by reference to the Registrant’s Current Report on Form 8-K/A filed with the
Commission on May 3, 2007.
(14)
Incorporated
by reference to the Registrant’s definitive proxy statement on Schedule 14A
filed with the Commission on May 11, 2005.
(*) An
asterisk (*) beside an exhibit number indicates the exhibit contains
a management contract, compensatory plan or arrangement which is required
to be
identified in this report.
ITEM
14.
|
PRINCIPAL
ACCOUNTANT FEES AND
SERVICES
|
Audit
Fees
For
the
years ended December 31, 2007 and December 31, 2006, Lazar, Levine & Felix
LLP, the Company’s principal accountants, billed the Company $85,000 and
$72,000, respectively, for fees for the audit of the Company’s annual financial
statements and review of financial statements included in the Company’s Forms
10-QSB and 10-KSB.
Audit-Related
Fees
For
the
years ended December 31, 2007 and December 31, 2006, Lazar, Levine & Felix
LLP, did not provide the Company with any assurance and related services
reasonably related to the performance of the audit or review of the Company’s
financial statements that are not reported above under “Audit
Fees.”
Tax
Fees
For
the
years ended December 31, 2007 and December 31, 2006, Lazar, Levine & Felix
LLP billed the Company $10,000 and $3,130, respectively, for professional
services for tax compliance, tax advice and tax planning.
All
Other Fees
For
the
years ended December 31, 2007 and December 31, 2006, Lazar, Levine & Felix
LLP billed the Company $42,500 and $30,200 for fees associated with the
preparation and filing of the Company’s registration statements, responses to
SEC comment letters and other related matters.
Audit
Committee Pre-Approval Policies
The
Audit
Committee (and prior to the adoption of the Audit Committee, the Board of
Directors) approves in advance all audit and non-audit services performed
by
Lazar, Levine & Felix LLP. There are no other specific policies
or procedures relating to the pre-approval of services performed by Lazar,
Levine & Felix LLP.
SIGNATURES
In
accordance with Section 13 or 15(d) of the Exchange Act, the registrant has
caused this report to be signed on its behalf by the undersigned, thereunto
duly
authorized.
CHEMBIO
DIAGNOSTICS,
INC.
Date: March
12,
2008 By
/s/ Lawrence A.
Siebert
Lawrence
A. Siebert
President,
Chief Executive Officer and
Chairman
of the Board
In
accordance with the requirements of the Exchange Act, this report has been
signed below by the following persons on behalf of the registrant and in
the
capacities and on the dates indicated.
|
|
|
|
|
/s/
Lawrence A.
Siebert
Lawrence
A. Siebert
|
|
Chief
Executive Officer, President and Chairman Of The Board
(Principal
Executive Officer)
|
|
March
12, 2008
|
/s/
Richard J.
Larkin
Richard
J. Larkin
|
|
Chief
Financial Officer (Principal Financial & Accounting
Officer)
|
|
March
12, 2008
|
/s/
Alan
Carus
Alan
Carus
|
|
Director
|
|
March
12, 2008
|
/s/
Gary
Meller
Dr.
Gary Meller
|
|
Director
|
|
March
12, 2008
|
/s/
Katherine L.
Davis
Katherine
L. Davis
|
|
Director
|
|
March
12, 2008
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
|
|
|
Index
to Consolidated Financial Statements
|
|
|
|
—INDEX—
|
|
|
Page(s)
|
Report
of Registered Independent Public Accounting Firm
|
F-2
|
|
|
Consolidated
Financial Statements:
|
|
|
|
Balance
Sheets
|
|
December
31, 2007 and 2006
|
F-3
|
|
|
Statements
of Operations
|
|
Years
ended December 31, 2007 and 2006
|
F-4
|
|
|
Statements
of Changes in Stockholders’ Equity (Deficit)
|
|
Year
ended December 31, 2006
|
F-5
|
|
|
Statements
Of Changes in Stockholders’ Equity (Deficit)
|
F-6
|
Year
ended December 31, 2007
|
|
|
|
Statements
of Cash Flows
|
|
Years
ended December 31, 2007 and 2006
|
F-7
- F-8
|
|
|
Notes
to Consolidated Financial Statements
|
F-9
- F-25
|
REPORT
OF REGISTERED INDEPENDENT PUBLIC ACCOUNTING FIRM
To
The
Board of Directors
Chembio
Diagnostics, Inc. and Subsidiaries
Medford,
New York
We
have
audited the consolidated balance sheets of Chembio Diagnostics, Inc. and
Subsidiaries (the “Company”) as of December 31, 2007 and 2006 and the
consolidated statements of operations, stockholders' equity (deficit) and
cash
flows for the two years in the period ended December 31, 2007. These
financial statements are the responsibility of the Company's management.
Our
responsibility is to express an opinion on these financial statements based
on
our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require
that we plan and perform the audits to obtain reasonable assurance about
whether
the financial statements are free of material misstatement. The
Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. Our audits included
consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but
not
for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no
such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis
for our opinion.
In
our
opinion, the financial statements referred to above present fairly, in all
material respects, the consolidated financial position of Chembio Diagnostics,
Inc. and Subsidiaries as of December 31, 2007 and 2006, and the consolidated
results of its operations and its cash flows for the two years in the period
ended December 31, 2007 in conformity with accounting principles generally
accepted in the United States of America.
LAZAR
LEVINE & FELIX LLP
/s/
LAZAR LEVINE & FELIX LLP
New
York,
New York
March
7,
2008
CHEMBIO
DIAGNOSTIC SYSTEMS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
BALANCE SHEETS
|
AS
OF DECEMBER 31,
|
|
|
|
|
|
|
|
-
ASSETS -
|
|
|
|
|
|
|
|
|
2007
|
|
|
2006
|
|
CURRENT
ASSETS:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$ |
2,827,369
|
|
|
$ |
4,290,386
|
|
Accounts
receivable, net of allowance for doubtful accounts of $10,045
and $42,967
for 2007 and 2006, respectively
|
|
|
946,340
|
|
|
|
1,350,240
|
|
Inventories
|
|
|
1,453,850
|
|
|
|
1,108,950
|
|
Prepaid
expenses and other current assets
|
|
|
243,748
|
|
|
|
204,092
|
|
TOTAL
CURRENT ASSETS
|
|
|
5,471,307
|
|
|
|
6,953,668
|
|
|
|
|
|
|
|
|
|
|
FIXED
ASSETS, net of accumulated depreciation
|
|
|
829,332
|
|
|
|
603,603
|
|
|
|
|
|
|
|
|
|
|
OTHER
ASSETS:
|
|
|
|
|
|
|
|
|
Deposits
and other assets
|
|
|
284,358
|
|
|
|
349,306
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,584,997
|
|
|
$ |
7,906,577
|
|
|
|
|
|
|
|
|
|
|
-
LIABILITIES AND STOCKHOLDERS’ EQUITY
(DEFICIENCY)-
|
|
|
|
|
|
|
|
|
CURRENT
LIABILITIES:
|
|
|
|
|
|
|
|
|
Accounts
payable and accrued liabilities
|
|
$ |
2,175,791
|
|
|
$ |
1,709,939
|
|
Deferred
research and development revenue
|
|
|
43,334
|
|
|
|
-
|
|
Accrued
interest payable
|
|
|
-
|
|
|
|
93,160
|
|
Current
portion of obligations under capital leases
|
|
|
23,458
|
|
|
|
37,336
|
|
TOTAL
CURRENT LIABILITIES
|
|
|
2,242,583
|
|
|
|
1,840,435
|
|
|
|
|
|
|
|
|
|
|
OTHER
LIABILITIES:
|
|
|
|
|
|
|
|
|
Obligations
under capital leases - net of current portion
|
|
|
79,588
|
|
|
|
7,081
|
|
Series
C preferred stock redemption put
|
|
|
-
|
|
|
|
449,677
|
|
TOTAL
LIABILITIES
|
|
|
2,322,171
|
|
|
|
2,297,193
|
|
|
|
|
|
|
|
|
|
|
COMMITMENTS
AND CONTINGENCIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PREFERRED
STOCK - Series C 7% Redeemable Convertible - $.01 par value:
None
and 165 shares issued and outstanding as of 2007 and 2006.
|
|
|
-
|
|
|
|
6,549,191
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’
EQUITY (DEFICIENCY):
|
|
|
|
|
|
|
|
|
Preferred
Stock – 10,000,000 shares authorized:
|
|
|
|
|
|
|
|
|
Series
A 8% Convertible - $.01 par value: None and 149.92119 shares
issued and
outstanding as of 2007 and 2006, respectively.
|
|
|
-
|
|
|
|
2,504,313
|
|
Series
B 9% Convertible - $.01 par value: None and 113.93591 shares
issued and
outstanding as of 2007 and 2006, respectively.
|
|
|
-
|
|
|
|
3,555,786
|
|
Common
stock - $.01 par value; 100,000,000 shares authorized 60,537,534
and
11,296,961 shares issued and outstanding as of 2007 and 2006,
respectively
|
|
|
605,375
|
|
|
|
112,970
|
|
Additional
paid-in capital
|
|
|
39,003,148
|
|
|
|
19,960,618
|
|
Accumulated
deficit
|
|
|
(35,345,697 |
) |
|
|
(27,073,494 |
) |
TOTAL
STOCKHOLDERS’ EQUITY (DEFICIENCY)
|
|
|
4,262,826
|
|
|
|
(939,807 |
) |
|
|
|
|
|
|
|
|
|
|
|
$ |
6,584,997
|
|
|
$ |
7,906,577
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
FOR
THE YEARS ENDED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
REVENUES:
|
|
|
|
|
|
|
Net
sales
|
|
$ |
8,764,877
|
|
|
$ |
6,294,012
|
|
Research
grant income
|
|
|
466,071
|
|
|
|
208,468
|
|
TOTAL
REVENUES
|
|
|
9,230,948
|
|
|
|
6,502,480
|
|
|
|
|
|
|
|
|
|
|
Cost
of sales
|
|
|
5,368,645
|
|
|
|
4,485,912
|
|
|
|
|
|
|
|
|
|
|
GROSS
PROFIT
|
|
|
3,862,303
|
|
|
|
2,016,568
|
|
|
|
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
|
|
|
Research
and development expenses
|
|
|
1,906,653
|
|
|
|
1,401,472
|
|
Selling,
general and administrative expenses
|
|
|
4,831,814
|
|
|
|
5,195,289
|
|
|
|
|
6,738,467
|
|
|
|
6,596,761
|
|
LOSS
FROM OPERATIONS
|
|
|
(2,876,164 |
) |
|
|
(4,580,193 |
) |
|
|
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSES):
|
|
|
|
|
|
|
|
|
Other
income
|
|
|
120,862
|
|
|
|
30,000
|
|
Loss
on extinguishment of debt
|
|
|
-
|
|
|
|
(386,895 |
) |
Interest
income
|
|
|
145,289
|
|
|
|
29,532
|
|
Interest
expense
|
|
|
(16,879 |
) |
|
|
(87,464 |
) |
|
|
|
249,272
|
|
|
|
(414,827 |
) |
|
|
|
|
|
|
|
|
|
LOSS
BEFORE INCOME TAXES
|
|
|
(2,626,892 |
) |
|
|
(4,995,020 |
) |
|
|
|
|
|
|
|
|
|
Provision
for income taxes
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS
|
|
|
(2,626,892 |
) |
|
|
(4,995,020 |
) |
|
|
|
|
|
|
|
|
|
Dividends
payable in stock to preferred stockholders
|
|
|
1,385,593
|
|
|
|
1,022,897
|
|
Non-recurring
deemed dividend
|
|
|
4,259,717
|
|
|
|
-
|
|
Dividend
accreted to preferred stock for associated costs and a beneficial
conversion feature
|
|
|
-
|
|
|
|
2,187,149
|
|
|
|
|
|
|
|
|
|
|
NET
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
|
|
$ |
(8,272,202 |
) |
|
$ |
(8,205,066 |
) |
|
|
|
|
|
|
|
|
|
Basic
and diluted loss per share
|
|
$ |
(0.57 |
) |
|
$ |
(0.80 |
) |
|
|
|
|
|
|
|
|
|
Weighted
average number of shares outstanding, basic and
diluted
|
|
|
14,608,478
|
|
|
|
10,293,168
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(DEFICIT)
|
FOR
THE YEAR ENDED DECEMBER 31, 2006
|
|
|
Series
A Preferred Stock
|
|
|
Series
B Preferred Stock
|
|
|
Common
Stock
|
|
|
Additional
paid in capital
|
|
|
Accumulated
Deficit
|
|
|
Total
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
Balance
at December 31, 2005
|
|
|
158.68099
|
|
|
$ |
2,628,879
|
|
|
|
102.19760
|
|
|
$ |
3,173,239
|
|
|
|
8,491,429
|
|
|
$ |
84,914
|
|
|
$ |
14,034,099
|
|
|
$ |
(18,868,428 |
) |
|
$ |
1,052,703
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
Stock Issued:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
cash
|
|
|
-
|
|
|
|
-
|
|
|
|
20.00000
|
|
|
|
1,000,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(112,750 |
) |
|
|
-
|
|
|
|
887,250
|
|
For
fees
|
|
|
-
|
|
|
|
-
|
|
|
|
2.00000
|
|
|
|
100,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(100,000 |
) |
|
|
-
|
|
|
|
-
|
|
For
dividends
|
|
|
-
|
|
|
|
-
|
|
|
|
1.79797
|
|
|
|
89,899
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(89,899 |
) |
|
|
-
|
|
|
|
-
|
|
Allocation
of fair value to warrants
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(481,470 |
) |
|
|
-
|
|
|
|
-
|
|
|
|
1,880,185
|
|
|
|
-
|
|
|
|
1,398,715
|
|
Allocation
of value of beneficial conversion
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(463,434 |
) |
|
|
-
|
|
|
|
-
|
|
|
|
2,187,149
|
|
|
|
-
|
|
|
|
1,723,715
|
|
Accretion
of preferred dividend
|
|
|
-
|
|
|
|
366,563
|
|
|
|
-
|
|
|
|
508,751
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,022,897 |
) |
|
|
(147,583 |
) |
Accretion
of beneficial conversion
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
463,434
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,187,149 |
) |
|
|
(1,723,715 |
) |
Payment
of dividends
|
|
|
-
|
|
|
|
(369,123 |
) |
|
|
-
|
|
|
|
(473,982 |
) |
|
|
959,608
|
|
|
|
9,596
|
|
|
|
633,284
|
|
|
|
-
|
|
|
|
(200,225 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock Issued:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
converted from preferred
|
|
|
(8.75980 |
) |
|
|
(122,006 |
) |
|
|
(12.05966 |
) |
|
|
(360,651 |
) |
|
|
1,426,483
|
|
|
|
14,265
|
|
|
|
468,392
|
|
|
|
-
|
|
|
|
|
|
For
services
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
178,750
|
|
|
|
1,788
|
|
|
|
137,890
|
|
|
|
-
|
|
|
|
139,678
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
and options:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consultants/Advisory
Board
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
137,022
|
|
|
|
-
|
|
|
|
137,022
|
|
Prior
CEO warrant
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
34,000
|
|
|
|
-
|
|
|
|
34,000
|
|
Exercised
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
240,691
|
|
|
|
2,407
|
|
|
|
143,914
|
|
|
|
-
|
|
|
|
146,321
|
|
Issued
for bridge
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
328,341
|
|
|
|
-
|
|
|
|
328,341
|
|
Option
valuation per 123R
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
278,991
|
|
|
|
-
|
|
|
|
278,991
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss for 2006
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,995,020 |
) |
|
|
(4,995,020 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2006
|
|
|
149.92119
|
|
|
$ |
2,504,313
|
|
|
|
113.93591
|
|
|
$ |
3,555,786
|
|
|
|
11,296,961
|
|
|
$ |
112,970
|
|
|
$ |
19,960,618
|
|
|
$ |
(27,073,494 |
) |
|
$ |
(939,807 |
) |
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(DEFICIT)
|
FOR
THE YEAR ENDED DECEMBER 31, 2007
|
|
|
Series
A Preferred Stock
|
|
|
Series
B Preferred Stock
|
|
|
Common
Stock
|
|
|
Additional
paid in capital
|
|
|
Accumulated
Deficit
|
|
|
Total
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
Balance
at December 31, 2006
|
|
|
149.92119
|
|
|
$ |
2,504,313
|
|
|
|
113.93591
|
|
|
$ |
3,555,786
|
|
|
|
11,296,961
|
|
|
$ |
112,970
|
|
|
$ |
19,960,618
|
|
|
$ |
(27,073,494 |
) |
|
$ |
(939,807 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred
Stock related:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accretion
of preferred dividend
|
|
|
-
|
|
|
|
331,375
|
|
|
|
- |
|
|
|
491,302
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,385,594 |
) |
|
|
(562,917 |
) |
Payment
of dividends
|
|
|
-
|
|
|
|
(391,343 |
) |
|
|
- |
|
|
|
(758,087 |
) |
|
|
3,442,467
|
|
|
|
34,425
|
|
|
|
1,705,505
|
|
|
|
- |
|
|
|
590,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock Issued:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
converted from preferred (including Series C)
|
|
|
(149.92119 |
) |
|
|
(2,444,345 |
) |
|
|
(113.93591 |
) |
|
|
(3,289,001 |
) |
|
|
41,861,540
|
|
|
|
418,615
|
|
|
|
16,425,733
|
|
|
|
(4,259,717 |
) |
|
|
6,851,285
|
|
For
services
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
200,000
|
|
|
|
2,000
|
|
|
|
117,800
|
|
|
|
- |
|
|
|
119,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
and options:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consultants/Advisory
Board
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
20,000
|
|
|
|
- |
|
|
|
20,000
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,736,566
|
|
|
|
37,365
|
|
|
|
1,082,996
|
|
|
|
|
|
|
|
1,120,361
|
|
Fee
for plan
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(561,816 |
) |
|
|
- |
|
|
|
(561,816 |
) |
Option
valuation per 123R
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
252,312
|
|
|
|
- |
|
|
|
252,312
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss for 2007
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(2,626,892 |
) |
|
|
(2,626,892 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at December 31, 2007
|
|
|
-
|
|
|
$ |
-
|
|
|
|
-
|
|
|
$ |
-
|
|
|
|
60,537,534
|
|
|
$ |
605,375
|
|
|
$ |
39,003,148
|
|
|
$ |
(35,345,697 |
) |
|
$ |
4,262,826
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes <
font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
FOR
THE YEARS ENDED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
Cash
received from customers
|
|
$ |
9,802,348
|
|
|
$ |
6,407,314
|
|
Cash
paid to suppliers and employees
|
|
|
(11,276,554 |
) |
|
|
(10,581,216 |
) |
Interest
received
|
|
|
145,289
|
|
|
|
29,532
|
|
Interest
paid
|
|
|
(16,879 |
) |
|
|
(58,553 |
) |
Net
cash used in operating activities
|
|
|
(1,345,796 |
) |
|
|
(4,202,923 |
) |
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Acquisition
of fixed assets
|
|
|
(410,425 |
) |
|
|
(374,513 |
) |
Net
cash used in investing activities
|
|
|
(410,425 |
) |
|
|
(374,513 |
) |
|
|
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
Sale
of Series C Preferred Stock and associated warrants, net of cash
cost of
financing of $110,000
|
|
|
-
|
|
|
|
7,440,285
|
|
Sale
of Series B Preferred Stock and associated warrants, net of cash
cost of
financing of $2,750
|
|
|
-
|
|
|
|
997,250
|
|
Payment
of obligation to related party
|
|
|
|
|
|
|
(182,181 |
) |
Proceeds
from bridge loan
|
|
|
-
|
|
|
|
1,300,000
|
|
Payment
on bridge loan
|
|
|
-
|
|
|
|
(699,755 |
) |
Payment
of accrued interest
|
|
|
(93,160 |
) |
|
|
(127,652 |
) |
Proceeds
from exercise of options and warrants, net of cash cost of financing
of
$561,816
|
|
|
558,545
|
|
|
|
146,321
|
|
Payment
of capital lease obligation
|
|
|
(52,181 |
) |
|
|
(38,368 |
) |
Payment
of dividends
|
|
|
(120,000 |
) |
|
|
(200,226 |
) |
Net
cash provided by financing activities
|
|
|
293,204
|
|
|
|
8,635,674
|
|
|
|
|
|
|
|
|
|
|
NET
(DECREASE) INCREASE IN CASH AND CASH
EQUIVALENTS
|
|
|
(1,463,017 |
) |
|
|
4,058,238
|
|
Cash
and cash equivalents - beginning of the period
|
|
|
4,290,386
|
|
|
|
232,148
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents - end of the period
|
|
$ |
2,827,369
|
|
|
$ |
4,290,386
|
|
|
|
|
|
|
|
|
|
|
Continues
on next page
|
|
|
|
|
|
|
|
|
|
See
accompanying notes
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
FOR
THE YEARS ENDED
|
(CONTINUED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
RECONCILIATION
OF NET INCOME TO NET CASH FROM OPERATING
ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Loss
|
|
$ |
(2,626,892 |
) |
|
$ |
(4,995,020 |
) |
Adjustments:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
283,359
|
|
|
|
209,541
|
|
Non-cash
interest expense
|
|
|
-
|
|
|
|
328,341
|
|
Loss
on retirement of fixed assests
|
|
|
12,146
|
|
|
|
-
|
|
Provision
for doubtful accounts
|
|
|
(32,922 |
) |
|
|
22,479
|
|
Common
stock, options and warrants issued as compensation
|
|
|
342,163
|
|
|
|
565,668
|
|
Expenses
related to conversion of bridge into Series C Preferred
Stock
|
|
|
-
|
|
|
|
99,469
|
|
Changes
in assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
436,822
|
|
|
|
(117,645 |
) |
Inventories
|
|
|
(344,900 |
) |
|
|
(420,967 |
) |
Prepaid
expenses and other current assets
|
|
|
(9,706 |
) |
|
|
88,895
|
|
Other
assets and deposits
|
|
|
64,948
|
|
|
|
(239,723 |
) |
Accounts
payable and accrued expenses
|
|
|
529,186
|
|
|
|
256,039
|
|
Net
cash used in operating activities
|
|
$ |
(1,345,796 |
) |
|
$ |
(4,202,923 |
) |
|
|
|
|
|
|
|
|
|
Supplemental
disclosures for non-cash investing and financing
activities:
|
|
|
|
|
|
|
|
|
Preferred
B issued as payment for financing fees
|
|
$ |
-
|
|
|
$ |
100,000
|
|
Warrants
issued with bridge loan
|
|
|
-
|
|
|
|
-
|
|
Value
of warrants issued allocated to additional paid-in capital
|
|
|
20,000
|
|
|
|
1,880,185
|
|
Value
of common stock and stock options issued
|
|
|
41,181
|
|
|
|
-
|
|
Cost
of royalty rate reduction in other assets
|
|
|
-
|
|
|
|
200,000
|
|
Accreted
beneficial conversion to preferred stock
|
|
|
-
|
|
|
|
2,187,149
|
|
Value
of deemed dividend
|
|
|
4,259,717
|
|
|
|
-
|
|
Accreted
dividend to preferred stock
|
|
|
1,385,594
|
|
|
|
1,022,897
|
|
Value
of Common stock issued as payment of dividend
|
|
|
1,739,930
|
|
|
|
642,879
|
|
Value
of Preferred B issued as payment of dividend
|
|
|
-
|
|
|
|
89,899
|
|
Value
of Preferred stock converted to common stock
|
|
|
5,733,346
|
|
|
|
482,657
|
|
Bridge
debt and associated interest converted into Series C Preferred
Stock
|
|
|
-
|
|
|
|
699,714
|
|
Assets
acquired under capital leases
|
|
|
110,810
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes
|
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
NOTE
1 — DESCRIPTION OF BUSINESS:
Chembio
Diagnostics, Inc. (the “Company” or “Chembio”) and its subsidiaries develop,
manufacture, and market rapid diagnostic tests that detect infectious diseases.
The Company’s main products presently commercially available are three rapid
tests for the detection of HIV antibodies in whole blood, serum and plasma
samples, two of which were approved by the FDA in 2006; the third is sold
for
export only. These products all employ single path lateral flow
technology. The Company also has a rapid test for Chagas
disease (a parasitic disease endemic in Latin America) as well as a line
of
rapid tests for veterinary tuberculosis, the first one of which is USDA
approved. The Company’s products are sold to medical
laboratories and hospitals, governmental and public health entities,
non-governmental organizations, medical professionals and retail establishments.
Chembio’s products are sold under the Company’s STAT PAK® or SURE CHECK ®
registered trademarks or under the private labels of its marketing partners,
such as is the case with the Clearview® label owned by Inverness Medical
Innovations, Inc., which is the Company’s exclusive marketing partner for its
rapid HIV test products in the United States.
The
Plan
On
December 19, 2007 (the “Closing Date”) amendments to the governing documents for
the Company’s Series A, Series B and Series C Convertible Preferred Stock
(collectively, the “Preferred Stock”) and for certain warrants and options
(collectively, the “Non-Employee Warrants”) not including options or warrants
issued to employees or directors in their capacity as such (these actions
collectively, the “Plan”) were approved by the Company and the requisite
percentages of the holders of the Preferred Stock and of the Non-Employee
Warrants.
Pursuant
to the terms of the Plan, on the Closing Date, all of the outstanding Series
A
and Series B Preferred Stock, other than the Series A Preferred and Series
B
Preferred held by the Company’s Chief Executive Officer (“CEO”), was converted
into 21,538,479 shares of the Company’s $.01 par value common stock (the “Common
Stock”) at a conversion rate of $0.40 per share of Common Stock. The
Series A Preferred and Series B Preferred held by the CEO was converted at
the
rate of $0.48 per share into 2,534,593 shares of Common Stock. All of
the outstanding Series C Preferred Stock was also converted into 17,187,496
shares of Common Stock at the rate of $0.48 per share, and the Company issued
1,273,235 shares of Common Stock as payment for any accrued but unpaid dividends
on any shares of the Preferred Stock outstanding on the Closing
Date.
On
the
Closing Date, the holders of all the Non-Employee Warrants were permitted
to
exercise their Non-Employee Warrants for cash at a reduced exercise price
of
$0.40 per share, or on a cashless basis at an exercise price of $0.45 per
share. The exercise of these Non-Employee Warrants on a cash and
cashless basis resulted in the Company issuing 3,686,566 shares of Common
Stock.
Non-Employee Warrant Holders that exercised at least 10% of their Non-Employee
Warrants for cash at $0.40 per share on the Closing Date are now permitted,
but
not required, to exercise the remaining balance of their Non-Employee Warrants
for cash or on a cashless basis at an exercise price of $0.45 per share at any
time on or before June 30, 2008.
Pursuant
to the terms of the approved Plan, if a Non-Employee Warrant holder exercised
at
least 10% of its warrants for cash at the Closing Date, but does not exercise
the remaining balance of its warrants for cash or on a cashless basis on
or
before June 30, 2008, the exercise price of its remaining warrants will revert
to the original exercise price on July 1, 2008, at which time they will be
permitted to exercise their Non-Employee Warrants on a cash or a cashless
basis.
For
a
consenting Non-Employee Warrant holder that did not exercise at least 10%
of its
warrants for cash at the Closing Date, the exercise price of its warrants
reverted to the original exercise price, subject to any applicable adjustment,
on December 20, 2007. Beginning April 1, 2008, in addition to
being exercisable for cash, a Non-Employee Warrant holder that did not exercise
at least 10% of its warrants for cash at the Closing Date will be permitted
to
exercise their warrants on a cashless basis based on the Volume Weighted
Average
Price (VWAP) for the ten-trading day period that ends on the first trading
day
immediately preceding the date of such warrant exercise. The Plan
amendments also provide that for those Non-Employee Warrant holders that
consented to the Plan, the anti-dilution and price reduction provisions of
the
Non-Employee Warrants will not cause any adjustment to the exercise price
or
number of shares issuable based on any issuance or other action taken in
connection with the Plan.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
Certain
holders of the Non-Employee Warrants did not consent to the Plan
transactions. Pursuant to the anti-dilution terms existing in certain
of the Non-Employee Warrants held by these non-consenting holders, the number
of
warrants that these non-consenting holders are permitted to exercise has
been
increased by 2,395,466. In addition, the exercise prices of certain
of the Non-Employee Warrants held by non-consenting holders was reduced to
$0.40
pursuant to the terms of these warrants, and these non-consenting holders
are
permitted to exercise their warrants for cash only at $0.40 per share until
the
expiration of the warrants.
The
Plan’s cashless exercise provision permits Non-Employee Warrant holders to use
any excess of the market price of the Company’s Common Stock over the exercise
price of a Non-Employee Warrant as part of the exercise price for another
Warrant by submitting both warrants at the time of exercise. Pursuant
to the Plan, Non-Employee Warrant holders were permitted at the Closing Date
to
use the greater of (i) $0.53 or (ii) the VWAP for the ten-trading day period
that ended on December 17, 2007 as the value of the Common Stock, so that
each
Non-Employee Warrant used as part of the exercise price payment on the Closing
Date represented the difference between the greater of these two values and
the
$0.45 Non-Employee Warrant exercise price. In addition, Non-Employee
Holders that exercised at least 10% of all of such holder's Non-Employee
Warrants for cash on the Closing Date are permitted between the Closing Date
and
June 30, 2008 to use the difference between the greater of these two values
and
the $0.45 Non-Employee Warrant exercise price as part of their exercise price
payment. Non-Employee Warrant Holders that did not exercise (x) at
least 10% of all of such holder's Non-Employee Warrants for cash at the Closing
Date, or (y) its Non-Employee Warrants on cashless basis at $0.45 per share
on
the Closing Date will only be permitted to exercise its Non-Employee Warrants
on
a cashless basis beginning on April 1, 2008, and at that point the value
of a
warrant to be used as part of the exercise price payment in such cashless
exercise will equal the excess of the VWAP for the ten-trading day period
that
ends on the first trading day immediately preceding the date of such warrant
exercise over the exercise price of a warrant.
In
connection with the Plan closing, the Company obtained $1,089,361 of
Non-Employee Warrant cash exercises on the Closing Date.
The
Company worked with Collins Stewart LLC (“Collins Stewart”), an investment
banking advisor, with respect to the Plan transactions. As
compensation for the services rendered by Collins Stewart, the Company paid
Collins Stewart certain cash fees, as well as reimbursement for its reasonable
counsel and out-of-pocket expenses related to the Plan, aggregating
approximately $312,000.
NOTE
2 — SIGNIFICANT ACCOUNTING POLICIES:
(a)
|
Principles
of Consolidation:
|
The
consolidated financial statements include the accounts of the Company, and
its
two wholly owned subsidiaries. All intercompany transactions and
balances have been eliminated in consolidation.
Inventories
are stated at the lower of cost or market. Cost is determined on the
first-in, first-out method.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
Fixed
assets are stated at cost less accumulated depreciation. Depreciation
is computed using the straight line method over the estimated useful lives
of
the respective assets, which range from three to seven
years. Leasehold improvements are amortized over the useful life of
the asset or the lease term, whichever is shorter.
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to
make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those
estimates.
The
Company accounts for income taxes under the provisions of Statement of Financial
Accounting Standards No. 109, “Accounting for Income Taxes” (SFAS
109). Under SFAS 109, deferred tax assets and liabilities are
determined based on the difference between the financial statement carrying
amounts and the tax bases of assets and liabilities using enacted tax rates
in
effect in the years in which the differences are expected to
reverse.
Effective
January 1, 2007, we adopted the Financial Accounting Standards Board (“FASB”)
Interpretation No. 48, Accounting for Uncertainty in Income Taxes,
an interpretation of FASB Statement No. 109 (“FIN 48”).
FIN 48 prescribes a more-likely-than-not threshold for financial statement
recognition and measurement of a tax position taken, or expected to be taken,
in
a tax return. FIN 48 also provides guidance related to, among other things,
classification, accounting for interest and penalties associated with tax
positions, and disclosure requirements. Any interest and penalties accrued
related to unrecognized tax benefits will be recorded in tax
expense. The adoption of FIN 48 had no impact on the Company’s
financial statements for the year ended December 31, 2007.
(f)
|
Research
and Development:
|
Research
and development costs are charged to expense as incurred.
(g)
|
Stock
Based Compensation:
|
Effective
January 1, 2006, the Company’s Plan is accounted for in accordance with the
recognition and measurement provisions of Statement of Financial Accounting
Standards ("FAS") No. 123 (revised 2004), Share-Based Payment ("FAS 123(R)"),
which replaces FAS No. 123, Accounting for Stock-Based Compensation, and
supersedes Accounting Principles Board Opinion ("APB") No. 25, Accounting
for
Stock Issued to Employees, and related interpretations. FAS 123(R) requires
compensation costs related to share-based payment transactions, including
employee stock options, to be recognized in the financial statements. In
addition, the Company adheres to the guidance set forth within Securities
and
Exchange Commission ("SEC") Staff Accounting Bulletin No. 107 ("SAB 107"),
which
provides the Staff's views regarding the interaction between SFAS No. 123(R)
and
certain SEC rules and regulations and provides interpretations with respect
to
the valuation of share-based payments for public companies. See
footnote 5 for further details.
(h)
|
Statements
of Cash Flows:
|
For
purposes of the statements of cash flows the Company considers all highly
liquid
investments with an original maturity of three months or less to be cash
equivalents.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
The
Company recognizes revenue in accordance with Securities and Exchange Commission
Staff Accounting Bulletin No. 104, “Revenue Recognition” (“SAB
104”). Under SAB 104, revenue is recognized when there is persuasive
evidence of an arrangement, delivery has occurred or services have been
rendered, the sales price is determinable, and collectability is reasonably
assured. Revenue typically is recognized at time of
shipment. Sales are recorded net of discounts, rebates and
returns.
The
Company recognizes income from research projects and grants when
earned. Grants are invoiced after expenses are
incurred. Any projects or grants funded in advance are deferred until
earned.
(j)
|
Concentrations
of Credit Risk:
|
Financial
instruments which potentially subject the Company to concentrations of credit
risk consist principally of temporary cash investments and trade receivables.
The Company places its temporary cash instruments with well-known financial
institutions and, at times, may maintain balances in excess of the $100,000
FDIC
Insurance limit. The Company monitors the credit ratings of the
financial institutions to mitigate this risk. The Company maintains
three accounts with a well established multi-national bank and as of December
31, 2007 had approximately $2.6 million above these limits. Concentration
of
credit risk with respect to trade receivables is principally mitigated by
the
Company’s obtaining of letters of credit from certain foreign customers, and its
diverse customer base both in number of customers and geographic
locations. We currently do not require collateral.
Fair
values of cash, accounts receivable, prepaid expenses and other current assets
and accounts payable and accrued expenses reflected in these financial
statements approximate carrying value as these are short-term in
nature.
(l)
|
Recent
Accounting Pronouncements Affecting the
Company:
|
In
September 2006, the staff of the SEC issued Staff Accounting Bulletin ("SAB")
No. 108, which provides interpretive guidance on how the effects of the
carryover or reversal of prior year misstatements should be considered in
quantifying a current year misstatement. SAB 108 became effective in fiscal
year
end December 31, 2007. Adoption of SAB 108 did not have a material impact
on the
Company's consolidated financial position, results of operations or cash
flows.
In
December 2006, the FASB issued FASB Staff Position ("FSP") EITF 00-19-2
"Accounting for Registration Payment Arrangements" ("FSP EITF 00-19-2") which
specifies that the contingent obligation to make future payments or otherwise
transfer consideration under a registration payment arrangement should be
separately recognized and measured in accordance with SFAS No. 5, "Accounting
for Contingencies." Adoption of FSP EITF 00-19-02 is required for fiscal
years
beginning after December 15, 2006, and isdid not have a material impact on
the
Company's consolidated financial position, results of operations or cash
flows.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements,
which defines fair value, establishes a framework for measuring fair value
in
generally accepted accounting principles, and expands disclosures about fair
value measurements. This statement does not require any new fair value
measurements, but provides guidance on how to measure fair value by providing
a
fair value hierarchy used to classify the source of the information. SFAS
No. 157 is effective for fiscal years beginning after November 15, 2007,
and all interim periods within those fiscal years. In December 2007, the
FASB
released a proposed FASB Staff Position (FSP FAS 157-b - Effective Date of
FASB
Statement No. 157) which, if adopted as proposed, would delay the effective
date of SFAS No. 157 for all nonfinancial assets and nonfinancial
liabilities, except those that are recognized or disclosed at fair value
in the
financial statements on a recurring basis (at least annually). We do not
believe
that adoption of this statement would have a material impact on our financial
statements.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
In
February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
Financial Assets and Financial Liabilities” (“SFAS No. 159”). SFAS No. 159
permits entities to choose to measure, on an item-by-item basis, specified
financial instruments and certain other items at fair
value. Unrealized gains and losses on items for which the fair value
option has been elected are required to be reported in earnings at each
reporting date. SFAS No. 159 is effective for fiscal years beginning
after November 15, 2007, the provisions of which are required to be applied
prospectively. The Company expects to adopt SFAS No. 159 in the first quarter
of
Fiscal 2008 and is still evaluating the effect, if any, on its financial
position or results of operations.
In
December 2007, the Financial Accounting Standards Board (“FASB”) issued
Statement of Financial Accounting Standards (“SFAS”) No. 141 (revised
2007), Business Combinations, which replaces SFAS No 141. The statement retains
the purchase method of accounting for acquisitions, but requires a number
of
changes, including changes in the way assets and liabilities are recognized
in
the purchase accounting. It also changes the recognition of assets acquired
and
liabilities assumed arising from contingencies, requires the capitalization
of
in-process research and development at fair value, and requires the expensing
of
acquisition-related costs as incurred. SFAS No. 141R is effective
for business combinations for which the acquisition date is on or after the
beginning of the first annual reporting period beginning on or after December
15, 2008.
In
December 2007, the FASB issued SFAS No. 160. “Noncontrolling
Interests in Consolidated Financial Statements-and Amendment of ARB No.
51.” SFAS 160 establishes accounting and reporting standards
pertaining to ownership interests in subsidiaries held by parties other than
the
parent, the amount of net income attributable to the parent and to the
noncontrolling interest, changes in a parent’s ownership interest, and the
valuation of any retained noncontrolling equity investment when a subsidiary
is
deconsolidated. This statement also establishes disclosure
requirements that clearly identify and distinguish between the interests
of the
parent and the interests of the noncontrolling owners. SFAS 160 is
effective for fiscal years beginning on or after December 15,
2008. The adoption of SFAS 160 is not currently expected to have a
material effect on the Company’s consolidated financial position, results of
operations, or cash flows.
Prior
to
the Plan (see Note 1), the Company’s Series C Preferred Stock contained
provisions whereby, under certain conditions outside of the control of
management, the holders could require redemption; accordingly, at December
31,
2006 it was classified outside of permanent equity.
As
per
the Plan (see Note 1) all classes of preferred stock were converted into
common
stock on December 19, 2007. Accordingly, no preferred stock was
outstanding on December 31, 2007.
The
following weighted average shares were used for the computation of basic
and
diluted earnings per share:
|
|
For
the years ended
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
Basic
|
|
|
14,608,478
|
|
|
|
10,293,168
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
14,608,478
|
|
|
|
10,293,168
|
|
Basic
loss per share is computed by dividing net loss attributable to common
stockholders by the weighted-average number of common shares outstanding
for the
period. Diluted loss per share reflects the potential dilution from the exercise
or conversion of other securities into Common Stock, but only if dilutive.
Diluted loss per share for the years ended December 31, 2007 and 2006 is
the
same as basic loss per share, since the effects of the calculation were
anti-dilutive due to the fact that the Company incurred losses for all periods
presented. The following securities, presented on a common share equivalent
basis, have been excluded from the per share computations:
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
|
|
For
the years ended
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
1999
Plan Stock Options
|
|
|
2,015,352
|
|
|
|
1,629,750
|
|
Other
Stock Options
|
|
|
124,625
|
|
|
|
144,625
|
|
Warrants
|
|
|
25,972,223
|
|
|
|
24,713,994
|
|
Convertible
Preferred Stock
|
|
|
25,872,315
|
|
|
|
16,835,036
|
|
NOTE
3 — GEOGRAPHIC INFORMATION:
SFAS
No.
131, “Disclosures about Segments of an Enterprise and Related Information”
establishes standards for the way that business enterprises report information
about operating segments in financial statements and requires that those
enterprises report selected information. It also establishes standards for
related disclosures about product and services, geographic areas, and major
customers.
The
Company produces only one group of similar products known collectively as
“rapid
medical tests”. As per the provisions of SFAS 131, management believes that it
operates in a single business segment. Net sales by geographic area are as
follows
|
|
For
the years ended
|
|
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
Africa
|
|
$ |
3,784,791
|
|
|
$ |
1,552,043
|
|
Asia
|
|
|
158,577
|
|
|
|
250,243
|
|
Europe
|
|
|
153,808
|
|
|
|
92,248
|
|
Middle
East
|
|
|
239,838
|
|
|
|
194,767
|
|
North
America
|
|
|
4,226,442
|
|
|
|
1,384,933
|
|
South
America
|
|
|
201,421
|
|
|
|
2,819,778
|
|
|
|
$ |
8,764,877
|
|
|
$ |
6,294,012
|
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
NOTE
4 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES:
Accounts
payable and accrued liabilities as of December 31:
|
|
December
31, 2007
|
|
|
December
31, 2006
|
|
Accounts
payable – suppliers
|
|
$ |
726,174
|
|
|
$ |
679,990
|
|
Accrued
commissions
|
|
|
14,251
|
|
|
|
91,920
|
|
Accrued
royalties / licenses
|
|
|
852,119
|
|
|
|
461,048
|
|
Accrued
payroll
|
|
|
279,598
|
|
|
|
87,637
|
|
Accrued
vacation
|
|
|
155,480
|
|
|
|
214,858
|
|
Accrued
legal and accounting
|
|
|
10,000
|
|
|
|
7,000
|
|
Accrued
expenses – other
|
|
|
138,169
|
|
|
|
167,486
|
|
TOTAL
|
|
$ |
2,175,791
|
|
|
$ |
1,709,939
|
|
NOTE
5 — EMPLOYEE STOCK OPTION PLAN:
The
Company had a 1999 Stock Option Plan (the “SOP”) originally covering 1,500,000
shares of Common Stock. Under the terms of the SOP, the Compensation Committee
of the Company’s board is authorized to grant incentive options to key employees
and to grant non-qualified options to key employees and key individuals.
The
options become exercisable at such times and under such conditions as determined
by the Compensation Committee. The SOP was amended at the Company’s
2005 stockholders’ meeting. The number of options under the SOP was
increased to cover 3,000,000 shares of common stock. It was also
amended to allow independent directors to be eligible for grants under the
portion of the SOP concerning non-qualified options.
Effective
January 1, 2006, the Company’s SOP is accounted for in accordance with the
recognition and measurement provisions of Statement of Financial Accounting
Standards ("FAS") No. 123 (revised 2004), Share-Based Payment ("FAS 123(R)"),
which replaces FAS No. 123, Accounting for Stock-Based Compensation, and
supersedes Accounting Principles Board Opinion ("APB") No. 25, Accounting
for
Stock Issued to Employees, and related interpretations. FAS 123(R) requires
compensation costs related to share-based payment transactions, including
employee stock options, to be recognized in the financial statements. In
addition, the Company adheres to the guidance set forth within Securities
and
Exchange Commission ("SEC") Staff Accounting Bulletin No. 107 ("SAB 107"),
which provides the Staff's views regarding the interaction between SFAS No.
123(R) and certain SEC rules and regulations and provides interpretations
with
respect to the valuation of share-based payments for public
companies.
As
a
result of the adoption of FAS 123(R), the Company's results for the years
ended
December 31, 2007 and 2006 include share-based compensation expense totaling
$252,000 and $279,000, respectively. Such amounts have been included
in the Condensed Consolidated Statements of Operations within cost of goods
sold
(none and $28,000, respectively), research and development ($100,000 and
$68,000, respectively) and selling, general and administrative expenses
($152,000 and $183,000, respectively). No income tax benefit has been
recognized in the income statement for share-based compensation arrangements
due
to the history of operating losses.
Stock
option compensation expense in the years ended December 31, 2007 and
2006 represent the estimated fair value of options outstanding which are
being amortized on a straight-line basis over the requisite vesting period
of
the entire award.
The
weighted average estimated fair value of stock options granted in the years
ended December 31, 2007 and 2006 was $.46 and $.53 per share,
respectively. The fair value of options at the date of grant was
estimated using the Black-Scholes option pricing model. The expected volatility
is based upon historical volatility of our stock and other contributing factors.
The expected term is determined using the simplified method as permitted
by SAB
107, as the Company has no history of employee exercise of options
to-date.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
The
assumptions made in calculating the fair values of options are as
follows:
|
|
For
the years ended
|
|
December
31, 2007
|
|
December
31, 2006
|
Expected
term (in years)
|
5
|
|
4
to 5
|
Expected
volatility
|
102.84%
to 106.31%
|
|
116.2%
to 118.16%
|
Expected
dividend yield
|
n/a
|
|
n/a
|
Risk-free
interest rate
|
4.50%
to 5.06%
|
|
4.39%
to 4.92%
|
The
Company granted 960,000 new options under the SOP during the year ended
December 31, 2007 at prices ranging from $.53 to $0.88 per share.
The
following table provides stock options activity for the years ended December
31,
2007 and 2006:
Stock
Options
|
|
Number
of Shares
|
|
|
Weighted
Average Exercise Price per Share
|
|
Weighted
Average Remaining Contractual Term
|
|
Aggregate
Intrinsic Value
|
|
Outstanding
at January 1, 2006
|
|
|
1,285,750
|
|
|
$ |
0.70
|
|
|
|
|
|
|
Granted
|
|
|
1,147,250
|
|
|
$ |
0.57
|
|
|
|
|
|
|
Exercised
|
|
|
(100,000 |
) |
|
$ |
0.62
|
|
|
|
|
|
|
Forfeited/expired
/cancelled
|
|
|
(803,250 |
) |
|
$ |
0.65
|
|
|
|
|
|
|
Outstanding
at December 31, 2006
|
|
|
1,529,750
|
|
|
$ |
0.65
|
|
3.60
years
|
|
$ |
204,866
|
|
Granted
|
|
|
960,000
|
|
|
$ |
0.57
|
|
|
|
|
|
|
|
Exercised
|
|
|
(50,000 |
) |
|
$ |
0.62
|
|
|
|
|
|
|
|
Forfeited/expired
|
|
|
(238,250 |
) |
|
$ |
0.67
|
|
|
|
|
|
|
|
Outstanding
at December 31, 2007
|
|
|
2,201,500
|
|
|
$ |
0.64
|
|
3.52
years
|
|
$ |
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable
at December 31, 2007
|
|
|
1,445,500
|
|
|
$ |
0.68
|
|
3.06
years
|
|
$ |
-
|
|
The
following table summarizes information about stock options outstanding as
of
December 31, 2007:
|
Stock
Options Outstanding
|
Stock
Options Exercisable
|
Range
of Exercise Prices
|
Shares
|
Average
Remaining Contract Life (Year)
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic Value
|
Shares
|
Weighted
Average Exercise Price
|
Aggregate
Intrinsic Value
|
$0.35
- 0.48
|
90,000
|
2.81
|
0.420
|
$ -
|
90,000
|
0.420
|
$ -
|
$0.53
- 0.60
|
887,500
|
4.29
|
0.557
|
-
|
243,500
|
0.572
|
-
|
$0.62
- 0.68
|
324,000
|
3.71
|
0.627
|
-
|
224,000
|
0.630
|
-
|
$0.75
- 0.88
|
900,000
|
2.80
|
0.755
|
-
|
888,000
|
0.755
|
-
|
Total
|
2,201,500
|
|
0.643
|
$ -
|
1,445,500
|
0.684
|
$ -
|
|
|
|
|
|
|
|
|
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
As
of
December 31, 2007, there was $217,000 of net unrecognized compensation cost
related to stock options that are not vested, which is expected to be recognized
over a weighted average period of approximately 0.53 years. The total
fair value of shares vested during the years ended December 31, 2007 and
2006,
was $276,000 and $421,000, respectively.
At
the
end of January 2008, subsequent to the balance sheet date, 210,000 options
were
forfeited. As of February 15, 2008, the board of directors voted to
re-price any SOP options in excess of $.48 to $.48, the estimated expense
related to this re-price is $20,000. In addition the board approved
the issuance of an additional 525,000 options under the SOP at an exercise
price, based on the closing market price on the date of grant, of $.22 per
share.
NOTE
6 — RELATED PARTIES:
The
Company had a liability to its President on December 31, 2006 for $65,000
of
accrued interest on prior debt that is not accruing additional
interest. The accrued interest was repaid in
2007. In addition, the Company had a liability to its
President for funds advanced by him to it or paid directly by him to vendors
on
its behalf of $182,000 (non-interest bearing and payable on demand) which
was
repaid in October of 2006.
In
September 2006, the Company received an investment of $2,000,000 from Inverness
Medical Innovations, Inc. (“Inverness”). Inverness markets the
Company’s FDA-approved rapid HIV tests under Inverness’ Clearview® brand,
Chembio received a nonexclusive license to Inverness’ lateral flow
patents. The distribution agreements with Inverness contain gross
margin sharing formulae among Inverness, the Company and, in the case of
the HIV
barrel product, StatSure Diagnostic Systems, Inc.
NOTE
7 — INVENTORIES:
Inventories
consist of at December 31:
|
|
2007
|
|
|
2006
|
|
Raw
Materials
|
|
$ |
705,873
|
|
|
$ |
629,967
|
|
Work
in Process
|
|
|
234,077
|
|
|
|
257,208
|
|
Finished
Goods
|
|
|
513,900
|
|
|
|
221,775
|
|
|
|
$ |
1,453,850
|
|
|
$ |
1,108,950
|
|
Fixed
assets consist of at December 31:
|
|
|
|
|
|
|
Machinery
and equipment
|
|
$ |
982,440
|
|
|
$ |
604,668
|
|
Furniture
and fixtures
|
|
|
156,313
|
|
|
|
139,624
|
|
Computer
and telephone equipment
|
|
|
308,591
|
|
|
|
259,078
|
|
Leasehold
improvements
|
|
|
306,676
|
|
|
|
226,415
|
|
Tooling
|
|
|
|
|
|
|
|
|
|
|
|
1,754,020
|
|
|
|
1,271,685
|
|
Less
accumulated depreciation and amortization
|
|
|
(924,688 |
) |
|
|
(668,082 |
) |
|
|
$ |
|
|
|
$ |
|
|
Included
in the above fixed assets is $121,000 and $53,000, net of accumulated
depreciation of $69,000 and $106,000 of assets held under capital leases
as of
December 31, 2007 and 2006, respectively. Depreciation expense
for the 2007 and 2006 years aggregated $283,359 and $209,541,
respectively.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
NOTE
9 — LONG-TERM DEBT / ACCRUED INTEREST PAYABLE:
In
connection with the Series B Preferred Stock offering interest payable on
certain debt was agreed to be paid over 33 months in installments of $10,000
per
month and a final payment of $3,160 in the 34th
month. These payments are subordinate to the redemption rights of the
Series B preferred stockholders. No additional interest accrues on
this payable. The accrued interest repaid was $93,160 and $120,000 in
the year ended 2007 and 2006, respectively. The balance
remaining unpaid was none and $93,160 as of December 31, 2007 and 2006,
respectively.
NOTE
10 — OBLIGATIONS UNDER CAPITAL LEASES:
The
Company is obligated under capitalized leases for certain manufacturing and
computer equipment.
Future
minimum lease payments under these capitalized lease obligations, including
interest as of December 31, 2007 were as follows:
Year
ending December 31,
2008
|
|
$ |
35,832
|
|
2009
|
|
|
28,572
|
|
2010
|
|
|
28,572
|
|
2011
|
|
|
28,572
|
|
2012
|
|
|
|
|
|
|
|
136,752
|
|
Less:
imputed interest
|
|
|
(33,706 |
) |
Present
value of future minimum lease payments
|
|
|
103,046
|
|
Less:
current maturities
|
|
|
(23,458 |
) |
|
|
$ |
|
|
These
leases have interest rates ranging from 9.5% - 15%.
NOTE
11 — RESEARCH GRANTS AND DEVELOPMENT CONTRACTS:
In
2007
and 2006, the Company earned research grants, feasibility and development
contracts in the amounts of $466,000 and $208,000,
respectively. The Company is now involved in additional
feasibility and development contracts related to its DPP™
technology. During 2007 we received $439,000 in fees for feasibility
studies and earned $396,000 on these contracts, the $43,000 difference is
reflected in deferred revenues. The Company expects to receive
additional feasibility and development contracts for its DPP technology in
2008.
No
provision for Federal income taxes was required for the years ended December
31,
2007 or 2006, due to the Company’s operating losses. At December 31,
2007 and 2006, the Company has unused net operating loss carry-forwards of
approximately $21,000,000 and $16,900,000 which expire at various dates through
2027. Most of this amount is subject to annual limitations under
certain provisions of the Internal Revenue Code related to “changes in
ownership”. In addition the Company has a research and development
credit carryforward of approximately $551,000 and $350,000 for the years
ended
December 31, 2007 and 2006, respectively which expire at various dates through
2027.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
As
of
December 31, 2007 and 2006, the deferred tax assets related to the
aforementioned carry-forwards have been fully offset by valuation allowances,
since significant utilization of such amounts is not presently expected in
the
foreseeable future.
Deferred
tax assets and valuation allowances consist of:
|
|
|
|
|
|
|
Net
operating loss carry-forwards
|
|
$ |
7,300,000
|
|
|
$ |
6,800,000
|
|
Research
and development credit
|
|
|
551,000
|
|
|
|
350,000
|
|
Other
|
|
|
|
|
|
|
|
|
Gross
deferred tax assets |
|
|
7,988,000
|
|
|
|
7,183,000
|
|
Valuation
allowances
|
|
|
(7,988,000 |
) |
|
|
(7,183,000 |
) |
Net
deferred tax assets
|
|
$ |
|
|
|
$ |
|
|
We
file
income tax returns in the U.S. federal and New York state
jurisdictions. Tax years for fiscal 2004 through 2006 are open and
potentially subject to examination by the federal and New York state taxing
authorities.
NOTE 13
— STOCKHOLDERS’ EQUITY:
(a) Common
Stock
On
December 19, 2007 the Company issued pursuant to the Plan (see Note
1):
i) 99,086,
599,331, and 574,818 shares of common stock for the payment of dividends
for the
Series A, B and C preferred stock, respectively. These shares were
valued, in the aggregate at $558,000, using the respective conversion price
at
the time of the conversion of the preferred stock;
ii) 10,134,954,
13,938,118, and 17,187,496 shares of common stock for the conversion of the
Series A, B and C preferred stock, respectively. These shares were valued,
in
the aggregate at $16,504,000, using the market price on December 19,
2007;
iii) 963,163
shares of common stock for the cashless exercise of 6,381,052 warrants,
and
iv) 2,723,403
shares of common stock for the cash exercise of warrants where the Company
received $1,089,000 less $562,000 paid in fees.
During
the year ended December 31, 2007, the Company issued 200,000 shares of its
Common Stock upon the execution of an employment agreement, of which 100,000
shares vested immediately, 50,000 shares will vest on March 5, 2008 and 50,000
shares will vest on March 5, 2009. These shares were valued at
the market price on the date of grant and aggregated $119,800 and are being
expensed over the vesting periods.
During
year ended December 31, 2007 the Company issued 50,000 shares of its Common
Stock upon the exercise of options and received cash of $31,000.
During
the year ended December 31, 2007 Series A Preferred shareholders, other than
in
the Plan, converted 8.33092 shares of Series A Preferred Stock into 416,546
shares of Common Stock.
During
the year ended December 31, 2007 Series B Preferred shareholders, other than
in
the Plan, converted 2.25 shares of Series B Preferred Stock into 184,426
shares
of Common Stock.
In
the
year ended December 31, 2007, other than in the Plan, the Company issued
897,896, 835,577 and 435,759 shares of its Common Stock as payment of dividends
on its Series C Preferred Stock, Series B Preferred Stock and Series A Preferred
Stock, respectively. These shares were valued, in the aggregate at $1,182,000,
using a volume weighted average price (VWAP) for the ten trading days
immediately preceding the issue date.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
During
the year ended December 31, 2006 the Company issued 163,750 shares, respectively
of its’ Common Stock to a consultant as compensation. The number of
shares issued was a fixed number set forth in the consultant’s contract, with
specific issue dates and without regard to the market price of the stock
on the
date of issuance. For accounting purposes, the shares were valued
based on the closing market price on dates of issuance from $0.55 to $0.91
per
share and the related compensation expense for the year ended December 31,
2006
was $129,029.
In
July
2006, the Company issued to a member of the Board of Directors 15,000 shares
of
common stock as additional compensation for services as the audit committee
chair. This stock was valued based on the market closing price on the
date of the grant and $10,650 was charged to expense.
During
the year ended December 31, 2006 Series A Preferred shareholders converted
8.75980 shares into 437,989 shares of Common Stock and Series B Preferred
shareholders converted 12.05966 shares into 988,494 shares of Common
Stock.
During
the year ended December 31, 2006 the Company issued 140,691 shares of its
Common
Stock upon the exercise of warrants and received cash of $86,321.
During
the year ended December 31, 2006 the Company issued 100,000 shares of its
Common
Stock upon the exercise of options and received cash of $60,000.
In
the
year ended December 31, 2006 the Company issued 543,168 shares of its Common
Stock as payment of dividends on its Series A Preferred Stock and 416,440
shares
of its Common Stock as payment of dividends on its Series B Preferred Stock,
These shares were valued using a 10 day volume weighted average price for
the
ten trading days immediately preceding the issue date.
(b) Warrants
On
December 19, 2007, in connection with the Plan (see Note 1) certain holders
of
the Non-Employee Warrants did not consent to the Plan
transactions. Pursuant to the anti-dilution terms existing in certain
of the Non-Employee Warrants held by these non-consenting holders, the number
of
warrants that these non-consenting holders are permitted to exercise has
been
increased by 2,395,466. In addition, the exercise prices of certain
of the Non-Employee Warrants held by non-consenting holders was reduced to
$0.40
pursuant to the terms of these warrants, and these non-consenting holders
are
permitted to exercise their warrants for cash only at $0.40 per share until
the
expiration of the warrants.
During
the year ended December 31, 2007, the Company issued warrants to purchase
33,381
shares of Common Stock at an exercise price of $0.81 per share to a sales
agent
as payment for commissions accrued at year end 2006 (value
$20,000). These warrants have a five-year life.
The
above
warrants were valued using a Black-Scholes option pricing model based on
assumptions for expected volatility of 104.8%, expected life of 5 years and
expected risk-free interest rate of 4.54%.
The
warrants to purchase 1,713,114 shares of Common Stock issued in connection
with
the March 2006 Series B offering were assigned a value of
$481,470. These warrants have an exercise price of $0.61 per
share and a five year life.
Warrants
to purchase 520,000 shares of Common Stock were issued in connection with
the
bridge loan and were assigned a value of $328,341. These warrants
have an exercise price of $0.75 per share and a five year life.
Warrants
to purchase 2,578,125 shares of Common Stock were issued in connection with
the
completed Series C Offering and were assigned a value of
$1,398,715. These warrants have an exercise price of $1.00 per
share and a five year life.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
During
the year ended December 31, 2006, the Company issued warrants to purchase
241,684 shares of Common Stock at exercise prices from $0.55 to $0.883 per
share
to a sales agent as payment for commissions (value $61,700) and commissions
accrued at year end 2005 (value $24,000) and to consultants as compensation
for
2006 ($51,324). These warrants have a five year life.
All
of
the above warrants were valued using a Black-Scholes option pricing model
based
on assumptions for expected volatilities from 116.2% to 118.16%, expected
lives
of 5 years and expected risk free interest rates from 4.39% to
5.13%.
(c) Series
A 8% Convertible Preferred Stock:
On
December 19, 2007, according to the Plan (see Note 1), all of the Series
A
preferred stock was converted into common stock. The common stock
issued was valued at the market price on December 19, 2007 of $.40 per
share. This value was adjusted against the carrying value of the
Series A Preferred Stock and the difference of $1,726,000 was charged to
deemed
dividends.
The
Series A Preferred Stock was issued in 2004 at a face value of $30,000 per
share
and came with detachable warrants. The recorded amount of the preferred shares
was calculated using a fair value allocation between the preferred shares
and
detachable warrants. Some key features included:
Dividends:
Holders of series A preferred stock are entitled to an 8% per annum dividend
per
share. The dividend accrues and is payable semi-annually either in
cash, in shares of series A preferred stock or in shares of common
stock. In June 2006, the Series A Preferred Stock was amended to
provide, among other amendments that dividends in Preferred or Common Stock
would be based on a 10 day volume weighted average market price at the time
of
the dividend. Accrued but unpaid dividends are also payable upon the
conversion or redemption of the shares of series A preferred stock and upon
our
liquidation, dissolution or winding up.
In
the
event the Company elects to pay any dividend in shares of common stock or
in
shares of series A preferred stock, so long as Vicis Capital Master Fund
owns
any shares of series A preferred stock, Vicis Capital Master Fund will receive
such dividend in cash unless it otherwise notifies the Company no later than
five (5) trading days prior to the date of the applicable dividend
payment. Such payment to Vicis Capital Master Fund will not affect
the Company’s election to make the applicable dividend payment in stock so long
as the only holder receiving the dividend payment in cash is Vicis Capital
Master Fund. To date all dividends have been paid in Common Shares, except
$180,000 which was paid in cash to Vicis Capital Master Fund.
Conversion:
Series A preferred stock is convertible, at the option of the holders, into
shares of Common Stock at a conversion price of $0.60 per share. Based on
its
original purchase price of $30,000 per share, each share of Series A Preferred
Stock is convertible into 50,000 shares of Common Stock.
Redemption:
The holders have the right, under certain conditions, to require redemption
of
all or a portion of such holder’s shares of Series A Preferred
Stock. As of December 31, 2007 and 2006 such conditions no longer
applied; accordingly, no accretion is being made to bring the value up to
its
redemption value. The liquidation preference was $30,000 per share
plus accrued and unpaid dividends. As of December 31, 2006, the
unpaid dividends were $400 per share, an aggregate for all such shares of
$4,557,604. Accrued but unpaid dividends of $62,528 are included in
the preferred stock carrying value as at December 31, 2006.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
(d) Series
B 9% Convertible Preferred Stock:
On
December 19, 2007, according to the Plan (see Note 1), all of the Series
B
preferred stock was converted into common stock. The common stock
issued was valued at the market price on December 19, 2007 of $.40 per
share. This value was adjusted against the carrying value of the
Series B Preferred Stock and the difference of $2,349,000 was charged to
deemed
dividends.
The
Series B Preferred Stock was issued in January 2005 at a face value of $50,000
per share with detachable warrants. The recorded amount of the preferred
shares
was calculated using a fair value allocation between the preferred shares
and
detachable warrants. On March 30, 2006, the Company sold $1 million of
additional Series B Preferred Stock to a Series B Preferred shareholder pursuant
to provisions of the January 2005 Series B 9% Preferred Stock financing
agreements. Such provisions were exclusive to said
shareholder. Approximately $140,000 of these proceeds was used to pay
cash dividends which were accrued as of December 31, 2005. The
recorded amount of the preferred shares was calculated using a fair value
allocation between the preferred shares and detachable warrants. Some
key features of the Series B Preferred Stock are as follows:
Dividends:
The 9% Series B Preferred Stock accrues dividends at 9% per annum, payable
semi-annually. Dividends are payable in Series B Preferred Stock, Common
Stock
or in cash. In June 2006, the Series B Preferred Stock was amended to provide,
among other amendments that the dividend could be paid in Common Stock (in
addition to Preferred Stock or cash) and that dividends in Preferred or Common
Stock would be based on a 10 day volume weighted average market price at
the
time of the dividend. The majority investor in the Series B financing
has the option as it pertains to its dividend payment to choose cash or
Preferred or Common shares. The Company has the option to choose cash or
Preferred or Common shares as to the balance of the dividends. To
date all dividends have been paid in Preferred or Common Shares, except $140,226
which was paid in cash at the option of the majority investor.
In
the
event any dividend is issued, any holder of the majority of the outstanding
series B preferred stock at the dividend payment date, may elect whether
to
receive dividends on series B preferred stock in cash, in common stock or
in
shares of series B preferred stock in its sole discretion.
Conversion:
The Series B Preferred Stock is convertible, at the option of the holders,
into
shares of Common Stock at a conversion price of $.61 per share. Based on
the
original purchase price of $50,000 per share, each share of Series B Stock
is
convertible into 81,967 shares of Common Stock.
Redemption:
The holders have the right, under certain conditions, to require redemption
of
all or a portion of such holder’s shares of Series B Preferred Stock. As of
December 31, 2006 and 2005 such conditions no longer applied; accordingly,
no
accretion is being made to bring the value up to its redemption value. The
liquidation preference is $50,000 per share plus accrued and unpaid dividends.
As of December 31, 2006, the unpaid dividends were $2,300 per share, an
aggregate for all such shares of $5,958,848. Accrued but unpaid
dividends of $262,053 are included in the preferred stock carrying value
as at
December 31, 2006.
As
per
EITF 00-27 “Application of Issue 98-5 to Certain Convertible Instruments”, the
Company evaluated the Series B Preferred Stock transaction that occurred
on
March 30, 2006, see above, and found that there was an associated beneficial
conversion feature totaling $463,434; the preferred stock was further discounted
by this amount. The beneficial conversion amount was then accreted back to
the
preferred stock in accordance with the conversion provision which allowed
for
100% to be converted immediately.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
(e) Series
C 7% Convertible Preferred
Stock:
On
December 19, 2007, according to the Plan (see Note 1), all of the Series
C
preferred stock was converted into common stock. The common stock
issued was valued at the market price on December 19, 2007 of $.40 per
share. This value was adjusted against the carrying value of the
Series C Preferred Stock and the difference of $185,102 was charged to deemed
dividends.
On
September 29, 2006 and October 5, 2006, the Company sold $8.25 million of
Series
C Preferred Stock (see Note 1) pursuant to provisions of the September 29,
2006
as amended on October 5, 2006 Series C 7% Preferred Stock financing
agreements. In addition the Company issued 2,578,125 warrants to the
investors. See Note 13(b) for information on the
warrants. A summary of the significant terms as amended on October 5,
2006 are as follows:
Dividends.
Holders of series C preferred stock are entitled to a 7% per annum
dividend per share. The dividend accrues and is payable semi-annually in
cash or
in shares of common stock, at our option. Accrued but unpaid
dividends are also payable upon the conversion or redemption of the shares
of
series C preferred stock and upon a liquidation event.
Conversion.
The series C preferred stock is convertible, at the option of the holders,
into shares of our common stock at a conversion price of $.80 per share.
Based
on the original purchase price of $50,000 per share, each share of series
C
preferred stock is convertible into 62,500 shares of our common
stock.
Redemption:
The holders have the right, under certain conditions, to require redemption
of
all or a portion of such holder’s shares of Series C Preferred Stock. The
redemption value is the greater of (i) 130% of the stated value or $65,000
and
(ii) the product of (a) daily volume weighted average price of the Company’s
common stock and (b) a quotient of $65,000 divided by the then existing
conversion price, plus accrued and unpaid dividends and all liquidated
damages.
Liquidation
preference: The liquidation preference is $50,000 per share plus accrued
and
unpaid dividends and all liquidated damages. The liquidation
preference is $50,000 per share plus accrued and unpaid
dividends. As of December 31, 2006, the unpaid dividends were
$894.44 per share, an aggregate for all such shares of $8,397,583. Accrued
but
unpaid dividends of $147,583 are included in the preferred stock carrying
value
as at December 31, 2006
The
Company has accounted for the Series C Offering pursuant to the provisions
of
Statement of Financial Accounting Standards No. 133, “Accounting for Derivative
Instruments and Hedging Activities” and EITF 00-19: “Accounting for
Derivative Financial Instruments Indexed to, and Potentially Settled in,
a
Company's Own Stock” (“EITF 00-19”). The Company has allocated the value
received between the preferred stock and the related warrants. The
allocated value for the preferred stock and the related warrants were $6,851,285
and $1,398,715, respectively. Further, the Company has determined
that the redemption feature in the Series C Preferred Stock needs to be
bifurcated and has valued the same at $449,677. The warrant value and
the value of the redemption feature is treated as a discount and the preferred
stock is reflected net of this discount. Due to the contingent
redemption feature, the Series C Preferred Stock is reflected as temporary
equity. The Series C Preferred Stock is not currently redeemable and
there is no likelihood that it will become redeemable; accordingly, no accretion
is being made to bring the carrying value up to its redemption value. The
liability for the value of the redemption feature will be “marked to market” in
future accounting periods until such time as the redemption is exercised
or the
feature meets the criteria for equity classification. See Note 13(b)
for the valuation of warrants.
In
addition, as per EITF 00-27 “Application of Issue 98-5 to Certain Convertible
Instruments”, the Company evaluated the Series C Preferred Stock transaction
that occurred in September 2006 and found that there were associated beneficial
conversion features totaling $1,723,715; the preferred stock was further
discounted by this amount. The beneficial conversion amount related to the
valuation of the preferred stock was then accreted back to the preferred
stock
in accordance with the conversion provision which allowed for 100% to be
converted immediately. The accretion was reflected as dividend
expense.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
NOTE
14 — COMMITMENTS AND CONTINGENCIES:
Employment
Contracts:
The
Company has contracts with two key employees. The contracts call for
salaries presently aggregating $425,000 per year. One contract
expires in May of 2008 and one contract expires in March of 2010. The
following table is a schedule of future minimum salary commitments:
2008
|
|
$ |
314,167
|
|
2009
|
|
|
230,833
|
|
2010
|
|
|
|
|
|
|
$ |
|
|
Pension
Plan:
The
Company has a 401(k) plan established for its employees. The Company
opted to match 20% of the first 5% (or 1% of salary) that an employee
contributes to their 401(k) plan. Expenses related to this match
aggregated $20,500 for the year ended December 31, 2007. The Company
did not elect to make any matching contributions for the year ended December
31,
2006.
Obligations
Under Operating Leases:
The
Company leases office and manufacturing facilities. The current lease
expires on April 30, 2009. The following is a schedule of future
minimum rental commitments:
Year
ending December 31,
The
Company has an option to renew the lease for an additional two year term
with a
nominal increase.
Rent
expense aggregated $123,500 and $100,500 for the years ended December 31,
2007
and 2006, respectively.
CHEMBIO
DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER
31, 2007 AND 2006
Economic
Dependency:
The
Company had sales to three customers each in excess of 10% of total sales
in the
year ended December 31, 2007. Sales to these customers aggregated
approximately $2,456,000, $2,249,000 and $1,398,000,
respectively. This represents approximately 70% of total
sales. Accounts receivable as of December 31, 2007 from these
customers approximated $222,000, none and none, respectively.
The
Company had sales to four customers each in excess of 10% of total sales
in the
year ended December 31, 2006. Sales to these customers aggregated
approximately $1,530,000, $1,223,000, $1,092,000 and $814,000,
respectively. This represents approximately 74% of total
sales. Accounts receivable as of December 31, 2007 from these
customers approximated $380,000, none, $568,000 and $174,000,
respectively.
The
Company had purchases from one vendor in excess of 10% of total purchases
for
the year ended December 31, 2007. Purchases from this vendor
aggregated approximately $356,000. Accounts payable as of December
31, 2007 to this vendor approximated $19,000.
The
Company had purchases from one vendor in excess of 10% of total purchases
for
the year ended December 31, 2006. Purchases from this vendor
aggregated approximately $244,000. Accounts payable as of December
31, 2006 to this vendor approximated $4,000.
Governmental
Regulation:
All
of
the Company’s existing and proposed diagnostic products are regulated by the
United States Food and Drug Administration (FDA), United States Department
of
Agriculture, certain state and local agencies, and/or comparable regulatory
bodies in other countries. Most aspects of development, production,
and marketing, including product testing, authorizations to market, labeling,
promotion, manufacturing, and record keeping are subject to
review. After marketing approval has been granted, Chembio must
continue to comply with governmental regulations. Failure to comply
with these regulations can result in significant penalties.
License
Agreement:
The
Company entered into a license agreement, effective February 1, 2008, whereby
it
agreed to pay $1,000,000 in non-refundable license fees: $500,000 during
2008
and $500,000 in 2009. The Company is also obligated to pay a royalty
based on eligible sales of the licensed product.
F-25
ex4_1.htm
Exhibit
4.1
SECOND
AMENDED AND RESTATED CERTIFICATE OF DESIGNATION
OF
THE RELATIVE RIGHTS AND PREFERENCES
OF
THE
SERIES
A CONVERTIBLE PREFERRED STOCK
OF
CHEMBIO
DIAGNOSTICS, INC.
The
undersigned, the Chief Financial Officer of Chembio Diagnostics, Inc., a
Nevada
corporation (the “Company”), in accordance with the provisions of the
Nevada Revised Statutes, does hereby certify that, pursuant to the authority
conferred upon the Board of Directors by the Articles of Incorporation of
the
Company, the following resolution amending and restating the Certificate
of
Designation of the Series A Convertible Preferred Stock, was duly adopted
with shareholder consent:
RESOLVED,
that pursuant to the authority expressly granted to and vested in the Board
of
Directors of the Company by provisions of the Articles of Incorporation of
the
Company (the “Articles of Incorporation”), there hereby is created out of
the shares of Preferred Stock, par value $.01 per share, of the Company
authorized in Article IV of the Articles of Incorporation (the
“Preferred Stock”), a series of Preferred Stock of the Company, to be
named “Series A Convertible Preferred Stock,” consisting of Two Hundred
Fifty (250) shares, which series shall have the following designations, powers,
preferences and relative and other special rights and the following
qualifications, limitations and restrictions:
1. Designation
and Rank. The designation of such series of the Preferred Stock
shall be the Series A Convertible Preferred Stock, par value $.01 per share
(the “Series A Preferred Stock”). The maximum number of
shares of Series A Preferred Stock shall be Two Hundred Fifty (250)
shares. The Series A Preferred Stock shall rank senior to the
common stock, par value $.01 per share (the “Common Stock”), and to all
other classes and series of equity securities of the Company which by their
terms do not rank senior to the Series A Preferred Stock (“Junior
Stock”). The Series A Preferred Stock shall be subordinate
to and rank junior to all indebtedness of the Company now or hereafter
outstanding.
2. Dividends.
(a) Payment
of Dividends. Subject to Section 5(c)(ii) hereof, the holders of
record of shares of Series A Preferred Stock shall be entitled to receive,
out of any assets at the time legally available therefor and when and as
declared by the Board of Directors, dividends at the rate of eight percent
(8%)
of the stated Liquidation Preference Amount (as defined in Section 4
hereof) per share per annum commencing on the date of issuance (the “Issuance
Date”) of the Series A Preferred Stock (the “Dividend Payment”),
and no more, payable semi-annually at the option of the Company in cash,
shares
of Series A Preferred Stock or shares of Common Stock. If the
Company elects to pay any dividend in shares of Common Stock, the number
of
shares of Common Stock to be issued to the holder shall be an amount equal
to
the quotient of (i) the Dividend Payment divided by (ii) the volume
weighted average trading price (the “VWAP”) of the Common Stock for the
10 trading days preceding the dividend record date. As used in this
Certificate, the term “volume weighted average trading price”, or “VWAP”, shall
mean, for any period of time, the sum of the purchase prices charged for
all
shares sold during that period of time divided by the number of shares sold
during that period of time. If the Company elects to pay any dividend
in shares of Series A Preferred Stock, the number of shares of
Series A Preferred Stock to be issued to the holder shall be an amount
equal to the quotient of (i) the Dividend Payment divided by (ii) the
VWAP of the Common Stock for the 10 trading days preceding the dividend record
date and then issuing that number of shares of Series A Preferred Stock
that would at the time of the calculation be convertible into the number
of
shares determined by dividing the Dividend Payment by the 10-day VWAP;
provided, that, the Company may only elect to pay any dividend in
shares of Series A Preferred Stock if the amount of such shares shall not
be less than one-tenth of one share of Series A Preferred Stock or a
multiple of one-tenth of one share of Series A Preferred
Stock. If the Company elects or is required to pay any dividend in
Common Stock or Series A Preferred Stock, the Company will give the holders
of record of shares of the Series A Preferred Stock ten (10) trading days
notice prior to the date of the applicable Dividend Payment. In the
case of shares of Series A Preferred Stock outstanding for less than a full
year, dividends shall be pro rated based on the portion of each year during
which such shares are outstanding. Dividends on the Series A
Preferred Stock shall be cumulative, shall accrue and be payable
semi-annually. Dividends on the Series A Preferred Stock are
prior and in preference to any declaration or payment of any distribution
(as
defined below) on any outstanding shares of Junior Stock. Such
dividends shall accrue on each share of Series A Preferred Stock from day
to day whether or not earned or declared so that if such dividends with respect
to any previous dividend period at the rate provided for herein have not
been
paid on, or declared and set apart for, all shares of Series A Preferred
Stock at the time outstanding, the deficiency shall be fully paid on, or
declared and set apart for, such shares on a pro rata basis with all other
equity securities of the Company ranking on a parity with the Series A
Preferred Stock as to the payment of dividends before any distribution shall
be
paid on, or declared and set apart for Junior Stock. Notwithstanding
the foregoing, if the Company elects to pay any dividend in shares of Common
Stock or in shares of Series A Preferred Stock, so long as Vicis Capital
Master Fund owns any shares of Series A Preferred Stock, Vicis Capital
Master Fund will be deemed to have elected to receive such dividend in cash
unless it otherwise notifies the Company no later than five (5) trading days
prior to the date of the applicable Dividend Payment. Such payment to
Vicis Capital Master Fund will not affect the Company’s election to make the
applicable Dividend Payment in stock so long as the only holder receiving
the
Dividend Payment in cash is Vicis Capital Master Fund.
(b) So
long
as any shares of Series A Preferred Stock are outstanding, the Company
shall not declare, pay or set apart for payment any dividend or make any
distribution on any Junior Stock (other than dividends or distributions payable
in additional shares of Junior Stock), unless at the time of such dividend
or
distribution the Company shall have paid all accrued and unpaid dividends
on the
outstanding shares of Series A Preferred Stock.
(c) In
the
event of a dissolution, liquidation or winding up of the Company pursuant
to
Section 4, all accrued and unpaid dividends on the Series A Preferred
Stock shall be payable on the date of payment of the preferential amount
to the
holders of Series A Preferred Stock. In the event of (i) a
mandatory redemption pursuant to Section 9 or (ii) a redemption upon
the occurrence of a Major Transaction (as defined in Section 8(c)) or a
Triggering Event (as defined in Section 8(d)), all accrued and unpaid dividends
on the Series A Preferred Stock shall be payable on the date of such
redemption. In the event of a voluntary conversion pursuant to
Section 5(a), all accrued and unpaid dividends on the Series A
Preferred Stock being converted shall be payable on the day immediately
preceding the Voluntary Conversion Date (as defined in Section
5(b)(i)).
(d) For
purposes hereof, unless the context otherwise requires, “distribution” shall
mean the transfer of cash or property without consideration, whether by way
of
dividend or otherwise, payable other than in shares of Common Stock or other
equity securities of the Company, or the purchase or redemption of shares
of the
Company (other than redemptions set forth in Section 8 below or repurchases
of Common Stock held by employees or consultants of the Company upon termination
of their employment or services pursuant to agreements providing for such
repurchase or upon the cashless exercise of options held by employees or
consultants) for cash or property.
3. Voting
Rights.
(a) Class
Voting Rights. The Series A Preferred Stock shall have the
following class voting rights (in addition to the voting rights set forth
in
Section 3(b) hereof). So long as any shares of the Series A
Preferred Stock remain outstanding, the Company shall not, without the
affirmative vote or consent of the holders of at least three-fourths (3/4)
of
the shares of the Series A Preferred Stock outstanding at the time, given
in person or by proxy, either in writing or at a meeting, in which the holders
of the Series A Preferred Stock vote separately as a
class: (i) amend, alter or repeal the provisions of the
Series A Preferred Stock, whether by merger, consolidation or otherwise, so
as to adversely affect any right, preference, privilege or voting power of
the
Series A Preferred Stock; provided, however, that any
creation and issuance of another series of Junior Stock shall not be deemed
to
adversely affect such rights, preferences, privileges or voting powers;
(ii) repurchase, redeem or pay dividends on, shares of Common Stock or any
other shares of the Company’s Junior Stock (other than de minimus repurchases
from employees of the Company in certain circumstances); (iii) amend the
Articles of Incorporation or By-Laws of the Company so as to affect materially
and adversely any right, preference, privilege or voting power of the
Series A Preferred Stock; provided, however, that any
creation and issuance of another series of Junior Stock shall not be deemed
to
adversely affect such rights, preferences, privileges or voting powers;
(iv) effect any distribution with respect to Junior Stock;
(v) reclassify the Company’s outstanding securities; (vi) voluntarily
file for bankruptcy, liquidate the Company’s assets or make an assignment for
the benefit of the Company’s creditors; or (vii) change the nature of the
Company’s business. Notwithstanding the foregoing to the contrary, so
long as at least $1,000,000 of Series A Preferred Stock is outstanding, the
Company shall not, without the affirmative vote or consent of the holders
of at
least three-fourths (3/4) of the shares of the Series A Preferred Stock
outstanding at the time, authorize, create, issue or increase the authorized
or
issued amount of any class or series of stock, including but not limited
to the
issuance of any more shares of previously authorized Common Stock or Preferred
Stock, ranking paripassu or senior to the Series A Preferred
Stock (except for shares of Series A Preferred Stock to be issued to
certain holders of promissory notes issued by the Company in satisfaction
of
outstanding indebtedness in an amount not to exceed $750,000 and the issuance
of
shares of Series A Preferred Stock with respect to the payment of dividends
on such shares of Series A Preferred Stock), with respect to the
distribution of assets on liquidation, dissolution or winding up.
(b) General
Voting Rights. Except with respect to transactions upon which the
Series A Preferred Stock shall be entitled to vote separately as a class
pursuant to Section 3(a) above and except as otherwise required by Nevada
law, the Series A Preferred Stock shall have no voting
rights. The Common Stock into which the Series A Preferred Stock
is convertible shall, upon issuance, have all of the same voting rights as
other
issued and outstanding Common Stock of the Company.
4. Liquidation
Preference.
(a) In
the
event of the liquidation, dissolution or winding up of the affairs of the
Company, whether voluntary or involuntary, the holders of shares of the
Series A Preferred Stock then outstanding shall be entitled to receive, out
of the assets of the Company available for distribution to its stockholders,
an
amount equal to $30,000 per share (the “Liquidation Preference Amount”)
of the Series A Preferred Stock plus any accrued and unpaid dividends
before any payment shall be made or any assets distributed to the holders
of the
Common Stock or any other Junior Stock. If the assets of the Company
are not sufficient to pay in full the Liquidation Preference Amount plus
any
accrued and unpaid dividends payable to the holders of outstanding shares
of the
Series A Preferred Stock and any series of preferred stock or any other
class of stock on a parity, as to rights on liquidation, dissolution or winding
up, with the Series A Preferred Stock, then all of said assets will be
distributed among the holders of the Series A Preferred Stock and the other
classes of stock on a parity with the Series A Preferred Stock, if any,
ratably in accordance with the respective amounts that would be payable on
such
shares if all amounts payable thereon were paid in full. The
liquidation payment with respect to each outstanding fractional share of
Series A Preferred Stock shall be equal to a ratably proportionate amount
of the liquidation payment with respect to each outstanding share of
Series A Preferred Stock. All payments for which this
Section 4(a) provides shall be in cash, property (valued at its fair market
value as determined by an independent appraiser reasonably acceptable to
the
holders of a majority of the Series A Preferred Stock) or a combination
thereof; provided, however, that no cash shall be paid to holders
of Junior Stock unless each holder of the outstanding shares of Series A
Preferred Stock has been paid in cash the full Liquidation Preference Amount
plus any accrued and unpaid dividends to which such holder is entitled as
provided herein. After payment of the full Liquidation Preference
Amount plus any accrued and unpaid dividends to which each holder is entitled,
such holders of shares of Series A Preferred Stock will not be entitled to
any further participation as such in any distribution of the assets of the
Company.
(b) A
consolidation or merger of the Company with or into any other corporation
or
corporations, or a sale of all or substantially all of the assets of the
Company, or the effectuation by the Company of a transaction or series of
related transactions in which more than 50% of the voting shares of the Company
is disposed of or conveyed, shall not be deemed to be a liquidation,
dissolution, or winding up within the meaning of this
Section 4. In the event of the merger or consolidation of the
Company with or into another corporation, the Series A Preferred Stock
shall maintain its relative powers, designations and preferences provided
for
herein and no merger inconsistent therewith shall result.
(c) Written
notice of any voluntary or involuntary liquidation, dissolution or winding
up of
the affairs of the Company, stating a payment date and the place where the
distributable amounts shall be payable, shall be given by mail, postage prepaid,
no less than forty-five (45) days prior to the payment date stated therein,
to
the holders of record of the Series A Preferred Stock at their respective
addresses as the same shall appear on the books of the Company.
5. Conversion. The
holder of Series A Preferred Stock shall have the following conversion
rights (the “Conversion Rights”):
(a) Right
to Convert.
(i) Subject
to Section 5(a)(ii) below, at any time on or after the Issuance Date, the
holder
of any such shares of Series A Preferred Stock may, at such holder’s
option, subject to the limitations set forth in Section 7 herein, elect to
convert (a “Voluntary Conversion”) all or any portion of the shares of
Series A Preferred Stock held by such person into a number of fully paid
and nonassessable shares of Common Stock equal to the quotient of (i) the
Liquidation Preference Amount of the shares of Series A Preferred Stock
being converted divided by (ii) the Conversion Price (as defined in
Section 5(d) below) then in effect as of the date of the delivery by such
holder of its notice of election to convert. In the event of a notice
of redemption of any shares of Series A Preferred Stock pursuant to
Section 8 hereof, the Conversion Rights of the shares designated for
redemption shall terminate at the close of business on the last full day
preceding the date fixed for redemption, unless the redemption price is not
paid
on such redemption date, in which case the Conversion Rights for such shares
shall continue until such price is paid in full. In the event of a
liquidation, dissolution or winding up of the Company, the Conversion Rights
shall terminate at the close of business on the last full day preceding the
date
fixed for the payment of any such amounts distributable on such event to
the
holders of Series A Preferred Stock. In the event of such a
redemption or liquidation, dissolution or winding up, the Company shall provide
to each holder of shares of Series A Preferred Stock notice of such
redemption or liquidation, dissolution or winding up, which notice shall
(i) be sent at least fifteen (15) days prior to the termination of the
Conversion Rights and (ii) state the amount per share of Series A
Preferred Stock that will be paid or distributed on such redemption or
liquidation, dissolution or winding up, as the case may be.
(ii) A
holder
of Series A Preferred Stock may not convert greater than twenty percent
(20%) of its shares of Series A Preferred Stock until the earlier of
(A) six (6) months following the effective date (the “Effectiveness
Date”) of the registration statement providing for the resale of the shares
of Common Stock issuable upon conversion of the Series A Preferred Stock
(the “Registration Statement”) or (B) ten (10) months following the
Issuance Date.
(b) Mechanics
of Voluntary Conversion. The Voluntary Conversion of
Series A Preferred Stock shall be conducted in the following
manner:
(i) Holder’s
Delivery Requirements. To convert Series A Preferred Stock
into full shares of Common Stock on any date (the “Voluntary Conversion
Date”), the holder thereof shall (A) transmit by facsimile (or
otherwise deliver), for receipt on or prior to 5:00 p.m., New York time on
such
date, a copy of a fully executed notice of conversion in the form attached
hereto as Exhibit I (the “Conversion Notice”), to the
Company, and (B) surrender to a common carrier for delivery to the Company
as soon as practicable following such Voluntary Conversion Date but in no
event
later than three (3) business days after such date the original certificates
representing the shares of Series A Preferred Stock being converted (or an
indemnification undertaking with respect to such shares in the case of their
loss, theft or destruction) (the “Preferred Stock Certificates”) and the
originally executed Conversion Notice.
(ii) Company’s
Response. Upon receipt by the Company of a facsimile copy of a
Conversion Notice, the Company shall immediately send, via facsimile, a
confirmation of receipt of such Conversion Notice to such
holder. Upon receipt by the Company of a copy of the fully executed
Conversion Notice, the Company or its designated transfer agent (the
“Transfer Agent”), as applicable, shall, within three (3) business days
following the date of receipt by the Company of the fully executed Conversion
Notice (so long as the applicable Preferred Stock Certificates and original
Conversion Notice are received by the Company on or before such third business
day), issue and deliver to the Depository Trust Company (“DTC”) account
on the Holder’s behalf via the Deposit Withdrawal Agent Commission System
(“DWAC”) as specified in the Conversion Notice, registered in the name of
the holder or its designee, for the number of shares of Common Stock to which
the holder shall be entitled. If the number of shares of Preferred
Stock represented by the Preferred Stock Certificate(s) submitted for conversion
is greater than the number of shares of Series A Preferred Stock being
converted, then the Company shall, as soon as practicable and in no event
later
than three (3) business days after receipt of the Preferred Stock Certificate(s)
and at the Company’s expense, issue and deliver to the holder a new Preferred
Stock Certificate representing the number of shares of Series A Preferred
Stock not converted.
(iii) Dispute
Resolution. In the case of a dispute as to the arithmetic
calculation of the number of shares of Common Stock to be issued upon
conversion, the Company shall cause its Transfer Agent to promptly issue
to the
holder the number of shares of Common Stock that is not disputed and shall
submit the arithmetic calculations to the holder via facsimile as soon as
possible, but in no event later than three (3) business days after receipt
of
such holder’s Conversion Notice. If such holder and the Company are
unable to agree upon the arithmetic calculation of the number of shares of
Common Stock to be issued upon such conversion within two (2) business days
of
such disputed arithmetic calculation being submitted to the holder, then
the
Company shall within two (2) business days submit via facsimile the disputed
arithmetic calculation of the number of shares of Common Stock to be issued
upon
such conversion to the Company’s independent, outside accountant. The
Company shall cause the accountant to perform the calculations and notify
the
Company and the holder of the results no later than four (4) business days
from
the time it receives the disputed calculations. Such accountant’s
calculation shall be binding upon all parties absent manifest
error. The reasonable expenses of such accountant in making such
determination shall be paid by the Company in the event the holder’s calculation
was correct, or by the holder in the event the Company’s calculation was
correct, or equally by the Company and the holder in the event that neither
the
Company’s or the holder’s calculation was correct. The period of time
in which the Company is required to effect conversions or redemptions under
this
Certificate of Designation shall be tolled with respect to the subject
conversion or redemption pending resolution of any dispute by the Company
made
in good faith and in accordance with this Section 5(b)(iii).
(iv) Record
Holder. The person or persons entitled to receive the shares of
Common Stock issuable upon a conversion of the Series A Preferred Stock
shall be treated for all purposes as the record holder or holders of such
shares
of Common Stock on the Conversion Date.
(v) Company’s
Failure to Timely Convert. If within five (5) business days of
the Company’s receipt of an executed copy of the Conversion Notice (so long as
the applicable Preferred Stock Certificates and original Conversion Notice
are
received by the Company on or before such third business day) (the “Share
Delivery Period”) the Transfer Agent shall fail to issue and deliver to a
holder the number of shares of Common Stock to which such holder is entitled
upon such holder’s conversion of the Series A Preferred Stock or to issue a
new Preferred Stock Certificate representing the number of shares of
Series A Preferred Stock to which such holder is entitled pursuant to
Section 5(b)(ii) (a “Conversion Failure”), in addition to all other
available remedies which such holder may pursue hereunder and under the
Series A Convertible Preferred Stock and Warrant Purchase Agreement (the
“Purchase Agreement”) among the Company and the initial holders of the
Series A Preferred Stock (including indemnification pursuant to
Section 6 thereof), the Company shall pay additional damages to such holder
on each business day after such fifth (5th) business day that such conversion
is
not timely effected in an amount equal 0.5% of the product of (A) the sum
of the number of shares of Common Stock not issued to the holder on a timely
basis pursuant to Section 5(b)(ii) and to which such holder is entitled and,
in
the event the Company has failed to deliver a Preferred Stock Certificate
to the
holder on a timely basis pursuant to Section 5(b)(ii), the number of shares
of
Common Stock issuable upon conversion of the shares of Series A Preferred
Stock represented by such Preferred Stock Certificate, as of the last possible
date which the Company could have issued such Preferred Stock Certificate
to
such holder without violating Section 5(b)(ii) and (B) the Closing Bid
Price (as defined in Section 5(c)(iii) below) of the Common Stock on the
last
possible date which the Company could have issued such Common Stock and such
Preferred Stock Certificate, as the case may be, to such holder without
violating Section 5(b)(ii). If the Company fails to pay the
additional damages set forth in this Section 5(b)(v) within five (5) business
days of the date incurred, then such payment shall bear interest at the rate
of
2.0% per month (pro rated for partial months) until such payments are
made.
(c) Mandatory
Conversion.
(i) One
minute after this Second Amended and Restated Certificate is effective with
the
Nevada Secretary of State (the "Conversion Time") on the Plan Closing Date
(defined below), each share of Series A Preferred Stock automatically and
without any action on the part of the holder thereof, shall convert into
a
number of fully paid and nonassessable shares of Common Stock equal to the
quotient of (i) the Liquidation Preference Amount of the shares of Series
A
Preferred Stock outstanding on the Plan Closing Date divided by (ii) the
Conversion Price in effect at the Conversion Time on the Plan Closing
Date. Any accrued but unpaid dividends on the Series A Preferred
Stock outstanding at the Conversion Time on the Plan Closing Date will be
issued
by the Company at the Conversion Time on the Plan Closing Date in shares
of
Common Stock, with the number of shares of Common Stock to be issued equal
to
the quotient of (i) the accrued unpaid dividend divided by (ii) the Conversion
Price in effect at the Conversion Time on the Plan Closing Date.
(ii) As
used
herein, “Plan Closing Date” shall be December 19, 2007.
(iii) The
term
“Closing Bid Price” shall mean, for any security as of any date, the last
closing bid price of such security on the OTC Bulletin Board for such security
as reported by Bloomberg, or, if no closing bid price is reported for such
security by Bloomberg, the last closing trade price of such security as reported
by Bloomberg, or, if no last closing trade price is reported for such security
by Bloomberg, the average of the bid prices of any market makers for such
security as reported in the “pink sheets” by the National Quotation Bureau,
Inc. If the Closing Bid Price cannot be calculated for such security
on such date on any of the foregoing bases, the Closing Bid Price of such
security on such date shall be the fair market value as mutually determined
by
the Company and the holders of a majority of the outstanding shares of
Series A Preferred Stock.
(iv) On
the
Plan Closing Date, the Corporation may cause the outstanding shares of Series
A
Preferred Stock to be converted automatically without any further action
by the
holders of such shares and regardless of whether the certificates representing
such shares are surrendered to the Company or its Transfer Agent; provided,
however, that the Company shall not be obligated to issue the shares of Common
Stock issuable upon conversion of any shares of Series A Preferred Stock
unless
certificates evidencing such shares of Series A Preferred Stock are either
delivered to the Company or the holder notifies the Company that such
certificates have been lost, stolen, or destroyed, and executes an agreement
satisfactory to the Company to indemnify the Company from any loss incurred
by
it in connection therewith. Upon the occurrence of the automatic
conversion of the Series A Preferred Stock pursuant to this Section 5, the
holders of the Series A Preferred Stock shall surrender to the Company the
certificates representing the Series A Preferred Stock that has been
automatically converted, and the Company shall cause its Transfer Agent to
deliver the shares of Common Stock issuable upon such conversion (in the
same
manner set forth in Section 5(b)(ii)) to the holder within three (3) business
days of the holder’s delivery of the applicable Preferred Stock
Certificates.
(d) Conversion
Price.
(i) The
term
“Conversion Price” shall mean $0.40 per share for the holders of the
Series A Preferred Stock on the Plan Closing Date, provided, however, that
the
Conversion Price for the Series A Preferred Stock held by Lawrence A. Siebert
shall be $0.48 per share on the Plan Closing Date.
(ii) Notwithstanding
the foregoing to the contrary, if during any period (a “Black-out
Period”), a holder of Series A Preferred Stock is unable to trade any
Common Stock issued or issuable upon conversion of the Series A Preferred
Stock immediately due to the postponement of filing or delay or suspension
of
effectiveness of a registration statement or because the Company has otherwise
informed such holder of Series A Preferred Stock that an existing
prospectus cannot be used at that time in the sale or transfer of such Common
Stock (provided that such postponement, delay, suspension or fact that the
prospectus cannot be used is not due to factors solely within the control
of the
holder of Series A Preferred Stock or due to the Company exercising its
rights under Section 3(n) of the Registration Rights Agreement (as defined
in the Purchase Agreement)), such holder of Series A Preferred Stock shall
have the option but not the obligation on any Conversion Date occurring within
ten (10) trading days following the expiration of the Black-out Period of
using
the Conversion Price applicable on such Conversion Date or any Conversion
Price
selected by such holder of Series A Preferred Stock that would have been
applicable had such Conversion Date been at any earlier time during the
Black-out Period or within the ten (10) trading days thereafter.
(e) Adjustments
of Conversion Price.
(i) Adjustments
for Stock Splits and Combinations. If the Company shall at any
time or from time to time after the Issuance Date, effect a stock split of
the
outstanding Common Stock, the Conversion Price shall be proportionately
decreased. If the Company shall at any time or from time to time
after the Issuance Date, combine the outstanding shares of Common Stock,
the
Conversion Price shall be proportionately increased. Any adjustments
under this Section 5(e)(i) shall be effective at the close of business on
the
date the stock split or combination becomes effective.
(ii) Adjustments
for Certain Dividends and Distributions. If the Company shall at
any time or from time to time after the Issuance Date, make or issue or set
a
record date for the determination of holders of Common Stock entitled to
receive
a dividend or other distribution payable in shares of Common Stock, then,
and in
each event, the Conversion Price shall be decreased as of the time of such
issuance or, in the event such record date shall have been fixed, as of the
close of business on such record date, by multiplying the Conversion Price
then
in effect by a fraction:
(1) the
numerator of which shall be the total number of shares of Common Stock issued
and outstanding immediately prior to the time of such issuance or the close
of
business on such record date; and
(2) the
denominator of which shall be the total number of shares of Common Stock
issued
and outstanding immediately prior to the time of such issuance or the close
of
business on such record date plus the number of shares of Common Stock issuable
in payment of such dividend or distribution.
(iii) Adjustment
for Other Dividends and Distributions. If the Company shall at
any time or from time to time after the Issuance Date, make or issue or set
a
record date for the determination of holders of Common Stock entitled to
receive
a dividend or other distribution payable in securities of the Company other
than
shares of Common Stock, then, and in each event, an appropriate revision
to the
applicable Conversion Price shall be made and provision shall be made (by
adjustments of the Conversion Price or otherwise) so that the holders of
Series A Preferred Stock shall receive upon conversions thereof, in
addition to the number of shares of Common Stock receivable thereon, the
number
of securities of the Company which they would have received had their
Series A Preferred Stock been converted into Common Stock on the date of
such event and had thereafter, during the period from the date of such event
to
and including the Conversion Date, retained such securities (together with
any
distributions payable thereon during such period), giving application to
all
adjustments called for during such period under this Section 5(e)(iii) with
respect to the rights of the holders of the Series A Preferred Stock;
provided, however, that if such record date shall have been fixed
and such dividend is not fully paid or if such distribution is not fully
made on
the date fixed therefor, the Conversion Price shall be adjusted pursuant
to this
paragraph as of the time of actual payment of such dividends or distributions;
and providedfurther, however, that no such adjustment shall be
made if the holders of Series A Preferred Stock simultaneously receive
(i) a dividend or other distribution of shares of Common Stock in a number
equal to the number of shares of Common Stock as they would have received
if all
outstanding shares of Series A Preferred Stock had been converted into
Common Stock on the date of such event or (ii) a dividend or other
distribution of shares of Series A Preferred Stock which are convertible,
as of the date of such event, into such number of shares of Common Stock
as is
equal to the number of additional shares of Common Stock being issued with
respect to each share of Common Stock in such dividend or
distribution.
(iv) Adjustments
for Reclassification, Exchange or Substitution. If the Common
Stock issuable upon conversion of the Series A Preferred Stock at any time
or from time to time after the Issuance Date shall be changed to the same
or
different number of shares of any class or classes of stock, whether by
reclassification, exchange, substitution or otherwise (other than by way
of a
stock split or combination of shares or stock dividends provided for in Sections
5(e)(i), (ii) and (iii), or a reorganization, merger, consolidation, or sale
of
assets provided for in Section 5(e)(v)), then, and in each event, an appropriate
revision to the Conversion Price shall be made and provisions shall be made
(by
adjustments of the Conversion Price or otherwise) so that the holder of each
share of Series A Preferred Stock shall have the right thereafter to
convert such share of Series A Preferred Stock into the kind and amount of
shares of stock and other securities receivable upon reclassification, exchange,
substitution or other change, by holders of the number of shares of Common
Stock
into which such share of Series A Preferred Stock might have been converted
immediately prior to such reclassification, exchange, substitution or other
change, all subject to further adjustment as provided herein.
(v) Adjustments
for Reorganization, Merger, Consolidation or Sales of Assets. If
at any time or from time to time after the Issuance Date there shall be a
capital reorganization of the Company (other than by way of a stock split
or
combination of shares or stock dividends or distributions provided for in
Section 5(e)(i), (ii) and (iii), or a reclassification, exchange or substitution
of shares provided for in Section 5(e)(iv)), or a merger or consolidation
of the
Company with or into another corporation where the holders of outstanding
voting
securities prior to such merger or consolidation do not own over 50% of the
outstanding voting securities of the merged or consolidated entity, immediately
after such merger or consolidation, or the sale of all or substantially all
of
the Company’s properties or assets to any other person (an “Organic
Change”), then as a part of such Organic Change an appropriate revision to
the Conversion Price shall be made if necessary so that the holder of each
share
of Series A Preferred Stock shall have the right thereafter to convert such
share of Series A Preferred Stock into the kind and amount of shares of
stock and other securities or property of the Company or any successor
corporation resulting from Organic Change. In any such case,
appropriate adjustment shall be made in the application of the provisions
of
this Section 5(e)(v) with respect to the rights of the holders of the
Series A Preferred Stock after the Organic Change to the end that the
provisions of this Section 5(e)(v) (including any adjustment in the Conversion
Price then in effect and the number of shares of stock or other securities
deliverable upon conversion of the Series A Preferred Stock) shall be
applied after that event in as nearly an equivalent manner as may be
practicable.
(vi) Adjustments
for Issuance of Additional Shares of Common Stock. In the event
the Company, shall, at any time, from time to time, issue or sell any additional
shares of Common Stock or any securities convertible or exercisable into,
or
exchangeable for, directly or indirectly, Common Stock (the “Additional
Shares of Common Stock”), at a price per share less than the Conversion
Price then in effect or without consideration, the Conversion Price then
in
effect shall be reduced to a price equal to the consideration per share paid
for
such Additional Shares of Common Stock.
(vii) Certain
Issues Excepted. Anything herein to the contrary notwithstanding,
the Company shall not be required to make any adjustment to the Conversion
Price
upon (i) the Company’s issuance of any Additional Shares of Common Stock
(other than for cash) and warrants therefore in connection with a merger,
acquisition or consolidation, (ii) the Company’s issuance of Additional
Shares of Common Stock pursuant to a bona fide firm underwritten public offering
of the Company’s securities, (iii) the Company’s issuance of Additional
Shares of Common Stock or warrants therefore in connection with strategic
alliances or other partnering arrangements so long as such issuances are
not for
the purpose of raising capital, (iv) the Company’s issuance of Common Stock
or the issuance or grants of options to purchase Common Stock pursuant to
the
Company’s stock option plans and employee stock purchase plans as they now
exist, (v) any issuances of warrants issued pursuant to the Purchase
Agreement, (vi) securities issued pursuant to the conversion or exercise of
convertible or exercisable securities issued or outstanding on or prior to
the
date hereof or issued pursuant to the Purchase Agreement, (vii) any
warrants issued to the placement agent for the transactions contemplated
by the
Purchase Agreement, and (viii) the payment of any dividends on the
Series A Preferred Stock.
(f) No
Impairment. The Company shall not, by amendment of its Articles
of Incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of
any of
the terms to be observed or performed hereunder by the Company, but will
at all
times in good faith, assist in the carrying out of all the provisions of
this
Section 5 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of the
Series A Preferred Stock against impairment. In the event a
holder shall elect to convert any shares of Series A Preferred Stock as
provided herein, the Company cannot refuse conversion based on any claim
that
such holder or any one associated or affiliated with such holder has been
engaged in any violation of law, unless, an injunction from a court, on notice,
restraining and/or adjoining conversion of all or of said shares of
Series A Preferred Stock shall have been issued and the Company posts a
surety bond for the benefit of such holder in an amount equal to 100% of
the
Liquidation Preference Amount of the Series A Preferred Stock such holder
has elected to convert, which bond shall remain in effect until the completion
of arbitration/litigation of the dispute and the proceeds of which shall
be
payable to such holder in the event it obtains judgment.
(g) Certificates
as to Adjustments. Upon occurrence of each adjustment or
readjustment of the Conversion Price or number of shares of Common Stock
issuable upon conversion of the Series A Preferred Stock pursuant to this
Section 5, the Company at its expense shall promptly compute such
adjustment or readjustment in accordance with the terms hereof and furnish
to
each holder of such Series A Preferred Stock a certificate setting forth
such adjustment and readjustment, showing in detail the facts upon which
such
adjustment or readjustment is based. The Company shall, upon written
request of the holder of such affected Series A Preferred Stock, at any
time, furnish or cause to be furnished to such holder a like certificate
setting
forth such adjustments and readjustments, the Conversion Price in effect
at the
time, and the number of shares of Common Stock and the amount, if any, of
other
securities or property which at the time would be received upon the conversion
of a share of such Series A Preferred Stock. Notwithstanding the
foregoing, the Company shall not be obligated to deliver a certificate unless
such certificate would reflect an increase or decrease of at least one percent
of such adjusted amount.
(h) Issue
Taxes. The Company shall pay any and all issue and other taxes,
excluding federal, state or local income taxes, that may be payable in respect
of any issue or delivery of shares of Common Stock on conversion of shares
of
Series A Preferred Stock pursuant thereto; provided, however,
that the Company shall not be obligated to pay any transfer taxes resulting
from
any transfer requested by any holder in connection with any such
conversion.
(i) Notices. All
notices and other communications hereunder shall be in writing and shall
be
deemed given if delivered personally or by facsimile or three (3) business
days
following being mailed by certified or registered mail, postage prepaid,
return-receipt requested, addressed to the holder of record at its address
appearing on the books of the Company. The Company will give written
notice to each holder of Series A Preferred Stock at least twenty (20) days
prior to the date on which the Company closes its books or sets a record
date
(I) with respect to any dividend or distribution upon the Common Stock,
(II) with respect to any pro rata subscription offer to holders of Common
Stock or (III) for determining rights to vote with respect to any Organic
Change, dissolution, liquidation or winding-up and in no event shall such
notice
be provided to such holder prior to such information being made known to
the
public. The Company will also give written notice to each holder of
Series A Preferred Stock at least twenty (20) days prior to the date on
which any Organic Change, dissolution, liquidation or winding-up will take
place; provided, however, no such notice shall be required to be
provided to such holder prior to such information being made known to the
public.
(j) Fractional
Shares. No fractional shares of Common Stock shall be issued upon
conversion of the Series A Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Company
shall pay cash equal to the product of such fraction multiplied by the average
of the Closing Bid Prices of the Common Stock for the five (5) consecutive
trading immediately preceding the Voluntary Conversion Date or any Mandatory
Conversion Date, as applicable.
(k) Reservation
of Common Stock. The Company shall, so long as any shares of
Series A Preferred Stock are outstanding, reserve and keep available out of
its authorized and unissued Common Stock, solely for the purpose of effecting
the conversion of the Series A Preferred Stock, such number of shares of
Common Stock as shall from time to time be sufficient to effect the conversion
of all of the Series A Preferred Stock then outstanding; provided that the
number of shares of Common Stock so reserved shall at no time be less than
the
number of shares of Common Stock for which the shares of Series A Preferred
Stock are at any time convertible. The initial number of shares of
Common Stock reserved for conversions of the Series A Preferred Stock and
each increase in the number of shares so reserved shall be allocated pro
rata
among the holders of the Series A Preferred Stock based on the number of
shares of Series A Preferred Stock held by each holder of record at the
time of issuance of the Series A Preferred Stock or increase in the number
of reserved shares, as the case may be. In the event a holder shall
sell or otherwise transfer any of such holder’s shares of Series A
Preferred Stock, each transferee shall be allocated a pro rata portion of
the
number of reserved shares of Common Stock reserved for such
transferor. Any shares of Common Stock reserved and which remain
allocated to any person or entity which does not hold any shares of
Series A Preferred Stock shall be allocated to the remaining holders of
Series A Preferred Stock, pro rata based on the number of shares of
Series A Preferred Stock then held by such holder.
(l) Regulatory
Compliance. If any shares of Common Stock to be reserved for the
purpose of conversion of Series A Preferred Stock require registration or
listing with or approval of any governmental authority, stock exchange or
other
regulatory body under any federal or state law or regulation or otherwise
before
such shares may be validly issued or delivered upon conversion, the Company
shall, at its sole cost and expense, in good faith and as expeditiously as
possible, endeavor to secure such registration, listing or approval, as the
case
may be.
6. No
Preemptive Rights. Except as provided in Section 5 hereof
and in the Purchase Agreement, no holder of the Series A Preferred Stock
shall be entitled to rights to subscribe for, purchase or receive any part
of
any new or additional shares of any class, whether now or hereinafter
authorized, or of bonds or debentures, or other evidences of indebtedness
convertible into or exchangeable for shares of any class, but all such new
or
additional shares of any class, or any bond, debentures or other evidences
of
indebtedness convertible into or exchangeable for shares, may be issued and
disposed of by the Board of Directors on such terms and for such consideration
(to the extent permitted by law), and to such person or persons as the Board
of
Directors in their absolute discretion may deem advisable.
7. Conversion
Restrictions.
(a) Notwithstanding
anything to the contrary set forth in Section 5 of this Certificate of
Designation, at no time may a holder of shares of Series A Preferred Stock
convert shares of the Series A Preferred Stock if the number of shares of
Common Stock to be issued pursuant to such conversion would exceed, when
aggregated with all other shares of Common Stock owned by such holder at
such
time, the number of shares of Common Stock which would result in such holder
beneficially owning (as determined in accordance with Section 13(d) of the
Securities Exchange Act of 1934, as amended, and the rules thereunder) in
excess
of 4.999% of the then issued and outstanding shares of Common Stock outstanding
at such time; provided, however, that upon a holder of
Series A Preferred Stock providing the Company with sixty-one (61) days
notice (pursuant to Section 5(i) hereof) (the “Waiver Notice”) that
such holder would like to waive Section 7(a) of this Certificate of
Designation with regard to any or all shares of Common Stock issuable upon
conversion of Series A Preferred Stock, this Section 7(a) shall be of
no force or effect with regard to those shares of Series A Preferred Stock
referenced in the Waiver Notice; provided,
further,
that this provision shall be of no further force or effect with respect to
Common Stock issuable upon conversion of the Series A Preferred Stock
in
connection with the Plan.
(b) Notwithstanding
anything to the contrary set forth in Section 5 of this Certificate of
Designation, at no time may a holder of shares of Series A Preferred Stock
convert shares of the Series A Preferred Stock if the number of shares of
Common
Stock to be issued pursuant to such conversion, when aggregated with all
other
shares of Common Stock owned by such holder at such time, would result in
such
holder beneficially owning (as determined in accordance with Section 13(d)
of
the Securities Exchange Act of 1934, as amended, and the rules thereunder)
in
excess of 9.999% of the then issued and outstanding shares of Common Stock
outstanding at such time; provided, however, that upon a holder of
Series A Preferred Stock providing the Company with a Waiver Notice that
such
holder would like to waive Section 7(b) of this Certificate of Designation
with
regard to any or all shares of Common Stock issuable upon conversion of Series
A
Preferred Stock, this Section 7(b) shall be of no force or effect with regard
to
those shares of Series A Preferred Stock referenced in the Waiver Notice;
provided, further, that this provision shall be of no further force or effect
with respect to Common Stock issuable upon conversion of the Series A Preferred
Stock in connection with the Plan.
(c) For
purposes of this Certificate of Designation, the term “Plan” shall mean any
action the Company takes, with any required approval of the holders thereof,
on
or before the Final Plan Date as contemplated by the Plan Summary and
accompanying materials provided to holders on December 4, 2007, in connection
with the reduction or other modification of terms of the Company's
then-outstanding preferred stock, warrants and options, including, but not
limited to, actions the Company takes to (i) facilitate the conversion of
the
Series A, B and C Convertible Preferred Stock; (ii) reduce the exercise price
of
any of the Company's outstanding warrants or options; (iii) offer the holders
of
the Company's warrants and options the opportunity to exercise such warrants
and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities. The term “Final Plan
Date” shall mean the date that is six months and twelve days after the Plan
Closing Date.
8. Redemption.
(a) Redemption
Option Upon Major Transaction. In addition to all other rights of
the holders of Series A Preferred Stock contained herein, simultaneous with
the occurrence of a Major Transaction (as defined below), each holder of
Series A Preferred Stock shall have the right, at such holder’s option, to
require the Company to redeem all or a portion of such holder’s shares of
Series A Preferred Stock at a price per share of Series A Preferred
Stock equal to 100% of the Liquidation Preference Amount, plus any accrued
but
unpaid dividends and liquidated damages (the “Major Transaction Redemption
Price”); provided that the Company shall have the sole option to pay the
Major Transaction Redemption Price in cash or shares of Common
Stock. If the Company elects to pay the Major Transaction Redemption
Price in shares of Common Stock, the price per share shall be based upon
the
lesser of (i) the Conversion Price then in effect on the day preceding the
date of delivery of the Notice of Redemption at Option of Buyer Upon Major
Transaction (as hereafter defined) or (ii) the Closing Bid Price on the day
preceding the date of delivery of the Notice of Redemption at Option of Buyer
Upon Major Transaction. The holder of such shares of Common Stock
shall have demand registration rights with respect to such shares.
(b) Redemption
Option Upon Triggering Event. In addition to all other rights of
the holders of Series A Preferred Stock contained herein, after a
Triggering Event (as defined below), each holder of Series A Preferred
Stock shall have the right, at such holder’s option, to require the Company to
redeem all or a portion of such holder’s shares of Series A Preferred Stock
at a price per share of Series A Preferred Stock equal to 120% of the
Liquidation Preference Amount, plus any accrued but unpaid dividends and
liquidated damages (the “Triggering Event Redemption Price” and,
collectively with the “Major Transaction Redemption Price,” the “Redemption
Price”); provided that with respect to the Triggering Events described in
clauses (i), (ii), (iii) and (v) of Section 8(d), the Company shall have
the sole option to pay the Triggering Event Redemption Price in cash or shares
of Common Stock; and provided, further, that with respect to the
Triggering Event described in clause (iv) of Section 8(d), the Company
shall pay the Triggering Event Redemption Price in cash. If the
Company elects to pay the Triggering Event Redemption Price in shares of
Common
Stock in accordance with this Section 8(b), the price per share shall be
based upon the lesser of (i) the Conversion Price then in effect on the day
preceding the date of delivery of the Notice of Redemption at Option of Buyer
Upon Triggering Event or (ii) the Closing Bid Price on the day preceding
the date of delivery of the Notice of Redemption at Option of Buyer Upon
Triggering Event. The holder of such shares of Common Stock shall
have demand registration rights with respect to such shares.
(c) “Major
Transaction”. A “Major Transaction” shall be deemed to
have occurred at such time as any of the following events:
(i) the
consolidation, merger or other business combination of the Company with or
into
another Person (other than (A) pursuant to a migratory merger effected
solely for the purpose of changing the jurisdiction of incorporation of the
Company or (B) a consolidation, merger or other business combination in
which holders of the Company’s voting power immediately prior to the transaction
continue after the transaction to hold, directly or indirectly, the voting
power
of the surviving entity or entities necessary to elect a majority of the
members
of the board of directors (or their equivalent if other than a corporation)
of
such entity or entities).
(ii) the
sale
or transfer of more than 50% of the Company’s assets other than inventory in the
ordinary course of business in one or a related series of transactions;
or
(iii) closing
of a purchase, tender or exchange offer made to the holders of more than
50% of
the outstanding shares of Common Stock in which more than 50% of the outstanding
shares of Common Stock were tendered and accepted.
(d) “Triggering
Event”. A “Triggering Event” shall be deemed to have
occurred at such time as any of the following events:
(i) at
any
time within two (2) years after the Issuance Date, the resale of the shares
of
Common Stock issuable upon conversion of the Series A Preferred Stock is
covered by the Registration Statement which has been declared effective,
(i) the effectiveness of the Registration Statement lapses for any reason
(including, without limitation, the issuance of a stop order) or (ii) the
Registration Statement is unavailable to the holder of the Series A
Preferred Stock for sale of the shares of Common Stock, and such lapse or
unavailability continues for a period of twenty (20) consecutive trading
days,
and the shares of Common Stock into which such holder’s Series A Preferred
Stock can be converted cannot be sold in the public securities market pursuant
to Rule 144(k) (“Rule 144(k)”) under the Securities Act of 1933, as
amended, provided that the cause of such lapse or unavailability is not
due to factors solely within the control of such holder of Series A
Preferred Stock.
(ii) the
suspension from listing, without subsequent listing on any one of, or the
failure of the Common Stock to be listed on at least one of the OTC Bulletin
Board, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York
Stock Exchange, Inc. or the American Stock Exchange, Inc., for a period of
seven
(7) consecutive trading days;
(iii) the
Company’s notice to any holder of Series A Preferred Stock, including by
way of public announcement, at any time, of its inability to comply (including
for any of the reasons described in Section 9) or its intention not to
comply with proper requests for conversion of any Series A Preferred Stock
into shares of Common Stock; or
(iv) the
Company’s failure to comply with a Conversion Notice tendered in accordance with
the provisions of this Certificate of Designation within ten (10) business
days
after the receipt by the Company of the Conversion Notice and the Preferred
Stock Certificates; or
(v) the
Company breaches any representation, warranty, covenant or other term or
condition of the Purchase Agreement, this Certificate of Designation or any
other agreement, document, certificate or other instrument delivered in
connection with the transactions contemplated thereby or hereby, except to
the
extent that such breach would not have a Material Adverse Effect (as defined
in
the Purchase Agreement) and except, in the case of a breach of a covenant
which
is curable, only if such breach continues for a period of a least ten (10)
days.
(e) Mechanics
of Redemption at Option of Buyer Upon Major Transaction. No
sooner than fifteen (15) days nor later than ten (10) days prior to the
consummation of a Major Transaction, but not prior to the public announcement
of
such Major Transaction, the Company shall deliver written notice thereof
via
facsimile and overnight courier (“Notice of Major Transaction”) to each
holder of Series A Preferred Stock. At any time after receipt of
a Notice of Major Transaction (or, in the event a Notice of Major Transaction
is
not delivered at least ten (10) days prior to a Major Transaction, at any
time
within ten (10) days prior to a Major Transaction), any holder of Series A
Preferred Stock then outstanding may require the Company to redeem, effective
immediately prior to the consummation of such Major Transaction, all of the
holder’s Series A Preferred Stock then outstanding by delivering written
notice thereof via facsimile and overnight courier (“Notice of Redemption at
Option of Buyer Upon Major Transaction”) to the Company, which Notice of
Redemption at Option of Buyer Upon Major Transaction shall indicate (i) the
number of shares of Series A Preferred Stock that such holder is electing
to redeem and (ii) the applicable Major Transaction Redemption Price, as
calculated pursuant to Section 8(a) above.
(f) Mechanics
of Redemption at Option of Buyer Upon Triggering Event. Within
two (2) days after the occurrence of a Triggering Event, the Company shall
deliver written notice thereof via facsimile and overnight courier (“Notice
of Triggering Event”) to each holder of Series A Preferred
Stock. At any time after the earlier of a holder’s receipt of a
Notice of Triggering Event and such holder becoming aware of a Triggering
Event,
any holder of Series A Preferred Stock then outstanding may require the
Company to redeem all of the Series A Preferred Stock by delivering written
notice thereof via facsimile and overnight courier (“Notice of Redemption at
Option of Buyer Upon Triggering Event”) to the Company, which Notice of
Redemption at Option of Buyer Upon Triggering Event shall indicate (i) the
number of shares of Series A Preferred Stock that such holder is electing
to redeem and (ii) the applicable Triggering Event Redemption Price, as
calculated pursuant to Section 8(b) above.
(g) Payment
of Redemption Price. Upon the Company’s receipt of a Notice(s) of
Redemption at Option of Buyer Upon Triggering Event or a Notice(s) of Redemption
at Option of Buyer Upon Major Transaction from any holder of Series A
Preferred Stock, the Company shall immediately notify each holder of
Series A Preferred Stock by facsimile of the Company’s receipt of such
Notice(s) of Redemption at Option of Buyer Upon Triggering Event or Notice(s)
of
Redemption at Option of Buyer Upon Major Transaction and each holder which
has
sent such a notice shall promptly submit to the Company such holder’s Preferred
Stock Certificates which such holder has elected to have
redeemed. Other than with respect to the Triggering Event described
in clause (iv) of Section 8(d), the Company shall have the sole option to
pay the Redemption Price in cash or shares of Common Stock in accordance
with
Sections 8(a) and (b) and Section 9 of this Certificate of
Designation. The Company shall deliver the applicable Major
Transaction Redemption Price immediately prior to the consummation of the
Major
Transaction; provided that a holder’s Preferred Stock Certificates shall
have been so delivered to the Company; provided further that if the
Company is unable to redeem all of the Series A Preferred Stock to be
redeemed, the Company shall redeem an amount from each holder of Series A
Preferred Stock being redeemed equal to such holder’s pro-rata amount (based on
the number of shares of Series A Preferred Stock held by such holder
relative to the number of shares of Series A Preferred Stock outstanding)
of all Series A Preferred Stock being redeemed. If the Company
shall fail to redeem all of the Series A Preferred Stock submitted for
redemption (other than pursuant to a dispute as to the arithmetic calculation
of
the Redemption Price), in addition to any remedy such holder of Series A
Preferred Stock may have under this Certificate of Designation and the Purchase
Agreement, the applicable Redemption Price payable in respect of such unredeemed
Series A Preferred Stock shall bear interest at the rate of .5% per month
(prorated for partial months) until paid in full. Until the Company
pays such unpaid applicable Redemption Price in full to a holder of shares
of
Series A Preferred Stock submitted for redemption, such holder shall have
the option (the “Void Optional Redemption Option”) to, in lieu of
redemption, require the Company to promptly return to such holder(s) all
of the
shares of Series A Preferred Stock that were submitted for redemption by
such holder(s) under this Section 8 and for which the applicable Redemption
Price has not been paid, by sending written notice thereof to the Company
via
facsimile (the “Void Optional Redemption Notice”). Upon the
Company’s receipt of such Void Optional Redemption Notice(s) and prior to
payment of the full applicable Redemption Price to such holder, (i) the
Notice(s) of Redemption at Option of Buyer Upon Major Transaction shall be
null
and void with respect to those shares of Series A Preferred Stock submitted
for redemption and for which the applicable Redemption Price has not been
paid
and (ii) the Company shall immediately return any Series A Preferred
Stock submitted to the Company by each holder for redemption under this
Section 8(d) and for which the applicable Redemption Price has not been
paid. A holder’s delivery of a Void Optional Redemption Notice and
exercise of its rights following such notice shall not effect the Company’s
obligations to make any payments which have accrued prior to the date of
such
notice other than interest payments. Payments provided for in this
Section 8 shall have priority to payments to other stockholders in
connection with a Major Transaction.
(h) Demand
Registration Rights. If the Redemption Price upon the occurrence
of a Major Transaction or a Triggering Event is paid in shares of Common
Stock
and such shares have not been previously registered on a registration statement
under the Securities Act, a holder of Series A Preferred Stock may make a
written request for registration under the Securities Act pursuant to this
Section 8(h) of all of its shares of Common Stock issued upon such Major
Transaction or Triggering Event. The Company shall use its reasonable
best efforts to cause to be filed and declared effective as soon as reasonably
practicable (but in no event later than the ninetieth (90th) day after such
holder’s request is made) a registration statement under the Securities Act,
providing for the sale of all of the shares of Common Stock issued upon such
Major Transaction or Triggering Event by such holder. The Company
agrees to use its reasonable best efforts to keep any such registration
statement continuously effective for resale of the Common Stock for so long
as
such holder shall request, but in no event later than the date that the shares
of Common Stock issued upon such Major Transaction or Triggering Event may
be
offered for resale to the public pursuant to Rule 144(k).
9. Inability
to Fully Convert.
(a) Holder’s
Option if Company Cannot Fully Convert. If, upon the Company’s
receipt of a Conversion Notice or on a Mandatory Conversion Date, the Company
cannot issue shares of Common Stock registered for resale under the Registration
Statement for any reason, including, without limitation, because the Company
(w) does not have a sufficient number of shares of Common Stock authorized
and available, (x) is otherwise prohibited by applicable law or by the
rules or regulations of any stock exchange, interdealer quotation system
or
other self-regulatory organization with jurisdiction over the Company or
its
securities from issuing all of the Common Stock which is to be issued to
a
holder of Series A Preferred Stock pursuant to a Conversion Notice or
(y) fails to have a sufficient number of shares of Common Stock registered
for resale under the Registration Statement, then the Company shall issue
as
many shares of Common Stock as it is able to issue in accordance with such
holder’s Conversion Notice and pursuant to Section 5(b)(ii) above and, with
respect to the unconverted Series A Preferred Stock, the holder, solely at
such holder’s option, can elect, within five (5) business days after receipt of
notice from the Company thereof to:
(i) require
the Company to redeem from such holder those Series A Preferred Stock for
which the Company is unable to issue Common Stock in accordance with such
holder’s Conversion Notice (“Mandatory Redemption”) at a price per share
equal to the Major Transaction Redemption Price as of such Conversion Date
(the
“Mandatory Redemption Price”); provided that the Company shall
have the sole option to pay the Mandatory Redemption Price in cash or shares
of
Common Stock;
(ii) if
the
Company’s inability to fully convert Series A Preferred Stock is pursuant
to Section 9(a)(y) above, require the Company to issue restricted shares
of
Common Stock in accordance with such holder’s Conversion Notice and pursuant to
Section 5(b)(ii) above;
(iii) void
its
Conversion Notice and retain or have returned, as the case may be, the shares
of
Series A Preferred Stock that were to be converted pursuant to such
holder’s Conversion Notice (provided that a holder’s voiding its Conversion
Notice shall not effect the Company’s obligations to make any payments which
have accrued prior to the date of such notice).
(b) Mechanics
of Fulfilling Holder’s Election. The Company shall immediately
send via facsimile to a holder of Series A Preferred Stock, upon receipt of
a facsimile copy of a Conversion Notice from such holder which cannot be
fully
satisfied as described in Section 9(a) above, a notice of the Company’s
inability to fully satisfy such holder’s Conversion Notice (the “Inability to
Fully Convert Notice”). Such Inability to Fully Convert Notice
shall indicate (i) the reason why the Company is unable to fully satisfy
such holder’s Conversion Notice, (ii) the number of Series A Preferred
Stock which cannot be converted and (iii) the applicable Mandatory
Redemption Price. Such holder shall notify the Company of its
election pursuant to Section 9(a) above by delivering written notice via
facsimile to the Company (“Notice in Response to Inability to
Convert”).
(c) Payment
of Redemption Price. If such holder shall elect to have its
shares redeemed pursuant to Section 9(a)(i) above, the Company shall pay
the Mandatory Redemption Price to such holder within thirty (30) days of
the
Company’s receipt of the holder’s Notice in Response to Inability to Convert,
provided that prior to the Company’s receipt of the holder’s Notice in Response
to Inability to Convert the Company has not delivered a notice to such holder
stating, to the satisfaction of the holder, that the event or condition
resulting in the Mandatory Redemption has been cured and all Conversion Shares
issuable to such holder can and will be delivered to the holder in accordance
with the terms of Section 8(g). If the Company shall fail to pay
the applicable Mandatory Redemption Price to such holder on a timely basis
as
described in this Section 9(c) (other than pursuant to a dispute as to the
determination of the arithmetic calculation of the Redemption Price), in
addition to any remedy such holder of Series A Preferred Stock may have
under this Certificate of Designation and the Purchase Agreement, such unpaid
amount shall bear interest at the rate of 1.0% per month (prorated for partial
months) until paid in full. Until the full Mandatory Redemption Price
is paid in full to such holder, such holder may (i) void the Mandatory
Redemption with respect to those Series A Preferred Stock for which the
full Mandatory Redemption Price has not been paid and (ii) receive back
such Series A Preferred Stock.
(d) Pro-rata
Conversion and Redemption. In the event the Company receives a
Conversion Notice from more than one holder of Series A Preferred Stock on
the same day and the Company can convert and redeem some, but not all, of
the
Series A Preferred Stock pursuant to this Section 9, the Company shall
convert and redeem from each holder of Series A Preferred Stock electing to
have Series A Preferred Stock converted and redeemed at such time an amount
equal to such holder’s pro-rata amount (based on the number shares of
Series A Preferred Stock held by such holder relative to the number shares
of Series A Preferred Stock outstanding) of all shares of Series A
Preferred Stock being converted and redeemed at such time.
10. Vote
to Change the Terms of or Issue Preferred Stock. The affirmative
vote at a meeting duly called for such purpose or the written consent without
a
meeting, of the holders of three-fourths (3/4) of the then outstanding shares
of
Series A Preferred Stock, shall be required (a) for any change to this
Certificate of Designation or the Articles of Incorporation which would amend,
alter, change or repeal any of the powers, designations, preferences and
rights
of the Series A Preferred Stock or (b) for the issuance of shares of
Series A Preferred Stock other than pursuant to the Purchase Agreement
except for shares of Series A Preferred Stock to be issued to certain
holders of promissory notes issued by the Company in satisfaction of outstanding
indebtedness in an amount not to exceed $750,000 and/or as dividends paid
in
shares of Series A Preferred Stock.
11. Lost
or Stolen Certificates. Upon receipt by the Company of evidence
satisfactory to the Company of the loss, theft, destruction or mutilation
of any
Preferred Stock Certificates representing the shares of Series A Preferred
Stock, and, in the case of loss, theft or destruction, of any indemnification
undertaking by the holder to the Company and, in the case of mutilation,
upon
surrender and cancellation of the Preferred Stock Certificate(s), the Company
shall execute and deliver new preferred stock certificate(s) of like tenor
and
date; provided, however, the Company shall not be obligated to
re-issue Preferred Stock Certificates if the holder contemporaneously requests
the Company to convert such shares of Series A Preferred Stock into Common
Stock.
12. Remedies,
Characterizations, Other Obligations, Breaches and Injunctive
Relief. The remedies provided in this Certificate of Designation
shall be cumulative and in addition to all other remedies available under
this
Certificate of Designation, at law or in equity (including a decree of specific
performance and/or other injunctive relief), no remedy contained herein shall
be
deemed a waiver of compliance with the provisions giving rise to such remedy
and
nothing herein shall limit a holder’s right to pursue actual damages for any
failure by the Company to comply with the terms of this Certificate of
Designation. Amounts set forth or provided for herein with respect to
payments, conversion and the like (and the computation thereof) shall be
the
amounts to be received by the holder thereof and shall not, except as expressly
provided herein, be subject to any other obligation of the Company (or the
performance thereof). The Company acknowledges that a breach by it of
its obligations hereunder will cause irreparable harm to the holders of the
Series A Preferred Stock and that the remedy at law for any such breach may
be inadequate. The Company therefore agrees that, in the event of any
such breach or threatened breach, the holders of the Series A Preferred
Stock shall be entitled, in addition to all other available remedies, to
an
injunction restraining any breach, without the necessity of showing economic
loss and without any bond or other security being required.
13. Specific
Shall Not Limit General; Construction. No specific provision
contained in this Certificate of Designation shall limit or modify any more
general provision contained herein. This Certificate of Designation
shall be deemed to be jointly drafted by the Company and all initial purchasers
of the Series A Preferred Stock and shall not be construed against any
person as the drafter hereof.
14. Failure
or Indulgence Not Waiver. No failure or delay on the part of a
holder of Series A Preferred Stock in the exercise of any power, right or
privilege hereunder shall operate as a waiver thereof, nor shall any single
or
partial exercise of any such power, right or privilege preclude other or
further
exercise thereof or of any other right, power or privilege.
IN
WITNESS WHEREOF, the undersigned has executed and subscribed this Second
Amended
and Restated Certificate and does affirm the foregoing as true this 19th
day of
December, 2007.
CHEMBIO
DIAGNOSTICS, INC.
By:
Name: Richard
J.
Larkin
Title: Chief
Financial
Officer
EXHIBIT
I
CHEMBIO
DIAGNOSTICS, INC.
CONVERSION
NOTICE
Reference
is made to the Second Amended and Restated Certificate of Designation of
the
Relative Rights and Preferences of the Series A Preferred Stock of Chembio
Diagnostics, Inc. (the “Certificate of Designation”). In
accordance with and pursuant to the Certificate of Designation, the undersigned
hereby elects to convert the number of shares of Series A Preferred Stock,
par value $.01 per share (the “Preferred Shares”), of Chembio
Diagnostics, Inc., a Nevada corporation (the “Company”), indicated below
into shares of Common Stock, par value $.01 per share (the “Common
Stock”), of the Company, by tendering the stock certificate(s) representing
the share(s) of Preferred Shares specified below as of the date specified
below.
Date
of
Conversion:
Number
of
Preferred Shares to be converted:
Stock
certificate no(s). of Preferred Shares to be converted:
The
Common Stock have been sold pursuant to the Registration Statement (as defined
in the Purchase Agreement): YES ____ NO____
Please
confirm the following information:
Conversion
Price:
Number
of
shares of Common Stock to be issued:
Number
of
shares of Common Stock beneficially owned or deemed beneficially owned by
the
Holder on the Date of
Conversion: _________________________
Please
issue the Common Stock into which the Preferred Shares are being converted
and,
if applicable, any check drawn on an account of the Company in the following
name and to the following address:
Issue
to:
Facsimile
Number:
Authorization:
By:
Title:
Dated:
ex4_4.htm
Exhibit
4.4
THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE
NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE
STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL
TO
THE HOLDER OF THE SECURITIES (UNLESS THE ISSUER IN ITS SOLE DISCRETION
DETERMINES TO USE ITS OWN COUNSEL), WITH ANY SUCH COUNSEL TO THE HOLDER AND
ANY
SUCH OPINION OF SUCH COUNSEL TO BE REASONABLY ACCEPTABLE TO THE ISSUER, THAT
REGISTRATION OF SUCH NOTE UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS
OF
APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
WARRANT
TO PURCHASE
SHARES
OF
COMMON STOCK
OF
CHEMBIO
DIAGNOSTICS, INC.
Expires
May 5, 2009
No.: _____________
|
Number
of Shares: ______________
|
Original
Date of Issuance: May 5,
2004
|
Reissuance
Date: December 19,
2007
|
FOR
VALUE
RECEIVED, subject to the provisions hereinafter set forth, the undersigned,
Chembio Diagnostics, Inc., a Nevada corporation (together with its successors
and assigns, the “Issuer”), hereby certifies that ___________________ or
its registered assigns is entitled to subscribe for and purchase, during
the
Term (as hereinafter defined), up to __________________ (___________) shares
(subject to adjustment as hereinafter provided) of the duly authorized, validly
issued, fully paid and non-assessable Common Stock of the Issuer, at an exercise
price per share equal to the Warrant Price then in effect, subject, however,
to
the provisions and upon the terms and conditions hereinafter set
forth. Capitalized terms used in this Warrant and not otherwise
defined herein shall have the respective meanings specified in Section 9
hereof.
1. Term. The
term of this Warrant shall commence on May 5, 2004 and shall expire at 5:00
p.m., Eastern Time, on May 5, 2009 (such period being the
“Term”).
2. Method
of Exercise Payment; Issuance of New Warrant; Transfer and
Exchange.
(a) Time
of Exercise. The purchase rights represented by this Warrant may
be exercised in whole or in part during the Term commencing on the effective
date of a registration statement under the Securities Act providing for the
resale of the Warrant Stock and the shares of Common Stock issuable upon
conversion of the Issuer’s Series A Convertible Preferred Stock issued pursuant
to the Purchase Agreement and expiring on May 5, 2009.
(b) Method
of Exercise.
(i) The
Holder hereof may exercise this Warrant, in whole or in part (A) by the
surrender of this Warrant (with the exercise form attached hereto duly executed)
at the principal office of the Issuer, and by the payment to the Issuer of
an
amount of consideration therefor equal to the Warrant Price in effect on
the
date of such exercise multiplied by the number of shares of Warrant Stock
with
respect to which this Warrant is then being exercised, payable by certified
or
official bank check or by wire transfer to an account designated by the Issuer;
or (B) by notifying the Company that this Warrant is being exercised pursuant
to
a Cashless Exercise (as defined in Section 2(b)(ii) below).
(ii) Cashless
Exercise At the option of the Holder, this Warrant may be exercised by means
of
a “cashless exercise” (a “Cashless Exercise”) in which the Holder shall be
entitled to receive a certificate for the number of Warrant Shares equal
to the
quotient obtained by dividing [(A-B) (X)] by (A), where:
(A)
= the
VWAP for the ten-Trading Day period that ends on the first Trading Day
immediately preceding the date of such election;
(B)
= the
applicable Exercise Price of this Warrant in effect on the date of exercise,
as
adjusted; and
(X)
= the
number of Warrant Shares issuable upon exercise of this Warrant in accordance
with the terms of this Warrant by means of a cash exercise rather than a
cashless exercise.
(iii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated on
the
Plan Closing Date received from a Holder who exercises its warrants on cashless
basis at $0.45 per share before 10:00p.m. ET on the Plan Closing Date, the
value
of (A) in the equation set forth in Section 2(b)(ii) above shall be equal
to the
greater of $0.53 or the VWAP for the ten-Trading Day period that ends on
the
second Trading Day prior to the date of the Notice of Exercise
Form.
(v) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated between
and inclusive of the Plan Closing Date and the Final Plan Date received from
a
Holder who exercises at least 10% of all of such Holder's warrants and options
for cash before 10:00p.m. ET on the Plan Closing Date the value of (A) in
the
equation set forth in Section 2(b)(ii) above shall be equal to the greater
of
$0.53 or the VWAP for the ten-Trading Day period that ends on the second
Trading
Day prior to the date of the Notice of Exercise Form. Any Exercise Form
dated on the Final Plan Date must be received by the Company within five
Trading
Days of the Final Plan Date to be effective.
(vi) Notwithstanding
anything herein to the contrary, a Holder who does not exercise (i) at least
10%
of all of such Holder's warrants and options issued by the Company for cash
at
an exercise price of $0.40 per share before 10:00p.m. ET on the Plan Closing
Date, or (ii) its warrants on cashless basis at $0.45 per share by 10:00p.m.
ET
on the Plan Closing Date shall not be permitted to exercise its Warrants
on a
cashless basis pursuant to Section 2(b)(ii) above until April 1,
2008.
(c) Issuance
of Stock Certificates. In the event of any exercise of the rights
represented by this Warrant in accordance with and subject to the terms and
conditions hereof, (i) certificates for the shares of Warrant Stock so purchased
shall be dated the date of such exercise and delivered to the Holder hereof
within a reasonable time, not exceeding three (3) Trading Days after such
exercise or, at the request of the Holder (provided that a registration
statement under the Securities Act providing for the resale of the Warrant
Stock
is then in effect), issued and delivered to the Depository Trust Company
(“DTC”) account on the Holder’s behalf via the Deposit Withdrawal Agent
Commission System (“DWAC”) within a reasonable time, not exceeding three
(3) Trading Days after such exercise, and the Holder hereof shall be deemed
for
all purposes to be the holder of the shares of Warrant Stock so purchased
as of
the date of such exercise and (ii) unless this Warrant has expired, a new
Warrant representing the number of shares of Warrant Stock, if any, with
respect
to which this Warrant shall not then have been exercised (less any amount
thereof which shall have been canceled in payment or partial payment of the
Warrant Price as hereinabove provided) shall also be issued to the Holder
hereof
at the Issuer’s expense within such time.
(d) Transferability
of Warrant. Subject to Section 2(f) and Section 2(g), this
Warrant may be transferred by a Holder without the consent of the
Issuer. If transferred pursuant to this paragraph and subject to the
provisions of subsection (f) of this Section 2, this Warrant may be transferred
on the books of the Issuer by the Holder hereof in person or by duly authorized
attorney, upon surrender of this Warrant at the principal office of the Issuer,
properly endorsed (by the Holder executing an assignment in the form attached
hereto) and upon payment of any necessary transfer tax or other governmental
charge imposed upon such transfer. This Warrant is exchangeable at
the principal office of the Issuer for Warrants for the purchase of the same
aggregate number of shares of Warrant Stock, each new Warrant to represent
the
right to purchase such number of shares of Warrant Stock as the Holder hereof
shall designate at the time of such exchange. All Warrants issued on
transfers or exchanges shall be dated the Original Issue Date and shall be
identical with this Warrant except as to the number of shares of Warrant
Stock
issuable pursuant thereto.
(e) Continuing
Rights of Holder. The Issuer will, at the time of or at any time
after each exercise of this Warrant, upon the request of the Holder hereof,
acknowledge in writing the extent, if any, of its continuing obligation to
afford to such Holder all rights to which such Holder shall continue to be
entitled after such exercise in accordance with the terms of this Warrant,
provided that if any such Holder shall fail to make any such request, the
failure shall not affect the continuing obligation of the Issuer to afford
such
rights to such Holder.
(f) Compliance
with Securities Laws.
(i) The
Holder of this Warrant, by acceptance hereof, acknowledges that this Warrant
or
the shares of Warrant Stock to be issued upon exercise hereof are being acquired
solely for the Holder’s own account and not as a nominee for any other party,
and for investment, and that the Holder will not offer, sell or otherwise
dispose of this Warrant or any shares of Warrant Stock to be issued upon
exercise hereof except pursuant to an effective registration statement, or
an
exemption from registration, under the Securities Act and any applicable
state
securities laws.
(ii) Except
as provided in paragraph (iii) below, this Warrant and all certificates
representing shares of Warrant Stock issued upon exercise hereof shall be
stamped or imprinted with a legend in substantially the following
form:
THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE
NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR
OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER
APPLICABLE STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION
OF
COUNSEL TO THE HOLDER OF THE SECURITIES (UNLESS THE ISSUER IN ITS SOLE
DISCRETION DETERMINES TO USE ITS OWN COUNSEL), WITH ANY SUCH COUNSEL TO THE
HOLDER AND ANY SUCH OPINION OF SUCH COUNSEL TO BE REASONABLY ACCEPTABLE TO
THE
ISSUER, THAT REGISTRATION OF SUCH NOTE UNDER THE SECURITIES ACT AND UNDER
THE
PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
(iii) The
Issuer agrees to reissue certificates representing any of the Warrant Stock,
without the legend set forth above if at such time, prior to making any transfer
of any such securities, the Holder shall give written notice to the Issuer
describing the manner and terms of such transfer and removal as the Issuer
may
reasonably request. Such proposed transfer and removal will not be
effected until: (a) either (i) the Issuer has received an opinion of
counsel reasonably satisfactory to the Issuer, to the effect that the
registration of such securities under the Securities Act is not required
in
connection with such proposed transfer, (ii) a registration statement under
the
Securities Act covering such proposed disposition has been filed by the Issuer
with the Securities and Exchange Commission and has become effective under
the
Securities Act, (iii) the Issuer has received other evidence reasonably
satisfactory to the Issuer that such registration and qualification under
the
Securities Act and state securities laws are not required, or (iv) the Holder
provides the Issuer with reasonable assurances that such security can be
sold
pursuant to Rule 144 under the Securities Act; and (b) either (i) the Issuer
has
received an opinion of counsel reasonably satisfactory to the Issuer, to
the
effect that registration or qualification under the securities or “blue sky”
laws of any state is not required in connection with such proposed disposition,
or (ii) compliance with applicable state securities or “blue sky” laws has been
effected or a valid exemption exists with respect thereto. The Issuer
will respond to any such notice from a holder within five (5) business
days. In the case of any proposed transfer under this Section 2(f),
the Issuer will use reasonable efforts to comply with any such applicable
state
securities or “blue sky” laws, but shall in no event be required, (x) to qualify
to do business in any state where it is not then qualified, (y) to take any
action that would subject it to tax or to the general service of process
in any
state where it is not then subject, or (z) to comply with state securities
or
“blue sky” laws of any state for which registration by coordination is
unavailable to the Issuer. The restrictions on transfer contained in
this Section 2(f) shall be in addition to, and not by way of limitation of,
any
other restrictions on transfer contained in any other section of this
Warrant. Whenever a certificate representing the Warrant Stock is
required to be issued to a the Holder without a legend, in lieu of delivering
physical certificates representing the Warrant Stock, provided the Issuer’s
transfer agent is participating in the DTC Fast Automated Securities Transfer
program, the Issuer shall use its reasonable best efforts to cause its transfer
agent to electronically transmit the Warrant Stock to the Holder by crediting
the account of the Holder’s Prime Broker with DTC through its DWAC system (to
the extent not inconsistent with any provisions of this Warrant or the Purchase
Agreement).
(g) In
no event may the Holder exercise this Warrant in whole or in part unless
the
Holder is an “accredited investor” as defined in Regulation D under the
Securities Act.
3. Stock
Fully Paid; Reservation and Listing of Shares; Covenants.
(a) Stock
Fully Paid. The Issuer represents, warrants, covenants and agrees
that all shares of Warrant Stock which may be issued upon the exercise of
this
Warrant or otherwise hereunder will, when issued in accordance with the terms
of
this Warrant, be duly authorized, validly issued, fully paid and non-assessable
and free from all taxes, liens and charges created by or through the
Issuer. The Issuer further covenants and agrees that during the
period within which this Warrant may be exercised, the Issuer will at all
times
have authorized and reserved for the purpose of the issue upon exercise of
this
Warrant a sufficient number of shares of Common Stock to provide for the
exercise of this Warrant.
(b) Reservation. If
any shares of Common Stock required to be reserved for issuance upon exercise
of
this Warrant or as otherwise provided hereunder require registration or
qualification with any governmental authority under any federal or state
law
before such shares may be so issued, the Issuer will in good faith use its
reasonable best efforts as expeditiously as possible at its expense to cause
such shares to be duly registered or qualified. If the Issuer shall
list any shares of Common Stock on any securities exchange or market it will,
at
its expense, list thereon, maintain and increase when necessary such listing,
of, all shares of Warrant Stock from time to time issued upon exercise of
this
Warrant or as otherwise provided hereunder (provided that such Warrant Stock
has
been registered pursuant to a registration statement under the Securities
Act
then in effect), and, to the extent permissible under the applicable securities
exchange rules, all unissued shares of Warrant Stock which are at any time
issuable hereunder, so long as any shares of Common Stock shall be so
listed. The Issuer will also so list on each securities exchange or
market, and will maintain such listing of, any other securities which the
Holder
of this Warrant shall be entitled to receive upon the exercise of this Warrant
if at the time any securities of the same class shall be listed on such
securities exchange or market by the Issuer.
(c) Covenants. The
Issuer shall not by any action including, without limitation, amending the
Articles of Incorporation or the by-laws of the Issuer, or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue
or
sale of securities or any other action, avoid or seek to avoid the observance
or
performance of any of the terms of this Warrant, but will at all times in
good
faith assist in the carrying out of all such terms and in the taking of all
such
actions as may be necessary or appropriate to protect the rights of the Holder
hereof against dilution (to the extent specifically provided herein) or
impairment. Without limiting the generality of the foregoing, the
Issuer will (i) not permit the par value, if any, of its Common Stock to
exceed
the then effective Warrant Price, (ii) not amend or modify any provision
of the
Articles of Incorporation or by-laws of the Issuer in any manner that would
adversely affect the rights of the Holders of the Warrants in their capacity
as
Holders of the Warrants, (iii) take all such action as may be reasonably
necessary in order that the Issuer may validly and legally issue fully paid
and
nonassessable shares of Common Stock, free and clear of any liens, claims,
encumbrances and restrictions (other than as provided herein) upon the exercise
of this Warrant, and (iv) use its reasonable best efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be reasonably necessary to enable the Issuer
to
perform its obligations under this Warrant.
(d) Loss,
Theft, Destruction of Warrants. Upon receipt of evidence
satisfactory to the Issuer of the ownership of and the loss, theft, destruction
or mutilation of any Warrant and, in the case of any such loss, theft or
destruction, upon receipt of indemnity or security satisfactory to the Issuer
or, in the case of any such mutilation, upon surrender and cancellation of
such
Warrant, the Issuer will make and deliver, in lieu of such lost, stolen,
destroyed or mutilated Warrant, a new Warrant of like tenor and representing
the
right to purchase the same number of shares of Common Stock.
4. Adjustment
of Warrant Price. The price at which such shares may be purchased
upon exercise of this Warrant shall be subject to adjustment from time to
time
as set forth in this Section 4. The Issuer shall give the Holder
notice of any event described below which requires an adjustment pursuant
to
this Section 4 in accordance with Section 5.
(a) Recapitalization,
Reorganization, Reclassification, Consolidation, Merger or
Sale.
(i) In
case the Issuer after the Original Issue Date shall do any of the following
(each, a “Triggering Event”): (a) consolidate or merge with or
into another corporation where the holders of outstanding Voting Stock prior
to
such merger or consolidation do not own over 50% of the outstanding Voting
Stock
of the merged or consolidated entity immediately after such merger or
consolidation, or (b) sell all or substantially all of its properties or
assets
to any other Person, or (c) change the Common Stock to the same or different
number of shares of any class or classes of stock, whether by reclassification,
exchange, substitution or otherwise (other than by way of a stock split or
combination of shares or stock dividends or distributions provided for in
Section 4(b) or Section 4(c)), or (d)
effect a capital reorganization (other than the transactions executed in
connection with the Plan or by way of a stock split or combination of shares
or
stock dividends or distributions provided for in Section 4(b) or Section
4(c)), then, and in the case of each such Triggering Event, proper
provision shall be made so that, upon the basis and the terms and in the
manner
provided in this Warrant, the Holder of this Warrant shall be entitled upon
the
exercise hereof at any time after the consummation of such Triggering Event,
to
the extent this Warrant is not exercised prior to such Triggering Event,
to
receive at the Warrant Price in effect at the time immediately prior to the
consummation of such Triggering Event in lieu of the Common Stock issuable
upon
such exercise of this Warrant prior to such Triggering Event, the securities,
cash and property to which such Holder would have been entitled upon the
consummation of such Triggering Event if such Holder had exercised the rights
represented by this Warrant immediately prior thereto, subject to adjustments
(subsequent to such corporate action) as nearly equivalent as possible to
the
adjustments provided for elsewhere in this Section 4.
(ii) Notwithstanding
anything contained in this Warrant to the contrary, a Triggering Event shall
not
be deemed to have occurred if, prior to the consummation thereof, each Person
(other than the Issuer) which may be required to deliver any securities,
cash or
property upon the exercise of this Warrant as provided herein shall assume,
by
written instrument delivered to, and reasonably satisfactory to, the Holder
of
this Warrant, (A) the obligations of the Issuer under this Warrant (and if
the
Issuer shall survive the consummation of such Triggering Event, such assumption
shall be in addition to, and shall not release the Issuer from, any continuing
obligations of the Issuer under this Warrant) and (B) the obligation to deliver
to such Holder such shares of securities, cash or property as, in accordance
with the foregoing provisions of this subsection (a), such Holder shall be
entitled to receive, and such Person shall have similarly delivered to such
Holder a written acknowledgement executed by the President or Chief Financial
Officer of the Company, stating that this Warrant shall thereafter continue
in
full force and effect and the terms hereof (including, without limitation,
all
of the provisions of this subsection (a)) shall be applicable to the securities,
cash or property which such Person may be required to deliver upon any exercise
of this Warrant or the exercise of any rights pursuant hereto.
(b) Stock
Dividends, Subdivisions and Combinations. If at any time the
Issuer shall:
(i) make
or issue or set a record date for the holders of its Common Stock for the
purpose of entitling them to receive a dividend payable in, or other
distribution of, shares of Common Stock,
(ii) subdivide
its outstanding shares of Common Stock into a larger number of shares of
Common
Stock, or
(iii) combine
its outstanding shares of Common Stock into a smaller number of shares of
Common
Stock,
then
(1)
the number of shares of Common Stock for which this Warrant is exercisable
immediately after the occurrence of any such event shall be adjusted to equal
the number of shares of Common Stock which a record holder of the same number
of
shares of Common Stock for which this Warrant is exercisable immediately
prior
to the occurrence of such event would own or be entitled to receive after
the
happening of such event, and (2) the Warrant Price then in effect shall be
adjusted to equal (A) the Warrant Price then in effect multiplied by the
number
of shares of Common Stock for which this Warrant is exercisable immediately
prior to the adjustment divided by (B) the number of shares of Common Stock
for
which this Warrant is exercisable immediately after such
adjustment.
Notwithstanding
the foregoing, if such record date shall have been fixed and such dividend
is
not fully paid or if such distribution is not fully made on the date fixed
therefor, the Warrant Price shall be adjusted pursuant to this paragraph
as of
the time of actual payment of such dividends or distributions.
(c) Certain
Other Distributions. If at any time the Issuer shall make or
issue or set a record date for the determination of the holders of its Common
Stock for the purpose of entitling them to receive any dividend or other
distribution of:
(i) cash
(other than a cash dividend payable out of earnings or earned surplus legally
available for the payment of dividends under the laws of the jurisdiction
of
incorporation of the Issuer),
(ii) any
evidences of its indebtedness, any shares of stock of any class or any other
securities or property of any nature whatsoever (other than cash, Convertible
Securities or Additional Shares of Common Stock), or
(iii) any
warrants or other rights to subscribe for or purchase any evidences of its
indebtedness, any shares of stock of any class or any other securities or
property of any nature whatsoever (other than cash, Convertible Securities
or
Additional Shares of Common Stock), then (1) the number of shares of Common
Stock for which this Warrant is exercisable shall be adjusted to equal the
product of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such adjustment multiplied by a fraction
(A)
the numerator of which shall be the Per Share Market Value of Common Stock
at
the date of taking such record and (B) the denominator of which shall be
such
Per Share Market Value minus the amount allocable to one share of Common
Stock
of any such cash so distributable and of the fair value (as determined in
good
faith by the Board of Directors of the Issuer and supported by an opinion
from
an investment banking firm of recognized national standing acceptable to
(but
not affiliated with) the Holder) of any and all such evidences of indebtedness,
shares of stock, other securities or property or warrants or other subscription
or purchase rights so distributable, and (2) the Warrant Price then in effect
shall be adjusted to equal (A) the Warrant Price then in effect multiplied
by
the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to the adjustment divided by (B) the number of shares of
Common Stock for which this Warrant is exercisable immediately after such
adjustment. A reclassification of the Common Stock (other than a
change in par value, or from par value to no par value or from no par value
to
par value) into shares of Common Stock and shares of any other class of stock
shall be deemed a distribution by the Issuer to the holders of its Common
Stock
of such shares of such other class of stock within the meaning of this Section
4(c) and, if the outstanding shares of Common Stock shall be changed into
a
larger or smaller number of shares of Common Stock as a part of such
reclassification, such change shall be deemed a subdivision or combination,
as
the case may be, of the outstanding shares of Common Stock within the meaning
of
Section 4(b).
Notwithstanding
the foregoing, if such record date shall have been fixed and such dividend
is
not fully paid or if such distribution is not fully made on the date fixed
therefor, the Warrant Price shall be adjusted pursuant to this Section 4(c)
as
of the time of actual payment of such dividends or distributions.
(d) Issuance
of Additional Shares of Common Stock. In the event the Issuer
shall at any time following the Original Issue Date issue any Additional
Shares
of Common Stock (otherwise than as provided in the foregoing subsections
(a)
through (c) of this Section 4), at a price per share less than $.60 or without
consideration, then the Warrant Price upon each such issuance shall be adjusted
to the price equal to the consideration per share paid for such Additional
Shares of Common Stock.
(e) Issuance
of Common Stock Equivalents. If at any time the Issuer shall
issue or sell any Common Stock Equivalents, whether or not the rights to
exchange or convert thereunder are immediately exercisable, and the aggregate
price per share for which Common Stock is issuable upon such conversion or
exchange plus the consideration received by the Issuer for issuance of such
Common Stock Equivalent divided by the number of shares of Common Stock issuable
pursuant to such Common Stock Equivalent shall be less than $.60 or without
consideration, then the Warrant Price then in effect shall be adjusted as
provided in Section 4(d). No further adjustment of the Warrant Price
then in effect shall be made under this Section 4(e) upon the issuance of
any
Common Stock Equivalents which are issued pursuant to the exercise of any
warrants or other subscription or purchase rights therefor, if any such
adjustment shall previously have been made upon the issuance of such warrants
or
other rights pursuant to this Section 4(e). No further adjustments of
the Warrant Price then in effect shall be made upon the actual issue of such
Common Stock upon conversion or exchange of such Common Stock
Equivalents.
(f) Other
Provisions applicable to Adjustments under this Section. The
following provisions shall be applicable to the making of adjustments of
the number of shares of Common Stock for which this Warrant is exercisable
and
the Warrant Price then in effect provided for in this Section 4:
(i) Computation
of Consideration. To the extent that any Additional Shares of
Common Stock shall be issued for cash consideration, the consideration received
by the Issuer therefor shall be the amount of the cash received by the Issuer
therefor, or, if such Additional Shares of Common Stock are offered by the
Issuer for subscription, the subscription price, or, if such Additional Shares
of Common Stock are sold to underwriters or dealers for public offering without
a subscription offering, the initial public offering price (in any such case
subtracting any amounts paid or receivable for accrued interest or accrued
dividends and without taking into account any compensation, discounts or
expenses paid or incurred by the Issuer for and in the underwriting of, or
otherwise in connection with, the issuance thereof). In connection
with any merger or consolidation in which the Issuer is the surviving
corporation (other than any consolidation or merger in which the previously
outstanding shares of Common Stock of the Issuer shall be changed to or
exchanged for the stock or other securities of another corporation), the
amount
of consideration therefore shall be, deemed to be the fair value, as determined
reasonably and in good faith by the Board, of such portion of the assets
and
business of the nonsurviving corporation as the Board may determine to be
attributable to such Additional Shares of Common Stock. The
consideration for any Additional Shares of Common Stock issuable pursuant
to any
Convertible Securities or warrants or other rights to subscribe for or purchase
the same shall be the consideration received by the Issuer for issuing such
Convertible Securities or warrants or other rights plus the additional
consideration payable to the Issuer upon exercise of such warrants or other
rights. In the event of any consolidation or merger of the Issuer in
which the Issuer is not the surviving corporation or in which the previously
outstanding shares of Common Stock of the Issuer shall be changed into or
exchanged for the stock or other securities of another corporation, or in
the
event of any sale of all or substantially all of the assets of the Issuer
for
stock or other securities of any corporation, the Issuer shall be deemed
to have
issued a number of shares of its Common Stock for stock or securities or
other
property of the other corporation computed on the basis of the actual exchange
ratio on which the transaction was predicated, and for a consideration equal
to
the fair market value on the date of such transaction of all such stock or
securities or other property of the other corporation. In the event
any consideration received by the Issuer for any securities consists of property
other than cash, the fair market value thereof at the time of issuance or
as
otherwise applicable shall be as determined in good faith by the
Board. In the event Common Stock is issued with other shares or
securities or other assets of the Issuer for consideration which covers both,
the consideration computed as provided in this Section 4(f)(i) shall be
allocated among such securities and assets as determined in good faith by
the
Board.
(ii) When
Adjustments to Be Made. The adjustments required by this Section
4 shall be made whenever and as often as any specified event requiring an
adjustment shall occur, except that any adjustment of the number of shares
of
Common Stock for which this Warrant is exercisable that would otherwise be
required may be postponed (except in the case of a subdivision or combination
of
shares of the Common Stock, as provided for in Section 4(b)) up to, but not
beyond the date of exercise if such adjustment either by itself or with other
adjustments not previously made adds or subtracts less than one percent (1%)
of
the shares of Common Stock for which this Warrant is exercisable immediately
prior to the making of such adjustment. Any adjustment representing a
change of less than such minimum amount (except as aforesaid) which is postponed
shall be carried forward and made as soon as such adjustment, together with
other adjustments required by this Section 4 and not previously made, would
result in a minimum adjustment or on the date of exercise. For the
purpose of any adjustment, any specified event shall be deemed to have occurred
at the close of business on the date of its occurrence.
(iii) Fractional
Interests. In computing adjustments under this Section 4,
fractional interests in Common Stock shall be taken into account to the
nearest one one-hundredth (1/100th) of a
share.
(iv) When
Adjustment Not Required. If the Issuer shall take a record of the
holders of its Common Stock for the purpose of entitling them to receive
a
dividend or distribution or subscription or purchase rights and shall,
thereafter and before the distribution to stockholders thereof, legally abandon
its plan to pay or deliver such dividend, distribution, subscription or purchase
rights, then thereafter no adjustment shall be required by reason of the
taking
of such record and any such adjustment previously made in respect thereof
shall
be rescinded and annulled.
(g) Form
of Warrant after Adjustments. The form of this Warrant need not
be changed because of any adjustments in the Warrant Price or the number
and
kind of Securities purchasable upon the exercise of this Warrant.
(h) Escrow
of Warrant Stock. If after any property becomes distributable
pursuant to this Section 4 by reason of the taking of any record of the holders
of Common Stock, but prior to the occurrence of the event for which such
record
is taken, and the Holder exercises this Warrant, any shares of Common Stock
issuable upon exercise by reason of such adjustment shall be deemed the last
shares of Common Stock for which this Warrant is exercised (notwithstanding
any
other provision to the contrary herein) and such shares or other property
shall
be held in escrow for the Holder by the Issuer to be issued to the Holder
upon
and to the extent that the event actually takes place, upon payment of the
current Warrant Price. Notwithstanding any other provision to the
contrary herein, if the event for which such record was taken fails to occur
or
is rescinded, then such escrowed shares shall be cancelled by the Issuer
and
escrowed property returned.
(i) Notwithstanding
any other provision set forth in this Section 4, no adjustment to the Warrant
Price shall be required because of any issuance or sale of Additional Shares
of
Common Stock or Common Stock Equivalents upon conversion of the preferred
stock
or the exercise of warrants and/or options in connection with the
Plan.
5. Notice
of Adjustments. Whenever the Warrant Price or Warrant Share
Number shall be adjusted pursuant to Section 4 hereof (for purposes of this
Section 5, each an “adjustment”), the Issuer shall cause its Chief Financial
Officer to prepare and execute a certificate setting forth, in reasonable
detail, the event requiring the adjustment, the amount of the adjustment,
the
method by which such adjustment was calculated (including a description of
the
basis on which the Board made any determination hereunder), and the Warrant
Price and Warrant Share Number after giving effect to such adjustment, and
shall
cause copies of such certificate to be delivered to the Holder of this Warrant
promptly after each adjustment. Any dispute between the Issuer and
the Holder of this Warrant with respect to the matters set forth in such
certificate may at the option of the Holder of this Warrant be submitted
to one
of the national accounting firms currently known as the “big four” selected by
the Holder, provided that the Issuer shall have ten (10) days after
receipt of notice from such Holder of its selection of such firm to object
thereto, in which case such Holder shall select another such firm and the
Issuer
shall have no such right of objection unless the Issuer identifies a valid
conflict of interest for such firm with any of the parties. The firm
selected by the Holder of this Warrant as provided in the preceding sentence
shall be instructed to deliver a written opinion as to such matters to the
Issuer and such Holder within thirty (30) days after submission to it of
such
dispute. Such opinion shall be final and binding on the parties
hereto. The costs and expenses of such accounting firm shall be paid
equally by the Company and the Holder.
6. Fractional
Shares. No fractional shares of Warrant Stock will be issued in
connection with any exercise hereof, but in lieu of such fractional shares,
the
Issuer shall make a cash payment therefor equal in amount to the product
of the
applicable fraction multiplied by the Per Share Market Value then in
effect.
7. Ownership
Cap and Certain Exercise Restrictions.
(a) Notwithstanding
anything to the contrary set forth in this Warrant, at no time may a Holder
of
this Warrant exercise this Warrant if the number of shares of Common Stock
to be
issued pursuant to such exercise would exceed, when aggregated with all other
shares of Common Stock owned by such Holder at such time, the number of shares
of Common Stock which would result in such Holder beneficially owning (as
determined in accordance with Section 13(d) of the Exchange Act and the rules
thereunder) in excess of 4.999% of the then issued and outstanding shares
of
Common Stock; provided, however, that upon a holder of this
Warrant providing the Issuer with sixty-one (61) days notice (pursuant to
Section 13 hereof) (the “Waiver Notice”) that such Holder would like to
waive this Section 7(a) with regard to any or all shares of Common Stock
issuable upon exercise of this Warrant, this Section 7(a) will be of no force
or
effect with regard to all or a portion of the Warrant referenced in the Waiver
Notice; provided, further, that this provision shall be of no
further force or effect (i) during the sixty-one (61) days immediately preceding
the expiration of the term of this Warrant, (ii) upon the Holder’s receipt of a
Call Notice (as defined in Section 8 hereof), or (iii) upon the issuance
of
Common Stock pursuant to the exercise of this Warrant in connection with
the
Plan.
(b) The
Holder may not exercise the Warrant hereunder to the extent such exercise
would
result in the Holder beneficially owning (as determined in accordance with
Section 13(d) of the Exchange Act and the rules thereunder) in excess of
9.999%
of the then issued and outstanding shares of Common Stock, including shares
issuable upon exercise of the Warrant held by the Holder after application
of
this Section; provided, however, that upon a holder of this
Warrant providing the Company with a Waiver Notice that such holder would
like
to waive this Section 7(b) with regard to any or all shares of Common Stock
issuable upon exercise of this Warrant, this Section 7(b) shall be of no
force
or effect with regard to those shares of Warrant Stock referenced in the
Waiver
Notice; provided, further, that this provision shall be of no
further force or effect (i) during the sixty-one (61) days immediately preceding
the expiration of the term of this Warrant, (ii) upon the Holder’s receipt of a
Call Notice, or (iii) upon the issuance of Common Stock pursuant to the exercise
of this Warrant in connection with the Plan.
8. Call. Notwithstanding
anything herein to the contrary, commencing twelve (12) months following
the
effective date of a registration statement under the Securities Act providing
for the resale of the Warrant Stock and the shares of Common Stock issuable
upon
conversion of the Issuer’s Series A Preferred Stock issued pursuant to the
Purchase Agreement (the “Registration Statement”), the Issuer, at its
option, may call up to one hundred percent (100%) of this Warrant if the
Per
Share Market Value of the Common Stock has been greater than $3.00 (as may
be
adjusted for any stock splits or combinations of the Common Stock) for a
period
of twenty (20) consecutive Trading Days immediately prior to the date of
delivery of the Call Notice (a “Call Notice Period”) by providing the
Holder of this Warrant written notice pursuant to Section 13 (the “Call
Notice”); provided, that (a) the Registration Statement is
then in effect and has been effective, without lapse or suspension of any
kind,
for a period of 60 consecutive calendar days, (b) trading in the Common Stock
shall not have been suspended by the Securities and Exchange Commission or
the
OTC Bulletin Board and (c) the Issuer is in material compliance with the
terms
and conditions of this Warrant and the other Transaction Documents (as defined
in the Purchase Agreement); provided, further, that the
Registration Statement is in effect from the date of delivery of the Call
Notice
until the date which is the later of (i) the date the Holder exercises the
Warrant pursuant to the Call Notice and (ii) the 20th day after
the
Holder receives the Call Notice (the “Early Termination
Date”). The rights and privileges granted pursuant to this
Warrant with respect to the shares of Warrant Stock subject to the Call Notice
(the “Called Warrant Shares”) shall expire on the Early Termination Date
if this Warrant is not exercised with respect to such Called Warrant Shares
prior to such Early Termination Date. In the event this Warrant is
not exercised with respect to the Called Warrant Shares, the Issuer shall
remit
to the Holder of this Warrant (A) $.01 per Called Warrant Share and (B) a
new
Warrant representing the number of shares of Warrant Stock, if any, which
shall
not have been subject to the Call Notice upon the Holder tendering to the
Issuer
the applicable Warrant certificate.
9. Definitions. For
the purposes of this Warrant, the following terms have the following
meanings:
“Additional
Shares of Common Stock” means all shares of Common Stock issued by the
Issuer after the original issue date, and all shares of Other Common, if
any,
issued by the Issuer after the original issue date, except: (i)
securities issued (other than for cash) in connection with a merger,
acquisition, or consolidation, (ii) securities issued pursuant to a bona
fide
firm underwritten public offering of the Issuer’s securities, (iii) securities
issued pursuant to the conversion or exercise of convertible or excercisable
securities issued or outstanding on or prior to the original issue date or
issued pursuant to the Purchase Agreement, (iv) the Warrant Stock, (v)
securities issued in connection with strategic alliances or other partnering
arrangements so long as such issuances are not for the purpose of raising
capital, (vi) Common Stock issued or options to purchase Common Stock granted
or
issued pursuant to the Issuer’s stock option plans and employee stock purchase
plans as they now exist, (vii) any warrants issued to the placement agent
for
the transactions contemplated by the Purchase Agreement, and (viii) the payment
of any dividend on the Series A Convertible Preferred Stock of the
Issuer.
“Articles
of Incorporation” means the Articles of Incorporation of the Issuer as in
effect on the Original Issue Date, and as hereafter from time to time amended,
modified, supplemented or restated in accordance with the terms hereof and
thereof and pursuant to applicable law.
“Board”
shall mean the Board of Directors of the Issuer.
“Capital
Stock” means and includes (i) any and all shares, interests, participations
or other equivalents of or interests in (however designated) corporate stock,
including, without limitation, shares of preferred or preference stock, (ii)
all
partnership interests (whether general or limited) in any Person which is
a
partnership, (iii) all membership interests or limited liability company
interests in any limited liability company, and (iv) all equity or ownership
interests in any Person of any other type.
“Common
Stock” means the Common Stock, par value $.01 per share, of the Issuer and
any other Capital Stock into which such stock may hereafter be
changed.
“Common
Stock Equivalent” means any Convertible Security or warrant, option or other
right to subscribe for or purchase any Additional Shares of Common Stock
or any
Convertible Security.
“Convertible
Securities” means evidences of Indebtedness, shares of Capital Stock or
other Securities which are or may be at any time convertible into or
exchangeable for Additional Shares of Common Stock. The term
“Convertible Security” means one of the Convertible Securities.
“Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
“Governmental
Authority” means any governmental, regulatory or self-regulatory entity,
department, body, official, authority, commission, board, agency or
instrumentality, whether federal, state or local, and whether domestic or
foreign.
“Holders”
mean the Persons who shall from time to time own any Warrant. The
term “Holder” means one of the Holders.
“Independent
Appraiser” means a nationally recognized or major regional investment
banking firm or firm of independent certified public accountants of recognized
standing (which may be the firm that regularly examines the financial statements
of the Issuer) that is regularly engaged in the business of appraising the
Capital Stock or assets of corporations or other entities as going concerns,
and
which is not affiliated with either the Issuer or the Holder of any
Warrant.
“Issuer”
means Chembio Diagnostics, Inc., a Nevada corporation, and its
successors.
“Majority
Holders” means at any time the Holders of Warrants exercisable for a
majority of the shares of Warrant Stock issuable under the Warrants at the
time
outstanding.
“Original
Issue Date” means May 5, 2004.
“OTC
Bulletin Board” means the over-the-counter electronic bulletin
board.
“Other
Common” means any other Capital Stock of the Issuer of any class which shall
be authorized at any time after the date of this Warrant (other than Common
Stock) and which shall have the right to participate in the distribution
of
earnings and assets of the Issuer without limitation as to amount.
“Outstanding
Common Stock” means, at any given time, the aggregate amount of outstanding
shares of Common Stock, assuming full exercise, conversion or exchange (as
applicable) of all options, warrants and other Securities which are convertible
into or exercisable or exchangeable for, and any right to subscribe for,
shares
of Common Stock that are outstanding at such time.
“Person”
means an individual, corporation, limited liability company, partnership,
joint
stock company, trust, unincorporated organization, joint venture, Governmental
Authority or other entity of whatever nature.
“Per
Share Market Value” means on any particular date (a) the closing bid price
for a share of Common Stock in the over-the-counter market, as reported by
the
OTC Bulletin Board or in the National Quotation Bureau Incorporated or similar
organization or agency succeeding to its functions of reporting prices) at
the
close of business on such date, or (b) if the Common Stock is not then reported
by the OTC Bulletin Board or the National Quotation Bureau Incorporated (or
similar organization or agency succeeding to its functions of reporting prices),
then the average of the “Pink Sheet” quotes for the relevant determination
period, or (c) if the Common Stock is not then publicly traded the fair market
value of a share of Common Stock as determined by the Board in good faith;
provided, however, that the Majority Holders, after receipt of the
determination by the Board, shall have the right to select, jointly with
the
Issuer, an Independent Appraiser, in which case, the fair market value shall
be
the determination by such Independent Appraiser; and provided,
further that all determinations of the Per Share Market Value shall
be
appropriately adjusted for any stock dividends, stock splits or other similar
transactions during such period. The determination of fair market
value shall be based upon the fair market value of the Issuer determined
on a
going concern basis as between a willing buyer and a willing seller and taking
into account all relevant factors determinative of value, and shall be final
and
binding on all parties. In determining the fair market value of any
shares of Common Stock, no consideration shall be given to any restrictions
on
transfer of the Common Stock imposed by agreement or by federal or state
securities laws, or to the existence or absence of, or any limitations on,
voting rights.
“Plan”
shall mean any action the Company takes, with any required approval of the
holders thereof, on or before the Final Plan Date as contemplated by the
Plan
Summary and accompanying materials provided to holders on December 4, 2007,
in
connection with the reduction or other modification of terms of the Company's
then-outstanding preferred stock, warrants and options, including, but not
limited to, actions the Company takes to (i) facilitate the conversion of
the
Series A, B and C Convertible Preferred Stock; (ii) reduce the exercise price
of
any of the Company's outstanding warrants or options; (iii) offer the holders
of
the Company's warrants and options the opportunity to exercise such warrants
and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
“Plan
Closing
Date”
shall
be
December 19, 2007.
“Purchase
Agreement” means the Series A Convertible Preferred Stock and Warrant
Purchase Agreement dated as of May 5, 2004 among the Issuer and the investors
a
party thereto.
“Securities”
means any debt or equity securities of the Issuer, whether now or hereafter
authorized, any instrument convertible into or exchangeable for Securities
or a
Security, and any option, warrant or other right to purchase or acquire any
Security. “Security” means one of the Securities.
“Securities
Act” means the Securities Act of 1933, as amended, or any similar federal
statute then in effect.
“Subsidiary”
means any corporation at least 50% of whose outstanding Voting Stock shall
at
the time be owned directly or indirectly by the Issuer or by one or more
of its
Subsidiaries, or by the Issuer and one or more of its Subsidiaries.
“Term”
has the meaning specified in Section 1 hereof.
“Trading
Day” means (a) a day on which the Common Stock is traded on the OTC Bulletin
Board, or (b) if the Common Stock is not traded on the OTC Bulletin Board,
a day
on which the Common Stock is quoted in the over-the-counter market as reported
by the National Quotation Bureau Incorporated (or any similar organization
or
agency succeeding its functions of reporting prices); provided,
however, that in the event that the Common Stock is not listed or
quoted
as set forth in (a) or (b) hereof, then Trading Day shall mean any day except
Saturday, Sunday and any day which shall be a legal holiday or a day on which
banking institutions in the State of New York are authorized or required
by law
or other government action to close.
“Voting
Stock” means, as applied to the Capital Stock of any corporation, Capital
Stock of any class or classes (however designated) having ordinary voting
power
for the election of a majority of the members of the Board of Directors (or
other governing body) of such corporation, other than Capital Stock having
such
power only by reason of the happening of a contingency.
“Warrant
Price” shall be as follows, except as may be adjusted from time to time as
shall result from the adjustments specified in this Warrant, including Section
4
hereto:
|
(i)
|
For
the period 4:01p.m. eastern time ET through 9:59p.m. ET on the
Plan
Closing Date, $0.40 per share for all or any portion of this Warrant
exercised for cash;
|
|
(ii)
|
For
the period 4:01p.m. ET through 9:59p.m. ET on the Plan Closing
Date, $0.45
per share for all or any portion of this Warrant exercised through
a
Cashless Exercise;
|
|
(iii)
|
For
the period beginning 10:00p.m. ET on the Plan Closing Date through
9:59p.m. ET on the Final Plan Date, $0.45 for all or any part of
this
Warrant exercised by a Holder who exercised at least 10% of all
of such
Holder’s warrants and options for cash at the Plan Closing
Date;
|
|
(iv)
|
For
the period beginning 10:00p.m. ET on the Plan Closing Date, $0.90
per
share for any Holder that did not exercise at least 10% of all
of such
Holder’s warrants and options for cash at an exercise price of $0.40 per
share at the Plan Closing Date; and
|
|
(v)
|
For
the period beginning 10:00p.m. ET on the Final Plan Date, $0.90
per share
for all or any portion of this Warrant that has not been exercised
on or
before 9:59p.m. ET on the Final Plan
Date.
|
“Warrant
Share Number” means at any time the aggregate number of shares of Warrant
Stock which may at such time be purchased upon exercise of this Warrant,
after
giving effect to all prior adjustments and increases to such number made
or
required to be made under the terms hereof.
“Warrant
Stock” means Common Stock issuable upon exercise of any Warrant or Warrants
or otherwise issuable pursuant to any Warrant or Warrants.
“Warrants”
means the Warrants issued and sold pursuant to the Purchase Agreement,
including, without limitation, this Warrant, and any other warrants of like
tenor issued in substitution or exchange for any thereof pursuant to the
provisions of Section 2(c), 2(d) or 2(e) hereof or of any of such other
Warrants.
10. Other
Notices. In case at any time:
(a) the
Issuer shall make any distributions to the holders of Common Stock;
or
(b) the
Issuer shall authorize the granting to all holders of its Common Stock of
rights
to subscribe for or purchase any shares of Capital Stock of any class or
other
rights; or
(c) there
shall be any reclassification of the Capital Stock of the Issuer;
or
(d) there
shall be any capital reorganization by the Issuer; or
(e) there
shall be any (i) consolidation or merger involving the Issuer or (ii) sale,
transfer or other disposition of all or substantially all of the Issuer’s
property, assets or business (except a merger or other reorganization in
which
the Issuer shall be the surviving corporation and its shares of Capital Stock
shall continue to be outstanding and unchanged and except a consolidation,
merger, sale, transfer or other disposition involving a wholly-owned
Subsidiary); or
(f) there
shall be a voluntary or involuntary dissolution, liquidation or winding-up
of
the Issuer or any partial liquidation of the Issuer or distribution to holders
of Common Stock; then, in each of such cases, the Issuer shall give written
notice to the Holder of the date on which (i) the books of the Issuer shall
close or a record shall be taken for such dividend, distribution or subscription
rights or (ii) such reorganization, reclassification, consolidation, merger,
disposition, dissolution, liquidation or winding-up, as the case may be,
shall
take place. Such notice also shall specify the date as of which the
holders of Common Stock of record shall participate in such dividend,
distribution or subscription rights, or shall be entitled to exchange their
certificates for Common Stock for securities or other property deliverable
upon
such reorganization, reclassification, consolidation, merger, disposition,
dissolution, liquidation or winding-up, as the case may be. Such
notice shall be given at least twenty (20) days prior to the record date
or
effective date for the event specified in such notice.
11. Amendment
and Waiver. Any term, covenant, agreement or condition in this
Warrant may be amended, or compliance therewith may be waived (either generally
or in a particular instance and either retroactively or prospectively), by
a
written instrument or written instruments executed by the Issuer and the
Majority Holders; provided, however, that no such amendment or
waiver shall reduce the Warrant Share Number, increase the Warrant Price,
shorten the period during which this Warrant may be exercised or modify any
provision of this Section 11 without the consent of the Holder of this
Warrant.
12. Governing
Law. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT
TO
PRINCIPLES OF CONFLICTS OF LAW.
13. Notices. Any
and all notices or other communications or deliveries required or permitted
to
be provided hereunder shall be in writing and shall be deemed given and
effective on the earlier of (i) the date of transmission, if such notice
or
communication is delivered via facsimile at the facsimile telephone number
specified for notice prior to 5:00 p.m., eastern time, on a Trading Day,
(ii)
the Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile telephone number specified for
notice later than 5:00 p.m., eastern time, on any date and earlier than 11:59
p.m., eastern time, on such date, or (iii) actual receipt by the party to
whom
such notice is required to be given. The addresses for such
communications shall be with respect to the Holder of this Warrant or of
Warrant
Stock issued pursuant hereto, addressed to such Holder at its last known
address
or facsimile number appearing on the books of the Issuer maintained for such
purposes, or with respect to the Issuer, addressed to:
Chembio
Diagnostics, Inc.
3661
Horseblock Road
Medford,
NY 11763
Attention: Lawrence
A. Siebert, President
Tel.
No.: (631) 924-1135
Fax
No.: (631) 924-6033
Copies
of
notices to the Issuer shall be sent to Patton Boggs LLP, 1801 California
Street,
Suite 4900, Denver, CO 80202, Attention: Alan Talesnick, Tel.
No.: (303) 830-1776, Fax No.: (303)
894-9239. Copies of notices to the Holder shall be sent to Jenkens
& Gilchrist Parker Chapin LLP, 405 Lexington Avenue, New York, New York
10174, Attention: Christopher S. Auguste, Facsimile
No.: (212) 704-6288. Any party hereto may from time to
time change its address for notices by giving at least ten (10) days written
notice of such changed address to the other party hereto.
14. Warrant
Agent. The Issuer may, by written notice to each Holder of this
Warrant, appoint an agent for the purpose of issuing shares of Warrant Stock
on
the exercise of this Warrant pursuant to subsection (b) of Section 2 hereof,
exchanging this Warrant pursuant to subsection (d) of Section 2 hereof or
replacing this Warrant pursuant to subsection (d) of Section 3 hereof, or
any of
the foregoing, and thereafter any such issuance, exchange or replacement,
as the
case may be, shall be made at such office by such agent.
15. Remedies. The
Issuer stipulates that the remedies at law of the Holder of this Warrant
in the
event of any default or threatened default by the Issuer in the performance
of
or compliance with any of the terms of this Warrant are not and will not
be
adequate and that, to the fullest extent permitted by law, such terms may
be
specifically enforced by a decree for the specific performance of any agreement
contained herein or by an injunction against a violation of any of the terms
hereof or otherwise.
16. Successors
and Assigns. This Warrant and the rights evidenced hereby shall
inure to the benefit of and be binding upon the successors and assigns of
the
Issuer, the Holder hereof and (to the extent provided herein) the Holders
of
Warrant Stock issued pursuant hereto, and shall be enforceable by any such
Holder or Holder of Warrant Stock.
17. Modification
and Severability. If, in any action before any court or agency
legally empowered to enforce any provision contained herein, any provision
hereof is found to be unenforceable, then such provision shall be deemed
modified to the extent necessary to make it enforceable by such court or
agency. If any such provision is not enforceable as set forth in the
preceding sentence, the unenforceability of such provision shall not affect
the
other provisions of this Warrant, but this Warrant shall be construed as
if such
unenforceable provision had never been contained herein.
18. Headings. The
headings of the Sections of this Warrant are for convenience of reference
only
and shall not, for any purpose, be deemed a part of this Warrant.
IN
WITNESS WHEREOF, the Issuer has executed this Warrant as of the day and year
first above written.
CHEMBIO
DIAGNOSTICS, INC.
By:
Name: Lawrence
A. Siebert
Title: President
No.: _____________
|
Number
of Shares: _____________
|
Original
Date of Issuance: May 5,
2009
|
Reissuance
Date: December 19,
2007
|
EXERCISE
FORM
CHEMBIO
DIAGNOSTICS, INC.
The
undersigned _______________, pursuant to the provisions of the within Warrant,
hereby elects to purchase _____ shares of Common Stock of Chembio Diagnostics,
Inc. covered by the within Warrant.
Dated: _________________
Signature
___________________________
Address
_____________________
_____________________
Number
of
shares of Common Stock beneficially owned or deemed beneficially owned by
the
Holder on the date of
Exercise: _________________________
ASSIGNMENT
FOR
VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the within Warrant and all rights evidenced thereby and
does
irrevocably constitute and appoint _____________, attorney, to transfer the said
Warrant on the books of the within named corporation.
Dated: _________________
Signature
___________________________
Address
_____________________
_____________________
No.: _____________
|
Number
of Shares: _____________
|
Original
Date of Issuance: May 5,
2009
|
Reissuance
Date: December 19,
2007
|
PARTIAL
ASSIGNMENT
FOR
VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the right to purchase _________ shares of Warrant Stock
evidenced by the within Warrant together with all rights therein, and does
irrevocably constitute and appoint ___________________, attorney, to transfer
that part of the said Warrant on the books of the within named
corporation.
Dated: _________________
Signature
___________________________
Address
_____________________
_____________________
FOR
USE
BY THE ISSUER ONLY:
This
Warrant No. W-___ canceled (or transferred or exchanged) this _____ day of
___________, _____, shares of Common Stock issued therefor in the name of
_______________, Warrant No. W-_____ issued for ____ shares of Common Stock
in
the name of _______________.
ex4_7.htm
Exhibit
4.7
CHEMBIO
DIAGNOSTICS, INC.
SECOND
AMENDED AND RESTATED
CERTIFICATE
OF DESIGNATION OF PREFERENCES,
RIGHTS
AND LIMITATIONS
OF
SERIES
B 9% CONVERTIBLE PREFERRED STOCK
PURSUANT
TO SECTION 78.1955 OF THE
NEVADA
REVISED STATUTES
The
undersigned, Richard J. Larkin, does hereby certify that:
1.
He is
the Chief Financial Officer of Chembio Diagnostics, Inc., a Nevada corporation
(the “Corporation”).
2.
The
Corporation is authorized to issue 10,000,000 shares of preferred
stock.
3.
The
following resolutions were duly adopted by the Board of Directors:
WHEREAS,
the Articles of Incorporation of the Corporation provides for a class of
its
authorized stock known as preferred stock, comprised of 10,000,000 shares,
$0.01
par value, issuable from time to time in one or more series;
WHEREAS,
the Board of Directors of the Corporation is authorized to fix the dividend
rights, dividend rate, voting rights, conversion rights, rights and terms
of
redemption and liquidation preferences of any wholly unissued series of
preferred stock and the number of shares constituting any Series and the
designation thereof, of any of them; and
WHEREAS,
it is the desire of the Board of Directors of the Corporation, pursuant to
its
authority as aforesaid, to fix the rights, preferences, restrictions and
other
matters relating to a series of the preferred stock, which shall consist
of,
except as otherwise set forth in the Purchase Agreement, up to 175 shares
of the
preferred stock which the Corporation has the authority to issue, as
follows;
WHEREAS,
the Board of Directors with shareholder consent desires to amend certain
provisions as follows;
NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide
for
the issuance of a series of preferred stock for cash or exchange of other
securities, rights or property and does hereby fix and determine the rights,
preferences, restrictions and other matters relating to such series of preferred
stock as follows:
TERMS
OF PREFERRED STOCK
Section
1. Definitions. Capitalized terms used and not otherwise
defined herein that are defined in the Purchase Agreement shall have the
meanings given such terms in the Purchase Agreement. For the purposes hereof,
the following terms shall have the following meanings:
“Alternate
Consideration” shall have the meaning set forth in Section
7(e).
“Bankruptcy
Event” means any of the following events: (a) the Corporation or any
Significant Subsidiary (as such term is defined in Rule 1.02(s) of Regulation
S-X) thereof commences a case or other proceeding under any bankruptcy,
reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction relating to
the
Corporation or any Significant Subsidiary thereof; (b) there is commenced
against the Corporation or any Significant Subsidiary thereof any such case
or
proceeding that is not dismissed within 60 days after commencement; (c) the
Corporation or any Significant Subsidiary thereof is adjudicated insolvent
or
bankrupt or any order of relief or other order approving any such case or
proceeding is entered; (d) the Corporation or any Significant Subsidiary
thereof
suffers any appointment of any custodian or the like for it or any substantial
part of its property that is not discharged or stayed within 60 days; (e)
the
Corporation or any Significant Subsidiary thereof makes a general assignment
for
the benefit of creditors; (f) the Corporation or any Significant Subsidiary
thereof calls a meeting of its creditors with a view to arranging a composition,
adjustment or restructuring of its debts; or (g) the Corporation or any
Significant Subsidiary thereof, by any act or failure to act, expressly
indicates its consent to, approval of or acquiescence in any of the foregoing
or
takes any corporate or other action for the purpose of effecting any of the
foregoing.
“Base
Conversion Price” shall have the meaning set forth in Section
7(b).
“Buy-In”
shall have the meaning set forth in Section 6(d)(iii).
“Change
of Control Transaction” means the occurrence after the date hereof of any of
(i) an acquisition after the date hereof by an individual or legal entity
or
“group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of
effective control (whether through legal or beneficial ownership of capital
stock of the Corporation, by contract or otherwise) of in excess of 50% of
the
voting securities of the Corporation, or (ii) the Corporation merges into
or
consolidates with any other Person, or any Person merges into or consolidates
with the Corporation and, after giving effect to such transaction, the
stockholders of the Corporation immediately prior to such transaction own
less
than 50% of the aggregate voting power of the Corporation or the successor
entity of such transaction, or (iii) the Corporation sells or transfers its
assets, as an entirety or substantially as an entirety, to another Person
and
the stockholders of the Corporation immediately prior to such transaction
own
less than 50% of the aggregate voting power of the acquiring entity immediately
after the transaction, (iv) a replacement at one time or within a one year
period of more than one-half of the members of the Corporation’s board of
directors which is not approved by a majority of those individuals who are
members of the board of directors on the date hereof (or by those individuals
who are serving as members of the board of directors on any date whose
nomination to the board of directors was approved by a majority of the members
of the board of directors who are members on the date hereof), or (v) the
execution by the Corporation of an agreement to which the Corporation is
a party
or by which it is bound, providing for any of the events set forth above
in (i)
or (iv).
“Closing
Date” means the Trading Day when all of the Transaction Documents have been
executed and delivered by the applicable parties thereto, and all conditions
precedent to (i) the Holders’ obligations to pay the Subscription Amount and
(ii) the Corporation’s obligations to deliver the Securities have been satisfied
or waived.
“Commission”
means the Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.01 per share, and
stock of any other class into which such shares may hereafter have been
reclassified or changed.
“Common
Stock Equivalents” means any securities of the Corporation or the
Subsidiaries which would entitle the holder thereof to acquire at any time
Common Stock, including without limitation, any debt, preferred stock, rights,
options, warrants or other instrument that is at any time convertible into
or
exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.
“Conversion
Amount” means the sum of the Stated Value at issue.
“Conversion
Date” shall have the meaning set forth in Section 6(a).
“Conversion
Price” shall have the meaning set forth in Section 6(b).
“Conversion
Shares” means, collectively, the shares of Common Stock into which the
shares of Preferred Stock are convertible in accordance with the terms
hereof.
“Conversion
Shares Registration Statement” means a registration statement that meets the
requirements of the Registration Rights Agreement and registers the resale
of
all Conversion Shares by the Holder, who shall be named as a “selling
stockholder” thereunder, all as provided in the Registration Rights
Agreement.
“Dividend
Payment Date” shall have the meaning set forth in Section 3(a).
“Dilutive
Issuance” shall have the meaning set forth in Section 7(b).
“Dilutive
Issuance Notice” shall have the meaning set forth in Section
7(b).
“Effective
Date” means the date that the Conversion Shares Registration Statement is
declared effective by the Commission.
“Equity
Conditions” shall mean, during the period in question, (i) the Corporation
shall have duly honored all conversions scheduled to occur or occurring by
virtue of one or more Notices of Conversion, if any, (ii) all liquidated
damages
and other amounts owing in respect of the Preferred Stock shall have been
paid;
(iii) there is an effective Conversion Shares Registration Statement pursuant
to
which the Holder is permitted to utilize the prospectus thereunder to resell
all
of the shares issuable pursuant to the Transaction Documents (and the
Corporation believes, in good faith, that such effectiveness will continue
uninterrupted for the foreseeable future), (iv) the Common Stock is trading
on
the Trading Market and all of the shares issuable pursuant to the Transaction
Documents are listed for trading on a Trading Market (and the Corporation
believes, in good faith, that trading of the Common Stock on a Trading Market
will continue uninterrupted for the foreseeable future), (v) there is a
sufficient number of authorized but unissued and otherwise unreserved shares
of
Common Stock for the issuance of all of the shares issuable pursuant to the
Transaction Documents, (vi) there is then existing no Triggering Event or
event
which, with the passage of time or the giving of notice, would constitute
a
Triggering Event, (vii) all of the shares issued or issuable pursuant to
the
transaction proposed would not violate the limitations set forth in Sections
6(c) and (viii) no public announcement of a pending or proposed Fundamental
Transaction, Change of Control Transaction or acquisition transaction has
occurred that has not been consummated.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended.
“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to
employees, officers, consultants, or directors of the Corporation pursuant
to
any stock or option plan or other resolution duly adopted by a majority of
the
non-employee members of the Board of Directors of the Corporation or a majority
of the members of a committee of non-employee directors established for such
purpose, up to a total of 400,000 shares of Common Stock in each of fiscal
2005
and 2006, subject in each case to adjustment for any subsequent stock splits
or
the like, (b) securities upon the exercise of or conversion of any Securities
issued hereunder, convertible securities, options or warrants issued and
outstanding on the date of this Agreement, provided that such securities
have
not been amended since the date of this Agreement to increase the number
of such
securities or to decrease the exercise or conversion price of any such
securities (except pursuant to any anti-dilution adjustment contained therein),
(c) securities issued pursuant to acquisitions or strategic transactions,
provided any such issuance shall only be to a Person which is, itself or
through
its subsidiaries, an operating company in a business reasonably deemed by
the
Corporation’s Board of Directors to be strategically advantageous to the
business of the Corporation and in which the Corporation receives benefits
in
addition to the investment of funds, but shall not include a transaction
in
which the Corporation is issuing securities primarily for the purpose of
raising
capital or to an entity whose primary business is investing in securities,
(d)
shares issued in Bona fide firm underwritten public offerings each of which
has
gross proceeds of at least equal to $20,000,000, (e) Securities underlying
placement agent warrants issued in connection with this transaction, and
(f)
shares issued as dividend payments on the Series A and Series B
Stock.
“Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
“Forced
Conversion Date” shall have the meaning set forth in Section
8(a).
“Fundamental
Transaction” shall have the meaning set forth in Section 7(e).
“Holder”
shall have the meaning given such term in Section 2.
“Junior
Securities” means the Common Stock and all other equity or equity equivalent
securities of the Corporation other than those securities that are (a)
outstanding on the Original Issue Date and (b) which are explicitly senior
or
pari passu in rights or liquidation preference to the Preferred
Stock.
“Liquidation”
shall have the meaning given such term in Section 5.
“New
York Courts” shall have the meaning given such term in Section
10(e).
“Notice
of Conversion” shall have the meaning given such term in Section
6(a).
“Original
Issue Date” shall mean the date of the first issuance of any shares of the
Preferred Stock regardless of the number of transfers of any particular shares
of Preferred Stock and regardless of the number of certificates which may
be
issued to evidence such Preferred Stock.
“Person”
means a corporation, an association, a partnership, an organization, a business,
an individual, a government or political subdivision thereof or a governmental
agency.
“Plan”
shall mean any action the Company takes, with any required approval of the
holders thereof, on or before the Final Plan Date as contemplated by the
Plan
Summary and accompanying materials provided to holders on December 4, 2007,
in
connection with the reduction or other modification of terms of the Company's
then-outstanding preferred stock, warrants and options, including, but not
limited to, actions the Company takes to (i) facilitate the conversion of
the
Series A, B and C Convertible Preferred Stock; (ii) reduce the exercise price
of
any of the Company's outstanding warrants or options; (iii) offer the holders
of
the Company's warrants and options the opportunity to exercise such warrants
and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and
to facilitate the conversion and exercise of these
securities.
“Plan
Closing Date” shall mean December 19, 2007.
“Purchase
Agreement” means the Securities Purchase Agreement, dated as of the Original
Issue Date, to which the Corporation and the original Holders are parties,
as
amended, modified or supplemented from time to time in accordance with its
terms.
“Registration
Rights Agreement” means the Registration Rights Agreement, dated as of the
date of the Purchase Agreement, to which the Corporation and the original
Holder
are parties, as amended, modified or supplemented from time to time in
accordance with its terms.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.
“Share
Delivery Date” shall have the meaning given such term in Section
6(d).
“Stated
Value” shall have the meaning given such term in Section 2.
“Subscription
Amount” shall mean, as to each Purchaser, the amount to be paid for the
Preferred Stock purchased pursuant to the Purchase Agreement as specified
below
such Purchaser’s name on the signature page of the Purchase Agreement and next
to the heading “Subscription Amount”, in United States Dollars and in
immediately available funds.
“Subsidiary”
shall have the meaning given to such term in the Purchase
Agreement.
“Threshold
Period” shall have the meaning set forth in Section 6(a).
“Trading
Day” means a day on which the Common Stock is traded on a Trading
Market.
“Trading
Market” means the following markets or exchanges on which the Common Stock
is listed or quoted for trading on the date in question: the OTC Bulletin
Board,
the Nasdaq SmallCap Market, the American Stock Exchange, the New York Stock
Exchange or the Nasdaq National Market.
“Transaction
Documents” shall have the meaning set forth in the Purchase
Agreement.
“Triggering
Event” shall have the meaning set forth in Section 9(a).
“Triggering
Redemption Amount” for each share of Preferred Stock means the sum of (i)
the greater of (A) 130% of the Stated Value and (B) the product of (a) the
VWAP
on the Trading Day immediately preceding the date of the Triggering Event
and
(b) the Stated Value divided by the then Conversion Price, (ii) all accrued
but
unpaid dividends thereon and (iii) all liquidated damages and other amounts
due
in respect of the Preferred Stock.
“Triggering
Redemption Payment Date” shall have the meaning set forth in Section
9(b).
“VWAP”
means, for any date, the price determined by the first of the following clauses
that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on the Trading Market on which the Common
Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based
on
a Trading Day from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (b)
if the
Common Stock is not then listed or quoted on a Trading Market and if prices
for
the Common Stock are then reported in the “Pink Sheets” published by the Pink
Sheets, LLC (or a similar organization or agency succeeding to its functions
of
reporting prices), the most recent bid price per share of the Common Stock
so
reported; or (c) in all other cases, the fair market value of a share of
Common
Stock as determined by an independent appraiser selected in good faith by
the
Purchasers and reasonably acceptable to the Corporation.
Section
2. Designation, Rank, Amount and Par Value. The series of
preferred stock shall be designated as its Series B 9% Convertible Preferred
Stock (the “Preferred Stock”) and the number of shares so designated
shall be 175 (which shall not be subject to increase without the consent
of all
of the holders of the Preferred Stock (each, a “Holder” and collectively,
the “Holders”)). Each share of Preferred Stock shall have a par value of
$0.01 per share and a stated value equal to $50,000 (the “Stated Value”).
The Preferred Stock shall rank pari passu to the Corporation’s Series A
Convertible Preferred Stock as to payment of dividends and liquidation
preference. Capitalized terms not otherwise defined herein shall have the
meaning given such terms in Section 1 hereof.
Section
3. Dividends.
a) Dividends
in Cash or in
Kind. Holders shall
be
entitled to receive and the Corporation shall pay, cumulative dividends at
the
rate per share (as a percentage of the Stated Value per share) of 9% per
annum
(subject to increase pursuant to Section 9(b)),
payable semiannually on July 1 and
January 1, beginning with the first such date after the Original Issue Date
and
on any Conversion Date (except that, if such date is not a Trading Day, the
payment date shall be the next succeeding Trading Day)(“Dividend Payment
Date”). The form of
dividend payments to each Holder shall be made at the sole election of the
Corporation, in cash, in shares of Preferred Stock, or in shares of Common
Stock, provided,
however, that any
Holder of a majority of the issued and outstanding Preferred Stock at any
Dividend Payment Date may elect whether to receive such dividend in cash,
in
Common Stock or in shares of Preferred Stock in its sole discretion. If the
Company elects to pay a dividend in shares of Common Stock, the number of
shares
of Common Stock to be issued to the Holder shall be an amount equal to the
quotient of (i) the dividend amount divided by (ii) the volume weighted average
trading price (the “VWAP”)
of the Common Stock for the 10
trading days preceding the dividend record date. As used in this Certificate,
the term “volume
weighted average trading price”, or VWAP, shall
mean, for any period
of time, the sum of the purchases charged for all shares sold during that
period
of time divided by the number of shares sold during that period of time.
If the
Company elects to pay any dividend in shares of Preferred Stock, the number
of
shares of Preferred Stock to be issued to the holder shall be an amount equal
to
the quotient of (i) the amount of the dividend payment divided by (ii) the
VWAP
of the Common Stock for the 10 trading days preceding the dividend record
date
and then issuing that number of shares of Preferred Stock that would at the
time
of calculation be convertible into the number of shares determined by dividing
the amount of the dividend payment by the 10-day VWAP. The Holders shall
have
the same rights and remedies with respect to the delivery of any such shares
as
if such shares were being issued pursuant to Section 6. On the Closing Date
the
Corporation shall have notified the Holders whether or not it may lawfully
pay
cash dividends. The Corporation shall promptly notify the Holders at any
time
the Corporation shall become able or unable, as the case may be, to lawfully
pay
cash dividends. The Corporation must provide the Holder with at least 15
calendar days’ notice of its election to pay a regularly scheduled dividend in
Preferred Stock or Common Stock. Dividends on the Preferred Stock shall be
calculated on the basis of a 360-day year, shall accrue daily commencing
on the
Original Issue Date, and shall be deemed to accrue from such date whether
or not
earned or declared and whether or not there are profits, surplus or other
funds
of the Corporation legally available for the payment of dividends. Except
as
otherwise provided herein, if at any time the Corporation pays dividends
partially in cash and partially in shares, then such payment shall be
distributed ratably among the Holders based upon the number of shares of
Preferred Stock held by each Holder. Any dividends, whether paid in cash
or
shares, that are not paid within three Trading Days following a Dividend
Payment
Date shall continue to accrue and shall entail a late fee, which must be
paid in
cash, at the rate of 18% per annum or the lesser rate permitted by applicable
law (such fees to accrue daily, from the Dividend Payment Date through and
including the date of payment).
b) So
long as any Preferred Stock shall
remain outstanding, neither the Corporation nor any Subsidiary thereof shall
redeem, purchase or otherwise acquire directly or indirectly any Junior
Securities. So long as any Preferred Stock shall remain outstanding, neither
the
Corporation nor any Subsidiary thereof shall directly or indirectly pay or
declare any dividend or make any distribution (other than a dividend or
distribution described in Section 6 or dividends due and paid in the ordinary
course on preferred stock of the Corporation at such times when the Corporation
is in compliance with its payment and other obligations hereunder) upon,
nor
shall any distribution be made in respect of, any Junior Securities so long
as
any dividends due on the Preferred Stock remain unpaid, nor shall any monies
be
set aside for or applied to the purchase or redemption (through a sinking
fund
or otherwise) of any Junior Securities or shares pari passu with the Preferred
Stock.
Section
4. Voting Rights. Except as otherwise provided herein and
as otherwise required by law, the Preferred Stock shall have no voting rights.
However, so long as any shares of Preferred Stock are outstanding, the
Corporation shall not, without the affirmative vote of the Holders of 51%
of the
shares of the Preferred Stock then outstanding, (a) alter or change adversely
the powers, preferences or rights given to the Preferred Stock or alter or
amend
this Certificate of Designation, (b) authorize or create any class of stock
ranking as to dividends, redemption or distribution of assets upon a Liquidation
(as defined in Section 5) senior to or otherwise pari passu with the Preferred
Stock, (c) amend its articles of incorporation or other charter documents
so as
to affect adversely any rights of the Holders, (d) increase the authorized
number of shares of Preferred Stock, or (e) enter into any agreement with
respect to the foregoing. Notwithstanding the foregoing, so long as any shares
of Preferred Stock are outstanding, the Corporation shall not, without the
affirmative vote of the Holders of 75% of the shares of Preferred Stock then
outstanding, (a) decrease the dividend rate of 9% per annum as provided in
Section 3a, (b) amend the anti-dilution adjustment for subsequent equity
sales
as provided in Section 7b, or (c) amend the terms for a forced conversion
as
provided in Section 8a.
Section
5. Liquidation. Upon any liquidation, dissolution or
winding-up of the Corporation, whether voluntary or involuntary (a
“Liquidation”), the Holders shall be entitled to receive out of the
assets of the Corporation, whether such assets are capital or surplus, for
each
share of Preferred Stock an amount equal to the Stated Value per share plus
any
accrued and unpaid dividends thereon and any other fees or liquidated damages
owing thereon before any distribution or payment shall be made to the holders
of
any Junior Securities, and if the assets of the Corporation shall be
insufficient to pay in full such amounts, then the entire assets to be
distributed to the Holders shall be distributed among the Holders ratably
in
accordance with the respective amounts that would be payable on such shares
if
all amounts payable thereon were paid in full, pari passu with the Corporation’s
Series A Convertible Preferred Stock treated together as a class based upon
the
liquidation preferences of each such series. A Fundamental Transaction or
Change
of Control Transaction shall not be treated as a Liquidation. The Corporation
shall mail written notice of any such Liquidation, not less than 45 days
prior
to the payment date stated therein, to each record Holder.
Section
6. Conversion.
a) Conversions
at Option of
Holder. Each share of
Preferred Stock shall be convertible into that number of shares of Common
Stock
(subject to the limitations set forth in Sections 6(c)) determined by dividing
the Stated Value of such share of Preferred Stock by the Conversion Price,
at
the option of the Holder, at any time and from time to time from and after
the
Original Issue Date. Holders shall effect conversions by providing the
Corporation with the form of conversion notice attached hereto as Annex A
(a “Notice of Conversion”).
Each Notice of Conversion shall
specify the number of shares of Preferred Stock to be converted, the number
of
shares of Preferred Stock owned prior to the conversion at issue, the number
of
shares of Preferred Stock owned subsequent to the conversion at issue and
the
date on which such conversion is to be effected, which date may not be prior
to
the date the Holder delivers such Notice of Conversion to the Corporation
by
facsimile (the “Conversion Date”).
If no Conversion Date is specified
in a Notice of Conversion, the Conversion Date shall be the date that such
Notice of Conversion to the Corporation is deemed delivered hereunder. The
calculations and entries set forth in the Notice of Conversion shall control
in
the absence of manifest or mathematical error. To effect conversions, as
the
case may be, of shares of Preferred Stock, a Holder shall not be required
to
surrender the certificate(s) representing such shares of Preferred Stock
to the
Corporation unless all of the shares of Preferred Stock represented thereby
are
so converted, in which case the Holder shall deliver the certificate
representing such share of Preferred Stock promptly following the Conversion
Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed
in accordance with the terms hereof shall be canceled and may not be
reissued.
b) Conversion
Price. The conversion price for the Preferred Stock shall equal
$0.40 per share for the holders of the Preferred Stock on the Plan Closing
Date
(the “Conversion Price”), provided, however, that the Conversion Price
for the Preferred Stock held by Lawrence A. Siebert shall be $0.48 per share
on
the Plan Closing Date.
c) Beneficial
Ownership Limitation. The Corporation shall not effect any
conversion of the Preferred Stock, and the Holder shall not have the right
to
convert any portion of the Preferred Stock to the extent that after giving
effect to such conversion, the Holder (together with the Holder’s affiliates),
as set forth on the applicable Notice of Conversion, would beneficially own
in
excess of 4.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to such conversion. For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially
owned
by the Holder and its affiliates shall include the number of shares of Common
Stock issuable upon conversion of the Preferred Stock with respect to which
the
determination of such sentence is being made, but shall exclude the number
of
shares of Common Stock which would be issuable upon (A) conversion of the
remaining, nonconverted Stated Value of Preferred Stock beneficially owned
by
the Holder or any of its affiliates and (B) exercise or conversion of the
unexercised or nonconverted portion of any other securities of the Corporation
(including the Warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder
or
any of its affiliates. Except as set forth in the preceding sentence,
for purposes of this Section 6(c), beneficial ownership shall be calculated
in
accordance with Section 13(d) of the Exchange Act. To the extent that the
limitation contained in this Section 6(c) applies, the determination of whether
the Preferred Stock is convertible (in relation to other securities owned
by the
Holder together with any affiliates) and of which shares of Preferred Stock
is
convertible shall be in the sole discretion of such Holder, and the submission
of a Notice of Conversion shall be deemed to be such Holder’s determination of
whether the shares of Preferred Stock may be converted (in relation to other
securities owned by such Holder) and which shares of the Preferred Stock
is
convertible, in each case subject to such aggregate percentage limitations.
To
ensure compliance with this restriction, the Holder will be deemed to represent
to the Corporation each time it delivers a Notice of Conversion that such
Notice
of Conversion has not violated the restrictions set forth in this paragraph
and
the Corporation shall have no obligation to verify or confirm the accuracy
of
such determination. For purposes of this Section 6(c), in determining the
number
of outstanding shares of Common Stock, the Holder may rely on the number
of
outstanding shares of Common Stock as reflected in the most recent of the
following: (A) the Corporation’s most recent Form 10-QSB or Form 10-KSB, as the
case may be, (B) a more recent public announcement by the Corporation or
(C) any
other notice by the Corporation or the Corporation’s transfer agent setting
forth the number of shares of Common Stock outstanding. Upon the
written or oral request of the Holder, the Corporation shall within two Trading
Days confirm orally and in writing to the Holder the number of shares of
Common
Stock then outstanding. In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion
or
exercise of securities of the Corporation, including the Preferred Stock,
by the
Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The provisions of this Section 6(c)
may be
waived by the Holder upon, at the election of the Holder, not less than 61
days’
prior notice to the Corporation, and the provisions of this Section 6(c)
shall
continue to apply until such 61st day (or such later date, as determined
by the
Holder, as may be specified in such notice of
waiver). Notwithstanding anything set forth in this Section 6(c), the
4.99% beneficial ownership restriction set forth in this Section 6(c) shall
not
apply to Common Stock issuable upon conversion of the Preferred Stock in
connection with the Plan.
d) Mechanics
of
Conversion
i. Delivery
of Certificate Upon
Conversion. Not later
than three Trading Days after each Conversion Date (the “Share Delivery
Date”), the Corporation
shall deliver to
the Holder (A) a certificate or certificates which, after the Effective Date,
shall be free of restrictive legends and trading restrictions (other than
those
required by the Purchase Agreement) representing the number of shares of
Common
Stock being acquired upon the conversion of shares of Preferred Stock, and
(B) a
bank check in the amount of accrued and unpaid dividends (if the Corporation
has
elected or is required to pay accrued dividends in cash). After the Effective
Date, the Corporation shall, upon request of the Holder, deliver any certificate
or certificates required to be delivered by the Corporation under this Section
electronically through the Depository Trust Corporation or another established
clearing corporation performing similar functions if the Corporation’s transfer
agent is a participant in such system. If in the case of any Notice of
Conversion such certificate or certificates are not delivered to or as directed
by the applicable Holder by the third Trading Day after the Conversion Date,
the
Holder shall be entitled to elect by written notice to the Corporation at
any
time on or before its receipt of such certificate or certificates thereafter,
to
rescind such conversion, in which event the Corporation shall immediately
return
the certificates representing the shares of Preferred Stock tendered for
conversion.
ii. Obligation
Absolute; Partial
Liquidated Damages.
The Corporation’s obligations to issue and deliver the Conversion Shares upon
conversion of Preferred Stock in accordance with the terms hereof are absolute
and unconditional, irrespective of any action or inaction by the Holder to
enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce
the
same, or any setoff, counterclaim, recoupment, limitation or termination,
or any
breach or alleged breach by the Holder or any other Person of any obligation
to
the Corporation or any violation or alleged violation of law by the Holder
or
any other person, and irrespective of any other circumstance which might
otherwise limit such obligation of the Corporation to the Holder in connection
with the issuance of such Conversion Shares. In the event a Holder shall
elect
to convert any or all of the Stated Value of its Preferred Stock, the
Corporation may not refuse conversion based on any claim that such Holder
or any
one associated or affiliated with the Holder of has been engaged in any
violation of law, agreement or for any other reason, unless, an injunction
from
a court, on notice, restraining and or enjoining conversion of all or part
of
this Preferred Stock shall have been sought and obtained and the Corporation
posts a surety bond for the benefit of the Holder in the amount of 150% of
the
Stated Value of Preferred Stock outstanding, which is subject to the injunction,
which bond shall remain in effect until the completion of arbitration/litigation
of the dispute and the proceeds of which shall be payable to such Holder
to the
extent it obtains judgment. In the absence of an injunction precluding the
same,
the Corporation shall issue Conversion Shares or, if applicable, cash, upon
a
properly noticed conversion. If the Corporation fails to deliver to the Holder
such certificate or certificates pursuant to Section 6(e)(i) within two Trading
Days of the Share Delivery Date applicable to such conversion, the Corporation
shall pay to such Holder, in cash, as liquidated damages and not as a penalty,
for each $5,000 of Stated Value of Preferred Stock being converted, $50 per
Trading Day (increasing to $100 per Trading Day after 3 Trading Days and
increasing to $200 per Trading Day 6 Trading Days after such damages begin
to
accrue) for each Trading Day after the Share Delivery Date until such
certificates are delivered. Nothing herein shall limit a Holder’s right to
pursue actual damages for the Corporation’s failure to deliver certificates
representing shares of Common Stock upon conversion within the period specified
herein and such Holder shall have the right to pursue all remedies available
to
it hereunder, at law or in equity including, without limitation, a decree
of
specific performance and/or injunctive relief.
iii. Compensation
for Buy-In on Failure
to Timely Deliver Certificates Upon Conversion. If the Corporation
fails to deliver
to the Holder such certificate or certificates pursuant to Section 6(d)(i)
by a
Share Delivery Date, and if after such Share Delivery Date and prior to any
subsequent delivery of the certificates to Holders the Holder purchases (in
an
open market transaction or otherwise) Common Stock to deliver in satisfaction
of
a sale by such Holder of the Conversion Shares which the Holder was entitled
to
receive upon the conversion relating to such Share Delivery Date (a
“Buy-In”),
then the Corporation shall pay in
cash to the Holder the amount by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the Common Stock so purchased
exceeds (y) the product of (1) the aggregate number of shares of Common Stock
that such Holder was entitled to receive from the conversion at issue multiplied
by (2) the price at which the sell order giving rise to such purchase obligation
was executed. For example, if the Holder purchases Common Stock having a
total
purchase price of $11,000 to cover a Buy-In with respect to an attempted
conversion of shares of Preferred Stock with respect to which the aggregate
sale
price giving rise to such purchase obligation is $10,000, under clause (A)
of
the immediately preceding sentence the Corporation shall be required to pay
the
Holder $1,000. The Holder shall provide the Corporation written notice
indicating the amounts payable to the Holder in respect of the Buy-In, together
with applicable confirmations and other evidence reasonably requested by
the
Corporation. Nothing herein shall limit a Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with
respect to the Corporation’s failure to timely deliver certificates representing
shares of Common Stock upon conversion of the shares of Preferred Stock as
required pursuant to the terms hereof.
iv. Reservation
of Shares Issuable Upon
Conversion. The
Corporation covenants that it will at all times after June 30, 2005 reserve
and
keep available out of its authorized and unissued shares of Common Stock
solely
for the purpose of issuance upon conversion of the Preferred Stock and payment
of dividends for three years from any point in time on the Preferred Stock,
each
as herein provided, free from preemptive rights or any other actual contingent
purchase rights of persons other than the Holders, not less than such number
of
shares of the Common Stock as shall (subject to any additional requirements
of
the Corporation as to reservation of such shares set forth in the Purchase
Agreement) be issuable (taking into account the adjustments and restrictions
of
Section 7) upon the conversion of all outstanding shares of Preferred Stock.
The
Corporation covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly and validly authorized, issued and fully paid,
nonassessable and, if the Conversion Shares Registration Statement is then
effective under the Securities Act, registered for public sale in accordance
with such Conversion Shares Registration Statement.
v. Fractional
Shares. Upon a conversion
hereunder, the
Corporation shall not be required to issue stock certificates representing
fractions of shares of the Common Stock, but may if otherwise permitted,
make a
cash payment in respect of any final fraction of a share based on the VWAP
at
such time. If the Corporation elects not, or is unable, to make such a cash
payment, the Holder shall be entitled to receive, in lieu of the final fraction
of a share, one whole share of Common Stock.
vi. Transfer
Taxes. The issuance
of certificates for
shares of the Common Stock on conversion of the Preferred Stock shall be
made
without charge to the Holders thereof for any documentary stamp or similar
taxes
that may be payable in respect of the issue or delivery of such certificate,
provided that the Corporation shall not be required to pay any tax that may
be
payable in respect of any transfer involved in the issuance and delivery
of any
such certificate upon conversion in a name other than that of the Holder
of such
shares of Preferred Stock so converted and the Corporation shall not be required
to issue or deliver such certificates unless or until the person or persons
requesting the issuance thereof shall have paid to the Corporation the amount
of
such tax or shall have established to the satisfaction of the Corporation
that
such tax has been paid.
Section
7. Certain Adjustments.
a) Stock
Dividends and Stock
Splits. If the
Corporation, at any time while the Preferred Stock is outstanding: (A) shall
pay
a stock dividend or otherwise make a distribution or distributions on shares
of
its Common Stock or any other equity or equity equivalent securities payable
in
shares of Common Stock (which, for avoidance of doubt, shall not include
any
shares of Common Stock issued by the Corporation pursuant to this Preferred
Stock or the Series A Convertible Preferred Stock), (B) subdivide outstanding
shares of Common Stock into a larger number of shares, (C) combine (including
by
way of reverse stock split) outstanding shares of Common Stock into a smaller
number of shares, or (D) issue by reclassification of shares of the Common
Stock
any shares of capital stock of the Corporation, then the Conversion Price
shall
be multiplied by a fraction of which the numerator shall be the number of
shares
of Common Stock (excluding treasury shares, if any) outstanding before such
event and of which the denominator shall be the number of shares of Common
Stock
outstanding after such event. Any adjustment made pursuant to this Section
7(a)
shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall
become effective immediately after the effective date in the case of a
subdivision, combination or re-classification.
b) Subsequent
Equity
Sales. If the
Corporation or any Subsidiary thereof, as applicable, at any time while
Preferred Stock is outstanding, shall offer, sell, grant any option to purchase
or offer, sell or grant any right to reprice its securities, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to
purchase or other disposition) any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock, at an effective price
per share less than the then Conversion Price (such lower price, the
“Base Conversion
Price” and such
issuances collectively, a “Dilutive Issuance”),
as adjusted hereunder (if the
holder of the Common Stock or Common Stock Equivalents so issued shall at
any
time, whether by operation of purchase price adjustments, reset provisions,
floating conversion, exercise or exchange prices or otherwise, or due to
warrants, options or rights per share which is issued in connection with
such
issuance, be entitled to receive shares of Common Stock at an effective price
per share which is less than the Conversion Price, such issuance shall be
deemed
to have occurred for less than the Conversion Price), then the Conversion
Price
shall be reduced to equal the Base Conversion Price. The Corporation shall
notify the Holder in writing, no later than the Business Day following the
issuance of any Common Stock or Common Stock Equivalents subject to this
section, indicating therein the applicable issuance price, or of applicable
reset price, exchange price, conversion price and other pricing terms (such
notice the “Dilutive
Issuance Notice”). For
purposes of clarification, whether or not the Corporation provides a Dilutive
Issuance Notice pursuant to this Section 7(b), upon the occurrence of any
Dilutive Issuance, after the date of such Dilutive Issuance the Holder is
entitled to receive a number of Conversion Shares based upon the Base Conversion
Price regardless of whether the Holder accurately refers to the Base Conversion
Price in the Notice of Conversion.
c) Subsequent
Rights
Offerings. If the
Corporation, at any time while the Preferred Stock is outstanding, shall
issue
rights, options or warrants to all holders of Common Stock (and not to Holders)
entitling them to subscribe for or purchase shares of Common Stock at a price
per share less than the VWAP at the record date mentioned below, then the
Conversion Price shall be multiplied by a fraction, of which the denominator
shall be the number of shares of the Common Stock outstanding on the date
of
issuance of such rights or warrants plus the number of additional shares
of
Common Stock offered for subscription or purchase, and of which the numerator
shall be the number of shares of the Common Stock outstanding on the date
of
issuance of such rights or warrants plus the number of shares which the
aggregate offering price of the total number of shares so offered (assuming
receipt by the Corporation in full of all consideration payable upon exercise
of
such rights, options or warrants) would purchase at such VWAP. Such adjustment
shall be made whenever such rights or warrants are issued, and shall become
effective immediately after the record date for the determination of
stockholders entitled to receive such rights, options or
warrants.
d) Pro
Rata
Distributions. If the
Corporation, at any time while Preferred Stock is outstanding, shall distribute
to all holders of Common Stock (and not to Holders) evidences of its
indebtedness or assets or rights or warrants to subscribe for or purchase
any
security, then in each such case the Conversion Price shall be determined
by
multiplying such Conversion Price in effect immediately prior to the record
date
fixed for determination of stockholders entitled to receive such distribution
by
a fraction of which the denominator shall be the VWAP determined as of the
record date mentioned above, and of which the numerator shall be such VWAP
on
such record date less the then fair market value at such record date of the
portion of such assets or evidence of indebtedness so distributed applicable
to
one outstanding share of the Common Stock as determined by the Board of
Directors in good faith. In either case the adjustments shall be described
in a
statement provided to the Holders of the portion of assets or evidences of
indebtedness so distributed or such subscription rights applicable to one
share
of Common Stock. Such adjustment shall be made whenever any such distribution
is
made and shall become effective immediately after the record date mentioned
above.
e) Fundamental
Transaction. If, at
any time while this Preferred Stock is outstanding, (A) the Corporation effects
any merger or consolidation of the Corporation with or into another Person,
(B)
the Corporation effects any sale of all or substantially all of its assets
in
one or a series of related transactions, (C) any tender offer or exchange
offer
(whether by the Corporation or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares
for
other securities, cash or property, or (D) the Corporation effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for
other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then
upon any subsequent conversion of this Preferred Stock, the Holder shall
have
the right to receive, for each Conversion Share that would have been issuable
upon such conversion absent such Fundamental Transaction, the same kind and
amount of securities, cash or property as it would have been entitled to
receive
upon the occurrence of such Fundamental Transaction if it had been, immediately
prior to such Fundamental Transaction, the holder of one share of Common
Stock
(the “Alternate
Consideration”). For
purposes of any such conversion, the determination of the Conversion Price
shall
be appropriately adjusted to apply to such Alternate Consideration based
on the
amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Corporation shall apportion
the
Conversion Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction,
then
the Holder shall be given the same choice as to the Alternate Consideration
it
receives upon any conversion of this Preferred Stock following such Fundamental
Transaction. To the extent necessary to effectuate the foregoing provisions,
any
successor to the Corporation or surviving entity in such Fundamental Transaction
shall file a new Certificate of Designations with the same terms and conditions
and issue to the Holder new preferred stock consistent with the foregoing
provisions and evidencing the Holder’s right to convert such preferred stock
into Alternate Consideration. The terms of any agreement pursuant to which
a
Fundamental Transaction is effected shall include terms requiring any such
successor or surviving entity to comply with the provisions of this Section
7(e)
and insuring that this Preferred Stock (or any such replacement security)
will
be similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.
f) Exempt
Issuance. Notwithstanding
the foregoing, no
adjustment will be made under this Section 7 in respect of an Exempt
Issuance.
g) Calculations.
All calculations under this Section 7
shall be made to the nearest cent or the nearest 1/100th of a share, as the
case
may be. The number of shares of Common Stock outstanding at any given time
shall
not include shares owned or held by or for the account of the Corporation,
and
the description of any such shares of Common Stock shall be considered on
issue
or sale of Common Stock. For purposes of this Section 7, the number of shares
of
Common Stock deemed to be issued and outstanding as of a given date shall
be the
sum of the number of shares of Common Stock (excluding treasury shares, if
any)
issued and outstanding.
h) Notice
to Holders.
i. Adjustment
to Conversion
Price. Whenever the
Conversion Price is adjusted pursuant to any of this Section 7, the Corporation
shall promptly mail to each Holder a notice setting forth the Conversion
Price
after such adjustment and setting forth a brief statement of the facts requiring
such adjustment. If the Corporation issues a variable rate security, despite
the
prohibition thereon in the Purchase Agreement, the Corporation shall be deemed
to have issued Common Stock or Common Stock Equivalents at the lowest possible
conversion or exercise price at which such securities may be converted or
exercised in the case of a Variable Rate Transaction (as defined in the Purchase
Agreement), or the lowest possible adjustment price in the case of an MFN
Transaction (as defined in the Purchase Agreement).
ii. Notice
to Allow Conversion by
Holder. If (A) the
Corporation shall declare a dividend (or any other distribution) on the Common
Stock; (B) the Corporation shall declare a special nonrecurring cash dividend
on
or a redemption of the Common Stock; (C) the Corporation shall authorize
the
granting to all holders of the Common Stock rights or warrants to subscribe
for
or purchase any shares of capital stock of any class or of any rights; (D)
the
approval of any stockholders of the Corporation shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger
to
which the Corporation is a party, any sale or transfer of all or substantially
all of the assets of the Corporation, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property; (E)
the
Corporation shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Corporation; then, in each
case,
the Corporation shall cause to be filed at each office or agency maintained
for
the purpose of conversion of the Preferred Stock, and shall cause to be mailed
to the Holders at their last addresses as they shall appear upon the stock
books
of the Corporation, at least 20 calendar days prior to the applicable record
or
effective date hereinafter specified, a notice stating (x) the date on which
a
record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date
as
of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined
or
(y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and
the
date as of which it is expected that holders of the Common Stock of record
shall
be entitled to exchange their shares of the Common Stock for securities,
cash or
other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided,
that the failure to mail such notice
or any defect therein or in the mailing thereof shall not affect the validity
of
the corporate action required to be specified in such notice. Holders are
entitled to convert the Conversion Amount of Preferred Stock during the 20-day
period commencing the date of such notice to the effective date of the event
triggering such notice.
Section
8. Forced Conversion.
a) As
used herein, the “Forced Conversion Date” shall be the Plan Closing
Date.
b) One
minute after this Second Amended and Restated Certificate is effective with
the
Nevada Secretary of State (the “Conversion Time”) on the Forced Conversion Date,
each share of Preferred Stock outstanding, automatically and without any
action
on the part of the holder thereof, shall convert into a number of fully paid
and
nonassessable shares of Common Stock equal to the quotient of (i) the Stated
Value of the shares of Preferred Stock outstanding on the Forced Conversion
Date
divided by (ii) the Conversion Price in effect at the Conversion Time on
the
Forced Conversion Date. Any accrued but unpaid dividends on the
Preferred Stock outstanding at the Conversion Time on the Forced Conversion
Date
will be issued by the Company at the Conversion Time on the Forced Conversion
Date in shares of Common Stock, with the number of shares of Common Stock
to be
issued equal to the quotient of (i) the accrued unpaid dividend divided by
(ii)
the Conversion Price in effect at the Conversion Time on the Forced Conversion
Date.
c) As
soon as practicable after the Forced Conversion Date, the Corporation will
send
a notice to all Holders stating (i) the date as of which the Forced Conversion
Date occurred, and (ii) how many shares of Common Stock the Holder’s Preferred
Stock was converted into.
Section
9. Redemption Upon Triggering Events.
a) “Triggering
Event” means any one
or more of the
following events (whatever the reason and whether it shall be voluntary or
involuntary or effected by operation of law or pursuant to any judgment,
decree
or order of any court, or any order, rule or regulation of any administrative
or
governmental body):
i. the
failure of a Conversion Shares
Registration Statement to be declared effective by the Commission on or prior
to
the 210th
day after the Original Issue
Date;
ii. if,
during the Effectiveness Period,
the effectiveness of the Conversion Shares Registration Statement lapses
for any
reason for more than an aggregate of 25 calendar days (which need not be
consecutive days) during any 12 month period, or the Holder shall not be
permitted to resell Registrable Securities under the Conversion Shares
Registration Statement for more than an aggregate of 25 calendar days (which
need not be consecutive days) during any 12 month period, and in each case
the
shares of Common Stock into which such Holder’s Preferred Stock can be converted
cannot be sold in the public securities market pursuant to Rule 144(k) under
the
Securities Act, provided, that the cause of such lapse or unavailability
is not
due to factors solely within the control of such holder of Preferred
Stock;
iii. the
Corporation shall fail to deliver
certificates representing Conversion Shares issuable upon a conversion hereunder
that comply with the provisions hereof prior to the 9th
Trading Day after such shares are
required to be delivered hereunder, or the Corporation shall provide written
notice to any Holder, including by way of public announcement, at any time,
of
its intention not to comply with requests for conversion of any shares of
Preferred Stock in accordance with the terms hereof;
iv. one
of the Events (as defined in the
Registration Rights Agreement) described in subsections (i), (ii) or (iii)
of
Section 2(b) of the Registration Rights Agreement shall not have been cured
to
the satisfaction of the Holders prior to the expiration of 30 days from the
Event Date (as defined in the Registration Rights Agreement) relating thereto
(other than an Event resulting from a failure of a Conversion Shares
Registration Statement to be declared effective by the Commission on or prior
to
the 210th day after the Original Issue Date, which shall be covered by Section
9(a)(i));
v. the
Corporation shall fail for any
reason to pay in full the amount of cash due pursuant to a Buy-In within
15 days
after notice therefor is delivered hereunder or shall fail to pay all amounts
owed on account of an Event within 15 days of the date due;
vi. the
Corporation shall fail to have
available a sufficient number of authorized and unreserved shares of Common
Stock to issue to such Holder upon a conversion hereunder;
vii. the
Corporation shall fail to observe
or perform any other covenant, agreement or warranty contained in, or otherwise
commit any breach of the Transaction Documents, and such failure or breach
shall
not, if subject to the possibility of a cure by the Corporation, have been
remedied within 30 calendar days after the date on which written notice of
such
failure or breach shall have been given;
viii. the
Corporation shall redeem more than
a de minimis number of Junior Securities;
ix. the
Corporation shall be party to a
Change of Control Transaction;
x. there
shall have occurred a Bankruptcy Event; or
xi. the
Common Stock shall fail to be
listed or quoted for trading on a Trading Market for more than 7 Trading
Days,
which need not be consecutive Trading Days.
b) Upon
the occurrence of a Triggering
Event, each Holder shall (in addition to all other rights it may have hereunder
or under applicable law) have the right, exercisable at the sole option of
such
Holder, to require the Corporation to redeem all of the Preferred Stock then
held by such Holder for a redemption price, in cash, equal to the Triggering
Redemption Amount. The Triggering Redemption Amount, if in cash or in shares,
shall be due and payable or issuable, as the case may be, within 5 Trading
Days
of the date on which the notice for the payment therefor is provided by a
Holder
(the “Triggering
Redemption Payment Date”). If the Corporation
fails to pay the
Triggering Redemption Amount hereunder in full pursuant to this Section on
the
date such amount is due in accordance with this Section (whether in cash
or
shares of Common Stock), the Corporation will pay interest thereon at a rate
of
18% per annum (or such lesser amount permitted by applicable law), accruing
daily from such date until the Triggering Redemption Amount, plus all such
interest thereon, is paid in full. For purposes of this Section, a share
of
Preferred Stock is outstanding until such date as the Holder shall have received
Conversion Shares upon a conversion (or attempted conversion) thereof that
meets
the requirements hereof or has been paid the Triggering Redemption Amount
plus
all accrued but unpaid dividends and all accrued but unpaid liquidated damages
in cash.
Section
10. Miscellaneous.
a) No
Debt. So long as any
shares of Preferred
Stock are outstanding, the Corporation will not and will not permit any of
its
Subsidiaries to directly or indirectly enter into, create, incur, assume
or
suffer to exist (or allow any of its Subsidiaries to do so) any indebtedness
or
liens of any kind on or with respect to any of its property or assets now
owned
or hereafter acquired or any interest therein or any income or profits
therefrom, other than (1) accounts payable, equipment leases, other current
payables and other accrued liabilities incurred in connection with short-term
operating liabilities, (2) accrued interest on the Corporation’s existing
indebtedness as set forth on Schedule 4 hereto; (3) up to $1,000,000 for
non-equity linked debt financing in the event the Corporation achieves at
least
$5,000,000 in contract revenues and an annualized gross profit of at least
$2,250,000 as of any fiscal quarter of 2005 (as reported in the SEC Reports);
and (4) an additional $1,000,000 for non-equity linked debt financing in
the
event the Corporation achieves at least $7,500,000 in contract revenues and
at
least a 45% corporate gross margin for any trailing 12 month period (as reported
in the SEC Reports).
b) Notices.
Any and all notices or other
communications or deliveries to be provided by the Holders hereunder, including,
without limitation, any Notice of Conversion, shall be in writing and delivered
personally, by facsimile, sent by a nationally recognized overnight courier
service, addressed to the Corporation, at the address set forth above, facsimile
number 631-924-6033,
Attn: Chief
Financial Officer, Richard Larkin such other
address or facsimile number
as the Corporation may specify for such purposes by notice to the Holders
delivered in accordance with this Section. Any and all notices or other
communications or deliveries to be provided by the Corporation hereunder
shall
be in writing and delivered personally, by facsimile, sent by a nationally
recognized overnight courier service addressed to each Holder at the facsimile
telephone number or address of such Holder appearing on the books of the
Corporation, or if no such facsimile telephone number or address appears,
at the
principal place of business of the Holder. Any notice or other communication
or
deliveries hereunder shall be deemed given and effective on the earliest
of (i)
the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile telephone number specified in this Section prior
to
5:30 p.m. (New York City time), (ii) the date after the date of transmission,
if
such notice or communication is delivered via facsimile at the facsimile
telephone number specified in this Section later than 5:30 p.m. (New York
City
time) on any date and earlier than 11:59 p.m. (New York City time) on such
date,
(iii) the second Business Day following the date of mailing, if sent by
nationally recognized overnight courier service, or (iv) upon actual receipt
by
the party to whom such notice is required to be given.
c) Absolute
Obligation. Except as expressly
provided herein,
no provision of this Certificate of Designation shall alter or impair the
obligation of the Corporation, which is absolute and unconditional, to pay
the
liquidated damages (if any) on, the shares of Preferred Stock at the time,
place, and rate, and in the coin or currency, herein
prescribed.
d) Lost
or Mutilated Preferred Stock
Certificate. If a
Holder’s Preferred Stock certificate shall be mutilated, lost, stolen or
destroyed, the Corporation shall execute and deliver, in exchange and
substitution for and upon cancellation of a mutilated certificate, or in
lieu of
or in substitution for a lost, stolen or destroyed certificate, a new
certificate for the shares of Preferred Stock so mutilated, lost, stolen
or
destroyed but only upon receipt of evidence of such loss, theft or destruction
of such certificate, and of the ownership hereof, and indemnity, if requested,
all reasonably satisfactory to the Corporation.
e) Governing
Law. All questions
concerning the
construction, validity, enforcement and interpretation of this Certificate
of
Designation shall be governed by and construed and enforced in accordance
with
the internal laws of the State of New York, without regard to the principles
of
conflicts of law thereof. Each party agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions
contemplated by any of the Transaction Documents (whether brought against
a
party hereto or its respective affiliates, directors, officers, shareholders,
employees or agents) shall be commenced in the state and federal courts sitting
in the City of New York, Borough of Manhattan (the “New York Courts”).
Each party hereto hereby
irrevocably submits to the exclusive jurisdiction of the New York Courts
for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect
to
the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court,
or such
New York Courts are improper or inconvenient venue for such proceeding. Each
party hereby irrevocably waives personal service of process and consents
to
process being served in any such suit, action or proceeding by mailing a
copy
thereof via registered or certified mail or overnight delivery (with evidence
of
delivery) to such party at the address in effect for notices to it under
this
Certificate of Designation and agrees that such service shall constitute
good
and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner
permitted by law. Each party hereto hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in
any
legal proceeding arising out of or relating to this Certificate of Designation
or the transactions contemplated hereby. If either party shall commence an
action or proceeding to enforce any provisions of this Certificate of
Designation, then the prevailing party in such action or proceeding shall
be
reimbursed by the other party for its attorneys fees and other costs and
expenses incurred with the investigation, preparation and prosecution of
such
action or proceeding.
f) Waiver.
Any waiver by the Corporation or the
Holder of a breach of any provision of this Certificate of Designation shall
not
operate as or be construed to be a waiver of any other breach of such provision
or of any breach of any other provision of this Certificate of Designation.
The
failure of the Corporation or the Holder to insist upon strict adherence
to any
term of this Certificate of Designation on one or more occasions shall not
be
considered a waiver or deprive that party of the right thereafter to insist
upon
strict adherence to that term or any other term of this Certificate of
Designation. Any waiver must be in writing.
g) Severability.
If any provision of this Certificate
of Designation is invalid, illegal or unenforceable, the balance of this
Certificate of Designation shall remain in effect, and if any provision is
inapplicable to any person or circumstance, it shall nevertheless remain
applicable to all other persons and circumstances. If it shall be found that
any
interest or other amount deemed interest due hereunder violates applicable
laws
governing usury, the applicable rate of interest due hereunder shall
automatically be lowered to equal the maximum permitted rate of
interest.
h) Next
Business Day. Whenever any
payment or other
obligation hereunder shall be due on a day other than a Business Day, such
payment shall be made on the next succeeding Business Day.
i) Headings.
The headings contained herein are for
convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions
hereof.
*********************
RESOLVED,
FURTHER, that the Chairman, the president or any vice-president, the Chief
Financial Officer or the secretary or any assistant secretary, of the
Corporation be and they hereby are authorized and directed to prepare and
file
an Amended and Restated Certificate of Designation of Preferences, Rights
and
Limitations in accordance with the foregoing resolution and the provisions
of
the Nevada Revised Statutes.
IN
WITNESS WHEREOF, the undersigned has executed this Amended and Restated
Certificate this 19th day of
December
2007.
__________________________
Name: Richard
J. Larkin
Title: Chief
Financial Officer
ANNEX
A
NOTICE
OF
CONVERSION
(TO
BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED
STOCK)
The
undersigned hereby elects to convert the number of shares of Series B 9%
Convertible Preferred Stock indicated below, into shares of common stock,
par
value $0.01 per share (the “Common Stock”), of Chembio Diagnostics, Inc.,
a Nevada corporation (the “Corporation”), according to the conditions
hereof, as of the date written below. If shares are to be issued in the name
of
a person other than undersigned, the undersigned will pay all transfer taxes
payable with respect thereto and is delivering herewith such certificates
and
opinions as reasonably requested by the Corporation in accordance therewith.
No
fee will be charged to the Holder for any conversion, except for such transfer
taxes, if any.
Conversion
calculations:
Date
to Effect Conversion:
_____________________________________________
|
Number
of shares of Preferred Stock owned prior to Conversion:
_______________
|
Number
of shares of Preferred Stock to be Converted:
________________________
|
Stated
Value of shares of Preferred Stock to be Converted:
____________________
|
Number
of shares of Common Stock to be Issued:
___________________________
|
Applicable
Conversion
Price:____________________________________________
|
Number
of shares of Preferred Stock subsequent to Conversion:
________________
|
[HOLDER]
By:___________________________________
Name:
Title:
|
ex4_9.htm
Exhibit
4.9
EXHIBIT
C
NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE
HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR
OTHER LOAN SECURED BY SUCH SECURITIES.
COMMON
STOCK PURCHASE WARRANT
To
Purchase__________ Shares of Common Stock of
CHEMBIO
DIAGNOSTICS, INC.
Original
Date of Issuance: ___________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: _______________
|
Expires: ____________
|
THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value
received, ___________________ (the “Holder”), is entitled, upon the terms
and subject to the limitations on exercise and the conditions hereinafter
set
forth, at any time on or after the original date of issuance (the “Initial
Exercise Date”) and on or prior to the close of business on the fifth
anniversary of the Initial Exercise Date (the “Termination Date”) but not
thereafter, to subscribe for and purchase from Chembio Diagnostics, Inc.,
a
Nevada corporation (the “Company”), up to ______________ (______________)
shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share,
of the Company (the “Common Stock”). The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price,
as defined in Section 2(b).
Section
1. Definitions. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth
in
that certain Securities Purchase Agreement (the “Purchase Agreement”),
dated January 26, 2005, among the Company and the purchasers
signatory thereto.
Section
2. Exercise.
(a) Exercise
of Warrant. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after
the
Initial Exercise Date and on or before the Termination Date by delivery to
the
Company of a duly executed facsimile copy of the Notice of Exercise Form
annexed
hereto (or such other office or agency of the Company as it may designate
by
notice in writing to the registered Holder at the address of such Holder
appearing on the books of the Company); provided, however, within
5 Trading Days of the date said Notice of Exercise is delivered to the Company,
the Holder shall have surrendered this Warrant to the Company and the Company
shall have received payment of the aggregate Exercise Price of the shares
thereby purchased by wire transfer or cashier’s check drawn on a United States
bank. If the Holder is Crestview Capital Master, LLC or any Affiliate
thereof, then such Holder shall give the Company 5 Trading Days advance notice
of any such exercise for the purpose of enabling the Company to notify other
holders of Warrants of such intended exercise. If the Holder or its
predecessor in interest received this Warrant as a result of the exercise
of its
rights to exchange securities purchased in connection with the Company’s
issuance and sale of Series A Preferred Stock, then this Warrant shall not
be
exercisable until and unless the Holder has received notice of Crestview’s
exercise pursuant to the previous sentence. The restrictions of the
foregoing two sentences shall not apply to any other category of
Holder.
(b) Exercise
Price. The exercise price of the Common Stock under this Warrant
shall be as follows, subject to adjustment hereunder (the “Exercise
Price”):
(i) For
the period 4:01p.m. eastern time (“ET”) through 9:59p.m. ET on the Plan
Closing Date, $0.40 per share for all or any portion of this Warrant exercised
for cash;
(ii) For
the period 4:01p.m. ET through 9:59p.m. ET on the Plan Closing Date, $0.45
per
share for all or any portion of this Warrant exercised through a Cashless
Exercise;
(iii) For
the period beginning 10:00p.m. ET on the Plan Closing Date through 9:59p.m.
ET
on the Final Plan Date, $0.45 for all or any part of this Warrant exercised
by a
Holder who exercised at least 10% of all of such Holder’s warrants and options
for cash at the Plan Closing Date;
(iv) For
the period beginning 10:00p.m. ET on the Plan Closing Date, $0.61 per share
for
any Holder that did not exercise at least 10% of all of such Holder’s warrants
and options for cash at an exercise price of $0.40 per share at the Plan
Closing
Date; and
(v) For
the period beginning 10:00p.m. ET on the Final Plan Date, $0.61 per share
for
all or any portion of this Warrant that has not been exercised on or before
9:59p.m. ET on the Final Plan Date.
(c) Cashless
Exercise.
(i) At
the option of the Holder, this Warrant may be exercised by means of a “cashless
exercise” (a “Cashless Exercise”) in which the Holder shall be entitled
to receive a certificate for the number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:
(A)
= the
VWAP for the ten-Trading Day period that ends on the first Trading Day
immediately preceding the date of such election;
(B)
= the
applicable Exercise Price of this Warrant in effect on the date of exercise,
as
adjusted; and
(X)
= the
number of Warrant Shares issuable upon exercise of this Warrant in accordance
with the terms of this Warrant by means of a cash exercise rather than a
cashless exercise.
(ii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated on
the
Plan Closing Date received from a Holder who exercises its warrants on cashless
basis at $0.45 per share before 10:00p.m. ET on the Plan Closing Date, the
value
of (A) in the equation set forth in Section 2(c)(i) above shall be equal
to the
greater of $0.53 or the VWAP for the ten-Trading Day period that ends on
the
second Trading Day prior to the date of the Notice of Exercise
Form.
(iii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated between
and inclusive of the Plan Closing Date and the Final Plan Date received from
a
Holder who exercises at least 10% of all of such Holder's warrants and options
for cash before 10:00p.m. ET on the Plan Closing Date the value of (A) in
the
equation set forth in Section 2(c)(i) above shall be equal to the greater
of
$0.53 or the VWAP for the ten-Trading Day period that ends on the second
Trading
Day prior to the date of the Notice of Exercise Form.
(iv) Notwithstanding
anything herein to the contrary, a Holder who does not exercise (i) at least
10%
of all of such Holder's warrants and options issued by the Company for cash
at
an exercise price of $0.40 per share before 10:00p.m. ET on the Plan Closing
Date, or (ii) its warrants on cashless basis at $0.45 per share by 10:00p.m.
ET
on the Plan Closing Date, shall not be permitted to exercise its Warrants
on a
cashless basis pursuant to Section 2(c)(i) above until April 1,
2008.
d) Exercise
Limitations.
(i) Holder’s
Restrictions. The Holder shall not have the right to exercise any
portion of this Warrant, pursuant to Section 2(c) or otherwise, to the extent
that after giving effect to such issuance after exercise, the Holder (together
with the Holder’s affiliates), as set forth on the applicable Notice of
Exercise, would beneficially own in excess of 4.99% of the number of shares
of
the Common Stock outstanding immediately after giving effect to such
issuance. For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its affiliates
shall
include the number of shares of Common Stock issuable upon exercise of this
Warrant with respect to which the determination of such sentence is being
made,
but shall exclude the number of shares of Common Stock which would be issuable
upon (A) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its affiliates and (B) exercise
or
conversion of the unexercised or nonconverted portion of any other securities
of
the Company (including, without limitation, any other shares of Preferred
Stock
or Warrants) subject to a limitation on conversion or exercise analogous
to the
limitation contained herein beneficially owned by the Holder or any of its
affiliates. Except as set forth in the preceding sentence, for
purposes of this Section 2(d), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act, it being acknowledged
by
Holder that the Company is not representing to Holder that such calculation
is
in compliance with Section 13(d) of the Exchange Act and Holder is solely
responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this
Section 2(d) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder) and of which a portion
of
this Warrant is exercisable shall be in the sole discretion of such Holder,
and
the submission of a Notice of Exercise shall be deemed to be such Holder’s
determination of whether this Warrant is exercisable (in relation to other
securities owned by such Holder) and of which portion of this Warrant is
exercisable, in each case subject to such aggregate percentage limitation,
and
the Company shall have no obligation to verify or confirm the accuracy of
such
determination. For purposes of this Section 2(d), in determining the
number of outstanding shares of Common Stock, the Holder may rely on the
number
of outstanding shares of Common Stock as reflected in (x) the Company’s most
recent Form 10-QSB or Form 10-KSB, as the case may be, (y) a more recent
public
announcement by the Company or (z) any other notice by the Company or the
Company’s Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of the Holder, the
Company shall within two Trading Days confirm orally and in writing to the
Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined
after
giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its affiliates since the date as
of
which such number of outstanding shares of Common Stock was
reported. The provisions of this Section 2(d) may be waived by the
Holder upon, at the election of the Holder, not less than 61 days’ prior notice
to the Company, and the provisions of this Section 2(d) shall continue to
apply
until such 61st day (or such later date, as determined by the Holder, as
may be
specified in such notice of waiver). Notwithstanding anything set
forth in this Section 2(d), the 4.99% beneficial ownership restriction set
forth
in this Section 2(d) shall not apply to Common Stock issuable upon the exercise
of Warrants in connection with the Plan.
(e) For
purposes of this warrant, the term “Plan” shall mean any action the
Company takes, with any required approval of the holders thereof, on or before
the Final Plan Date as contemplated by the Plan Summary and accompanying
materials provided to holders on December 4, 2007, in connection with the
reduction or other modification of terms of the Company’s then-outstanding
preferred stock, warrants and options, including, but not limited to, actions
the Company takes to (i) facilitate the conversion of the Series A, B and
C
Convertible Preferred Stock; (ii) reduce the exercise price of any of the
Company’s outstanding warrants or options; (iii) offer the holders of the
Company’s warrants and options the opportunity to exercise such warrants and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
(f) “Plan
Closing Date” shall be December 19, 2007.
(g) “Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
(h) Mechanics
of Exercise.
(i) Authorization
of Warrant Shares. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented
by this
Warrant will, upon exercise of the purchase rights represented by this Warrant,
be duly authorized, validly issued, fully paid and nonassessable and free
from
all taxes, liens and charges in respect of the issue thereof (other than
taxes
in respect of any transfer occurring contemporaneously with such
issue).
(ii) Delivery
of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the transfer agent of the Company to the
Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”)
system if the Company is a participant in such system, and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise
within
3 Trading Days from the delivery to the Company of the Notice of Exercise
Form,
surrender of this Warrant and payment of the aggregate Exercise Price as
set
forth above (“Warrant Share Delivery Date”). This Warrant
shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Warrant Shares shall be deemed to have
been issued, and Holder or any other person so designated to be named therein
shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Warrant has been exercised by payment to the
Company of the Exercise Price and all taxes required to be paid by the Holder,
if any, pursuant to Section 2(e)(vii) prior to the issuance of such shares,
have
been paid.
(iii) Delivery
of New Warrants Upon Exercise. If this Warrant shall have been
exercised in part, the Company shall, at the time of delivery of the certificate
or certificates representing Warrant Shares, deliver to Holder a new Warrant
evidencing the rights of Holder to purchase the unpurchased Warrant Shares
called for by this Warrant, which new Warrant shall in all other respects
be
identical with this Warrant.
(iv) Rescission
Rights. If the Company fails to cause its transfer agent to
transmit to the Holder a certificate or certificates representing the Warrant
Shares pursuant to this Section 2(e)(iv) by the Warrant Share Delivery Date,
then the Holder will have the right to rescind such exercise.
(v) Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon
Exercise. In addition to any other rights available to the
Holder, if the Company fails to cause its transfer agent to transmit to the
Holder a certificate or certificates representing the Warrant Shares pursuant
to
an exercise on or before the Warrant Share Delivery Date, and if after such
date
the Holder is required by its broker to purchase (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale
by the
Holder of the Warrant Shares which the Holder anticipated receiving upon
such
exercise (a “Buy-In”), then the Company shall (1) pay in cash to the
Holder the amount by which (x) the Holder’s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased
exceeds (y) the amount obtained by multiplying (A) the number of Warrant
Shares
that the Company was required to deliver to the Holder in connection with
the
exercise at issue times (B) the price at which the sell order giving rise
to
such purchase obligation was executed, and (2) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant
Shares for which such exercise was not honored or deliver to the Holder the
number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations
hereunder. For example, if the Holder purchases Common Stock having a
total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise
to
such purchase obligation of $10,000, under clause (1) of the immediately
preceding sentence the Company shall be required to pay the Holder
$1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In, together
with applicable confirmations and other evidence reasonably requested by
the
Company. Nothing herein shall limit a Holder’s right to pursue any
other remedies available to it hereunder, at law or in equity including,
without
limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required pursuant
to the
terms hereof.
(vi) No
Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise
be entitled to purchase upon such exercise, the Company shall pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price.
(vii) Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax
or
other incidental expense in respect of the issuance of such certificate,
all of
which taxes and expenses shall be paid by the Company, and such certificates
shall be issued in the name of the Holder or in such name or names as may
be
directed by the Holder; provided, however, that in the event
certificates for Warrant Shares are to be issued in a name other than the
name
of the Holder, this Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder; and the
Company may require, as a condition thereto, the payment of a sum sufficient
to
reimburse it for any transfer tax incidental thereto.
(viii) Closing
of Books. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
Section
3. Certain
Adjustments.
(a) Stock
Dividends and Splits. If the Company, at any time while this
Warrant is outstanding: (A) pays a stock dividend or otherwise make a
distribution or distributions on shares of its Common Stock or any other
equity
or equity equivalent securities payable in shares of Common Stock (which,
for
avoidance of doubt, shall not include any shares of Common Stock issued by
the
Company pursuant to this Warrant, the Company’s Series A Convertible Preferred
Stock or the Company’s Series B Convertible Preferred Stock), (B) subdivides
outstanding shares of Common Stock into a larger number of shares, (C) combines
(including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares, or (D) issues by reclassification of shares
of
the Common Stock any shares of capital stock of the Company, then in each
case
the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares,
if
any) outstanding before such event and of which the denominator shall be
the
number of shares of Common Stock outstanding after such event and the number
of
shares issuable upon exercise of this Warrant shall be proportionately
adjusted. Any adjustment made pursuant to this Section 3(a) shall
become effective immediately after the record date for the determination
of
stockholders entitled to receive such dividend or distribution and shall
become
effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
(b) Subsequent
Equity Sales. If the Company or any Subsidiary thereof, as
applicable, at any time while this Warrant is outstanding, shall offer, sell,
grant any option to purchase or offer, sell or grant any right to reprice
its
securities, or otherwise dispose of or issue (or announce any offer, sale,
grant
or any option to purchase or other disposition) any Common Stock or Common
Stock
Equivalents entitling any Person to acquire shares of Common Stock, at an
effective price per share less than the then Exercise Price (such lower price,
the “Base Share Price” and such issuances collectively, a “Dilutive
Issuance”), as adjusted hereunder (if the holder of the Common Stock or
Common Stock Equivalents so issued shall at any time, whether by operation
of
purchase price adjustments, reset provisions, floating conversion, exercise
or
exchange prices or otherwise, or due to warrants, options or rights per share
which is issued in connection with such issuance, be entitled to receive
shares
of Common Stock at an effective price per share which is less than the Exercise
Price, such issuance shall be deemed to have occurred for less than the Exercise
Price), then, the Exercise Price shall be reduced to equal the Base Share
Price
and the number of Warrant Shares issuable hereunder shall be increased such
that
the aggregate Exercise Price payable hereunder, after taking into account
the
decrease in the Exercise Price, shall be equal to the aggregate Exercise
Price
prior to such adjustment. Such adjustment shall be made whenever such
Common Stock or Common Stock Equivalents are issued. The Company
shall notify the Holder in writing, no later than the Trading Day following
the
issuance of any Common Stock or Common Stock Equivalents subject to this
section, indicating therein the applicable issuance price, or of applicable
reset price, exchange price, conversion price and other pricing terms (such
notice the “Dilutive Issuance Notice”). For purposes of
clarification, whether or not the Company provides a Dilutive Issuance Notice
pursuant to this Section 3(b), upon the occurrence of any Dilutive Issuance,
after the date of such Dilutive Issuance the Holder is entitled to receive
a
number of Warrant Shares based upon the Base Share Price regardless of whether
the Holder accurately refers to the Base Share Price in the Notice of
Exercise.
(c) Pro
Rata Distributions. If the Company, at any time prior to the
Termination Date, shall distribute to all holders of Common Stock (and not
to
Holders of the Warrants) evidences of its indebtedness or assets or rights
or
warrants to subscribe for or purchase any security other than the Common
Stock
(which shall be subject to Section 3(b)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately
prior to the record date fixed for determination of stockholders entitled
to
receive such distribution by a fraction of which the denominator shall be
the
VWAP determined as of the record date mentioned above, and of which the
numerator shall be such VWAP on such record date less the then per share
fair
market value at such record date of the portion of such assets or evidence
of
indebtedness so distributed applicable to one outstanding share of the Common
Stock as determined by the Board of Directors in good faith. In
either case the adjustments shall be described in a statement provided to
the
Holders of the portion of assets or evidences of indebtedness so distributed
or
such subscription rights applicable to one share of Common
Stock. Such adjustment shall be made whenever any such distribution
is made and shall become effective immediately after the record date mentioned
above.
(d) Fundamental
Transaction. If, at any time while this Warrant is outstanding,
(A) the Company effects any merger or consolidation of the Company with or
into
another Person, (B) the Company effects any sale of all or substantially
all of
its assets in one or a series of related transactions, (C) any tender offer
or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects
any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for
other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then, upon any subsequent conversion of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would
have
been issuable upon such exercise absent such Fundamental Transaction, at
the
option of the Holder, (a) upon exercise of this Warrant, the number of shares
of
Common Stock of the successor or acquiring corporation or of the Company,
if it
is the surviving corporation, and Alternate Consideration receivable upon
or as
a result of such reorganization, reclassification, merger, consolidation
or
disposition of assets by a Holder of the number of shares of Common Stock
for
which this Warrant is exercisable immediately prior to such event or (b)
if the
Company is acquired in an all cash transaction, cash equal to the value of
this
Warrant as determined in accordance with the Black-Scholes option pricing
formula (the “Alternate Consideration”). For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock
in such
Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall
be
given the same choice as to the Alternate Consideration it receives upon
any
exercise of this Warrant following such Fundamental Transaction. To
the extent necessary to effectuate the foregoing provisions, any successor
to
the Company or surviving entity in such Fundamental Transaction shall issue
to
the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate
Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such
successor or surviving entity to comply with the provisions of this Section
3(d)
and insuring that this Warrant (or any such replacement security) will be
similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.
(e) Exempt
Issuance. Notwithstanding the foregoing, no adjustments,
Alternate Consideration nor notices shall be made, paid or issued under this
Section 3 in respect of an Exempt Issuance or any issuance of Common Stock
or
Common Stock Equivalents upon conversion of the preferred stock or the exercise
of warrants and/or options in connection with the Plan.
(f) Calculations. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. The number of shares
of Common Stock outstanding at any given time shall not include shares of
Common
Stock owned or held by or for the account of the Company, and the description
of
any such shares of Common Stock shall be considered on issue or sale of Common
Stock. For purposes of this Section 3, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the
sum of
the number of shares of Common Stock (excluding treasury shares, if any)
issued
and outstanding.
(g) Voluntary
Adjustment By Company. The Company may at any time during the
term of this Warrant reduce the then current Exercise Price to any amount
and
for any period of time deemed appropriate by the Board of Directors of the
Company.
(h) Notice
to Holders.
(i) Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted
pursuant to this Section 3, the Company shall promptly mail to each Holder
a
notice setting forth the Exercise Price after such adjustment and setting
forth
a brief statement of the facts requiring such adjustment. If the
Company issues a variable rate security, despite the prohibition thereon
in the
Purchase Agreement, the Company shall be deemed to have issued Common Stock
or
Common Stock Equivalents at the lowest possible conversion or exercise price
at
which such securities may be converted or exercised in the case of a Variable
Rate Transaction (as defined in the Purchase Agreement), or the lowest possible
adjustment price in the case of an MFN Transaction (as defined in the Purchase
Agreement.
(ii) Notice
to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution) on the Common Stock; (B) the Company
shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock; (C) the Company shall authorize the granting to all holders of the
Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; (D) the approval of any stockholders
of the
Company shall be required in connection with any reclassification of the
Common
Stock, any consolidation or merger to which the Company is a party, any sale
or
transfer of all or substantially all of the assets of the Company, of any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Company shall authorize the voluntary
or
involuntary dissolution, liquidation or winding up of the affairs of the
Company; then, in each case, the Company shall cause to be mailed to the
Holder
at its last addresses as it shall appear upon the Warrant Register of the
Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record
is
to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the
holders
of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer
or
share exchange; provided, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of
the
corporate action required to be specified in such notice. The Holder
is entitled to exercise this Warrant during the 20-day period commencing
on the
date of such notice to the effective date of the event triggering such
notice.
Section
4. Transfer
of Warrant.
(a) Transferability. Subject
to compliance with any applicable securities laws and the conditions set
forth
in Sections 5(a) and 4(d) hereof and to the provisions of Section 4.1 of
the
Purchase Agreement, this Warrant and all rights hereunder are transferable,
in
whole or in part, upon surrender of this Warrant at the principal office
of the
Company, together with a written assignment of this Warrant substantially
in the
form attached hereto duly executed by the Holder or its agent or attorney
and
funds sufficient to pay any transfer taxes payable upon the making of such
transfer. Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of
the
assignee or assignees and in the denomination or denominations specified
in such
instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant
shall
promptly be cancelled. A Warrant, if properly assigned, may be
exercised by a new holder for the purchase of Warrant Shares without having
a
new Warrant issued.
(b) New
Warrants. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in
which
new Warrants are to be issued, signed by the Holder or its agent or
attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall
execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to
be divided or combined in accordance with such notice.
(c) Warrant
Register. The Company shall register this Warrant, upon records
to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof
or
any distribution to the Holder, and for all other purposes, absent actual
notice
to the contrary.
(d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in
connection with any transfer of this Warrant, the transfer of this Warrant
shall
not be registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the
Holder or transferee of this Warrant, as the case may be, furnish to the
Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities
Act and under applicable state securities or blue sky laws, (ii) that the
holder
or transferee execute and deliver to the Company an investment letter in
form
and substance acceptable to the Company and (iii) that the transferee be
an
“accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or
(a)(8) promulgated under the Securities Act or a qualified institutional
buyer
as defined in Rule 144A(a) under the Securities Act.
Section
5. Miscellaneous.
(a) Title
to Warrant. Prior to the Termination Date and subject to
compliance with applicable laws and Section 4 of this Warrant, this Warrant
and
all rights hereunder are transferable, in whole or in part, at the office
or
agency of the Company by the Holder in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed
hereto
properly endorsed. The transferee shall sign an investment letter in
form and substance reasonably satisfactory to the Company.
(b) No
Rights as Shareholder Until Exercise. This Warrant does not
entitle the Holder to any voting rights or other rights as a shareholder
of the
Company prior to the exercise hereof. Upon the surrender of this
Warrant and the payment of the aggregate Exercise Price (or by means of a
cashless exercise), the Warrant Shares so purchased shall be and be deemed
to be
issued to such Holder as the record owner of such shares as of the close
of
business on the later of the date of such surrender or payment.
(c) Loss,
Theft, Destruction or Mutilation of Warrant. The Company
covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any
stock
certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which,
in
the case of the Warrant, shall not include the posting of any bond), and
upon
surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.
(d) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall be a Saturday, Sunday or a legal holiday, then such action may be taken
or
such right may be exercised on the next succeeding day not a Saturday, Sunday
or
legal holiday.
(e) Authorized
Shares. The Company covenants that during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock
a
sufficient number of shares to provide for the issuance of the Warrant Shares
upon the exercise of any purchase rights under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing
stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements
of
the Trading Market upon which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall
not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms
of this
Warrant, but will at all times in good faith assist in the carrying out of
all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant
against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase
in
par value, (b) take all such action as may be necessary or appropriate in
order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
(f) Jurisdiction. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of
the
Purchase Agreement.
(g) Restrictions. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of
this
Warrant, if not registered, will have restrictions upon resale imposed by
state
and federal securities laws.
(h) Nonwaiver
and Expenses. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver
of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover
any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting
any
amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers
or remedies hereunder.
(i) Notices. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
(j) Limitation
of Liability. No provision hereof, in the absence of any
affirmative action by Holder to exercise this Warrant or purchase Warrant
Shares, and no enumeration herein of the rights or privileges of Holder,
shall
give rise to any liability of Holder for the purchase price of any Common
Stock
or as a stockholder of the Company, whether such liability is asserted by
the
Company or by creditors of the Company.
(k) Remedies. Holder,
in addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach
by it
of the provisions of this Warrant and hereby agrees to waive the defense
in any
action for specific performance that a remedy at law would be
adequate.
(l) Successors
and Assigns. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit
of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
(m) Amendment. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
(n) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner
as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions
of
this Warrant.
(o) Headings. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized.
Dated: December
_____, 2007
CHEMBIO
DIAGNOSTICS, INC.
By:
Name: Lawrence
A. Siebert
Title: President
Original
Date of Issuance: ___________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: ______________
|
Expires: ________________
|
NOTICE
OF EXERCISE
TO: CHEMBIO
DIAGNOSTICS, INC.
(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full),
and
tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.
(2) Payment
shall take the form of (check applicable box):
[
] in
lawful money of the United States; or
[
] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).
(3) Please
issue a certificate or certificates representing said Warrant Shares in the
name
of the undersigned or in such other name as is specified below:
_______________________________
The
Warrant Shares shall be delivered to the following:
_______________________________
_______________________________
_______________________________
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name
of
Investing
Entity: _______________________________________________________
Signature
of Authorized Signatory of Investing
Entity: _________________________________
Name
of
Authorized
Signatory: ___________________________________________________
Title
of
Authorized
Signatory:_____________________________________________________
Date:_________________________________________________________________________
Original
Date of Issuance: ___________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: _________________
|
Expires: ___________________
|
ASSIGNMENT
FORM
(To
assign the foregoing warrant, execute this form and supply required
information.
Do
not
use this form to exercise the warrant.)
FOR
VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to
_______________________________________________
whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________,
_______
Holder’s
Signature: _____________________________
Holder’s
Address: __________________________________________________________
Signature
Guaranteed: ___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears
on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to
assign
the foregoing Warrant.
ex4_13.htm
Exhibit
4.13
CHEMBIO
DIAGNOSTICS, INC.
SECOND
AMENDED AND RESTATED
CERTIFICATE
OF DESIGNATION OF PREFERENCES,
RIGHTS
AND LIMITATIONS
OF
SERIES
C 7% CONVERTIBLE PREFERRED STOCK
PURSUANT
TO SECTION 78.1955 OF THE
NEVADA
REVISED STATUTES
The
undersigned, Richard J. Larkin, does hereby certify that:
1.
He is
the Chief Financial Officer of Chembio Diagnostics, Inc., a Nevada corporation
(the “Corporation”).
2.
The
Corporation is authorized to issue 10,000,000 shares of preferred stock,
297.82698 of which have been issued.
3.
The
following resolutions were duly adopted by the Board of Directors:
WHEREAS,
the Articles of Incorporation of the Corporation provides for a class of
its
authorized stock known as preferred stock, comprised of 10,000,000 shares,
$0.01
par value, issuable from time to time in one or more series;
WHEREAS,
the Board of Directors of the Corporation is authorized to fix the dividend
rights, dividend rate, voting rights, conversion rights, rights and terms
of
redemption and liquidation preferences of any wholly unissued series of
preferred stock and the number of shares constituting any Series and the
designation thereof, of any of them; and
WHEREAS,
it is the desire of the Board of Directors of the Corporation, pursuant to
its
authority as aforesaid, to fix the rights, preferences, restrictions and
other
matters relating to a series of the preferred stock, which shall consist
of,
except as otherwise set forth in the Purchase Agreement, up to 205 shares
of the
preferred stock which the Corporation has the authority to issue, as
follows;
WHEREAS,
the Board of Directors with shareholder consent desires to amend certain
provisions as follows:
NOW,
THEREFORE, BE IT RESOLVED, that the Board of Directors does hereby provide
for
the issuance of a series of preferred stock for cash or exchange of other
securities, rights or property and does hereby fix and determine the rights,
preferences, restrictions and other matters relating to such series of preferred
stock as follows:
TERMS
OF PREFERRED STOCK
Section
1. Definitions. Capitalized terms used and not
otherwise defined herein that are defined in the Purchase Agreement shall
have
the meanings given such terms in the Purchase Agreement. For the
purposes hereof, the following terms shall have the following
meanings:
“Alternate
Consideration” shall have the meaning set forth in Section
7(e).
“Bankruptcy
Event” means any of the following events: (a) the Corporation or any
Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation
S-X) thereof commences a case or other proceeding under any bankruptcy,
reorganization, arrangement, adjustment of debt, relief of debtors, dissolution,
insolvency or liquidation or similar law of any jurisdiction relating to
the
Corporation or any Significant Subsidiary thereof; (b) there is commenced
against the Corporation or any Significant Subsidiary thereof any such case
or
proceeding that is not dismissed within 60 days after commencement; (c) the
Corporation or any Significant Subsidiary thereof is adjudicated insolvent
or
bankrupt or any order of relief or other order approving any such case or
proceeding is entered; (d) the Corporation or any Significant Subsidiary
thereof
suffers any appointment of any custodian or the like for it or any substantial
part of its property that is not discharged or stayed within 60 calendar
days
after such appointment; (e) the Corporation or any Significant Subsidiary
thereof makes a general assignment for the benefit of creditors; (f) the
Corporation or any Significant Subsidiary thereof calls a meeting of its
creditors with a view to arranging a composition, adjustment or restructuring
of
its debts; or (g) the Corporation or any Significant Subsidiary thereof,
by any
act or failure to act, expressly indicates its consent to, approval of or
acquiescence in any of the foregoing or takes any corporate or other action
for
the purpose of effecting any of the foregoing.
“Base
Conversion Price” shall have the meaning set forth in Section
7(b).
“Buy-In”
shall have the meaning set forth in Section 6(d)(iii).
“Change
of Control Transaction” means the occurrence after the date hereof of any of
(i) an acquisition after the date hereof by an individual or legal entity
or
“group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of
effective control (whether through legal or beneficial ownership of capital
stock of the Corporation, by contract or otherwise) of in excess of 50% of
the
aggregate voting power of the Corporation, or (ii) the Corporation merges
into
or consolidates with any other Person, or any Person merges into or consolidates
with the Corporation and, after giving effect to such transaction, the
stockholders of the Corporation immediately prior to such transaction own
less
than 50% of the aggregate voting power of the Corporation or the successor
entity of such transaction, or (iii) the Corporation sells or transfers its
assets, as an entirety or substantially as an entirety, to another Person
and
the stockholders of the Corporation immediately prior to such transaction
own
less than 50% of the aggregate voting power of the acquiring entity immediately
after the transaction, or (iv) the execution by the Corporation of an agreement
to which the Corporation is a party or by which it is bound, providing for
any
of the events set forth above.
“Closing
Date” means the Trading Day when all of the Transaction Documents have been
executed and delivered by the applicable parties thereto, and all conditions
precedent to (i) each Holder’s obligations to pay the Subscription Amount and
(ii) the Corporation’s obligations to deliver the Securities have been satisfied
or waived.
“Commission”
means the Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.01 per share, and
stock of any other class of securities into which such securities may hereafter
be reclassified or changed into.
“Common
Stock Equivalents” means any securities of the Corporation or the
Subsidiaries which would entitle the holder thereof to acquire, directly
or
indirectly, at any time Common Stock, including without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that is at
any
time convertible into or exchangeable for, or otherwise entitles the holder
thereof to receive, Common Stock.
“Conversion
Amount” means the sum of the Stated Value at issue.
“Conversion
Date” shall have the meaning set forth in Section 6(a).
“Conversion
Price” shall have the meaning set forth in Section 6(b).
“Conversion
Shares” means, collectively, the shares of Common Stock into which the
shares of Preferred Stock are convertible in accordance with the terms
hereof.
“Conversion
Shares Registration Statement” means a registration statement that meets the
requirements of the Registration Rights Agreement and registers the resale
of
all Conversion Shares by the Holder, who shall be named as a “selling
stockholder” thereunder, all as provided in the Registration Rights
Agreement.
“Dilutive
Issuance” shall have the meaning set forth in Section 7(b).
“Dilutive
Issuance Notice” shall have the meaning set forth in Section
7(b).
“Dividend
Payment Date” shall have the meaning set forth in Section 3(a).
“Effective
Date” means the date that the Conversion Shares Registration Statement is
declared effective by the Commission.
“Equity
Conditions” means, during the period in question, (i) the Corporation shall
have duly honored all conversions scheduled to occur or occurring by virtue
of
one or more Notices of Conversion of the applicable Holder on or prior to
the
dates so requested or required, if any, (ii) the Corporation shall have paid
all
liquidated damages and other amounts owing to the applicable Holder in respect
of the Preferred Stock, (iii) there is an effective Conversion Shares
Registration Statement pursuant to which the Holders are permitted to utilize
the prospectus thereunder to resell all of the shares of Common Stock issuable
pursuant to the Transaction Documents (and the Corporation believes, in good
faith, that such effectiveness will continue uninterrupted for the foreseeable
future), (iv) the Common Stock is trading on a Trading Market and all of
the
shares issuable pursuant to the Transaction Documents are listed for trading
on
such Trading Market (and the Corporation believes, in good faith, that trading
of the Common Stock on a Trading Market will continue uninterrupted for the
foreseeable future), (v) there is a sufficient number of authorized, but
unissued and otherwise unreserved, shares of Common Stock for the issuance
of
all of the shares of Common Stock issuable pursuant to the Transaction
Documents, (vi) there is no existing Triggering Event or no existing event
which, with the passage of time or the giving of notice, would constitute
a
Triggering Event, (vii) the issuance of the shares in question to the applicable
Holder would not violate the limitations set forth in Section 6(c), (viii)
there
has been no public announcement of a pending or proposed Fundamental Transaction
or Change of Control Transaction that has not been consummated and (ix) the
applicable Holder is not in possession of any information that constitutes,
or
may constitute, material non-public information.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulation promulgated thereunder.
“Exempt
Issuance” means the issuance of (a) shares of Common Stock or options to
employees, officers, consultants, or directors of the Corporation pursuant
to
any stock or option plan or other resolution duly adopted by a majority of
the
non-employee members of the Board of Directors of the Corporation or a majority
of the members of a committee of non-employee directors established for such
purpose, (b) securities upon the exercise of or conversion of any Securities
issued hereunder, convertible securities, options or warrants issued and
outstanding on the date of the Purchase Agreement, provided that such securities
have not been amended since the date of the Purchase Agreement to increase
the
number of such securities or to decrease the exercise or conversion price
of any
such securities (except pursuant to any anti-dilution adjustment contained
therein), (c) securities issued pursuant to acquisitions or strategic
transactions, provided any such issuance shall only be to a Person which
is,
itself or through its subsidiaries, an operating company in a business
reasonably deemed by the Corporation’s Board of Directors to be strategically
advantageous to the business of the Corporation and in which the Corporation
receives benefits in addition to the investment of funds, but shall not include
a transaction in which the Corporation is issuing securities primarily for
the
purpose of raising capital or to an entity whose primary business is investing
in securities, (d) shares issued as dividend payments on the Series A
Convertible Preferred Stock, the Series B 9% Convertible Preferred Stock
and the
Preferred Stock, and (e) shares of Common Stock or Common Stock Equivalents
issued between the Plan Closing Date and the Final Plan Date in connection
with
the Company’s Plan.
“Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
“Fundamental
Transaction” shall have the meaning set forth in Section 7(e).
“Holder”
shall have the meaning given such term in Section 2.
“Junior
Securities” means the Common Stock and all other Common Stock Equivalents of
the Corporation other than those securities which are explicitly senior or
paripassu to the Preferred Stock in dividend rights or liquidation
preference.
“Liquidation”
shall have the meaning given such term in Section 5.
“New
York Courts” shall have the meaning given such term in Section
10(e).
“Notice
of Conversion” shall have the meaning given such term in Section
6(a).
“Original
Issue Date” shall mean the date of the first issuance of any shares of the
Preferred Stock regardless of the number of transfers of any particular shares
of Preferred Stock and regardless of the number of certificates which may
be
issued to evidence such Preferred Stock.
“Person”
means a corporation, an association, a partnership, an organization, a business,
an individual, a government or political subdivision thereof or a governmental
agency.
“Plan”
shall mean any action the Company takes, with any required approval of the
holders thereof, on or before the Final Plan Date as contemplated by the
Plan
Summary and accompanying materials provided to holders on December 4, 2007,
in
connection with the reduction or other modification of terms of the Company’s
then-outstanding preferred stock, warrants and options, including, but not
limited to, actions the Company takes to (i) facilitate the conversion of
the
Series A, B and C Convertible Preferred Stock; (ii) reduce the exercise price
of
any of the Company’s outstanding warrants or options; (iii) offer the holders of
the Company’s warrants and options the opportunity to exercise such warrants and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
“Plan
Closing Date” shall mean December 19, 2007.
“Purchase
Agreement” means the Securities Purchase Agreement, dated as of September
29, 2006, to which the Corporation and the original Holders are parties,
as
amended, modified or supplemented from time to time in accordance with its
terms.
“Registration
Rights Agreement” as to a Holder, means the Registration Rights Agreement
entered into to which the Corporation and such Holder are parties, as amended,
modified or supplemented from time to time in accordance with its
terms.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.
“Share
Delivery Date” shall have the meaning given such term in Section
6(d).
“Stated
Value” shall have the meaning given such term in Section 2.
“Subscription
Amount” shall mean, as to each Purchaser, the amount to be paid for the
Preferred Stock purchased pursuant to the Purchase Agreement (or, if applicable
to a Holder, any other Securities Purchase Agreement entered into for the
sale
of Preferred Stock as permitted hereunder) as specified below such Purchaser’s
name on the signature page of the Purchase Agreement (or other Securities
Purchase Agreement, as applicable) and next to the heading “Subscription
Amount”, in United States Dollars and in immediately available
funds.
“Subsidiary”
shall have the meaning given to such term in the Purchase
Agreement.
“Threshold
Period” shall have the meaning set forth in Section 6(a).
“Trading
Day” means a day on which the Common Stock is traded on a Trading
Market.
“Trading
Market” means the following markets or exchanges on which the Common Stock
is listed or quoted for trading on the date in question: the OTC Bulletin
Board,
the Nasdaq SmallCap Market, the American Stock Exchange, the New York Stock
Exchange or the Nasdaq National Market.
“Transaction
Documents” shall have the meaning set forth in the Purchase Agreement or, as
to any Holders party to another Securities Purchase Agreement, as such term
is
defined in such agreement.
“Triggering
Event” shall have the meaning set forth in Section 9(a).
“Triggering
Redemption Amount” for each share of Preferred Stock means the sum of (i)
the greater of (A) 130% of the Stated Value and (B) the product of (a) the
VWAP
on the Trading Day immediately preceding the date of the Triggering Event
and
(b) the Stated Value divided by the then Conversion Price, (ii) all accrued
but
unpaid dividends thereon and (iii) all liquidated damages and other amounts
due
in respect of the Preferred Stock.
“Triggering
Redemption Payment Date” shall have the meaning set forth in Section
9(b).
“VWAP”
means, for any date, the price determined by the first of the following clauses
that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on the Trading Market on which the Common
Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based
on
a Trading Day from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (b)
if the
Common Stock is not then listed or quoted on a Trading Market and if prices
for
the Common Stock are then reported in the “Pink Sheets” published by the Pink
Sheets, LLC (or a similar organization or agency succeeding to its functions
of
reporting prices), the most recent bid price per share of the Common Stock
so
reported; or (c) in all other cases, the fair market value of a share of
Common
Stock as determined by an independent appraiser selected in good faith by
the
Purchasers and reasonably acceptable to the Corporation.
Section
2. Designation, Rank, Amount and Par Value. The
series of preferred stock shall be designated as its Series C 7% Convertible
Preferred Stock (the “Preferred Stock”) and the number of shares so
designated shall be 205 (which shall not be subject to increase without the
consent of all of the holders of the Preferred Stock (each, a “Holder”
and collectively, the “Holders”)). Each share of Preferred
Stock shall have a par value of $0.01 per share and a stated value equal
to
$50,000 (the “Stated Value”). The Preferred Stock shall rank
pari passu to the Corporation’s Series A Convertible Preferred Stock and the
Corporation’s Series B 9% Convertible Preferred Stock as to payment of dividends
and liquidation preference. Capitalized terms not otherwise defined
herein shall have the meaning given such terms in Section 1 hereof.
Section
3. Dividends.
a) Dividends
in Cash or in
Kind. Holders shall
be entitled
to receive, and the Corporation shall pay, cumulative dividends at the rate
per
share (as a percentage of the Stated Value per share) of 7% per
annum,
payable semi-annually on January 1 and
July 1, beginning on July 1, 2007 and on each Conversion Date (with respect
only
to Preferred Stock being converted) (each such date, a “Dividend Payment
Date”) (if any
Dividend Payment Date is not a Trading Day, the applicable payment shall
be due
on the next succeeding Trading Day) in cash or duly authorized, validly issued,
fully paid and non-assessable shares of Common Stock as set forth in this
Section 3(a), or a combination thereof (the amount to be paid in shares of
Common Stock, the “Dividend Share
Amount”). The form of dividend
payments to each Holder shall be determined in the following order of priority:
(i) if funds are legally available for the payment of dividends and the Equity
Conditions have not been met during the 20 consecutive Trading Days immediately
prior to the applicable Dividend Payment Date, in cash only; (ii) if funds
are
legally available for the payment of dividends and the Equity Conditions
have
been met during the 20 consecutive Trading Days immediately prior to the
applicable Dividend Payment Date, at the sole election of the Corporation,
in
cash or shares of Common Stock which shall be valued solely for such purpose
at
90% of the average of the VWAPs for the 20 consecutive Trading Days ending
on
the Trading Day that is immediately prior to the Dividend Payment Date; (iii)
if
funds are not legally available for the payment of dividends and the Equity
Conditions have been met during the 20 consecutive Trading Days immediately
prior to the applicable Dividend Payment Date, in shares of Common Stock
which
shall be valued solely for such purpose at 90% of the average of the VWAPs
for
the 20 consecutive Trading Days ending on the Trading Day that is immediately
prior to the Dividend Payment Date; (iv) if funds are not legally available
for
the payment of dividends and the Equity Condition relating to an effective
Conversion Shares Registration Statement has been waived by such Holder,
as to
such Holder only, in unregistered shares of Common Stock which shall be valued
solely for such purpose at 90% of the average of the VWAPs for the 20
consecutive Trading Days ending on the Trading Day that is immediately prior
to
the Dividend Payment Date; and (v) if funds are not legally available for
the
payment of dividends and the Equity Conditions have not been met during the
20
consecutive Trading Days immediately prior to the applicable Dividend Payment
Date, then, at the election of such Holder, such dividends shall accrue to
the
next Dividend Payment Date or shall be accreted to, and increase, the
outstanding Stated Value. The Holders shall have the same rights and
remedies with respect to the delivery of any such shares as if such shares
were
being issued pursuant to Section 6. On the Closing Date the
Corporation shall have notified the Holders whether or not it may legally
pay
cash dividends as of the Closing Date. The Corporation shall promptly
notify the Holders at any time the Corporation shall become able or unable,
as
the case may be, to legally pay cash dividends. If at any time the
Corporation has the right to pay dividends in cash or Common Stock, the
Corporation must provide the Holders with at least 20 Trading Days’ notice of
its election to pay a regularly scheduled dividend in Common Stock (the
Corporation may indicate in such notice that the election contained in such
notice shall continue for later periods until revised by a subsequent
notice). Dividends on the Preferred Stock shall be calculated on the
basis of a 360-day year, consisting of twelve 30 calendar day periods, shall
accrue daily commencing on the Original Issue Date, and shall be deemed to
accrue from such date whether or not earned or declared and whether or not
there
are profits, surplus or other funds of the Corporation legally available
for the
payment of dividends. Except as otherwise provided herein, if at any
time the Corporation pays dividends partially in cash and partially in shares,
then such payment shall be distributed ratably among the Holders based upon
the
number of shares of Preferred Stock held by each Holder on such Dividend
Payment
Date. Any dividends, whether paid in cash or shares of Common Stock,
that are not paid within three Trading Days following a Dividend Payment
Date
shall continue to accrue and shall entail a late fee, which must be paid
in
cash, at the rate of 18% per annum or the lesser rate permitted by applicable
law (such fees to accrue daily, from the Dividend Payment Date through and
including the date of payment). If at any time the Corporation
delivers a notice to the Holders of its election to pay the dividends in
shares
of Common Stock, the Corporation shall timely file a prospectus supplement
pursuant to Rule 424 disclosing such election.
b) So
long as any Preferred Stock shall
remain outstanding, neither the Corporation nor any Subsidiary thereof shall
redeem, purchase or otherwise acquire directly or indirectly any Junior
Securities. So long as any Preferred Stock shall remain outstanding,
neither the Corporation nor any Subsidiary thereof shall directly or indirectly
pay or declare any dividend or make any distribution (other than a dividend
or
distribution described in Section 6 or dividends due and paid in the ordinary
course on preferred stock of the Corporation at such times when the Corporation
is in compliance with its payment and other obligations hereunder) upon,
nor
shall any distribution be made in respect of, any Junior Securities so long
as
any dividends due on the Preferred Stock remain unpaid, nor shall any monies
be
set aside for or applied to the purchase or redemption (through a sinking
fund
or otherwise) of any Junior Securities.
Section
4. Voting Rights. Except as otherwise provided
herein and as otherwise required by law, the Preferred Stock shall have no
voting rights. However, so long as any shares of Preferred Stock are
outstanding, the Corporation shall not, without the affirmative vote of the
Holders of at least 81% of the shares of the Preferred Stock then outstanding,
(a) alter or change adversely the powers, preferences or rights given to
the
Preferred Stock or alter or amend this Certificate of Designation, (b) authorize
or create any class of stock ranking as to dividends, redemption or distribution
of assets upon a Liquidation (as defined in Section 5) senior to or otherwise
pari passu with the Preferred Stock, (c) amend its articles of incorporation
or
other charter documents so as to affect adversely any rights of the Holders,
(d)
increase the authorized number of shares of Preferred Stock, or (e) enter
into
any agreement with respect to the foregoing.
Section
5. Liquidation. Upon any liquidation,
dissolution or winding-up of the Corporation, whether voluntary or involuntary
(a “Liquidation”), the Holders shall be entitled to receive out of the
assets of the Corporation, whether such assets are capital or surplus, for
each
share of Preferred Stock an amount equal to the Stated Value per share plus
any
accrued and unpaid dividends thereon and any other fees or liquidated damages
owing thereon before any distribution or payment shall be made to the holders
of
any Junior Securities, and if the assets of the Corporation shall be
insufficient to pay in full such amounts, then the entire assets to be
distributed to the Holders shall be distributed among the Holders ratably
in
accordance with the respective amounts that would be payable on such shares
if
all amounts payable thereon were paid in full, paripassu with the
Corporation’s Series A Convertible Preferred Stock and the Series B 9%
Convertible Preferred Stock treated together as a class based upon the
liquidation preferences of each such series. A Fundamental
Transaction or Change of Control Transaction shall not be treated as a
Liquidation. The Corporation shall mail written notice of any such
Liquidation, not less than 45 days prior to the payment date stated therein,
to
each record Holder.
Section
6. Conversion.
a) Conversions
at Option of
Holder. Each share of
Preferred
Stock shall be convertible into that number of shares of Common Stock (subject
to the limitations set forth in Sections 6(c)) determined by dividing the
Stated
Value of such share of Preferred Stock by the Conversion Price, at the option
of
the Holder, at any time and from time to time from and after the Original
Issue
Date. Holders shall effect conversions by providing the Corporation
with the form of conversion notice attached hereto as Annex A
(a “Notice of Conversion”). Each
Notice of
Conversion shall specify the number of shares of Preferred Stock to be
converted, the number of shares of Preferred Stock owned prior to the conversion
at issue, the number of shares of Preferred Stock owned subsequent to the
conversion at issue and the date on which such conversion is to be effected,
which date may not be prior to the date the Holder delivers such Notice of
Conversion to the Corporation by facsimile (the “Conversion Date”). If
no Conversion Date is
specified in a Notice of Conversion, the Conversion Date shall be the date
that
such Notice of Conversion to the Corporation is deemed delivered
hereunder. The calculations and entries set forth in the Notice of
Conversion shall control in the absence of manifest or mathematical
error. To effect conversions, as the case may be, of shares of
Preferred Stock, a Holder shall not be required to surrender the certificate(s)
representing such shares of Preferred Stock to the Corporation unless all
of the
shares of Preferred Stock represented thereby are so converted, in which
case
such Holder shall deliver the certificate representing such shares of Preferred
Stock promptly following the Conversion Date at issue. Shares of
Preferred Stock converted into Common Stock or redeemed in accordance with
the
terms hereof shall be canceled and may not be reissued.
b) Conversion
Price. The conversion price for the Preferred Stock shall equal
$0.48 per share for the holders of the Preferred Stock on the Plan Closing
Date
(the “Conversion Price”).
c) Beneficial
Ownership Limitation. The Corporation shall not effect any
conversion of the Preferred Stock, and a Holder shall not have the right
to
convert any portion of the Preferred Stock, to the extent that, after giving
effect to the conversion set forth on the applicable Notice of Conversion,
such
Holder (together with such Holder’s Affiliates, and any other Person or entity
acting as a group together with such Holder or any of such Holder’s Affiliates)
would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by such Holder and its Affiliates
shall include the number of shares of Common Stock issuable upon conversion
of
the Preferred Stock with respect to which such determination is being made,
but
shall exclude the number of shares of Common Stock which are issuable upon
(A)
conversion of the remaining, unconverted Stated Value of Preferred Stock
beneficially owned by such Holder or any of its Affiliates and (B) exercise
or
conversion of the unexercised or unconverted portion of any other securities
of
the Corporation subject to a limitation on conversion or exercise analogous
to
the limitation contained herein (including the Warrants) beneficially owned
by
such Holder or any of its Affiliates. Except as set forth in the
preceding sentence, for purposes of this Section 6(c), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act
and the
rules and regulations promulgated thereunder. To the extent that the limitation
contained in this Section 6(c) applies, the determination of whether the
Preferred Stock is convertible (in relation to other securities owned by
such
Holder together with any Affiliates) and of how many shares of Preferred
Stock
are convertible shall be in the sole discretion of such Holder, and the
submission of a Notice of Conversion shall be deemed to be such Holder’s
determination of whether the shares of Preferred Stock may be converted (in
relation to other securities owned by such Holder together with any Affiliates)
and how many shares of the Preferred Stock are convertible, in each case
subject
to such aggregate percentage limitations. To ensure compliance with this
restriction, each Holder will be deemed to represent to the Corporation each
time it delivers a Notice of Conversion that such Notice of Conversion has
not
violated the restrictions set forth in this paragraph and the Corporation
shall
have no obligation to verify or confirm the accuracy of such determination.
In
addition, a determination as to any group status as contemplated above shall
be
determined in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder. For purposes of this Section 6(c),
in
determining the number of outstanding shares of Common Stock, a Holder may
rely
on the number of outstanding shares of Common Stock as stated in the most
recent
of the following: (A) the Corporation’s most recent Form 10-QSB or Form 10-KSB,
as the case may be, (B) a more recent public announcement by the Corporation
or
(C) a more recent notice by the Corporation or the Corporation’s transfer agent
setting forth the number of shares of Common Stock outstanding. Upon
the written or oral request of a Holder, the Corporation shall within two
Trading Days confirm orally and in writing to such Holder the number of shares
of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect
to
the conversion or exercise of securities of the Corporation, including the
Preferred Stock, by such Holder or its Affiliates since the date as of which
such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of
Common
Stock issuable upon conversion of Preferred Stock held by the applicable
Holder.
The Beneficial Ownership Limitation provisions of this Section 6(c) may be
waived by such Holder, at the election of such Holder, upon not less than
61
days’ prior notice to the Corporation, to change the Beneficial Ownership
Limitation to 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock
upon
conversion of Preferred Stock held by the applicable Holder and the provisions
of this Section 6(c) shall continue to apply. Upon such a change by a Holder
of
the Beneficial Ownership Limitation from such 4.99% limitation to such 9.99%
limitation, the Beneficial Ownership Limitation shall not be further waived
by
such Holder. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section
6(c) to correct this paragraph (or any portion hereof) which may be defective
or
inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give
effect
to such limitation. The limitations contained in this paragraph shall apply
to a
successor holder of Preferred Stock. Notwithstanding anything set
forth in this Section 6(c), the 4.99% and 9.99% beneficial ownership limitations
imposed by this Section 6(c) shall not apply to Common Stock issuable upon
conversion of the Preferred Stock in connection with the Plan.
d) Mechanics
of
Conversion.
i. Delivery
of Certificate Upon
Conversion. Not later than
three
Trading Days after each Conversion Date (the “Share Delivery
Date”), the Corporation
shall deliver to
the Holder (A) a certificate or certificates which, after the Effective Date,
shall be free of restrictive legends and trading restrictions (other than
those
required by the Purchase Agreement) representing the number of shares of
Common
Stock being acquired upon the conversion of shares of Preferred Stock, and
(B) a
bank check in the amount of accrued and unpaid dividends (if the Corporation
has
elected or is required to pay accrued dividends in cash). After the
Effective Date, the Corporation shall, upon request of the Holder, deliver
any
certificate or certificates required to be delivered by the Corporation under
this Section electronically through the Depository Trust Company or another
established clearing corporation performing similar functions if the
Corporation’s transfer agent is a participant in such system. If in
the case of any Notice of Conversion such certificate or certificates are
not
delivered to or as directed by the applicable Holder by the third Trading
Day
after the Conversion Date, the Holder shall be entitled to elect by written
notice to the Corporation at any time on or before its receipt of such
certificate or certificates thereafter, to rescind such conversion, in which
event the Corporation shall immediately return the certificates representing
the
shares of Preferred Stock tendered for conversion.
ii. Obligation
Absolute; Partial
Liquidated Damages. The Corporation’s
obligation to issue and deliver the Conversion Shares upon conversion of
Preferred Stock in accordance with the terms hereof are absolute and
unconditional, irrespective of any action or inaction by a Holder to enforce
the
same, any waiver or consent with respect to any provision hereof, the recovery
of any judgment against any Person or any action to enforce the same, or
any
setoff, counterclaim, recoupment, limitation or termination, or any breach
or
alleged breach by such Holder or any other Person of any obligation to the
Corporation or any violation or alleged violation of law by such Holder or
any
other Person, and irrespective of any other circumstance which might otherwise
limit such obligation of the Corporation to such Holder in connection with
the
issuance of such Conversion Shares; provided,
however,
that such delivery shall not operate
as a waiver by the Corporation of any such action that the Corporation may
have
against such Holder. In the event a Holder shall elect to convert any
or all of the Stated Value of its Preferred Stock, the Corporation may not
refuse conversion based on any claim that such Holder or any one associated
or
affiliated with such Holder has been engaged in any violation of law, agreement
or for any other reason, unless an injunction from a court, on notice to
Holder,
restraining and/or enjoining conversion of all or part of the Preferred Stock
of
such Holder shall have been sought and obtained, and the Corporation posts
a
surety bond for the benefit of such Holder in the amount of 150% of the Stated
Value of Preferred Stock which is subject to the injunction, which bond shall
remain in effect until the completion of arbitration/litigation of the
underlying dispute and the proceeds of which shall be payable to such Holder
to
the extent it obtains judgment. In the absence of such injunction,
the Corporation shall issue Conversion Shares and, if applicable, cash, upon
a
properly noticed conversion. If the Corporation fails to deliver to a
Holder such certificate or certificates pursuant to Section 6(e)(i) on the
second Trading Day after the Share Delivery Date applicable to such conversion,
the Corporation shall pay to such Holder, in cash, as liquidated damages
and not
as a penalty, for each $5,000 of Stated Value of Preferred Stock being
converted, $50 per Trading Day (increasing to $100 per Trading Day after
the
third Trading Day and increasing to $200 per Trading Day after the sixth
Trading
Day after such damages begin to accrue) for each Trading Day after such second
Trading Day after the Share Delivery Date until such certificates are
delivered. Nothing herein shall limit a Holder’s right to pursue
actual damages or declare a Triggering Event pursuant to Section 9 for the
Corporation’s failure to deliver Conversion Shares within the period specified
herein and such Holder shall have the right to pursue all remedies available
to
it hereunder, at law or in equity including, without limitation, a decree
of
specific performance and/or injunctive relief. The Exercise of any
such rights shall not prohibit a Holder from seeking to enforce damages pursuant
to any other Section hereof or under applicable law.
iii. Compensation
for Buy-In on Failure
to Timely Deliver Certificates Upon Conversion. If the Corporation
fails
to deliver to a Holder the applicable certificate or certificates by the
Share
Delivery Date pursuant to Section 6(e)(i), and if after such Share Delivery
Date
such Holder is required by its brokerage firm to purchase (in an open market
transaction or otherwise), or the Holder’s brokerage firm purchases, shares of
Common Stock to deliver in satisfaction of a sale by such Holder of the
Conversion Shares which such Holder was entitled to receive upon the conversion
relating to such Share Delivery Date (a “Buy-In”),
then the Corporation shall (A) pay
in cash to such Holder (in addition to any other remedies available to or
elected by such Holder) the amount by which (x) such Holder’s total purchase
price (including any brokerage commissions) for the shares of Common Stock
so
purchased exceeds (y) the product of (1) the aggregate number of shares of
Common Stock that such Holder was entitled to receive from the conversion
at
issue multiplied by (2) the actual sale price at which the sell order giving
rise to such purchase obligation was executed (including any brokerage
commissions) and (B) at the option of such Holder, either reissue (if
surrendered) the shares of Preferred Stock equal to the number of shares
of
Preferred Stock submitted for conversion or deliver to such Holder the number
of
shares of Common Stock that would have been issued if the Corporation had timely
complied with its delivery requirements under Section 6(e)(i). For
example, if a Holder purchases shares of Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted conversion
of
shares of Preferred Stock with respect to which the actual sale price (including
any brokerage commissions) giving rise to such purchase obligation was a
total
of $10,000 under clause (A) of the immediately preceding sentence, the
Corporation shall be required to pay such Holder $1,000. The Holder
shall provide the Corporation written notice indicating the amounts payable
to
such Holder in respect of the Buy-In and, upon request of the Corporation,
evidence of the amount of such loss. Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance
and/or
injunctive relief with respect to the Corporation’s failure to timely deliver
certificates representing shares of Common Stock upon conversion of the shares
of Preferred Stock as required pursuant to the terms hereof.
iv. Reservation
of Shares Issuable Upon
Conversion. The Corporation
covenants
that it will at all times reserve and keep available out of its authorized
and
unissued shares of Common Stock solely for the purpose of issuance upon
conversion of the Preferred Stock and payment of dividends for three years
from
any point in time on the Preferred Stock, each as herein provided, free from
preemptive rights or any other actual contingent purchase rights of Persons
other than the Holders, not less than such number of shares of the Common
Stock
as shall (subject to any additional requirements of the Corporation as to
reservation of such shares set forth in the Purchase Agreement) be issuable
(taking into account the adjustments and restrictions of Section 7) upon
the
conversion of all outstanding shares of Preferred Stock. The
Corporation covenants that all shares of Common Stock that shall be so issuable
shall, upon issue, be duly and validly authorized, issued and fully paid,
nonassessable and, if the Conversion Shares Registration Statement is then
effective under the Securities Act, registered for public sale in accordance
with such Conversion Shares Registration Statement.
v. Fractional
Shares. Upon a conversion
hereunder, the Corporation shall not be required to issue stock certificates
representing fractions of shares of Common Stock, but may if otherwise
permitted, make a cash payment in respect of any final fraction of a share
based
on the VWAP at such time. If the Corporation elects not, or is
unable, to make such a cash payment, the Holders shall be entitled to receive,
in lieu of the final fraction of a share, one whole share of Common
Stock.
vi. Transfer
Taxes. The issuance of
certificates for shares of the Common Stock on conversion of the Preferred
Stock
shall be made without charge to the Holders thereof for any documentary stamp
or
similar taxes that may be payable in respect of the issue or delivery of
such
certificates, provided that the Corporation shall not be required to pay
any tax
that may be payable in respect of any transfer involved in the issuance and
delivery of any such certificate upon conversion in a name other than that
of
the Holders of such shares of Preferred Stock so converted and the Corporation
shall not be required to issue or deliver such certificates unless or until
the
Person or Persons requesting the issuance thereof shall have paid to the
Corporation the amount of such tax or shall have established to the satisfaction
of the Corporation that such tax has been paid.
Section
7. Certain Adjustments.
a) Stock
Dividends and Stock
Splits. If
the Corporation, at any time while this Preferred Stock is outstanding: (A)
pays
a stock dividend or otherwise makes a distribution or distributions payable
in
shares of Common Stock on shares of Common Stock or any other Common Stock
Equivalents (which, for avoidance of doubt, shall not include any shares
of
Common Stock issued by the Corporation upon conversion of, or payment of
a
dividend on, this Preferred Stock, the Series A Convertible Preferred Stock
or
the Series B 9% Convertible Preferred Stock); (B) subdivides outstanding
shares
of Common Stock into a larger number of shares; (C) combines (including by
way
of a reverse stock split) outstanding shares of Common Stock into a smaller
number of shares; or (D) issues, in the event of a reclassification of shares
of
the Common Stock, any shares of capital stock of the Corporation, then the
Conversion Price shall be multiplied by a fraction of which the numerator
shall
be the number of shares of Common Stock (excluding any treasury shares of
the
Corporation) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to this
Section 7(a) shall become effective immediately after the record date for
the
determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case
of a
subdivision, combination or re-classification.
b) Subsequent
Equity Sales. If, at any time while this Preferred Stock is
outstanding, the Corporation or any Subsidiary, as applicable, sells or grants
any option to purchase or sells or grants any right to reprice its securities,
or otherwise disposes of or issues (or announces any sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock at an effective price
per
share that is lower than the then Conversion Price (such lower price, the
“Base Conversion Price” and such issuances collectively, a “Dilutive
Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so
issued shall at any time, whether by operation of purchase price adjustments,
reset provisions, floating conversion, exercise or exchange prices or otherwise,
or due to warrants, options or rights per share which are issued in connection
with such issuance, be entitled to receive shares of Common Stock at an
effective price per share that is lower than the Conversion Price, such issuance
shall be deemed to have occurred for less than the Conversion Price on such
date
of the Dilutive Issuance), then the Conversion Price shall be reduced to
equal
the Base Conversion Price. Notwithstanding the foregoing, no
adjustment will be made under this Section 7(b) in respect of an Exempt
Issuance. The Corporation shall notify the Holders in writing, no
later than the Business Day following the issuance of any Common Stock or
Common
Stock Equivalents subject to this Section 7(b), indicating therein the
applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the “Dilutive Issuance
Notice”). For purposes of clarification, whether or not the
Corporation provides a Dilutive Issuance Notice pursuant to this Section
7(b),
upon the occurrence of any Dilutive Issuance, the Holders are entitled to
receive a number of Conversion Shares based upon the Base Conversion Price
on or
after the date of such Dilutive Issuance, regardless of whether a Holder
accurately refers to the Base Conversion Price in the Notice of
Conversion.
c) Subsequent
Rights
Offerings. If the Corporation,
at any
time while the Preferred Stock is outstanding, shall issue rights, options
or
warrants to all holders of Common Stock (and not to Holders) entitling them
to
subscribe for or purchase shares of Common Stock at a price per share less
than
the VWAP at the record date mentioned below, then the Conversion Price shall
be
multiplied by a fraction, of which the denominator shall be the number of
shares
of the Common Stock outstanding on the date of issuance of such rights or
warrants plus the number of additional shares of Common Stock offered for
subscription or purchase, and of which the numerator shall be the number
of
shares of the Common Stock outstanding on the date of issuance of such rights
or
warrants plus the number of shares which the aggregate offering price of
the
total number of shares so offered (assuming receipt by the Corporation in
full
of all consideration payable upon exercise of such rights, options or warrants)
would purchase at such VWAP. Such adjustment shall be made whenever
such rights or warrants are issued, and shall become effective immediately
after
the record date for the determination of stockholders entitled to receive
such
rights, options or warrants.
d) Pro
Rata
Distributions. If the Corporation,
at any
time while Preferred Stock is outstanding, shall distribute to all holders
of
Common Stock (and not to Holders) evidences of its indebtedness or assets
or
rights or warrants to subscribe for or purchase any security, then in each
such
case the Conversion Price shall be determined by multiplying such Conversion
Price in effect immediately prior to the record date fixed for determination
of
stockholders entitled to receive such distribution by a fraction of which
the
denominator shall be the VWAP determined as of the record date mentioned
above,
and of which the numerator shall be such VWAP on such record date less the
then
fair market value at such record date of the portion of such assets or evidence
of indebtedness so distributed applicable to one outstanding share of the
Common
Stock as determined by the Board of Directors in good faith. In
either case the adjustments shall be described in a statement provided to
the
Holders of the portion of assets or evidences of indebtedness so distributed
or
such subscription rights applicable to one share of Common
Stock. Such adjustment shall be made whenever any such distribution
is made and shall become effective immediately after the record date mentioned
above.
e) Fundamental
Transaction. If, at any time
while this
Preferred Stock is outstanding, (A) the Corporation effects any merger or
consolidation of the Corporation with or into another Person, (B) the
Corporation effects any sale of all or substantially all of its assets in
one or
a series of related transactions, (C) any tender offer or exchange offer
(whether by the Corporation or another Person) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares
for
other securities, cash or property, or (D) the Corporation effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for
other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then
upon any subsequent conversion of this Preferred Stock, the Holders shall
have
the right to receive, for each Conversion Share that would have been issuable
upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the same kind and amount of securities, cash or property as
it
would have been entitled to receive upon the occurrence of such Fundamental
Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of one share of Common Stock (the “Alternate
Consideration”). For purposes of
any such
conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock
in such
Fundamental Transaction, and the Corporation shall apportion the Conversion
Price among the Alternate Consideration in a reasonable manner reflecting
the
relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to
the securities, cash or property to be received in a Fundamental Transaction,
then the Holders shall be given the same choice as to the Alternate
Consideration it receives upon any conversion of this Preferred Stock following
such Fundamental Transaction. To the extent necessary to effectuate
the foregoing provisions, any successor to the Corporation or surviving entity
in such Fundamental Transaction shall file a new Certificate of Designation
with
the same terms and conditions and issue to the Holders new preferred stock
consistent with the foregoing provisions and evidencing the Holders’ right to
convert such preferred stock into Alternate Consideration. The terms
of any agreement pursuant to which a Fundamental Transaction is effected
shall
include terms requiring any such successor or surviving entity to comply
with
the provisions of this Section 7(e) and insuring that this Preferred Stock
(or
any such replacement security) will be similarly adjusted upon any subsequent
transaction analogous to a Fundamental Transaction.
f) Exempt
Issuance. Notwithstanding the foregoing, no adjustment will be
made under this Section 7 in respect of an Exempt Issuance.
g) Calculations. All
calculations under
this Section 7 shall be made to the nearest cent or the nearest 1/100th of
a
share, as the case may be. The number of shares of Common Stock
outstanding at any given time shall not include shares owned or held by or
for
the account of the Corporation, and the description of any such shares of
Common
Stock shall be considered on issue or sale of Common Stock. For
purposes of this Section 7, the number of shares of Common Stock deemed to
be
issued and outstanding as of a given date shall be the sum of the number
of
shares of Common Stock (excluding treasury shares, if any) issued and
outstanding.
h) Notice
to Holders.
i. Adjustment
to Conversion
Price. Whenever the Conversion
Price is adjusted pursuant to any provisions of this Section 7, the Corporation
shall promptly mail to each Holder a notice setting forth the Conversion
Price
after such adjustment and setting forth a brief statement of the facts requiring
such adjustment. If the Corporation issues a variable rate security,
despite the prohibition thereon in the Purchase Agreement (or other Securities
Purchase Agreement if applicable to a Holder), the Corporation shall be deemed
to have issued Common Stock or Common Stock Equivalents at the lowest possible
conversion or exercise price at which such securities may be converted or
exercised in the case of a Variable Rate Transaction (as defined in the Purchase
Agreement), or the lowest possible adjustment price in the case of an MFN
Transaction (as defined in the Purchase Agreement).
ii. Notice
to Allow Conversion by
Holder. If
(A) the Corporation shall declare a dividend (or any other distribution)
on the
Common Stock; (B) the Corporation shall declare a special nonrecurring cash
dividend on or a redemption of the Common Stock; (C) the Corporation shall
authorize the granting to all holders of the Common Stock rights or warrants
to
subscribe for or purchase any shares of capital stock of any class or of
any
rights; (D) the approval of any stockholders of the Corporation shall be
required in connection with any reclassification of the Common Stock, any
consolidation or merger to which the Corporation is a party, any sale or
transfer of all or substantially all of the assets of the Corporation, of
any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Corporation shall authorize the voluntary
or involuntary dissolution, liquidation or winding up of the affairs of the
Corporation; then, in each case, the Corporation shall cause to be filed
at each
office or agency maintained for the purpose of conversion of the Preferred
Stock, and shall cause to be mailed to the Holders at their last addresses
as
they shall appear upon the stock books of the Corporation, at least 20 calendar
days prior to the applicable record or effective date hereinafter specified,
a
notice stating (x) the date on which a record is to be taken for the purpose
of
such dividend, distribution, redemption, rights or warrants, or if a record
is
not to be taken, the date as of which the holders of the Common Stock of
record
to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders
of the
Common Stock of record shall be entitled to exchange their shares of the
Common
Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange;
provided,
that the failure to mail such notice
or any defect therein or in the mailing thereof shall not affect the validity
of
the corporate action required to be specified in such notice. Holders
are entitled to convert the Conversion Amount of Preferred Stock during the
20-day period commencing the date of such notice to the effective date of
the
event triggering such notice.
Section
8. Forced Conversion.
a) As
used herein, the “Forced Conversion Date” shall be the Plan Closing
Date.
b) One
minute after this Second Amended and Restated Certificate is effective with
the
Nevada Secretary of State (the "Conversion Time") on the Forced Conversion
Date,
each share of Preferred Stock outstanding, automatically and without any
action
on the part of the holder thereof, shall convert into a number of fully paid
and
nonassessable shares of Common Stock equal to the quotient of (i) the Stated
Value of the shares of Preferred Stock outstanding on the Forced Conversion
Date
divided by (ii) the Conversion Price in effect at the Conversion Time on
the
Forced Conversion Date. Any accrued but unpaid dividends on the
Preferred Stock outstanding at the Conversion Time on the Forced Conversion
Date
will be issued by the Company at the Conversion Time on the Forced Conversion
Date in shares of Common Stock, with the number of shares of Common Stock
to be
issued equal to the quotient of (i) the accrued unpaid dividend divided by
(ii)
the Conversion Price in effect at the Conversion Time on the Forced Conversion
Date.
c) As
soon as practicable after the Forced Conversion Date, the Corporation will
send
a notice to all Holders stating (i) the date as of which the Forced Conversion
Date occurred, and (ii) how many shares of Common Stock the Holder’s Preferred
Stock was converted into.
Section
9. Redemption Upon Triggering Events.
a) “Triggering
Event” means any one
or more of the
following events (whatever the reason and whether it shall be voluntary or
involuntary or effected by operation of law or pursuant to any judgment,
decree
or order of any court, or any order, rule or regulation of any administrative
or
governmental body):
i. the
failure of a Conversion Shares
Registration Statement to be declared effective by the Commission on or prior
to
the 210th
day after the Original Issue
Date;
ii. if,
during the Effectiveness Period,
the effectiveness of the Conversion Shares Registration Statement lapses
for any
reason for more than an aggregate of 25 calendar days (which need not be
consecutive days) during any 12 month period, or the Holder shall not be
permitted to resell Registrable Securities under the Conversion Shares
Registration Statement for more than an aggregate of 25 calendar days (which
need not be consecutive days) during any 12 month period, and in each case
the
shares of Common Stock into which such Holder’s Preferred Stock can be converted
cannot be sold in the public securities market pursuant to Rule 144(k) under
the
Securities Act, provided, that the cause of such lapse or unavailability
is not
due to factors solely within the control of such holder of Preferred
Stock;
iii. the
Corporation shall fail to deliver
certificates representing Conversion Shares issuable upon a conversion hereunder
that comply with the provisions hereof prior to the 9th
Trading Day after such shares are
required to be delivered hereunder, or the Corporation shall provide written
notice to any Holder, including by way of public announcement, at any time,
of
its intention not to comply with requests for conversion of any shares of
Preferred Stock in accordance with the terms hereof;
iv. one
of the Events (as defined in the
Registration Rights Agreement) described in subsections (i), (ii) or (iii)
of
Section 2(b) of the Registration Rights Agreement shall not have been cured
to
the satisfaction of the Holders prior to the expiration of 30 days from the
Event Date (as defined in the Registration Rights Agreement) relating thereto
(other than an Event resulting from a failure of a Conversion Shares
Registration Statement to be declared effective by the Commission on or prior
to
the 210th day after the Original Issue Date, which shall be covered by Section
9(a)(i));
v. the
Corporation shall fail for any
reason to pay in full the amount of cash due pursuant to a Buy-In within
15 days
after notice therefor is delivered hereunder or shall fail to pay all amounts
owed on account of an Event within 15 days of the date due;
vi. the
Corporation shall fail to have
available a sufficient number of authorized and unreserved shares of Common
Stock to issue to such Holder upon a conversion hereunder;
vii. the
Corporation shall fail to observe
or perform any other covenant, agreement or warranty contained in, or otherwise
commit any breach of the Transaction Documents, and such failure or breach
shall
not, if subject to the possibility of a cure by the Corporation, have been
remedied within 30 calendar days after the date on which written notice of
such
failure or breach shall have been given;
viii. the
Corporation shall redeem more than
a de minimis
number of Junior Securities other than
as to repurchases of Common Stock or Common Stock Equivalents from departing
officers and directors of the Corporation, provided that, while any of the
Preferred Stock remains outstanding, such repurchases shall not exceed an
aggregate of $100,000 from all officers and directors;
ix. the
Corporation shall be party to a
Change of Control Transaction;
x. there
shall have occurred a Bankruptcy
Event; or
xi. the
Common Stock shall fail to be
listed or quoted for trading on a Trading Market for more than 7 Trading
Days,
which need not be consecutive Trading Days.
b) Upon
the occurrence of a Triggering
Event, each Holder shall (in addition to all other rights it may have hereunder
or under applicable law) have the right, exercisable at the sole option of
such
Holder, to require the Corporation to redeem all of the Preferred Stock then
held by such Holder for a redemption price, in cash, equal to the Triggering
Redemption Amount. The Triggering Redemption Amount shall be due and
payable within 5 Trading Days of the date on which the notice for the payment
therefor is provided by a Holder (the “Triggering Redemption
Payment
Date”). If
the Corporation fails to pay the Triggering Redemption Amount hereunder in
full
pursuant to this Section on the date such amount is due in accordance with
this
Section, the Corporation will pay interest thereon at a rate of 18% per annum
(or such lesser amount permitted by applicable law), accruing daily from
such
date until the Triggering Redemption Amount, plus all such interest thereon,
is
paid in full. For purposes of this Section, a share of Preferred
Stock is outstanding until such date as the Holder shall have received
Conversion Shares upon a conversion (or attempted conversion) thereof that
meets
the requirements hereof or has been paid the Triggering Redemption Amount
plus
all accrued but unpaid dividends and all accrued but unpaid liquidated damages
in cash.
Section
10. Miscellaneous.
a) No
Debt. So long as at
least 5 shares of
Preferred Stock are outstanding, the Corporation will not and will not permit
any of its Subsidiaries to directly or indirectly enter into, create, incur,
assume or suffer to exist (or allow any of its Subsidiaries to do so) any
indebtedness or liens of any kind on or with respect to any of its property
or
assets now owned or hereafter acquired or any interest therein or any income
or
profits therefrom, other than (1) accounts payable, equipment leases, other
current payables and other accrued liabilities incurred in connection with
short-term operating liabilities, (2) accrued interest on the Corporation’s
existing indebtedness as set forth on Schedule 10 hereto, and (3) up to
$2,000,000 for non-equity linked debt financing.
b) Notices. Any
and all notices or
other communications or deliveries to be provided by the Holders hereunder,
including, without limitation, any Notice of Conversion, shall be in writing
and
delivered personally, by facsimile, sent by a nationally recognized overnight
courier service, addressed to the Corporation, at the address set forth above,
facsimile number 631-924-6033,
Attn: Chief
Financial Officer, Richard Larkin such other
address or facsimile number
as the Corporation may specify for such purposes by notice to the Holders
delivered in accordance with this Section. Any and all notices or
other communications or deliveries to be provided by the Corporation hereunder
shall be in writing and delivered personally, by facsimile, sent by a nationally
recognized overnight courier service addressed to each Holder at the facsimile
telephone number or address of such Holder appearing on the books of the
Corporation, or if no such facsimile telephone number or address appears,
at the
principal place of business of the Holder. Any notice or other
communication or deliveries hereunder shall be deemed given and effective
on the
earliest of (i) the date of transmission, if such notice or communication
is
delivered via facsimile at the facsimile telephone number specified in this
Section prior to 5:30 p.m. (New York City time), (ii) the date after the
date of
transmission, if such notice or communication is delivered via facsimile
at the
facsimile telephone number specified in this Section later than 5:30 p.m.
(New
York City time) on any date and earlier than 11:59 p.m. (New York City time)
on
such date, (iii) the second Business Day following the date of mailing, if
sent
by nationally recognized overnight courier service, or (iv) upon actual receipt
by the party to whom such notice is required to be given.
c) Absolute
Obligation. Except as expressly
provided herein, no provision of this Certificate of Designation shall alter
or
impair the obligation of the Corporation, which is absolute and unconditional,
to pay the liquidated damages (if any) on, the shares of Preferred Stock
at the
time, place, and rate, and in the coin or currency, herein
prescribed.
d) Lost
or Mutilated Preferred Stock
Certificate. If a Holder’s Preferred
Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation
shall execute and deliver, in exchange and substitution for and upon
cancellation of a mutilated certificate, or in lieu of or in substitution
for a
lost, stolen or destroyed certificate, a new certificate for the shares of
Preferred Stock so mutilated, lost, stolen or destroyed but only upon receipt
of
evidence of such loss, theft or destruction of such certificate, and of the
ownership hereof, and indemnity, if requested, all reasonably satisfactory
to
the Corporation.
e) Governing
Law. All questions
concerning
the construction, validity, enforcement and interpretation of this Certificate
of Designation shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all
legal proceedings concerning the interpretations, enforcement and defense
of the
transactions contemplated by any of the Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers,
shareholders, employees or agents) shall be commenced in the state and federal
courts sitting in the City of New York, Borough of Manhattan (the “New York Courts”). Each
party hereto hereby
irrevocably submits to the exclusive jurisdiction of the New York Courts
for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect
to
the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court,
or such
New York Courts are improper or inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address
in
effect for notices to it under this Certificate of Designation and agrees
that
such service shall constitute good and sufficient service of process and
notice
thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve process in any manner permitted by law. Each party
hereto hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out
of
or relating to this Certificate of Designation or the transactions contemplated
hereby. If either party shall commence an action or proceeding to
enforce any provisions of this Certificate of Designation, then the prevailing
party in such action or proceeding shall be reimbursed by the other party
for
its attorneys fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.
f) Waiver. Any
waiver by the
Corporation or the Holder of a breach of any provision of this Certificate
of
Designation shall not operate as or be construed to be a waiver of any other
breach of such provision or of any breach of any other provision of this
Certificate of Designation. The failure of the Corporation or the
Holder to insist upon strict adherence to any term of this Certificate of
Designation on one or more occasions shall not be considered a waiver or
deprive
that party of the right thereafter to insist upon strict adherence to that
term
or any other term of this Certificate of Designation. Any waiver must
be in writing.
g) Severability. If
any provision of this
Certificate of Designation is invalid, illegal or unenforceable, the balance
of
this Certificate of Designation shall remain in effect, and if any provision
is
inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances. If it shall be
found that any interest or other amount deemed interest due hereunder violates
applicable laws governing usury, the applicable rate of interest due hereunder
shall automatically be lowered to equal the maximum permitted rate of
interest.
h) Next
Business Day. Whenever any payment
or
other obligation hereunder shall be due on a day other than a Business Day,
such
payment shall be made on the next succeeding Business Day.
i) Headings. The
headings contained
herein are for convenience only, do not constitute a part of this Certificate
of
Designation and shall not be deemed to limit or affect any of the provisions
hereof.
j) Status
of Converted or Redeemed
Preferred Stock. Shares of Preferred
Stock
may only be issued if permitted pursuant to the Purchase
Agreement. If any shares of Preferred Stock shall be converted,
redeemed or reacquired by the Corporation, such shares shall resume the status
of authorized but unissued shares of preferred stock and shall no longer
be
designated as Series C 7% Convertible Preferred Stock.
*********************
RESOLVED,
FURTHER, that the Chairman, the president or any vice-president, the Chief
Financial Officer and the secretary or any assistant secretary, of the
Corporation be and they hereby are authorized and directed to prepare and
file a
Restated and Amended Certificate of Designation of Preferences, Rights and
Limitations in accordance with the foregoing resolution and the provisions
of
the Nevada Revised Statutes.
IN
WITNESS WHEREOF, the undersigned have executed this Certificate this 19th
day of
December, 2007.
__________________________
Richard
J. Larkin
Title:
Chief Financial Officer
ANNEX
A
NOTICE
OF
CONVERSION
(TO
BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF PREFERRED
STOCK)
The
undersigned hereby elects to convert the number of shares of Series C 7%
Convertible Preferred Stock indicated below, into shares of common stock,
par
value $0.01 per share (the “Common Stock”), of Chembio Diagnostics, Inc.,
a Nevada corporation (the “Corporation”), according to the conditions
hereof, as of the date written below. If shares are to be issued in
the name of a Person other than undersigned, the undersigned will pay all
transfer taxes payable with respect thereto and is delivering herewith such
certificates and opinions as reasonably requested by the Corporation in
accordance therewith. No fee will be charged to the Holder for any
conversion, except for such transfer taxes, if any.
Conversion
calculations:
Date
to Effect Conversion:
_____________________________________________
|
Number
of shares of Preferred Stock owned prior to Conversion:
_______________
|
Number
of shares of Preferred Stock to be Converted:
________________________
|
Stated
Value of shares of Preferred Stock to be Converted:
____________________
|
Number
of shares of Common Stock to be Issued:
___________________________
|
Applicable
Conversion
Price:____________________________________________
|
Number
of shares of Preferred Stock subsequent to Conversion:
________________
|
[HOLDER]
By:___________________________________
Name:
Title:
|
ex4_16.htm
Exhibit
4.16
EXHIBIT
C
NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE
HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR
OTHER LOAN SECURED BY SUCH SECURITIES.
COMMON
STOCK PURCHASE WARRANT
To
Purchase _________ Shares of Common Stock of
CHEMBIO
DIAGNOSTICS, INC.
Original
Date of Issuance: ____________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: ________________
|
Expires: _________________
|
THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value
received, ___________(the “Holder”), is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set
forth,
at any time on or after the original date of issuance (the “Initial Exercise
Date”) and on or prior to the close of business on the fifth anniversary of
the Initial Exercise Date (the “Termination Date”) but not thereafter, to
subscribe for and purchase from Chembio Diagnostics, Inc., a Nevada corporation
(the “Company”), up to __________ (__________) shares (the “Warrant
Shares”) of Common Stock, par value $0.01 per share, of the Company (the
“Common Stock”). The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined
in
Section 2(b).
Section
1. Definitions. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth
in
that certain Securities Purchase Agreement (the “Purchase Agreement”),
dated October 5, 2006, among the Company and the purchasers
signatory thereto.
Section
2. Exercise.
(a) Exercise
of the purchase rights represented by this Warrant may be made, in whole
or in
part, at any time or times on or after the Initial Exercise Date and on or
before the Termination Date by delivery to the Company of a duly executed
facsimile copy of the Notice of Exercise Form annexed hereto (or such other
office or agency of the Company as it may designate by notice in writing
to the
registered Holder at the address of such Holder appearing on the books of
the
Company); and, within 3 Trading Days of the date said Notice of Exercise
is
delivered to the Company, the Company shall have received payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer
or
cashier’s check drawn on a United States bank. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all
of the
Warrant Shares available hereunder and the Warrant has been exercised in
full,
in which case, the Holder shall surrender this Warrant to the Company for
cancellation within 3 Trading Days of the date the final Notice of Exercise
is
delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number
of
Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of
Exercise Form within 1 Business Day of receipt of such notice. In the
event of any dispute or discrepancy, the records of the Holder shall be
controlling and determinative in the absence of manifest error. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase
of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated
on
the face hereof.
(b) The
exercise price of the Common Stock under this Warrant shall be as follows,
subject to adjustment hereunder (the “Exercise Price”):
(i) For
the period 4:01p.m. eastern time (“ET”) through 9:59p.m. ET on the Plan
Closing Date, $0.40 per share for all or any portion of this Warrant exercised
for cash;
(ii) For
the period 4:01p.m. ET through 9:59p.m. ET on the Plan Closing Date, $0.45
per
share for all or any portion of this Warrant exercised through a Cashless
Exercise;
(iii) For
the period beginning 10:00p.m. ET on the Plan Closing Date through 9:59p.m.
ET
on the Final Plan Date, $0.45 for all or any part of this Warrant exercised
by a
Holder who exercised at least 10% of all of such Holder’s warrants and options
for cash at the Plan Closing Date;
(iv) For
the period beginning 10:00p.m. ET on the Plan Closing Date, $1.00 per share
for
any Holder that did not exercise at least 10% of all of such Holder’s warrants
and options for cash at an exercise price of $0.40 per share at the Plan
Closing
Date; and
(v) For
the period beginning 10:00p.m. ET on the Final Plan Date, $1.00 per share
for
all or any portion of this Warrant that has not been exercised on or before
9:59p.m. ET on the Final Plan Date.
(c) Cashless
Exercise.
(i) At
the option of the Holder, this Warrant may be exercised by means of a “cashless
exercise” (a “Cashless Exercise”) in which the Holder shall be entitled
to receive a certificate for the number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:
(A)
= the
VWAP for the ten-Trading Day period that ends on the first Trading Day
immediately preceding the date of such election;
(B)
= the
applicable Exercise Price of this Warrant in effect on the date of exercise,
as
adjusted; and
(X)
= the
number of Warrant Shares issuable upon exercise of this Warrant in accordance
with the terms of this Warrant by means of a cash exercise rather than a
cashless exercise.
(ii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated on
the
Plan Closing Date received from a Holder who exercises its warrants on cashless
basis at $0.45 per share before 10:00p.m. ET on the Plan Closing Date, the
value
of (A) in the equation set forth in Section 2(c)(i) above shall be equal
to the
greater of $0.53 or the VWAP for the ten-Trading Day period that ends on
the
second Trading Day prior to the date of the Notice of Exercise
Form.
(iii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated between
and inclusive of the Plan Closing Date and the Final Plan Date received from
a
Holder who exercises at least 10% of all of such Holder's warrants and options
for cash before 10:00p.m. ET on the Plan Closing Date the value of (A) in
the
equation set forth in Section 2(c)(i) above shall be equal to the greater
of
$0.53 or the VWAP for the ten-Trading Day period that ends on the second
Trading
Day prior to the date of the Notice of Exercise Form. Any Exercise
Form dated on the Final Plan Date must be received by the Company within
five
Trading Days of the Final Plan Date to be effective.
(iv) Notwithstanding
anything herein to the contrary, a Holder who does not exercise (i) at least
10%
of all of such Holder's warrants and options issued by the Company for cash
at
an exercise price of $0.40 per share before 10:00p.m. ET on the Plan Closing
Date, or (ii) its warrants on cashless basis at $0.45 per share by 10:00p.m.
ET
on the Plan Closing Date, shall not be permitted to exercise its Warrants
on a
cashless basis pursuant to Section 2(c)(i) above until April 1,
2008.
(d) The
Company shall not effect any exercise of this Warrant, and a Holder shall
not
have the right to exercise any portion of this Warrant, pursuant to Section
2(c)
or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, such Holder
(together with such Holder’s Affiliates, and any other person or entity acting
as a group together with such Holder or any of such Holder’s Affiliates), as set
forth on the applicable Notice of Exercise, would beneficially own in excess
of
the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially
owned by such Holder and its Affiliates shall include the number of shares
of
Common Stock issuable upon exercise of this Warrant with respect to which
such
determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (A) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by such Holder or any of its
Affiliates and (B) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company (including, without limitation,
any other Preferred Stock or Warrants) subject to a limitation on conversion
or
exercise analogous to the limitation contained herein beneficially owned
by such
Holder or any of its affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(d)(i), beneficial ownership shall
be
calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder, it being acknowledged by a Holder
that
the Company is not representing to such Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and such Holder is solely
responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this
Section 2(d) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder together with any
Affiliates) and of which a portion of this Warrant is exercisable shall be
in
the sole discretion of a Holder, and the submission of a Notice of Exercise
shall be deemed to be each Holder’s determination of whether this Warrant is
exercisable (in relation to other securities owned by such Holder together
with
any Affiliates) and of which portion of this Warrant is exercisable, in each
case subject to such aggregate percentage limitation, and the Company shall
have
no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of
the
Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(d), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number
of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent
Form 10-QSB or Form 10-KSB, as the case may be, (y) a more recent public
announcement by the Company or (z) any other notice by the Company or the
Company’s Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the
Company shall within two Trading Days confirm orally and in writing to such
Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined
after
giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by such Holder or its Affiliates since the date as
of
which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be 4.99%
of the number of shares of the Common Stock outstanding immediately after
giving
effect to the issuance of shares of Common Stock issuable upon exercise of
this
Warrant. The Beneficial Ownership Limitation provisions of this
Section 2(d)(i) may be waived by such Holder, at the election of such Holder,
upon not less than 61 days’ prior notice to the Company to change the Beneficial
Ownership Limitation to 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of
Common
Stock upon exercise of this Warrant, and the provisions of this Section 2(d)
shall continue to apply. Upon such a change by a Holder of the
Beneficial Ownership Limitation from such 4.99% limitation to such 9.99%
limitation, the Beneficial Ownership Limitation may not be further waived
by
such Holder. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms
of
this Section 2(d)(i) to correct this paragraph (or any portion hereof) which
may
be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable
to
properly give effect to such limitation. The limitations contained in
this paragraph shall apply to a successor holder of this
Warrant. Notwithstanding anything set forth in this Section 2(d), the
4.99% and 9.99% beneficial ownership limitations imposed by this Section
2(d)
shall not apply to Common Stock issuable upon the exercise of Warrants in
connection with the Plan.
(e) Mechanics
of Exercise.
(i) Authorization
of Warrant Shares. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented
by this
Warrant will, upon exercise of the purchase rights represented by this Warrant,
be duly authorized, validly issued, fully paid and nonassessable and free
from
all taxes, liens and charges in respect of the issue thereof (other than
taxes
in respect of any transfer occurring contemporaneously with such
issue).
(ii) Delivery
of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the transfer agent of the Company to the
Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”)
system if the Company is a participant in such system, and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise
within
3 Trading Days from the delivery to the Company of the Notice of Exercise
Form,
surrender of this Warrant and payment of the aggregate Exercise Price as
set
forth above (“Warrant Share Delivery Date”). This Warrant
shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Warrant Shares shall be deemed to have
been issued, and Holder or any other person so designated to be named therein
shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Warrant has been exercised by payment to the
Company of the Exercise Price (or by cashless exercise, if permitted) and
all
taxes required to be paid by the Holder, if any, pursuant to Section 2(e)(vii)
prior to the issuance of such shares, have been paid.
(iii) Delivery
of New Warrants Upon Exercise. If this Warrant shall have been
exercised in part, the Company shall, at the time of delivery of the certificate
or certificates representing Warrant Shares, deliver to Holder a new Warrant
evidencing the rights of Holder to purchase the unpurchased Warrant Shares
called for by this Warrant, which new Warrant shall in all other respects
be
identical with this Warrant.
(iv) Rescission
Rights. If the Company fails to cause its transfer agent to
transmit to the Holder a certificate or certificates representing the Warrant
Shares pursuant to this Section 2(e)(iv) by the Warrant Share Delivery Date,
then the Holder will have the right to rescind such exercise.
(v) Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon
Exercise. In addition to any other rights available to the
Holder, if the Company fails to cause its transfer agent to transmit to the
Holder a certificate or certificates representing the Warrant Shares pursuant
to
an exercise on or before the Warrant Share Delivery Date, and if after such
date
the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases shares of
Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a
“Buy-In”), then the Company shall (1) pay in cash to the Holder the
amount by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the
amount obtained by multiplying (A) the number of Warrant Shares that the
Company
was required to deliver to the Holder in connection with the exercise at
issue
times (B) the price at which the sell order giving rise to such purchase
obligation was executed, and (2) at the option of the Holder, either reinstate
the portion of the Warrant and equivalent number of Warrant Shares for which
such exercise was not honored or deliver to the Holder the number of shares
of
Common Stock that would have been issued had the Company timely complied
with
its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to
cover
a Buy-In with respect to an attempted exercise of shares of Common Stock
with an
aggregate sale price giving rise to such purchase obligation of $10,000,
under
clause (1) of the immediately preceding sentence the Company shall be required
to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of
the
Buy-In, together with applicable confirmations and other evidence reasonably
requested by the Company. Nothing herein shall limit a Holder’s right
to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver
certificates representing shares of Common Stock upon exercise of the Warrant
as
required pursuant to the terms hereof.
(vi) No
Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise
be entitled to purchase upon such exercise, the Company shall pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price.
(vii) Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax
or
other incidental expense in respect of the issuance of such certificate,
all of
which taxes and expenses shall be paid by the Company, and such certificates
shall be issued in the name of the Holder or in such name or names as may
be
directed by the Holder; provided, however, that in the event
certificates for Warrant Shares are to be issued in a name other than the
name
of the Holder, this Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder; and the
Company may require, as a condition thereto, the payment of a sum sufficient
to
reimburse it for any transfer tax incidental thereto.
(viii) Closing
of Books. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
(f) For
purposes of this warrant, the term “Plan” shall mean any action the
Company takes, with any required approval of the holders thereof, on or before
the Final Plan Date as contemplated by the Plan Summary and accompanying
materials provided to holders on December 4, 2007, in connection with the
reduction or other modification of terms of the Company’s then-outstanding
preferred stock, warrants and options, including, but not limited to, actions
the Company takes to (i) facilitate the conversion of the Series A, B and
C
Convertible Preferred Stock; (ii) reduce the exercise price of any of the
Company’s outstanding warrants or options; (iii) offer the holders of the
Company’s warrants and options the opportunity to exercise such warrants and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
(g) “Plan
Closing Date” shall be December 19, 2007.
(h) “Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
Section
3. Certain
Adjustments.
(a) Stock
Dividends and Splits. If the Company, at any time while this
Warrant is outstanding: (A) pays a stock dividend or otherwise make a
distribution or distributions on shares of its Common Stock or any other
equity
or equity equivalent securities payable in shares of Common Stock (which,
for
avoidance of doubt, shall not include any shares of Common Stock issued by
the
Company upon exercise of this Warrant, the Company’s Series A Convertible
Preferred Stock, the Company’s Series B 9% Convertible Preferred Stock or the
Company’s Series C 7% Convertible Preferred Stock), (B) subdivides outstanding
shares of Common Stock into a larger number of shares, (C) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a
smaller
number of shares, or (D) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number
of shares of Common Stock outstanding immediately after such event and the
number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted. Any adjustment made pursuant to this Section 3(a) shall
become effective immediately after the record date for the determination
of
stockholders entitled to receive such dividend or distribution and shall
become
effective immediately after the effective date in the case of a subdivision,
combination or re-classification.
(b) Subsequent
Equity Sales. If the Company or any Subsidiary thereof, as
applicable, at any time while this Warrant is outstanding, shall offer, sell,
grant any option to purchase or offer, sell or grant any right to reprice
its
securities, or otherwise dispose of or issue (or announce any offer, sale,
grant
or any option to purchase or other disposition) any Common Stock or Common
Stock
Equivalents entitling any Person to acquire shares of Common Stock, at an
effective price per share less than the then Exercise Price (such lower price,
the “Base Share Price” and such issuances collectively, a “Dilutive
Issuance”), as adjusted hereunder (if the holder of the Common Stock or
Common Stock Equivalents so issued shall at any time, whether by operation
of
purchase price adjustments, reset provisions, floating conversion, exercise
or
exchange prices or otherwise, or due to warrants, options or rights per share
which are issued in connection with such issuance, be entitled to receive
shares
of Common Stock at an effective price per share which is less than the Exercise
Price, such issuance shall be deemed to have occurred for less than the Exercise
Price on such date of the Dilutive Issuance), then, the Exercise Price shall
be
reduced to equal the Base Share Price and the number of Warrant Shares issuable
hereunder shall be increased such that the aggregate Exercise Price payable
hereunder, after taking into account the decrease in the Exercise Price,
shall
be equal to the aggregate Exercise Price prior to such
adjustment. Such adjustment shall be made whenever such Common Stock
or Common Stock Equivalents are issued. The Company shall notify the
Holder in writing, no later than the Trading Day following the issuance of
any
Common Stock or Common Stock Equivalents subject to this section, indicating
therein the applicable issuance price, or of applicable reset price, exchange
price, conversion price and other pricing terms (such notice the “Dilutive
Issuance Notice”). For purposes of clarification, whether or not
the Company provides a Dilutive Issuance Notice pursuant to this Section
3(b),
upon the occurrence of any Dilutive Issuance, after the date of such Dilutive
Issuance the Holder is entitled to receive a number of Warrant Shares based
upon
the Base Share Price regardless of whether the Holder accurately refers to
the
Base Share Price in the Notice of Exercise.
(c) Pro
Rata Distributions. If the Company, at any time prior to the
Termination Date, shall distribute to all holders of Common Stock (and not
to
Holders of the Warrants) evidences of its indebtedness or assets or rights
or
warrants to subscribe for or purchase any security other than the Common
Stock
(which shall be subject to Section 3(b)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately
prior to the record date fixed for determination of stockholders entitled
to
receive such distribution by a fraction of which the denominator shall be
the
VWAP determined as of the record date mentioned above, and of which the
numerator shall be such VWAP on such record date less the then per share
fair
market value at such record date of the portion of such assets or evidence
of
indebtedness so distributed applicable to one outstanding share of the Common
Stock as determined by the Board of Directors in good faith. In
either case the adjustments shall be described in a statement provided to
the
Holders of the portion of assets or evidences of indebtedness so distributed
or
such subscription rights applicable to one share of Common
Stock. Such adjustment shall be made whenever any such distribution
is made and shall become effective immediately after the record date mentioned
above.
(d) Fundamental
Transaction. If, at any time while this Warrant is outstanding,
(A) the Company effects any merger or consolidation of the Company with or
into
another Person, (B) the Company effects any sale of all or substantially
all of
its assets in one or a series of related transactions, (C) any tender offer
or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects
any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for
other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would
have
been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder, (a) upon exercise of
this
Warrant, the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation and any
additional consideration, and Alternate Consideration receivable upon or
as a
result of such reorganization, reclassification, merger, consolidation or
disposition of assets by a Holder of the number of shares of Common Stock
for
which this Warrant is exercisable immediately prior to such event or (b)
if the
Company is acquired in an all cash transaction, cash equal to the value of
this
Warrant as determined in accordance with the Black-Scholes option pricing
formula (the “Alternate Consideration”). For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock
in such
Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall
be
given the same choice as to the Alternate Consideration it receives upon
any
exercise of this Warrant following such Fundamental Transaction. To
the extent necessary to effectuate the foregoing provisions, any successor
to
the Company or surviving entity in such Fundamental Transaction shall issue
to
the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate
Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such
successor or surviving entity to comply with the provisions of this Section
3(d)
and insuring that this Warrant (or any such replacement security) will be
similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.
(e) Exempt
Issuance. Notwithstanding the foregoing, no adjustments,
Alternate Consideration nor notices shall be made, paid or issued under this
Section 3 in respect of an Exempt Issuance, or in respect of any issuance
of
Common Stock or Common Stock Equivalents upon conversion of the preferred
stock
or the exercise of warrants and/or options in connection with the
Plan.
(f) Calculations. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. The number of shares
of Common Stock outstanding at any given time shall not include shares of
Common
Stock owned or held by or for the account of the Company, and the description
of
any such shares of Common Stock shall be considered on issue or sale of Common
Stock. For purposes of this Section 3, the number of shares of Common
Stock deemed to be issued and outstanding as of a given date shall be the
sum of
the number of shares of Common Stock (excluding treasury shares, if any)
issued
and outstanding.
(g) Voluntary
Adjustment By Company. The Company may at any time during the
term of this Warrant reduce the then current Exercise Price to any amount
and
for any period of time deemed appropriate by the Board of Directors of the
Company.
(h) Notice
to Holders.
(i) Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted
pursuant to this Section 3, the Company shall promptly mail to each Holder
a
notice setting forth the Exercise Price after such adjustment and setting
forth
a brief statement of the facts requiring such adjustment. If the
Company issues a variable rate security, despite the prohibition thereon
in the
Purchase Agreement, the Company shall be deemed to have issued Common Stock
or
Common Stock Equivalents at the lowest possible conversion or exercise price
at
which such securities may be converted or exercised in the case of a Variable
Rate Transaction (as defined in the Purchase Agreement), or the lowest possible
adjustment price in the case of an MFN Transaction (as defined in the Purchase
Agreement.
(ii) Notice
to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution) on the Common Stock; (B) the Company
shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock; (C) the Company shall authorize the granting to all holders of the
Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; (D) the approval of any stockholders
of the
Company shall be required in connection with any reclassification of the
Common
Stock, any consolidation or merger to which the Company is a party, any sale
or
transfer of all or substantially all of the assets of the Company, of any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Company shall authorize the voluntary
or
involuntary dissolution, liquidation or winding up of the affairs of the
Company; then, in each case, the Company shall cause to be mailed to the
Holder
at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is
to be
taken for the purpose of such dividend, distribution, redemption, rights
or
warrants, or if a record is not to be taken, the date as of which the holders
of
the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer
or
share exchange; provided, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of
the
corporate action required to be specified in such notice. The Holder
is entitled to exercise this Warrant during the 20-day period commencing
on the
date of such notice to the effective date of the event triggering such
notice.
Section
4. Transfer
of Warrant.
(a) Transferability. Subject
to compliance with any applicable securities laws and the conditions set
forth
in Sections 5(a) and 4(d) hereof and to the provisions of Section 4.1 of
the
Purchase Agreement, this Warrant and all rights hereunder are transferable,
in
whole or in part, upon surrender of this Warrant at the principal office
of the
Company, together with a written assignment of this Warrant substantially
in the
form attached hereto duly executed by the Holder or its agent or attorney
and
funds sufficient to pay any transfer taxes payable upon the making of such
transfer. Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of
the
assignee or assignees and in the denomination or denominations specified
in such
instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant
shall
promptly be cancelled. A Warrant, if properly assigned, may be
exercised by a new holder for the purchase of Warrant Shares without having
a
new Warrant issued.
(b) New
Warrants. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in
which
new Warrants are to be issued, signed by the Holder or its agent or
attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall
execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to
be divided or combined in accordance with such notice.
(c) Warrant
Register. The Company shall register this Warrant, upon records
to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof
or
any distribution to the Holder, and for all other purposes, absent actual
notice
to the contrary.
(d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in
connection with any transfer of this Warrant, the transfer of this Warrant
shall
not be registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the
Holder or transferee of this Warrant, as the case may be, furnish to the
Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities
Act and under applicable state securities or blue sky laws, (ii) that the
holder
or transferee execute and deliver to the Company an investment letter in
form
and substance acceptable to the Company and (iii) that the transferee be
an
“accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or
(a)(8) promulgated under the Securities Act or a qualified institutional
buyer
as defined in Rule 144A(a) promulgated under the Securities Act.
Section
5. Miscellaneous.
(a) Title
to Warrant. Prior to the Termination Date and subject to
compliance with applicable laws and Section 4 of this Warrant, this Warrant
and
all rights hereunder are transferable, in whole or in part, at the office
or
agency of the Company by the Holder in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed hereto
properly endorsed. The transferee shall sign an investment letter in
form and substance reasonably satisfactory to the Company.
(b) No
Rights as Shareholder Until Exercise. This Warrant does not
entitle the Holder to any voting rights or other rights as a shareholder
of the
Company prior to the exercise hereof. Upon the surrender of this
Warrant and the payment of the aggregate Exercise Price (or by means of a
cashless exercise), the Warrant Shares so purchased shall be and be deemed
to be
issued to such Holder as the record owner of such shares as of the close
of
business on the later of the date of such surrender or payment.
(c) Loss,
Theft, Destruction or Mutilation of Warrant. The Company
covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any
stock
certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which,
in
the case of the Warrant, shall not include the posting of any bond), and
upon
surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.
(d) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall be a Saturday, Sunday or a legal holiday, then such action may be taken
or
such right may be exercised on the next succeeding day not a Saturday, Sunday
or
legal holiday.
(e) Authorized
Shares. The Company covenants that during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock
a
sufficient number of shares to provide for the issuance of the Warrant Shares
upon the exercise of any purchase rights under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing
stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements
of
the Trading Market upon which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall
not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms
of this
Warrant, but will at all times in good faith assist in the carrying out of
all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant
against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase
in
par value, (b) take all such action as may be necessary or appropriate in
order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
(f) Jurisdiction. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of
the
Purchase Agreement.
(g) Restrictions. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of
this
Warrant, if not registered, will have restrictions upon resale imposed by
state
and federal securities laws.
(h) Nonwaiver
and Expenses. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver
of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover
any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting
any
amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers
or remedies hereunder.
(i) Notices. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
(j) Limitation
of Liability. No provision hereof, in the absence of any
affirmative action by Holder to exercise this Warrant or purchase Warrant
Shares, and no enumeration herein of the rights or privileges of Holder,
shall
give rise to any liability of Holder for the purchase price of any Common
Stock
or as a stockholder of the Company, whether such liability is asserted by
the
Company or by creditors of the Company.
(k) Remedies. Holder,
in addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach
by it
of the provisions of this Warrant and hereby agrees to waive the defense
in any
action for specific performance that a remedy at law would be
adequate.
(l) Successors
and Assigns. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit
of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
(m) Amendment. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
(n) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner
as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions
of
this Warrant.
(o) Headings. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized.
Dated: December
_____, 2007
CHEMBIO
DIAGNOSTICS, INC.
By:
Name: Lawrence
A. Siebert
Title: President
Original
Date of Issuance: October 5, 2006
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: _______________
|
Expires: October
5, 2011
|
NOTICE
OF EXERCISE
TO: CHEMBIO
DIAGNOSTICS, INC.
(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full),
and
tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.
(2) Payment
shall take the form of (check applicable box):
[
] in
lawful money of the United States; or
[
] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).
(3) Please
issue a certificate or certificates representing said Warrant Shares in the
name
of the undersigned or in such other name as is specified below:
_______________________________
The
Warrant Shares shall be delivered to the following:
_______________________________
_______________________________
_______________________________
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name
of
Investing
Entity: _______________________________________________________
Signature
of Authorized Signatory of Investing
Entity: _________________________________
Name
of
Authorized
Signatory: ___________________________________________________
Title
of
Authorized
Signatory: ____________________________________________________
Date: ________________________________________________________________________
Original
Date of Issuance: October 5, 2006
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: ___________________
|
Expires: October
5, 2011
|
ASSIGNMENT
FORM
(To
assign the foregoing warrant, execute this form and supply required
information.
Do
not
use this form to exercise the warrant.)
FOR
VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to
_______________________________________________
whose address is
_______________________________________________________________.
_______________________________________________________________
Dated: ______________,
_______
Holder’s
Signature: _____________________________
Holder’s
Address: __________________________________________________________
Signature
Guaranteed: ___________________________________________
NOTE: The
signature to this Assignment Form must correspond with the name as it appears
on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to
assign
the foregoing Warrant.
ex4_17.htm
Exhibit
4.17
NEITHER
THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE
COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN SECURED BY SUCH SECURITIES.
COMMON
STOCK PURCHASE WARRANT
To
Purchase __________ Shares of Common Stock of
CHEMBIO
DIAGNOSTICS, INC.
Original
Date of Issuance: _____________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: ____________
|
Expires: _______________
|
THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value
received, ________________ (the “Holder”), is entitled, upon the terms and
subject to the limitations on exercise and the conditions hereinafter set forth,
at any time on or after the original date of issuance (the “Initial Exercise
Date”) and on or prior to the close of business on the fifth anniversary of the
Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe
for and purchase from Chembio Diagnostics, Inc., a Nevada corporation (the
“Company”), up to _______________ (__________) shares (the “Warrant
Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common
Stock”). The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in Section
2(b).
Section
1. Definitions. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth
in
that certain Securities Purchase Agreement (the “Purchase Agreement”), dated
October 5, 2006, among the Company and the purchasers signatory
thereto.
Section
2. Exercise.
(a) Exercise
of the purchase rights represented by this Warrant may be made, in whole or
in
part, at any time or times on or after the Initial Exercise Date and on or
before the Termination Date by delivery to the Company of a duly executed
facsimile copy of the Notice of Exercise Form annexed hereto (or such other
office or agency of the Company as it may designate by notice in writing to
the
registered Holder at the address of such Holder appearing on the books of the
Company); and, within 3 Trading Days of the date said Notice of Exercise is
delivered to the Company, the Company shall have received payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer or
cashier’s check drawn on a United States bank. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of
the
Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for
cancellation within 3 Trading Days of the date the final Notice of Exercise
is
delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of
Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of
Exercise Form within 1 Business Day of receipt of such notice. In the
event of any dispute or discrepancy, the records of the Holder shall be
controlling and determinative in the absence of manifest error. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase
of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated
on
the face hereof.
(b) Exercise
Price. The exercise price of the Common Stock under this Warrant
shall be as follows, subject to adjustment hereunder (the “Exercise
Price”):
|
(i)
|
For
the period 4:01p.m. eastern time ET through 9:59p.m. ET on the Plan
Closing Date, $0.40 per share for all or any portion of this Warrant
exercised for cash;
|
|
(ii)
|
For
the period 4:01p.m. ET through 9:59p.m. ET on the Plan Closing Date,
$0.45
per share for all or any portion of this Warrant exercised through
a
Cashless Exercise;
|
|
(iii)
|
For
the period beginning 10:00p.m. ET on the Plan Closing Date through
9:59p.m. ET on the Final Plan Date, $0.45 for all or any part of
this
Warrant exercised by a Holder who exercised at least 10% of all of
such
Holder’s warrants and options for cash at the Plan Closing
Date;
|
|
(iv)
|
For
the period beginning 10:00p.m. ET on the Plan Closing Date, $1.00
per
share for any Holder that did not exercise at least 10% of all of
such
Holder’s warrants and options for cash at an exercise price of $0.40 per
share at the Plan Closing Date; and
|
|
(v)
|
For
the period beginning 10:00p.m. ET on the Final Plan Date, $1.00 per
share
for all or any portion of this Warrant that has not been exercised
on or
before 9:59p.m. ET on the Final Plan
Date.
|
(c) Cashless
Exercise.
(i) At
the option of the Holder, this Warrant may be exercised by means of a “cashless
exercise” (a “Cashless Exercise”) in which the Holder shall be entitled
to receive a certificate for the number of Warrant Shares equal to the quotient
obtained by dividing [(A-B) (X)] by (A), where:
(A)
= the
VWAP for the ten-Trading Day period that ends on the first Trading Day
immediately preceding the date of such election;
(B)
= the
applicable Exercise Price of this Warrant in effect on the date of exercise,
as
adjusted; and
(X)
= the
number of Warrant Shares issuable upon exercise of this Warrant in accordance
with the terms of this Warrant by means of a cash exercise rather than a
cashless exercise.
(ii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated on the
Plan Closing Date received from a Holder who exercises its warrants on cashless
basis at $0.45 per share before 10:00p.m. ET on the Plan Closing Date, the
value
of (A) in the equation set forth in Section 2(c)(i) above shall be equal to
the
greater of $0.53 or the VWAP for the ten-Trading Day period that ends on the
second Trading Day prior to the date of the Notice of Exercise
Form.
(iii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated between
and inclusive of the Plan Closing Date and the Final Plan Date received from
a
Holder who exercises at least 10% of all of such Holder's warrants and options
for cash before 10:00p.m. ET on the Plan Closing Date the value of (A) in the
equation set forth in Section 2(c)(i) above shall be equal to the greater of
$0.53 or the VWAP for the ten-Trading Day period that ends on the second Trading
Day prior to the date of the Notice of Exercise Form. Any Exercise Form
dated on the Final Plan Date must be received by the Company within five Trading
Days of the Final Plan Date to be effective.
(iv) Notwithstanding
anything herein to the contrary, a Holder who does not exercise (i) at least
10%
of all of such Holder's warrants and options issued by the Company for cash
at
an exercise price of $0.40 per share before 10:00p.m. ET on the Plan Closing
Date, or (ii) its warrants on cashless basis at $0.45 per share by 10:00p.m.
ET
on the Plan Closing Date, shall not be permitted to exercise its Warrants on
a
cashless basis pursuant to Section 2(c)(i) above until April 1,
2008.
(d) The
Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section
2(c)
or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, such Holder
(together with such Holder’s Affiliates, and any other person or entity acting
as a group together with such Holder or any of such Holder’s Affiliates), as set
forth on the applicable Notice of Exercise, would beneficially own in excess
of
the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially
owned by such Holder and its Affiliates shall include the number of shares
of
Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (A) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by such Holder or any of its
Affiliates and (B) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company (including, without limitation,
any other [Preferred Stock or Warrants) subject to a limitation on conversion
or
exercise analogous to the limitation contained herein beneficially owned by
such
Holder or any of its affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(d)(i), beneficial ownership shall
be
calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder, it being acknowledged by a Holder that
the Company is not representing to such Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and such Holder is solely
responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this
Section 2(d) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by such Holder together with any
Affiliates) and of which a portion of this Warrant is exercisable shall be
in
the sole discretion of a Holder, and the submission of a Notice of Exercise
shall be deemed to be each Holder’s determination of whether this Warrant is
exercisable (in relation to other securities owned by such Holder together
with
any Affiliates) and of which portion of this Warrant is exercisable, in each
case subject to such aggregate percentage limitation, and the Company shall
have
no obligation to verify or confirm the accuracy of such
determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of
the
Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(d), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number
of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent
Form 10-QSB or Form 10-KSB, as the case may be, (y) a more recent public
announcement by the Company or (z) any other notice by the Company or the
Company’s Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the
Company shall within two Trading Days confirm orally and in writing to such
Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined
after
giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by such Holder or its Affiliates since the date as
of
which such number of outstanding shares of Common Stock was
reported. The “Beneficial Ownership Limitation” shall be 4.99%
of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of
this
Warrant. The Beneficial Ownership Limitation provisions of this
Section 2(d)(i) may be waived by such Holder, at the election of such Holder,
upon not less than 61 days’ prior notice to the Company to change the Beneficial
Ownership Limitation to 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common
Stock upon exercise of this Warrant, and the provisions of this Section 2(d)
shall continue to apply. Upon such a change by a Holder of the
Beneficial Ownership Limitation from such 4.99% limitation to such 9.99%
limitation, the Beneficial Ownership Limitation may not be further waived by
such Holder. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms
of
this Section 2(d)(i) to correct this paragraph (or any portion hereof) which
may
be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in
this paragraph shall apply to a successor holder of this
Warrant. Notwithstanding anything set forth in this Section 2(d), the
4.99% and 9.99% beneficial ownership limitations imposed by this Section 2(d)
shall not apply to Common Stock issuable upon the exercise of Warrants in
connection with the Plan.
(e) Mechanics
of Exercise.
(i) Authorization
of Warrant Shares. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by
this
Warrant will, upon exercise of the purchase rights represented by this Warrant,
be duly authorized, validly issued, fully paid and nonassessable and free from
all taxes, liens and charges in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously with such
issue).
(ii) Delivery
of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the transfer agent of the Company to the
Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”)
system if the Company is a participant in such system, and otherwise by physical
delivery to the address specified by the Holder in the Notice of Exercise within
3 Trading Days from the delivery to the Company of the Notice of Exercise Form,
surrender of this Warrant and payment of the aggregate Exercise Price as set
forth above (“Warrant Share Delivery Date”). This Warrant
shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Warrant Shares shall be deemed to have
been issued, and Holder or any other person so designated to be named therein
shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Warrant has been exercised by payment to the
Company of the Exercise Price (or by cashless exercise, if permitted) and all
taxes required to be paid by the Holder, if any, pursuant to Section 2( e)(
vii)
prior to the issuance of such shares, have been paid.
(iii) Delivery
of New Warrants Upon Exercise. If this Warrant shall have been
exercised in part, the Company shall, at the time of delivery of the certificate
or certificates representing Warrant Shares, deliver to Holder a new Warrant
evidencing the rights of Holder to purchase the unpurchased Warrant Shares
called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.
(iv) Rescission
Rights. If the Company fails to cause its transfer agent to
transmit to the Holder a certificate or certificates representing the Warrant
Shares pursuant to this Section 2(e)(iv) by the Warrant Share Delivery Date,
then the Holder will have the right to rescind such exercise.
(v) Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon
Exercise. In addition to any other rights available to the
Holder, if the Company fails to cause its transfer agent to transmit to the
Holder a certificate or certificates representing the Warrant Shares pursuant
to
an exercise on or before the Warrant Share Delivery Date, and if after such
date
the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder’s brokerage firm otherwise purchases shares of
Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Shares which the Holder anticipated receiving upon such exercise (a
“Buy-In”), then the Company shall (1) pay in cash to the Holder the
amount by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y)
the
amount obtained by multiplying (A) the number of Warrant Shares that the Company
was required to deliver to the Holder in connection with the exercise at issue
times (B) the price at which the sell order giving rise to such purchase
obligation was executed, and (2) at the option of the Holder, either reinstate
the portion of the Warrant and equivalent number of Warrant Shares for which
such exercise was not honored or deliver to the Holder the number of shares
of
Common Stock that would have been issued had the Company timely complied with
its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of shares of Common Stock with
an
aggregate sale price giving rise to such purchase obligation of $10,000, under
clause (1) of the immediately preceding sentence the Company shall be required
to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the
Buy-In, together with applicable confirmations and other evidence reasonably
requested by the Company. Nothing herein shall limit a Holder’s right
to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver
certificates representing shares of Common Stock upon exercise of the Warrant
as
required pursuant to the terms hereof.
(vi) No
Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which Holder would otherwise
be entitled to purchase upon such exercise, the Company shall pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price.
(vii) Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such certificate, all
of
which taxes and expenses shall be paid by the Company, and such certificates
shall be issued in the name of the Holder or in such name or names as may be
directed by the Holder; provided, however, that in the event
certificates for Warrant Shares are to be issued in a name other than the name
of the Holder, this Warrant when surrendered for exercise shall be accompanied
by the Assignment Form attached hereto duly executed by the Holder; and the
Company may require, as a condition thereto, the payment of a sum sufficient
to
reimburse it for any transfer tax incidental thereto.
(viii) Closing
of Books. The Company will not close its stockholder books or
records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.
(f) For
purposes of this warrant, the term “Plan” shall mean any action the
Company takes, with any required approval of the holders thereof, on or before
the Final Plan Date as contemplated by the Plan Summary and accompanying
materials provided to holders on December 4, 2007, in connection with the
reduction or other modification of terms of the Company's then-outstanding
preferred stock, warrants and options, including, but not limited to, actions
the Company takes to (i) facilitate the conversion of the Series A, B and C
Convertible Preferred Stock; (ii) reduce the exercise price of any of the
Company's outstanding warrants or options; (iii) offer the holders of the
Company's warrants and options the opportunity to exercise such warrants and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
(g) “Plan
Closing Date” shall be December 19, 2007.
(h) “Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
Section
3. Certain
Adjustments.
(a) Stock
Dividends and Splits. If the Company, at any time while this
Warrant is outstanding: (A) pays a stock dividend or otherwise make a
distribution or distributions on shares of· its Common Stock or any other equity
or equity equivalent securities payable in shares of Common Stock (which, for
avoidance of doubt, shall not include any shares of Common Stock issued by
the
Company upon exercise of this Warrant, the Company’s Series A Convertible
Preferred Stock, the Company’s Series B 9% Convertible Preferred Stock or the
Company’s Series C 7% Convertible Preferred Stock), (B) subdivides
outstanding shares of Common Stock into a larger number of shares, (C) combines
(including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares, or (D) issues by reclassification of shares
of
the Common Stock any shares of capital stock of the Company, then in each case
the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after
such
event and the number of shares issuable upon exercise of this Warrant shall
be
proportionately adjusted. Any adjustment made pursuant to this
Section 3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case
of a
subdivision, combination or re-classification.
(b) Subsequent
Equity Sales. If the Company or any Subsidiary thereof, as
applicable, at any time while this Warrant is outstanding, shall offer, sell,
grant any option to purchase or offer, sell or grant any right to reprice its
securities, or otherwise dispose of or issue (or announce any offer, sale,
grant
or any option to purchase or other disposition) any Common Stock or Common
Stock
Equivalents entitling any Person to acquire shares of Common Stock, at an
effective price per share less than the then Exercise Price (such lower price,
the “Base Share Price” and such issuances collectively, a “Dilutive
Issuance”), as adjusted hereunder (if the holder of the Common Stock or
Common Stock Equivalents so issued shall at any time, whether by operation
of
purchase price adjustments, reset provisions, floating conversion, exercise
or
exchange prices or otherwise, or due to warrants, options or rights per share
which are issued in connection with such issuance, be entitled to receive shares
of Common Stock at an effective price per share which is less than the Exercise
Price, such issuance shall be deemed to have occurred for less than the Exercise
Price on such date of the Dilutive Issuance), then, the Exercise Price shall
be
reduced to equal the Base Share Price and the number of Warrant Shares issuable
hereunder shall be increased such that the aggregate Exercise Price payable
hereunder, after taking into account the decrease in the Exercise Price, shall
be equal to the aggregate Exercise Price prior to such
adjustment. Such adjustment shall be made whenever such Common Stock
or Common Stock Equivalents are issued. The Company shall notify the
Holder in writing, no later than the Trading Day following the issuance of
any
Common Stock or Common Stock Equivalents subject to this section, indicating
therein the applicable issuance price, or of applicable reset price, exchange
price, conversion price and other pricing terms (such notice the “Dilutive
Issuance Notice”). For purposes of clarification, whether or not
the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b),
upon the occurrence of any Dilutive Issuance, after the date of such Dilutive
Issuance the Holder is entitled to receive a number of Warrant Shares based
upon
the Base Share Price regardless of whether the Holder accurately refers to
the
Base Share Price in the Notice of Exercise.
(c) Pro
Rata Distributions. If the Company, at any time prior to the
Termination Date, shall distribute to all holders of Common Stock (and not
to
Holders of the Warrants) evidences of its indebtedness or assets or rights
or
warrants to subscribe for or purchase any security other than the Common Stock
(which shall be subject to Section 3(b)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately
prior to the record date fixed for determination of stockholders entitled to
receive such distribution by a fraction of which the denominator shall be the
VWAP determined as of the record date mentioned above, and of which the
numerator shall be such VWAP on such record date less the then per share fair
market value at such record date of the portion of such assets or evidence
of
indebtedness so distributed applicable to one outstanding share of the Common
Stock as determined by the Board of Directors in good faith. In
either case the adjustments shall be described in a statement provided to the
Holders of the portion of assets or evidences of indebtedness so distributed
or
such subscription rights applicable to one share of Common
Stock. Such adjustment shall be made whenever any such distribution
is made and shall become effective immediately after the record date mentioned
above.
(d) Fundamental
Transaction. If, at any time while this Warrant is outstanding,
(A) the Company effects any merger or consolidation of the Company with or
into
another Person, (B) the Company effects any sale of all or substantially all
of
its assets in one or a series of related transactions, (C) any tender offer
or
exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to tender or exchange their
shares for other securities, cash or property, or (D) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (in any such case, a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such
Fundamental Transaction, at the option of the Holder, (a) upon exercise of
this
Warrant, the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation and any
additional consideration, and Alternate Consideration receivable upon or as
a
result of such reorganization, reclassification, merger, consolidation or
disposition of assets by a Holder of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such event or (b) if
the
Company is acquired in an all cash transaction, cash equal to the value of
this
Warrant as determined in accordance with the Black-Scholes option pricing
formula (the “Alternate Consideration”). For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in
such
Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Holder shall
be
given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. To
the extent necessary to effectuate the foregoing provisions, any successor
to
the Company or surviving entity in such Fundamental Transaction shall issue
to
the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate
Consideration. The terms of any agreement pursuant to which a
Fundamental Transaction is effected shall include terms requiring any such
successor or surviving entity to comply with the provisions of this Section
3(d)
and insuring that this Warrant (or any such replacement security) will be
similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.
(e) Exempt
Issuance. Notwithstanding the foregoing, no adjustments,
Alternate Consideration nor notices shall be made, paid or issued under this
Section 3 in respect of an Exempt Issuance, or in respect of any issuance of
Common Stock or Common Stock Equivalents upon conversion of the preferred stock
or the exercise of warrants and/or options in connection with the
Plan.
(f) Calculations. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share,
as the case may be. The number of shares of Common Stock outstanding
at any given time shall not include shares of Common Stock owned or held by
or
for the account of the Company, and the description of any such shares of Common
Stock shall be considered on issue or sale of Common Stock. For
purposes of this Section 3, the number of shares of Common Stock deemed to
be
issued and outstanding as of a given date shall be the sum of the number of
shares of Common Stock (excluding treasury shares, if any) issued and
outstanding.
(g) Voluntary
Adjustment By Company. The Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any
amount and for any period of time deemed appropriate by the Board of Directors
of the Company.
(h) Notice
to Holders.
(i) Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted
pursuant to this Section 3, the Company shall promptly mail to each Holder
a
notice setting forth the Exercise Price after such adjustment and setting forth
a brief statement of the facts requiring such adjustment. If the
Company issues a variable rate security, despite the prohibition thereon in
the
Purchase Agreement, the Company shall be deemed to have issued Common Stock
or
Common Stock Equivalents at the lowest possible conversion or exercise price
at
which such securities may be converted or exercised in the case of a Variable
Rate Transaction (as defined in the Purchase Agreement), or the lowest possible
adjustment price in the case of an MFN Transaction (as defined in the Purchase
Agreement.
(ii) Notice
to Allow Exercise by Holder. If (A) the Company shall declare a
dividend (or any other distribution) on the Common Stock; (B) the Company shall
declare a special nonrecurring cash dividend on or a redemption of the Common
Stock; (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights; (D) the approval of any stockholders of
the
Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger to which the Company is a party, any sale
or
transfer of all or substantially all of the assets of the Company, of any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property; (E) the Company shall authorize the voluntary
or
involuntary dissolution, liquidation or winding up of the affairs of the
Company; then, in each case, the Company shall cause to be mailed to the Holder
at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date
hereinafter specified, a notice stating (x) the date on which a record is to
be
taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders
of
the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer
or
share exchange; provided, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice. The Holder
is entitled to exercise this Warrant during the 20-day period commencing on
the
date of such notice to the effective date of the event triggering such
notice.
Section
4. Transfer
of Warrant.
(a) Transferability. Subject
to compliance with any applicable securities laws and the conditions set forth
in Sections 5(a) and 4(d) hereof and to the provisions of Section 4.1 of the
Purchase Agreement, this Warrant and all rights hereunder are transferable,
in
whole or in part, upon surrender of this Warrant at the principal office of
the
Company, together with a written assignment of this Warrant substantially in
the
form attached hereto duly executed by the Holder or its agent or attorney and
funds sufficient to pay any transfer taxes payable upon the making of such
transfer. Upon such surrender and, if required, such payment, the
Company shall execute and deliver a new Warrant or Warrants in the name of
the
assignee or assignees and in the denomination or denominations specified in
such
instrument of assignment, and shall issue to the assignor a new Warrant
evidencing the portion of this Warrant not so assigned, and this Warrant shall
promptly be cancelled. A Warrant, if properly assigned, may be
exercised by a new holder for the purchase of Warrant Shares without having
a
new Warrant issued.
(b) New
Warrants. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which
new Warrants are to be issued, signed by the Holder or its agent or
attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to
be divided or combined in accordance with such notice.
(c) Warrant
Register. The Company shall register this Warrant, upon records
to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to
time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.
(d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in
connection with any transfer of this Warrant, the transfer of this Warrant
shall
not be registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws, the
Company may require, as a condition of allowing such transfer (i) that the
Holder or transferee of this Warrant, as the case may be, furnish to the Company
a written opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities
Act and under applicable state securities or blue sky laws, (ii) that the holder
or transferee execute and deliver to the Company an investment letter in form
and substance acceptable to the Company and (iii) that the transferee be an
“accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or
(a)(8) promulgated under the Securities Act or a qualified institutional buyer
as defined in Rule 144A(a) promulgated under the Securities Act.
Section
5. Miscellaneous.
(a) Title
to Warrant. Prior to the Termination Date and subject to
compliance with applicable laws and Section 4 of this Warrant, this Warrant
and
all rights hereunder are transferable, in whole or in part, at the office or
agency of the Company by the Holder in person or by duly authorized attorney,
upon surrender of this Warrant together with the Assignment Form annexed hereto
properly endorsed. The transferee shall sign an investment letter in
form and substance reasonably satisfactory to the Company.
(b) No
Rights as Shareholder Until Exercise. This Warrant does not
entitle the Holder to any voting rights or other rights as a shareholder of
the
Company prior to the exercise hereof. Upon the surrender of this
Warrant and the payment of the aggregate Exercise Price (or by means of a
cashless exercise), the Warrant Shares so purchased shall be and be deemed
to be
issued to such Holder as the record owner of such shares as of the close of
business on the later of the date of such surrender or payment.
(c) Loss,
Theft, Destruction or Mutilation of Warrant. The Company
covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any
stock
certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which,
in
the case of the Warrant, shall not include the posting of any bond), and upon
surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.
(d) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall be a Saturday, Sunday or a legal holiday, then such action may be taken
or
such right may be exercised on the next succeeding day not a Saturday, Sunday
or
legal holiday.
(e) Authorized
Shares. The Company covenants that during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock
a
sufficient number of shares to provide for the issuance of the Warrant Shares
upon the exercise of any purchase rights under this Warrant. The
Company further covenants that its issuance of this Warrant shall constitute
full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for the Warrant
Shares upon the exercise of the purchase rights under this
Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements
of
the Trading Market upon which the Common Stock may be listed.
Except
and to the extent as waived or consented to by the Holder, the Company shall
not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of
this
Warrant, but will at all times in good faith assist in the carrying out of
all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the
Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase
in
par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant, and (c) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof as may be necessary
to enable the Company to perform its obligations under this
Warrant.
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
(f) Jurisdiction. All
questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.
(g) Restrictions. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, will have restrictions upon resale imposed by state
and federal securities laws.
(h) Nonwaiver
and Expenses. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver
of
such right or otherwise prejudice Holder’s rights, powers or remedies,
notwithstanding the fact that all rights hereunder terminate on the Termination
Date. If the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover
any
costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by Holder in collecting
any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers
or remedies hereunder.
(i) Notices. Any
notice, request or other document required or permitted to be given or delivered
to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.
(j) Limitation
of Liability. No provision hereof, in the absence of any
affirmative action by Holder to exercise this Warrant or purchase Warrant
Shares, and no enumeration herein of the rights or privileges of Holder, shall
give rise to any liability of Holder for the purchase price of any Common Stock
or as a stockholder of the Company, whether such liability is asserted by the
Company or by creditors of the Company.
(k) Remedies. Holder,
in addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by
it
of the provisions of this Warrant and hereby agrees to waive the defense in
any
action for specific performance that a remedy at law would be
adequate.
(1) Successors
and Assigns. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit
of
and be binding upon the successors of the Company and the successors and
permitted assigns of Holder. The provisions of this Warrant are
intended to be for the benefit of all Holders from time to time of this Warrant
and shall be enforceable by any such Holder or holder of Warrant
Shares.
(m) Amendment. This
Warrant may be modified or amended or the provisions hereof waived with the
written consent of the Company and the Holder.
(n) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner
as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
(o) Headings. The
headings used in this Warrant are for the convenience of reference only and
shall not, for any purpose, be deemed a part of this Warrant.
********************
IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
officer thereunto duly authorized.
Dated: December _____,
2007
By:
Name: Lawrence
A. Siebert
Title: President
Original
Date of Issuance: _______________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: ________________
|
Expires: _________________
|
NOTICE
OF EXERCISE
TO: CHEMBIO
DIAGNOSTICS, INC.
(1) The
undersigned hereby elects to purchase _______ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full),
and
tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.
(2) Payment
shall take the form of (check applicable box):
[
] in
lawful money of the United States; or
[
] the
cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in subsection 2(c).
(3) Please
issue a certificate or certificates representing said Warrant Shares in the
name
of the undersigned or in such other name as is specified below:
The
Warrant Shares shall be delivered to the following:
(4) Accredited
Investor. The undersigned is an “accredited investor” as defined
in Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE
OF HOLDER]
Name
of
Investing
Entity:
Signature
of Authorized Signatory of Investing
Entity:
Name
of
Authorized
Signatory:
Title
of
Authorized
Signatory:
Date:
div>
Original
Date of Issuance: _________
|
Reissuance
Date: December 19, 2007
|
Warrant
No.: _______________
|
Expires: _________________
|
ASSIGNMENT
FORM
(To
assign the foregoing warrant, execute this form and supply required
information.
Do
not
use this form to exercise the warrant.)
FOR
VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby
assigned to ______________ whose address is
________________________________.
Dated: December
__, 2007
Holder’s
Signature: __________________________________________
Holder’s
Address: __________________________________________
Signature
Guaranteed:
NOTE: The
signature to this Assignment Form must correspond with the name as it appears
on
the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust
company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Warrant.
ex4_18.htm
Exhibit
4.18
CHEMBIO
DIAGNOSTICS, INC.
STOCK
OPTION AGREEMENT
(Incentive
Option)
THIS
STOCK OPTION AGREEMENT (the “Agreement”) is made and entered into as of the
______________________ day of ____________________________ by and between
Chembio Diagnostics, Inc., a Nevada corporation (the “Company”), and
_________________________ (the “Optionee”).
WITNESSETH:
WHEREAS,
the Optionee has received an incentive stock option to purchase shares of
the
Company’s Common Stock pursuant to the Company’s 1999 Stock Option Plan (the
“Plan”) in order to provide the Optionee with an opportunity for investment in
the Company and additional incentive to pursue the success of the Company,
and
this option is to be for the number of shares, at the price per share and
on the
terms set forth in this Agreement;
WHEREAS,
the Company intends that the stock option granted pursuant to this Agreement
qualify as an incentive stock option pursuant to Section 422 of the Internal
Revenue Code of 1986, as amended (the “Code”); and
WHEREAS,
the Optionee desires to receive an option on the terms and conditions set
forth
in this Agreement.
NOW,
THEREFORE, the parties agree as follows:
1. Grant
Of Option. The Company hereby grants to the Optionee, as a matter
of separate agreement and not in lieu of salary or any other compensation
for
services, the right and option (the “Option”) to purchase all or any part of an
aggregate of _____________________ (________________)
shares of the authorized and unissued $.01 par value common stock of the
Company
(the “Option Shares”) pursuant to the terms and conditions set forth in this
Agreement.
2. Option
Price. At any time when shares are to be purchased pursuant to
the Option, the purchase price for each Option Share shall be $_________
(the
“Option Price”).
3. Exercise
Period.
(a) The
Option may be exercised at any time after _____________ (the “Trigger
Date”).
(b) The
period for exercise of the Option shall terminate at 5:00 p.m., Eastern Standard
Time on _______________, unless terminated earlier as provided in this
Agreement, which date is the seventh anniversary of the date of this
Agreement.
4. Exercise
Of Option.
(a) The
Option may be exercised in whole or in part by delivering to the Treasurer
of
the Company (i) a Notice And Agreement Of Exercise Of Option, substantially
in
the form attached hereto as Exhibit A, specifying the number of Option Shares
with respect to which the Option is exercised, and (ii) full payment of the
Option Price for such shares. Payment in cash shall be made by
certified check or cleared funds. The Option may not be exercised in part
unless
the purchase price for the Option Shares purchased is at least $1,000 or
unless
the entire remaining portion of the Option is being exercised.
(b) Promptly
upon receipt of the Notice And Agreement Of Exercise Of Option together with
the
full payment of the Option Price, the Company shall deliver to the Optionee
a
properly executed certificate or certificates representing the Option Shares
being purchased.
(c) During
the lifetime of the Optionee, the Option shall be exercisable only by the
Optionee; provided, however, that in the event of the legal disability of
an
Optionee, the guardian or personal representative of the Optionee may exercise
the Option if such guardian or personal representative obtains a ruling from
the
Internal Revenue Service or an opinion of counsel to the effect that neither
the
grant nor the exercise of such power is violative of Section 422(b)(5), or
its
successor provision, of the Internal Revenue Code of 1986, as amended (the
“Code”). Any opinion of counsel must be acceptable to the Option
Committee both with respect to the counsel rendering the opinion and with
respect to the form of opinion.
(d) If
for
any reason other than the termination of Optionee’s employment by the Company
for cause or other than the termination of Optionee’s employment by Optionee’s
resignation or other voluntary act, the Optionee ceases to be employed by
the
Company, any Option held by the Optionee at the time the Optionee’s employment
ceases may be exercised within thirty days after the date his employment
ceases,
but only to the extent that (i) the Option was exercisable according to its
terms on the date of termination of the Optionee’s employment, and (ii) the
period for exercise of the Option, as defined in Section 3 of this Agreement,
has not terminated as of the date of exercise. Upon termination of
the period ending thirty days after cessation of the Optionee’s employment for
any reason other than for cause and other than by Optionee’s voluntary act, any
unexercised portion of an Option shall expire. If the Optionee ceases to
be
employed by the Company because of termination by the Optionee by resignation
or
other voluntary act, any Option held by the Optionee at the time the Optionee’s
employment ceases shall terminate immediately upon the cessation of employment
and all rights to purchase shares pursuant to the Option shall terminate
immediately. If the Optionee’s employment by the Company is
terminated by the Company for cause, any Option held by the Optionee at the
time
Optionee’s employment is terminated shall expire upon delivery to the Optionee
of notice of termination, which may be oral or in writing, and all rights
to
purchase shares pursuant to the Option shall terminate
immediately. As used in this Section 4(d), termination “for cause”
means a discharge on account of dishonesty, disloyalty or insubordination
on the
part of the Optionee as determined by the Board Of Directors of the Corporation
or a Committee of the Board Of Directors.
5. Withholding
Taxes. The Company may take such steps as it deems necessary or
appropriate for the withholding of any taxes which the Company is required
by
any law or regulation or any governmental authority, whether federal, state
or
local, domestic or foreign, to withhold in connection with the Option including,
but not limited to, the withholding of all or any portion of any payment
owed by
the Company to the Optionee or the withholding of issuance of Option Shares
to
be issued upon the exercise of the Option.
6. Securities
Laws Requirements. The issuance of the Option has not been
registered under the 1933 Act, in reliance upon an exemption from
registration. In addition, no Option Shares shall be issued unless
and until, in the opinion of the Company, there has been full compliance
with
any applicable registration requirements of the 1933 Act, any applicable
listing
requirements of any securities exchange on which stock of the same class
has
been listed, and any other requirements of law or any regulatory bodies having
jurisdiction over such issuance and delivery. Optionee hereby
acknowledges, represents, warrants and agrees as follows, and, pursuant to
the
terms of the Notice And Agreement Of Exercise Of Option (Exhibit A) that
shall
be delivered to the Company upon each exercise of the Option, Optionee shall
acknowledge, represent, warrant and agree as follows:
(a) Optionee
is acquiring the Option and the Option Shares for investment purposes only
and
the Option and the Option Shares that Optionee is acquiring will be held
by
Optionee without sale, transfer or other disposition for an indefinite period
unless the transfer of those securities is subsequently registered under
the
federal securities laws or unless exemptions from registration are
available;
(b) Optionee’s
overall commitment to investments that are not readily marketable is not
disproportionate to Optionee’s net worth and Optionee’s investment in the Option
and the Option Shares will not cause such overall commitments to become
excessive;
(c) Optionee’s
financial condition is such that Optionee is under no present or contemplated
future need to dispose of any portion of the Option or the Option Shares
to
satisfy any existing or contemplated undertaking, need or
indebtedness;
(d) Optionee
has sufficient knowledge and experience in business and financial matters
to
evaluate, and Optionee has evaluated, the merits and risks of an investment
in
the Option and the Option Shares;
(e) The
address set forth in this Agreement is Optionee’s true and correct residence,
and Optionee has no present intention of becoming a resident of any other
state
or jurisdiction;
(f) Optionee
confirms that all documents, records and books pertaining to an investment
in
the Option and the Option Shares have been made available or delivered to
Optionee and Optionee has had the opportunity to discuss the acquisition
of the
Option and the Option Shares with the Company. Optionee also confirms that
Optionee has obtained or been given access to all information concerning
the
Company that Optionee has reasonably requested;
(g) Optionee
has had the opportunity to ask questions of, and receive the answers from,
the
Company concerning the terms of the investment in the Option and the Option
Shares and to receive additional information necessary to verify the accuracy
of
the information delivered to Optionee, to the extent that the Company possesses
such information or can acquire it without unreasonable effort or
expense;
(h) Optionee
understands that the Option has not been, and the Option Shares issuable
upon
exercise of the Options will not be, registered under the 1933 Act or any
state
securities laws in reliance on an exemption for private offerings, and no
federal or state agency has made any finding or determination as to the fairness
of this investment or any recommendation or endorsement of the issuance of
the
Option or the Option Shares;
(i) The
Option and the Option Shares that Optionee is acquiring will be solely for
Optionee’s own account, for investment, and are not being purchased with a view
to or for the resale, distribution, subdivision or fractionalization
thereof. Optionee has no agreement or arrangement for any such
resale, distribution, subdivision or fractionalization thereof; and
(j) Optionee
acknowledges and is aware of the following:
(i) The
Company has a history of losses. The Option and the Option Shares
constitute a speculative investment and involve a high degree of risk of
loss by
Optionee of Optionee’s total investment in the Option and the Option
Shares.
(ii) There
are
substantial restrictions on the transferability of the Option and the Option
Shares. The Option is not transferable except as provided in Section
7 below. The Option Shares cannot be transferred, pledged,
hypothecated, sold or otherwise disposed of unless they are registered under
the
1933 Act or an exemption from such registration is available and established
to
the satisfaction of the Company; investors in the Company have no rights
to
require that the Option Shares be registered; there is no right of presentment
of the Option Shares and there is no obligation by the Company to repurchase
any
of the Option Shares; and, accordingly, Optionee may have to hold the Option
Shares indefinitely and it may not be possible for Optionee to liquidate
Optionee’s investment in the Company.
(iii) Each
certificate issued representing the Option Shares shall be imprinted with
a
legend that sets forth a description of the restrictions on transferability
of
those securities, which legend will read substantially as follows:
“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED
UNDER FEDERAL OR STATE SECURITIES LAWS. THESE SECURITIES MAY NOT BE
OFFERED FOR SALE, SOLD, PLEDGED, OR OTHERWISE DISPOSED OF UNLESS SO REGISTERED
OR QUALIFIED OR UNLESS AN EXEMPTION EXISTS, THE AVAILABILITY OF WHICH IS
TO BE
ESTABLISHED BY AN OPINION OF COUNSEL (WHICH OPINION AND COUNSEL SHALL BOTH
BE
REASONABLY SATISFACTORY TO THE COMPANY).”
The
restrictions described above, or notice thereof may be placed on the
certificates representing the Option Shares purchased pursuant to the Option,
and the Company may refuse to issue the certificates or to transfer the shares
on its books unless it is satisfied that no violation of such restrictions
will
occur.
7. Transferability
Of Option. The Option shall not be transferable except by will or
the laws of descent and distribution, and any attempt to do so shall void
the
Option.
8. Adjustment
By Stock Split, Stock Dividend, Etc. If at any time the Company
increases or decreases the number of its outstanding shares of common stock,
or
changes in any way the rights and privileges of such shares, by means of
the
payment of a stock dividend or the making of any other distribution on such
shares payable in its common stock, or through a stock split or subdivision
of
shares, or a consolidation or combination of shares, or through a
reclassification or recapitalization involving its common stock, the numbers,
rights and privileges of the shares of common stock included in the Option
shall
be increased, decreased or changed in like manner as if such shares had been
issued and outstanding, fully paid and nonassessable at the time of such
occurrence.
9. Common
Stock To Be Received Upon Exercise. Optionee understands that the
Company is under no obligation to register the issuance of the Option Shares,
the resale (by directors and officers) of the Option Shares, or the Option
Shares, under the Securities Act of 1933, as amended (the “1933 Act”), and that
in the absence of any such registration, the Option Shares cannot be sold
unless
they are sold pursuant to an exemption from registration under the 1933
Act. The Company is under no obligation to comply, or to assist the
Optionee in complying, with any exemption from such registration requirement,
including supplying the Optionee with any information necessary to permit
routine sales of the Stock under Rule 144 of the Securities and Exchange
Commission. Optionee also understands that with respect to Rule 144,
routine sales of securities made in reliance upon such Rule can be made only
in
limited amounts in accordance with the terms and conditions of the Rule,
and
that in cases in which the Rule is inapplicable, compliance with either
Regulation A or another disclosure exemption under the 1933 Act will be
required. Thus, the Option Shares will have to be held indefinitely
in the absence of registration under the 1933 Act or an exemption from
registration.
Furthermore,
the Optionee fully understands that issuance of the Option Shares may not
be
registered under the 1933 Act and that if their issuance is not registered,
they
will be issued in reliance upon an exemption which is available only if Optionee
acquires such shares for investment and not with a view to
distribution. Optionee is familiar with the phrase “acquired for
investment and not with a view to distribution” as it relates to the 1933 Act
and the special meaning given to such term in various releases of the Securities
And Exchange Commission.
10. Privilege
Of Ownership. Optionee shall not have any of the rights of a
stockholder with respect to the shares covered by the Option except to the
extent that one or more certificates for such shares shall be delivered to
him
upon exercise of the Option.
11. Relationship
To Employment Or Position. Nothing contained in this Agreement
(i) shall confer upon the Optionee any right with respect to continuance of
Optionee’s employment by, or position or affiliation with, or relationship to,
the Company, or (ii) shall interfere in any way with the right of the
Company at any time to terminate the Optionee’s employment by, position or
affiliation with, or relationship to, the Company.
12. Notices. All
notices, requests, demands, directions and other communications (“Notices”)
concerning this Agreement shall be in writing and shall be mailed or delivered
personally or sent by telecopier or facsimile to the applicable party at
the
address of such party set forth below in this Section 12. When
mailed, each such Notice shall be sent by first class, certified mail, return
receipt requested, enclosed in a postage prepaid wrapper, and shall be effective
on the fifth business day after it has been deposited in the
mail. When delivered personally, each such Notice shall be effective
when delivered to the address for the respective party set forth in this
Section
12, provided that it is delivered on a business day and further provided
that it
is delivered prior to 5:00 p.m., local time of the party to whom the notice
is
being delivered, on that business day; otherwise, each such Notice shall
be
effective on the first business day occurring after the Notice is
delivered. When sent by telecopier or facsimile, each such Notice
shall be effective on the day on which it is sent provided that it is sent
on a
business day and further provided that it is sent prior to 5:00 p.m., local
time
of the party to whom the Notice is being sent, on that business day; otherwise,
each such Notice shall be effective on the first business day occurring after
the Notice is sent. Each such Notice shall be addressed to the party
to be notified as shown below:
(a) if
to the
Company: Chembio
Diagnostics, Inc.
Attn:
President
3361
Horseblock Road
Medford,
New York 11763
Facsimile
No. (516)
924-6033
(b) if
to the
Optionee: ________________________________
________________________________
________________________________
________________________________
Either
party may change its respective address for purposes of this Section 12 by
giving the other party Notice of the new address in the manner set forth
above.
13. General
Provisions. This instrument (a) contains the entire agreement
between the parties, (b) may not be amended nor may any rights hereunder
be
waived except by an instrument in writing signed by the party sought to be
charged with such amendment or waiver, (c) shall be construed in accordance
with, and governed by the laws of the State of New York, except where conflicts
of law rules require the application of Colorado law, and (d) shall be binding
upon and shall inure to the benefit of the parties and their respective personal
representatives and assigns, except as above set forth. All pronouns
contained herein and any variations thereof shall be deemed to refer to the
masculine, feminine or neuter, singular or plural as the identity of the
parties
hereto may require.
IN
WITNESS WHEREOF, the parties have executed this Agreement on the dates set
forth
below.
CHEMBIO
DIAGNOSTICS, INC.
Date:
__________
Lawrence
Siebert,
President
OPTIONEE
Date:
Name
EXHIBIT
A
(To
Chembio Diagnostic Systems Inc
Stock
Option Agreement)
CHEMBIO
DIAGNOSTICS, INC.
NOTICE
AND AGREEMENT OF EXERCISE OF OPTION
I
hereby
exercise my Chembio Diagnostics, Inc. Stock Option dated as of _____________
as
to ________ shares of the $.01 par value common stock (the “Option Shares”) of
Chembio Diagnostics, Inc. (the “Company”) at a purchase price of $______ per
share. The total exercise price for these Option Shares is
$________. Enclosed is payment in the form of
___________________.
Enclosed
are the documents and payment specified in Paragraph 4 of my Option
Agreement.
I
understand that no Option Shares will be issued unless and until, in the
opinion
of the Company, there has been full compliance with any applicable registration
requirements of the Securities Act of 1933, as amended, any applicable listing
requirements of any securities exchange on which stock of the same class
is then
listed, and any other requirements of law or any regulatory bodies having
jurisdiction over such issuance and delivery. I hereby acknowledge,
represent, warrant and agree, to and with the Company as follows:
a.
|
The
Option Shares I am purchasing are being acquired for my own account
for
investment purposes only and with no view to their resale or other
distribution of any kind, and no other person (except, if I am
married, my
spouse) will own any interest therein. (Note: This
provision to be included only if issuance of Option Shares is not
registered at the time of
exercise.)
|
b.
|
I
will not sell or dispose of my Option Shares in violation of the
Securities Act of 1933, as amended, or any other applicable federal
or
state securities laws.
|
c.
|
I
will report all sales of Option Shares to the Company in writing
on a form
prescribed by the Company.
|
d.
|
I
agree that the Company may, without liability for its good faith
actions,
place legend restrictions upon my Option Shares and issue “stop transfer”
instructions requiring compliance with applicable securities laws
and the
terms of my Option.
|
e.
|
[For
officers only.] If and so long as I am subject to reporting
requirements under Section 16(a) of the Securities Exchange Act
of 1934,
as amended (the “1934 Act”), I recognize that any sale by me or my
immediate family of the Company’s $.001 par value common stock may create
liability for me under Section 16(b) of the 1934 Act (“Section
16(b)”). Therefore, I have consulted with my counsel regarding
the application of Section 16(b) to this exercise of my
Option.
|
f.
|
[For
officers only.] I will consult with my counsel regarding the
application of Section 16(b) before I can make any sale of the
Company’s
$.01 par value common stock, including the Option Shares, and I
will
furnish the Company with a copy of each Form 4 filed by me and
will timely
file all reports that I may be required to file under the federal
securities laws.
|
The
number of Option Shares specified above are to be issued in the name or names
set forth below in the left-hand column.
Name Signature
(Optionee
- Print Name of
Spouse Address
if
you
wish joint
registration)
City, State and Zip Code
*
* * *
*
ex4_19.htm
Exhibit
4.19
THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE
STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL
TO
THE HOLDER OF THE SECURITIES (UNLESS THE ISSUER IN ITS SOLE DISCRETION
DETERMINES TO USE ITS OWN COUNSEL), WITH ANY SUCH COUNSEL TO THE HOLDER AND
ANY
SUCH OPINION OF SUCH COUNSEL TO BE REASONABLY ACCEPTABLE TO THE ISSUER, THAT
REGISTRATION UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.
WARRANT
TO PURCHASE
SHARES
OF
COMMON STOCK
OF
CHEMBIO
DIAGNOSTICS, INC.
Expires
May 4, 2009
No.:
|
Number
of Shares:
|
Original
Date of Issuance: May 5, 2004
|
Reissuance
Date: December 19,
2007
|
FOR
VALUE
RECEIVED, subject to the provisions hereinafter set forth, the undersigned,
Chembio Diagnostics, Inc., a Nevada corporation (together with its successors
and assigns, the "Issuer"), hereby certifies that ________ or its
registered assigns is entitled to subscribe for and purchase, during the Term
(as hereinafter defined), up to ________ (__________) shares (subject to
adjustment as hereinafter provided) of the duly authorized, validly issued,
fully paid and non-assessable Common Stock of the Issuer, at an exercise price
per share equal to the Exercise Price then in effect, subject, however, to
the
provisions and upon the terms and conditions hereinafter set
forth. Capitalized terms used in this Warrant and not otherwise
defined herein shall have the respective meanings specified in Section 6
hereof.
1. Term. The
term of this Warrant shall commence on ______ and shall expire at 5:00 p.m.,
eastern time, on May 4, 2009 (such period being the "Term").
2. Method
of Exercise Payment; Issuance of New Warrant; Transfer and
Exchange.
(a) Time
of Exercise. The purchase rights represented by this Warrant may
be exercised in whole or in part anytime during the Term.
(b) Method
of Exercise. The Holder hereof may exercise this Warrant, in
whole or in part, by the surrender of this Warrant (with the exercise form
attached hereto duly executed) at the principal office of the Issuer, and by
the
payment to the Issuer of an amount of consideration therefor equal to the
Exercise Price in effect on the date of such exercise multiplied by the number
of shares of Warrant Stock with respect to which this Warrant is then being
exercised, payable at
such Holder's election (i) by certified or official bank check or by
wire transfer to an account designated by the Issuer, or
(ii) by "cashless exercise" in accordance with the provisions of section
(2)(c).
(c) Cashless
Exercise. (i) At the option of the Holder, this Warrant may be
exercised by means of a “cashless exercise” (a “Cashless Exercise”) in which the
Holder shall be entitled to receive a certificate for the number
of shares of Warrant Stock equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:
(A)
= the
VWAP for the ten-Trading Day period that ends on the first Trading Day
immediately preceding the date of such election;
(B)
= the
Exercise Price of this Warrant in effect on the date of exercise, as adjusted;
and
(X)
= the
number of shares of Warrant Stock issuable upon exercise of this Warrant in
accordance with the terms of this Warrant by means of a cash exercise rather
than a cashless exercise.
(ii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated on the
Plan Closing Date received from a Holder who exercises its warrants on cashless
basis at $0.45 per share before 10:00p.m. ET on the Plan Closing Date, the
value
of (A) in the equation set forth in Section 2(c)(i) above shall be equal to
the
greater of $0.53 or the VWAP for the ten-Trading Day period that ends on the
second Trading Day prior to the date of the Notice of Exercise
Form.
(iii) Notwithstanding
anything herein to the contrary, for any Notice of Exercise Form dated between
and inclusive of the Plan Closing Date and the Final Plan Date received from
a
Holder who exercises at least 10% of all of such Holder's warrants and options
for cash before 10:00p.m. ET on the Plan Closing Date the value of (A) in the
equation set forth in Section 2(c)(i) above shall be equal to the greater of
$0.53 or the VWAP for the ten-Trading Day period that ends on the second Trading
Day prior to the date of the Notice of Exercise Form.
(iv) Notwithstanding
anything herein to the contrary, a Holder who does not exercise (i) at least
10%
of all of such Holder's warrants and options issued by the Company for cash
at
an exercise price of $0.40 per share before 10:00p.m. ET on the Plan Closing
Date, or (ii) its warrants on cashless basis at $0.45 per share by 10:00p.m.
ET
on the Plan Closing Date, shall not be permitted to exercise its Warrants on
a
cashless basis pursuant to Section 2(c)(i) above until April 1,
2008.
(d) Issuance
of Stock Certificates. In the event of any exercise of the rights
represented by this Warrant in accordance with and subject to the terms and
conditions hereof, (i) certificates for the shares of Warrant Stock so purchased
shall be dated the date of such exercise and delivered to the Holder hereof
within a reasonable time, after such exercise, and (ii) unless this Warrant
has
expired, a new Warrant representing the number of shares of Warrant Stock,
if
any, with respect to which this Warrant shall not then have been exercised
(less
any amount thereof which shall have been canceled in payment or partial payment
of the Exercise Price as hereinabove provided) shall also be issued to the
Holder hereof at the Issuer's expense within such time.
(e) Transferability
of Warrant. Subject to Section 2(f), this Warrant may be
transferred by a Holder without the consent of the Issuer. If
transferred pursuant to this paragraph and subject to the provisions of
subsection (f) of this Section 2, this Warrant may be transferred on the books
of the Issuer by the Holder hereof in person or by duly authorized attorney,
upon surrender of this Warrant at the principal office of the Issuer, properly
endorsed (by the Holder executing an assignment in the form attached hereto)
and
upon payment of any necessary transfer tax or other governmental charge imposed
upon such transfer. This Warrant is exchangeable at the principal
office of the Issuer for Warrants for the purchase of the same aggregate number
of shares of Warrant Stock, each new Warrant to represent the right to purchase
such number of shares of Warrant Stock as the Holder hereof shall designate
at
the time of such exchange. All Warrants issued on transfers or
exchanges shall be dated the Original Issue Date and shall be identical with
this Warrant except as to the number of shares of Warrant Stock issuable
pursuant thereto.
(f) Compliance
with Securities Laws.
(i)
The
Holder of this Warrant, by acceptance hereof, acknowledges that this Warrant
or
the shares of Warrant Stock to be issued upon exercise hereof are being acquired
solely for the Holder's own account and not as a nominee for any other party,
and for investment, and that the Holder will not offer, sell or otherwise
dispose of this Warrant or any shares of Warrant Stock to be issued upon
exercise hereof except pursuant to an effective registration statement, or
an
exemption from registration, under the Securities Act and any applicable state
securities laws.
(ii)
The
Holder of this Warrant by acceptance hereof, represents that it has not been
organized, reorganized or recapitalized specifically for the purpose of
investing in the Issuer; has sufficient business and financial
knowledge and experience so as to be capable of evaluating the merits and risks
of its investment in the Issuer; has had an opportunity to discuss the Issuer’s
business, management and financial affairs with the Issuer’s management, and had
all questions answered to its satisfaction.
(iii) This
Warrant and all certificates representing shares of Warrant Stock issued upon
exercise hereof shall be stamped or imprinted with a legend in substantially
the
following form:
THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE
STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL
TO
THE HOLDER OF THE SECURITIES (UNLESS THE ISSUER IN ITS SOLE DISCRETION
DETERMINES TO USE ITS OWN COUNSEL), WITH ANY SUCH COUNSEL TO THE HOLDER AND
ANY
SUCH OPINION OF SUCH COUNSEL TO BE REASONABLY ACCEPTABLE TO THE ISSUER, THAT
REGISTRATION UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.
3. Loss,
Theft, Destruction of Warrants. Upon receipt of evidence
satisfactory to the Issuer of the ownership of and the loss, theft, destruction
or mutilation of any Warrant and, in the case of any such loss, theft or
destruction, upon receipt of indemnity or security satisfactory to the Issuer
or, in the case of any such mutilation, upon surrender and cancellation of
such
Warrant, the Issuer will make and deliver, in lieu of such lost, stolen,
destroyed or mutilated Warrant, a new Warrant of like tenor and representing
the
right to purchase the same number of shares of Common Stock.
4. Adjustment
of Exercise Price. The price at which such shares may be
purchased upon exercise of this Warrant shall be subject to adjustment from
time
to time as set forth in this Section 4.
(a) Subdivisions
and Combinations. If at any time the Issuer shall:
(i) subdivide
its outstanding shares of Common Stock into a larger number of shares of Common
Stock, or
(ii) combine
its outstanding shares of Common Stock into a smaller number of shares of Common
Stock,
then
(1)
the number of shares of Common Stock for which this Warrant is exercisable
immediately after the occurrence of any such event shall be adjusted to equal
the number of shares of Common Stock which a record holder of the same number
of
shares of Common Stock for which this Warrant is exercisable immediately prior
to the occurrence of such event would own or be entitled to receive after the
happening of such event, and (2) the Exercise Price then in effect shall be
adjusted to equal (A) the Exercise Price then in effect multiplied by the number
of shares of Common Stock for which this Warrant is exercisable immediately
prior to the adjustment divided by (B) the number of shares of Common Stock
for
which this Warrant is exercisable immediately after such
adjustment.
(b) Form
of Warrant after
Adjustments. The form of this Warrant need not be changed because
of any adjustments in the Exercise Price or the number and kind of Securities
purchasable upon the exercise of this Warrant.
(c) Notwithstanding
any other provision set forth in this Section 4, no adjustment to the Exercise
Price shall be required because of any issuance or sale of Additional Shares
of
Common Stock or Common Stock Equivalents in connection with the
Plan.
5. Fractional
Share. No fractional shares of Warrant Stock will be issued in
connection with any exercise of this Warrant. As to the remaining
fraction of a share, if any, which Holder would otherwise be entitled to
purchase at the time, if any, that all whole shares of Warrant Stock available
hereunder have been purchased purchase to the exercise of this Warrant, the
Issuer shall pay a cash adjustment in respect of such final fraction in an
amount equal to such fraction multiplied by the Exercise Price. The
Issuer shall pay this cash adjustment for fractional shares one time
only.
6. Definitions. For
the purposes of this Warrant, the following terms have the following
meanings:
"Board"
shall mean the Board of Directors of the Issuer.
"Common
Stock" means the Common Stock, par value $.01 per share, of the Issuer and
any other Capital Stock into which such stock may hereafter be
changed.
“Final
Plan Date” shall mean the date that is six months and twelve days after the
Plan Closing Date.
"Holders"
mean the Persons who shall from time to time own any Warrant. The
term "Holder" means one of the Holders.
"Issuer"
means Chembio Diagnostics, Inc., a Nevada corporation, and its
successors.
"Original
Issue Date" means «Year_Issued».
"OTC
Bulletin Board" means the
over-the-counter electronic bulletin board.
"Person"
means an individual,
corporation, limited liability company, partnership, joint stock company, trust,
unincorporated organization, joint venture, Governmental Authority or other
entity of whatever nature.
“Plan”
shall mean any action the Company takes, with any required approval of the
holders thereof, on or before the Final Plan Date as contemplated by the Plan
Summary and accompanying materials provided to holders on December 4, 2007, in
connection with the reduction or other modification of terms of the Company’s
then-outstanding preferred stock, warrants and options, including, but not
limited to, actions the Company takes to (i) facilitate the conversion of the
Series A, B and C Convertible Preferred Stock; (ii) reduce the exercise price
of
any of the Company’s outstanding warrants or options; (iii) offer the holders of
the Company’s warrants and options the opportunity to exercise such warrants and
options on a cash and/or cashless basis; and (iv) make other amendments to
the
documents governing these securities to effect these modifications, and to
facilitate the conversion and exercise of these securities.
“Plan
Closing Date” shall be December 19, 2007.
"Securities"
means any debt or equity securities of the Issuer, whether now or hereafter
authorized, any instrument convertible into or exchangeable for Securities
or a
Security, and any option, warrant or other right to purchase or acquire any
Security. "Security" means one of the Securities.
"Securities
Act" means the Securities Act of 1933, as amended, or any similar federal
statute then in effect.
"Term"
has the meaning specified in Section 1 hereof.
"Trading
Day" means (a) a day on which the Common Stock is traded on the OTC Bulletin
Board, or (b) if the Common Stock is not traded on the OTC Bulletin Board,
a day
on which the Common Stock is quoted in the over-the-counter market as reported
by the National Quotation Bureau Incorporated (or any similar organization
or
agency succeeding its functions of reporting prices); provided,
however, that in the event that the Common Stock is not listed or
quoted
as set forth in (a) or (b) hereof, then Trading Day shall mean any day except
Saturday, Sunday and any day which shall be a legal holiday or a day on which
banking institutions in the State of New York are authorized or required by
law
or other government action to close.
"Warrants"
means this Warrants, and any other warrants of like tenor issued in substitution
or exchange for any thereof pursuant to the provisions hereof.
"Exercise
Price"
shall
be
as follows, except as may be adjusted from time to time as shall result from
the
adjustments specified in this Warrant:
(i) For
the period 4:01p.m. eastern time (“ET”) through 9:59p.m. ET on the Plan
Closing Date, $0.40 per share for all or any portion of this Warrant exercised
for cash;
(ii) For
the period 4:01p.m. ET through 9:59p.m. ET on the Plan Closing Date, $0.45
per
share for all or any portion of this Warrant exercised through a Cashless
Exercise;
(iii) For
the period beginning 10:00p.m. ET on the Plan Closing Date through 9:59p.m.
ET
on the Final Plan Date, $0.45 for all or any part of this Warrant exercised
by a
Holder who exercised at least 10% of all of such Holder’s warrants and options
for cash at the Plan Closing Date;
(iv) For
the period beginning 10:00p.m. ET on the Plan Closing Date, $___ per share
for
any Holder that did not exercise at least 10% of all of such Holder’s warrants
and options for cash at an exercise price of $0.40 per share at the Plan Closing
Date; and
(v) For
the period beginning 10:00p.m. ET on the Final Plan Date, $___ per share for
all
or any portion of this Warrant that has not been exercised on or before 9:59p.m.
ET on the Final Plan Date.
"Warrant
Stock" means Common Stock issuable upon exercise of any Warrant or Warrants
or otherwise issuable pursuant to any Warrant or Warrants.
7. Amendment
and Waiver. Any term, covenant, agreement or condition in this
Warrant may be amended, or compliance therewith may be waived (either generally
or in a particular instance and either retroactively or prospectively), by
a
written instrument or written instruments executed by the Issuer and the
majority of the Holders.
8. Governing
Law. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO
PRINCIPLES OF CONFLICTS OF LAW.
9. Notices. Any
and all notices or other communications or deliveries required or permitted
to
be provided hereunder shall be in writing and shall be deemed given and
effective on the earlier of (i) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile telephone number
specified for notice prior to 5:00 p.m., eastern time, on a Trading Day, (ii)
the Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile telephone number specified for
notice later than 5:00 p.m., eastern time, on any date and earlier than 11:59
p.m., eastern time, on such date, or (iii) actual receipt by the party to whom
such notice is required to be given. The addresses for such
communications shall be with respect to the Holder of this Warrant or of Warrant
Stock issued pursuant hereto, addressed to such Holder at its last known address
or facsimile number appearing on the books of the Issuer maintained for such
purposes, or with respect to the Issuer, addressed to:
Chembio
Diagnostics, Inc.
3661
Horseblock Road
Medford,
NY 11763
Attention:
Lawrence A. Siebert,
President
Tel.
No.: (631)
924-1135
Fax
No.: (631) 924-6033
Copies
of
notices to the Issuer shall be sent to Patton Boggs LLP, 1801 California Street,
Suite 4900, Denver, CO 80202, Attention: Alan Talesnick, Tel. No.:
(303) 830-1776, Fax No.: (303) 894-9239. Copies of notices to the
Holder shall be sent to _______________, Facsimile No.: . Any party
hereto may from time to time change its address for notices by giving at least
ten (10) days written notice of such changed address to the other party
hereto.
10. Successors
and Assigns. This Warrant and the rights evidenced hereby shall
inure to the benefit of and be binding upon the successors and assigns of the
Issuer, the Holder hereof and (if applicable) the Holders of Warrant
Stock.
11. Modification
and Severability. If, in any action before any court or agency
legally empowered to enforce any provision contained herein, any provision
hereof is found to be unenforceable, then such provision shall be deemed
modified to the extent necessary to make it enforceable by such court or
agency. If any such provision is not enforceable as set forth in the
preceding sentence, the unenforceability of such provision shall not affect
the
other provisions of this Warrant, but this Warrant shall be construed as if
such
unenforceable provision had never been contained herein.
12. Headings. The
headings of the Sections of this Warrant are for convenience of reference only
and shall not, for any purpose, be deemed a part of this Warrant.
IN
WITNESS WHEREOF, the Issuer has caused this Warrant to be executed by its
officer thereunto duly authorized.
Original
Issue
Date: May
5, 2004
Revised
Issue
Date: December
19, 2007
CHEMBIO
DIAGNOSTICS,
INC.
Lawrence
A. Siebert,
President
No.: ________
|
Number
of Shares: ____________
|
Original
Date of Issuance: May 5, 2004
|
Reissuance
Date: December 19,
2007
|
EXERCISE
FORM
CHEMBIO
DIAGNOSTICS, INC.
The
undersigned ______________________________________, pursuant to the provisions
of the within Warrant, hereby elects to purchase _____________ shares of Common
Stock of Chembio Diagnostics, Inc. covered by the within Warrant.
Date:
_________________ Signature ___________________________________
Address ___________________________________
___________________________________
Number
of
shares of Common Stock beneficially owned or deemed beneficially owned by the
Holder on the date of Exercise: _________________________
ASSIGNMENT
FOR
VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the within Warrant and all rights evidenced thereby and
does
irrevocably constitute and appoint _____________, attorney, to transfer the
said
Warrant on the books of the within named corporation.
Date:
_________________ Signature ___________________________________
Address ___________________________________
___________________________________
PARTIAL
ASSIGNMENT
FOR
VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the right to purchase _________ shares of Warrant Stock
evidenced by the within Warrant together with all rights therein, and does
irrevocably constitute and appoint ___________________, attorney, to transfer
that part of the said Warrant on the books of the within named
corporation.
Date:
_________________ Signature ___________________________________
Address ___________________________________
___________________________________
FOR
USE BY THE ISSUER ONLY:
This
Warrant No. W-_________ canceled (or transferred or exchanged) this _____ day
of
_________________, _________, shares of Common Stock issued therefor in the
name
of ________________________________________________________________, Warrant
No.
W-___________ issued for ____________ shares of Common Stock in the name of
_____________________________________________________________________________.
ex21.htm
Exhibit
21
List
of Subsidiaries
Chembio
Diagnostics Systems, Inc. (Delaware)
Chembio
Diagnostics Nigeria Limited (Nigeria)
Chembio
Diagnostics (Africa) Limited (Tanzania)
ex23_1.htm
Exhibit
23.1
CONSENT
OF REGISTERED INDEPENDENT PUBLIC ACCOUNTING FIRM
We
hereby
consent to the incorporation by reference in Registration Statement No.
333-69460 and Registration Statement No. 333-141555 on Form S-8 of our report
dated March 7, 2008 relating to the consolidated balance sheets of Chembio
Diagnostics Inc. and Subsidiaries as of December 31, 2007 and 2006 and the
consolidated statements of operations, stockholders’ equity (deficit) and cash
flows for the two years in the period ended December 31, 2007 appearing in
this
Annual Report on Form 10-KSB of Chembio Diagnostics, Inc. for the year ended
December 31, 2007.
/s/Lazar
Levine & Felix LLP
New
York,
New York
March
11,
2008
ex31_1.htm
EXHIBIT
31.1
CERTIFICATION
I,
Lawrence A. Siebert, certify that:
1.
|
I
have reviewed this annual report on Form 10-KSB of Chembio Diagnostics,
Inc.;
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
3.
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
4.
|
The
registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f) for the registrant and
have:
|
|
a.
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is
being
prepared;
|
|
b.
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision,
to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
c.
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
d.
|
Disclosed
in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case
of an
annual report) that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
5.
|
The
registrant's other certifying officer and I have disclosed, based
on our
most recent evaluation of internal control over financial reporting,
to
the registrant's auditors and the audit committee of the registrant's
board of directors (or persons performing the equivalent
functions):
|
|
a.
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record,
process, summarize and report financial information;
and
|
|
b.
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
Date: March
12, 2008
/s
/
Lawrence A.
Siebert
Lawrence
A. Siebert
Chief
Executive Officer, President, and Chairman
(Principal
Executive Officer)
ex31_2.htm
EXHIBIT
31.2
CERTIFICATION
I,
Richard J. Larkin, certify that:
|
1.
|
I
have reviewed this annual report on Form 10-KSB of Chembio Diagnostics,
Inc.;
|
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
|
3.
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
|
4.
|
The
registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f) for the registrant and
have:
|
|
a.
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is
being
prepared;
|
|
b.
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision,
to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
|
c.
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
d.
|
Disclosed
in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case
of an
annual report) that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
|
5.
|
The
registrant's other certifying officer and I have disclosed, based
on our
most recent evaluation of internal control over financial reporting,
to
the registrant's auditors and the audit committee of the registrant's
board of directors (or persons performing the equivalent
functions):
|
|
a.
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record,
process, summarize and report financial information;
and
|
|
b.
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
Date: March
12, 2008
/s
/
Richard J.
Larkin
Richard
J. Larkin
Chief
Financial Officer
(Principal
Financial Officer)
ex32.htm
EXHIBIT
32
CHEMBIO
DIAGNOSTICS, INC.
SARBANES-OXLEY
ACT SECTION 906 CERTIFICATION
In
connection with this annual report on Form 10-KSB of Chembio Diagnostics, Inc.
(the “Company”) for the fiscal year ended December 31, 2007, each of the
undersigned, Lawrence A. Siebert, the Chief Executive Officer, President and
Chairman of the Company, and Richard J. Larkin, the Chief Financial Officer
of
the Company, hereby certify pursuant to 18 U.S.C. section 1350, as adopted
pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:
|
1.
|
This
Form 10-KSB for the fiscal year ended December 31, 2007 fully complies
with the requirements of section 13(a) or 15(d) of the Securities
Exchange
Act of 1934; and
|
|
2.
|
The
information contained in this Form 10-KSB for the fiscal year ended
December 31, 2007 fairly presents, in all material respects, the
financial
condition and results of operations of Chembio Diagnostics, Inc.
for the
periods presented therein.
|
Date:
March 12, 2008
/s
/
Lawrence A.
Siebert
Lawrence
A. Siebert
Chief
Executive Officer, President and Chairman
(Principle
Executive Officer)
/s./
Richard J.
Larkin
Richard
J. Larkin
Chief
Financial Officer
(Principle
Financial Officer)